0000012208-17-000012.txt : 20170301 0000012208-17-000012.hdr.sgml : 20170301 20170228201141 ACCESSION NUMBER: 0000012208-17-000012 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 95 CONFORMED PERIOD OF REPORT: 20161231 FILED AS OF DATE: 20170301 DATE AS OF CHANGE: 20170228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO RAD LABORATORIES INC CENTRAL INDEX KEY: 0000012208 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 941381833 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-07928 FILM NUMBER: 17650921 BUSINESS ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 BUSINESS PHONE: 5107247000 MAIL ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 10-K 1 a10k123116.htm 10-K 2016 Document
0.07false--12-31FY20162016-12-3110-K0000012208244600685116824YesLarge Accelerated Filer3001889921BIO RAD LABORATORIES INCNoYes2441800023367000100000000.00010.00010.00010.000180000000200000008000000020000000242304485130558244540485123883242303265129641244539265122966.101P10YP1YP10YP2YP12YP4YP10YP3YP7YP3YP0YP0YP9YP5YP9YP1YP8YP1YP12YP3YP9YP1YP9YP2YP0YP0YP8YP4Y018000000.00010.0001750000075000000000P12YP3YP5YP5Y00122917122917 0000012208 2016-01-01 2016-12-31 0000012208 2016-06-30 0000012208 us-gaap:CommonClassBMember 2017-02-14 0000012208 us-gaap:CommonClassAMember 2017-02-14 0000012208 2015-12-31 0000012208 us-gaap:CommonClassBMember 2015-12-31 0000012208 2016-12-31 0000012208 us-gaap:CommonClassAMember 2016-12-31 0000012208 us-gaap:CommonClassBMember 2016-12-31 0000012208 us-gaap:CommonClassAMember 2015-12-31 0000012208 bio:TreasuryClassBMember 2015-12-31 0000012208 bio:TreasuryClassAMember 2015-12-31 0000012208 bio:TreasuryClassBMember 2016-12-31 0000012208 bio:TreasuryClassAMember 2016-12-31 0000012208 2014-01-01 2014-12-31 0000012208 2015-01-01 2015-12-31 0000012208 2013-12-31 0000012208 2014-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-12-31 0000012208 us-gaap:RetainedEarningsMember 2014-01-01 2014-12-31 0000012208 us-gaap:CommonStockMember 2015-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-12-31 0000012208 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0000012208 us-gaap:TreasuryStockMember 2014-12-31 0000012208 us-gaap:RetainedEarningsMember 2013-12-31 0000012208 us-gaap:CommonStockMember 2014-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-12-31 0000012208 us-gaap:RetainedEarningsMember 2016-12-31 0000012208 us-gaap:CommonStockMember 2013-12-31 0000012208 us-gaap:TreasuryStockMember 2013-12-31 0000012208 us-gaap:TreasuryStockMember 2015-12-31 0000012208 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-01-01 2014-12-31 0000012208 us-gaap:RetainedEarningsMember 2014-12-31 0000012208 us-gaap:RetainedEarningsMember 2015-12-31 0000012208 us-gaap:TreasuryStockMember 2016-12-31 0000012208 us-gaap:CommonStockMember 2016-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000012208 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:EquipmentMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 bio:ReagentRentalEquipmentMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:EquipmentMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2015-12-31 0000012208 bio:ReagentRentalEquipmentMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2016-12-31 0000012208 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:ComputerSoftwareIntangibleAssetMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:ComputerSoftwareIntangibleAssetMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-01-06 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-01-01 2016-03-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2016-01-01 2016-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2016-12-31 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2016-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2016-01-01 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2015-12-31 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2015-12-31 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2015-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2015-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2015-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2015-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2015-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2015-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2015-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2015-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2015-12-31 0000012208 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2015-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2015-12-31 0000012208 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2015-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2015-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2015-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2015-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2015-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2015-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2015-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2015-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2015-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 bio:CellsorterMember 2012-09-30 2016-12-31 0000012208 bio:CellsorterMember 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoicesMember 2016-12-31 0000012208 bio:GnuBIOMember 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoiceslowMember 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestoneminimumamountMember 2016-12-31 0000012208 bio:GnuBIOMember 2014-04-10 0000012208 bio:CellsorterMember 2012-09-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:DiscountrateMember 2016-01-01 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:CostofdebtMember 2016-01-01 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 bio:CellsorterMember 2016-01-01 2016-12-31 0000012208 bio:CellsorterMember 2015-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-01-01 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 bio:GnuBIOMember 2015-12-31 0000012208 bio:LifeScienceMember 2014-12-31 0000012208 bio:LifeScienceMember 2016-12-31 0000012208 bio:ClinicalDiagnosticsMember 2015-12-31 0000012208 bio:LifeScienceMember 2015-12-31 0000012208 bio:ClinicalDiagnosticsMember 2014-12-31 0000012208 bio:LifeScienceMember 2016-01-01 2016-12-31 0000012208 bio:ClinicalDiagnosticsMember 2016-12-31 0000012208 bio:LifeScienceMember 2015-01-01 2015-12-31 0000012208 bio:ClinicalDiagnosticsMember 2016-01-01 2016-12-31 0000012208 bio:ClinicalDiagnosticsMember 2015-01-01 2015-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2016-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2016-12-31 0000012208 bio:KnowHowMember 2016-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2016-12-31 0000012208 us-gaap:TradeNamesMember 2016-12-31 0000012208 us-gaap:LicensingAgreementsMember 2016-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2015-12-31 0000012208 bio:KnowHowMember 2015-12-31 0000012208 us-gaap:LicensingAgreementsMember 2015-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2015-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2015-12-31 0000012208 us-gaap:TradeNamesMember 2015-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember us-gaap:NoncompeteAgreementsMember 2016-01-01 2016-03-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember us-gaap:DevelopedTechnologyRightsMember 2016-01-01 2016-03-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0000012208 bio:KnowHowMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0000012208 bio:KnowHowMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0000012208 bio:KnowHowMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:TradeNamesMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:TradeNamesMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0000012208 us-gaap:TradeNamesMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 bio:KnowHowMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0000012208 us-gaap:TradeNamesMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2015-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2015-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2016-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2016-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2010-12-31 0000012208 us-gaap:StandbyLettersOfCreditMember 2016-12-31 0000012208 us-gaap:PerformanceGuaranteeMember 2016-12-31 0000012208 us-gaap:LineOfCreditMember 2014-06-30 0000012208 us-gaap:LineOfCreditMember 2016-12-31 0000012208 us-gaap:DomesticCountryMember 2016-01-01 2016-12-31 0000012208 us-gaap:DomesticCountryMember 2014-01-01 2014-12-31 0000012208 us-gaap:DomesticCountryMember 2015-01-01 2015-12-31 0000012208 us-gaap:StateAndLocalJurisdictionMember 2016-12-31 0000012208 us-gaap:ForeignCountryMember 2016-12-31 0000012208 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2016-12-31 0000012208 bio:NetofprepaidtaxesMember 2016-12-31 0000012208 us-gaap:DomesticCountryMember 2016-12-31 0000012208 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2016-12-31 0000012208 us-gaap:DomesticCountryMember bio:LimitationsOnUseMember 2016-12-31 0000012208 bio:QuantalifeMember us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2016-12-31 0000012208 bio:IncludingaccruedinterestandpenaltiesMember 2016-12-31 0000012208 us-gaap:DomesticCountryMember bio:ForeignTaxCreditCarryforwardMember 2016-12-31 0000012208 bio:TreasuryClassAMember 2012-04-01 2012-06-30 0000012208 us-gaap:CommonClassAMember 2016-01-01 2016-12-31 0000012208 us-gaap:CommonClassBMember 2016-01-01 2016-12-31 0000012208 bio:TreasuryClassBMember 2012-04-01 2012-06-30 0000012208 us-gaap:CommonClassBMember 2014-01-01 2014-12-31 0000012208 us-gaap:CommonClassAMember 2014-12-31 0000012208 us-gaap:CommonClassAMember 2013-12-31 0000012208 us-gaap:CommonClassAMember 2014-01-01 2014-12-31 0000012208 us-gaap:CommonClassAMember 2015-01-01 2015-12-31 0000012208 us-gaap:CommonClassBMember 2014-12-31 0000012208 us-gaap:CommonClassBMember 2015-01-01 2015-12-31 0000012208 us-gaap:CommonClassBMember 2013-12-31 0000012208 us-gaap:ParentMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2015-01-01 2015-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:ParentMember 2015-01-01 2015-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-01-01 2015-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2014-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-01-01 2015-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-12-31 0000012208 us-gaap:ParentMember 2015-12-31 0000012208 us-gaap:ParentMember 2014-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2014-12-31 0000012208 us-gaap:ParentMember 2016-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-01-01 2015-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-01-01 2015-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2016-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2014-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2015-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2013-12-31 0000012208 us-gaap:EmployeeStockMember 2014-01-01 2014-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-12-31 0000012208 us-gaap:EmployeeStockMember 2015-01-01 2015-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2014-01-01 2014-12-31 0000012208 bio:StockOptionAndAwardPlansMember bio:IncentiveAwardPlan2007Member 2016-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-12-31 0000012208 us-gaap:EmployeeStockMember 2016-01-01 2016-12-31 0000012208 us-gaap:EmployeeStockMember 2016-12-31 0000012208 bio:StockAwardPlansMember bio:IncentiveAwardPlan2007Member 2016-01-01 2016-12-31 0000012208 bio:A2011EmployeeStockPurchasePlanMember 2016-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2014-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2013-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2015-12-31 0000012208 us-gaap:EmployeeStockMember 2014-12-31 0000012208 us-gaap:EmployeeStockMember 2015-12-31 0000012208 country:US 2016-12-31 0000012208 us-gaap:EuropeMember 2015-12-31 0000012208 us-gaap:AmericasMember 2015-12-31 0000012208 us-gaap:AmericasMember 2016-12-31 0000012208 country:US 2016-12-31 0000012208 us-gaap:AsiaPacificMember 2015-12-31 0000012208 us-gaap:EuropeMember 2016-12-31 0000012208 country:US 2015-12-31 0000012208 us-gaap:AsiaPacificMember 2016-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2014-01-01 2014-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2014-01-01 2014-12-31 0000012208 us-gaap:OperatingSegmentsMember 2016-01-01 2016-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2016-01-01 2016-12-31 0000012208 us-gaap:OperatingSegmentsMember 2014-01-01 2014-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2015-01-01 2015-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2014-01-01 2014-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2015-01-01 2015-12-31 0000012208 us-gaap:OperatingSegmentsMember 2015-01-01 2015-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2015-01-01 2015-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-01-01 2016-12-31 0000012208 bio:ClinicalDiagnosticsMember 2014-01-01 2014-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2014-01-01 2014-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2016-12-31 0000012208 bio:LifeScienceMember 2014-01-01 2014-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2015-01-01 2015-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2015-12-31 0000012208 us-gaap:AmericasMember 2014-01-01 2014-12-31 0000012208 us-gaap:EuropeMember 2016-01-01 2016-12-31 0000012208 us-gaap:AmericasMember 2015-01-01 2015-12-31 0000012208 us-gaap:EuropeMember 2014-01-01 2014-12-31 0000012208 us-gaap:AsiaPacificMember 2015-01-01 2015-12-31 0000012208 us-gaap:AsiaPacificMember 2014-01-01 2014-12-31 0000012208 country:US 2014-01-01 2014-12-31 0000012208 us-gaap:EuropeMember 2015-01-01 2015-12-31 0000012208 country:US 2015-01-01 2015-12-31 0000012208 us-gaap:AmericasMember 2016-01-01 2016-12-31 0000012208 us-gaap:AsiaPacificMember 2016-01-01 2016-12-31 0000012208 country:US 2016-01-01 2016-12-31 0000012208 us-gaap:CorporateNonSegmentMember bio:NonAllocatedExpenseLossContingencyMember 2014-01-01 2014-12-31 0000012208 us-gaap:GoodwillMember us-gaap:MaterialReconcilingItemsMember 2015-12-31 0000012208 bio:PropertyPlantandEquipmentexcludingsegmentspecificMember us-gaap:MaterialReconcilingItemsMember 2016-12-31 0000012208 us-gaap:OtherNoncurrentAssetsMember us-gaap:MaterialReconcilingItemsMember 2015-12-31 0000012208 bio:PropertyPlantandEquipmentexcludingsegmentspecificMember us-gaap:MaterialReconcilingItemsMember 2015-12-31 0000012208 us-gaap:OtherNoncurrentAssetsMember us-gaap:MaterialReconcilingItemsMember 2016-12-31 0000012208 us-gaap:OperatingSegmentsMember 2016-12-31 0000012208 us-gaap:OtherCurrentAssetsMember us-gaap:MaterialReconcilingItemsMember 2016-12-31 0000012208 us-gaap:OperatingSegmentsMember 2015-12-31 0000012208 us-gaap:GoodwillMember us-gaap:MaterialReconcilingItemsMember 2016-12-31 0000012208 us-gaap:OtherCurrentAssetsMember us-gaap:MaterialReconcilingItemsMember 2015-12-31 0000012208 us-gaap:EmployeeSeveranceMember 2016-01-01 2016-12-31 0000012208 us-gaap:CostOfGoodsTotalMember 2016-01-01 2016-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-12-31 0000012208 2015-01-01 2015-03-31 0000012208 2015-07-01 2015-09-30 0000012208 2016-04-01 2016-06-30 0000012208 2016-10-01 2016-12-31 0000012208 2015-04-01 2015-06-30 0000012208 2015-10-01 2015-12-31 0000012208 2016-07-01 2016-09-30 0000012208 2016-01-01 2016-03-31 0000012208 us-gaap:SubsequentEventMember 2017-02-15 2017-02-15 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2015-01-01 2015-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-01-01 2016-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2015-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2014-01-01 2014-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2013-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2014-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2014-01-01 2014-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2014-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2015-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2016-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2013-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2015-01-01 2015-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:pure xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 10-K
(Mark One)
 
x
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the year ended December 31, 2016
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the transition period from ___________________________ to _________________________________
 
Commission file number 1-7928
 
BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
94-1381833
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
 
 
 
1000 Alfred Nobel Drive, Hercules, California
 
94547
(Address of principal executive offices)
 
(Zip Code)
 
 
Registrant's telephone number, including area code
 
   (510) 724-7000 
Securities registered pursuant to Section 12(b) of the Act:
 
 
 
Title of Each Class
 
Name of Each Exchange on Which Registered
Class A Common Stock Par Value $0.0001 per share
 
New York Stock Exchange
Class B Common Stock Par Value $0.0001 per share
 
New York Stock Exchange
 
Securities registered pursuant to Section 12(g) of the Act:  NONE
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
 
  ý Yes
 
 ¨ No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
 
 ¨ Yes
 
   ý  No
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
 ý Yes
 
¨ No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period
that the registrant was required to submit and post such files).
    ý Yes
 
¨ No
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  ý
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
 
 
 
 
 
 
Large accelerated filer
ý
 
 
Accelerated filer
¨
Non-accelerated file
¨
(Do not check if a smaller reporting company)
 
Smaller reporting company
¨
  
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  
   ¨  Yes
 
   ý No
 
As of June 30, 2016, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the Registrant's Class A Common Stock held by non-affiliates was approximately $2,959,730,250 and the aggregate market value of the registrant's Class B Common Stock held by non-affiliates was approximately $42,159,671.
 
As of February 14, 2017, there were 24,460,068 shares of Class A Common Stock and 5,116,824 shares of Class B Common Stock outstanding.
Documents Incorporated by Reference
 
 
 
 
 
 
 
 
 
Document
 
 
Form 10-K Parts 
(1)
Definitive Proxy Statement to be mailed to stockholders in connection with the
 
 
 
 
registrant's 2017 Annual Meeting of Stockholders (specified portions)
 
 III



BIO-RAD LABORATORIES, INC.

FORM 10-K DECEMBER 31, 2016

TABLE OF CONTENTS



2


INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

Other than statements of historical fact, statements made in this Annual Report include forward-looking statements, such as statements with respect to our future financial performance, operating results, plans and objectives that involve risk and uncertainties.  Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions.  Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements.  We have based these forward-looking statements on our current expectations and projections about future events.  However, actual results may differ materially from those currently anticipated depending on a variety of risk factors including but not limited to those identified under “Item 1A, Risk Factors” of this Annual Report. We caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

PART I.

ITEM 1.  BUSINESS

General

Founded in 1952 and incorporated in 1957, Bio-Rad Laboratories, Inc. (referred to in this report as “Bio-Rad,” “we,” “us,” and “our”) was initially engaged in the development and production of specialty chemicals used in biochemical, pharmaceutical and other life science research applications.  We entered the field of clinical diagnostics with the development of our first test kit based on separation techniques and materials developed for life science research.  Through internal research and development efforts and acquisitions we have expanded into various markets.  Today, Bio-Rad manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a broad range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

As we broadened our product lines, we also expanded our geographical market.  We have direct distribution channels in over 35 countries outside the United States through subsidiaries whose focus is sales, customer service and product distribution. In some locations outside and inside these 35 countries, sales efforts are supplemented by distributors and agents.

Description of Business

Business Segments

Today, Bio-Rad operates in two industry segments designated as Life Science and Clinical Diagnostics.  Both segments operate worldwide.  Our Life Science segment and our Clinical Diagnostics segment generated 35% and 64%, respectively, of our net sales for the year ended December 31, 2016. We generated approximately 37% of our consolidated net sales for the year ended December 31, 2016 from U.S. sales and approximately 63% from sales in our remaining worldwide markets.

For a description of business and financial information on industry and geographic segments, see Note 14 of Item 8 of Part II of this report.

Life Science Segment

Our Life Science segment is at the forefront of discovery, creating advanced tools to answer complex biological questions.  We are a leader in the life sciences market and develop, manufacture and market a range of more than 5,000 reagents, apparatus and laboratory instruments that serve a global customer base. Many of our products are

3


used in established research techniques, biopharmaceutical production processes and food testing regimes. These techniques are typically used to separate, purify and identify biological materials such as proteins, nucleic acids and bacteria within a laboratory or production setting.  We focus on selected segments of the life sciences market in proteomics (the study of proteins), genomics (the study of genes), biopharmaceutical production, cell biology and food safety.  We estimate that the worldwide market for products in these selected segments was approximately
$8 billion. Our principal life science customers include universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers and food testing laboratories.

Clinical Diagnostics Segment

Our Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.  Our products currently address specific niches within the in vitro diagnostics (IVD) test market, and we seek to focus on the higher margin, higher growth segments of this market.
We supply more than 3,000 different products that cover more than 300 clinical diagnostic tests to the IVD test market. We estimate that the worldwide sales for products in the markets we serve were approximately $12 billion. IVD tests are conducted outside the human body and are used to identify and measure substances in a patient’s tissue, blood or urine. Our products consist of reagents, instruments and software, typically provided to our customers as an integrated package to allow them to generate reproducible test results. Revenue in this business is highly recurring, as laboratories typically standardize test methodologies, which are dependent on a particular supplier’s equipment, reagents and consumable products. An installed base of diagnostic test systems therefore typically creates an ongoing source of revenue through the sale of test kits for each sample analyzed on an installed system.  Our principal clinical diagnostic customers include hospital laboratories, reference laboratories, transfusion laboratories and physician office laboratories.

Raw Materials and Components

We utilize a wide variety of chemicals, biological materials, electronic components, machined metal parts, optical parts, computing and peripheral devices.  Most of these materials and components are available from numerous sources, and generally we have not experienced difficulty in securing adequate supplies. However, in certain instances we acquire components and materials from a sole supplier. Due to the regulatory environment in which we operate, we may be unable to quickly establish additional or replacement sources for some components or materials.

Patents, Trademarks and Licenses

We own numerous U.S. and international patents and trademarks.  We also pay royalties on the sales of certain products under several patent license agreements.  We view these patents, trademarks and license agreements as valuable assets; however, we believe that our ability to develop and manufacture our products depends primarily on our knowledge, technology and special skills rather than our patent, trademark and licensing positions.

Seasonal Operations and Backlog

Our business is not inherently seasonal.  However, the European custom of concentrating vacation during the summer months usually tempers third quarter sales volume and operating income.

For the most part, we operate in markets characterized by short lead times and the absence of significant backlogs. Management has concluded that backlog information is not material to our business as a whole.


4


Sales and Marketing

We conduct our worldwide operations through an extensive direct sales force, employing approximately 990 direct sales and sales management personnel around the world. Our sales force typically consists of experienced industry practitioners with scientific training, and we maintain a separate specialist sales force for each of our segments. We believe that this direct sales approach allows us to sell a broader range of our products and have more direct contact with our customers.

We also use a range of sales and marketing intermediaries (SMIs) in our international markets. The types of SMIs we utilize are distributors, agents, brokers and resellers. We have programs and policies in place with our SMIs that require compliance with all applicable laws, including adhering to our anti-corruption standards to ensure a transparent sale to our customers.

Our customer base is broad and diversified. Our worldwide customer base includes (1) prominent university and research institutions, providing us access to more than 180,000 scientists in the United States alone; (2) hospital, public health and commercial laboratories; (3) other leading diagnostic manufacturers; and (4) leading companies in the biotechnology, pharmaceutical, chemical and food industries.  In 2016, no single customer accounted for more than three percent of our total net sales.  Our sales are affected by a number of external factors.  For example, a number of our customers, particularly in the Life Science segment, are substantially dependent on government grants and research contracts for their funding.  A significant reduction of government funding has in the past and could in the future have a detrimental effect on the results of this segment.

Most of our international sales are generated by our wholly-owned subsidiaries and their branch offices.  Certain of these subsidiaries also have manufacturing facilities.  Bio-Rad’s international operations are subject to certain risks common to foreign operations in general, such as changes in governmental regulations, import restrictions and foreign exchange fluctuations.  

Competition

The markets served by our product groups are highly competitive.  Our competitors range in size from start-ups to large multinational corporations with significant resources and reach.  We seek to compete primarily in market segments where our products and technology offer customers specific advantages over the competition.

Because of the breadth of its product lines, our Life Science segment does not face the same competitors for all of its products.  Competitors in this market include GE Biosciences, Merck Millipore and Thermo Fisher Scientific. We compete primarily based on meeting performance specifications and offering complete solutions.
Major competitors of our Clinical Diagnostics segment include Roche, Abbott Laboratories, Siemens, Danaher, Thermo Fisher, Becton Dickinson, bioMérieux, Ortho Clinical Diagnostics, Tosoh, Immucor and DiaSorin.
Research and Development

We conduct extensive research and development activities in all areas of our business, employing approximately 875 employees worldwide in these activities, including degreed scientists and technical support staff.  Research and development has played a major role in Bio-Rad’s growth and is expected to continue to do so in the future.  Our research teams are continuously developing new products and new applications for existing products.  In our development of new products and applications, we interact with scientific and medical professionals at universities, hospitals and medical schools, and within our industry. We spent approximately $205.9 million, $193.0 million and $220.3 million on research and development activities in 2016, 2015 and 2014, respectively.

5



Regulatory Matters

The development, testing, manufacturing, marketing, post-market surveillance, distribution, advertising and labeling of certain of our products (primarily diagnostic products) are subject to regulation in the United States by the Center for Devices and Radiological Health of the U.S. Food and Drug Administration (FDA) and in other jurisdictions by state and foreign government authorities.  FDA regulations require that some new products have pre-marketing clearance or approval by the FDA and require certain products to be manufactured in accordance with FDA’s “good manufacturing practice” regulations, to be extensively tested and to be properly labeled to disclose test results and performance claims and limitations. After a product that is subject to FDA regulation is placed on the market, numerous regulatory requirements apply, including, for example, the requirement that we comply with recordkeeping and reporting requirements, such as the FDA’s medical device reporting regulations and reporting of corrections and removals. The FDA enforces these requirements by inspection and market surveillance. The FDA has authority to take various administrative and legal actions against us for our, or our products’, failure to comply with relevant legal or regulatory requirements, including issuing warning letters, initiating product seizures, requesting or requiring product recalls or withdrawals, and other civil or criminal sanctions, among other things.

We are also subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security and physician sunshine laws and regulations. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and our financial results.

Sales of our products will depend, in part, on the extent to which our products or diagnostic tests using our products will be covered by third-party payors, such as government health care programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly reducing reimbursements for certain medical products and services. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost containment programs, including price controls and restrictions on reimbursement. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our products or diagnostic tests using our products, or a decision by a third-party payor to not cover our products could reduce or eliminate utilization of our products and have a material adverse effect on our sales, results of operations and financial condition. In addition, healthcare reform measures have been and will be adopted in the future, any of which could limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures.

As a multinational manufacturer and distributor of sophisticated instrumentation, we must meet a wide array of electromagnetic compatibility and safety compliance requirements to satisfy regulations in the United States, the European Union and other jurisdictions.  

Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissions to air and discharges to water, as well as handling and disposal practices for solid, hazardous and medical wastes.  In addition to environmental laws that regulate our operations, we are also subject to environmental laws and regulations that create liabilities and clean-up responsibility for spills, disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise impacting real property that we own or operate.  The environmental laws and regulations could also subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of our properties.

These regulatory requirements vary widely among countries.

6



Employees

At December 31, 2016, Bio-Rad had approximately 8,250 employees.  Approximately seven percent of our approximately 3,300 U.S. employees are covered by a collective bargaining agreement, which will expire on November 7, 2019.  Many of our non-U.S. full-time employees, especially in France, are covered by collective bargaining agreements.  We consider our employee relations in general to be good.

Available Information

Bio-Rad files annual, quarterly, and current reports, proxy statements, and other documents with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, as amended.  The public may read and copy any materials that we file with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549.  The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.  Also, the SEC maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers, including Bio-Rad, that file electronically with the SEC.  The public can obtain any documents that we file with the SEC at http://www.sec.gov.

Bio-Rad’s website address is www.bio-rad.com.  We make available, free of charge through our website, our Form 10-Ks, 10-Qs and 8-Ks, and any amendments to these forms, as soon as reasonably practicable after filing with the SEC. The information on our website is not part of this Annual Report on Form 10-K.


ITEM 1A. RISK FACTORS

In evaluating our business and whether to invest in any of our securities, you should carefully read the following risk factors in addition to the other information contained in this Annual Report.  We believe that any of the following risks could have a material effect on our business, results of operations or financial condition, our industry or the trading price of our common stock.  We operate in a continually changing business environment, and new risks and uncertainties emerge from time to time. We cannot predict these new risks and uncertainties, nor can we assess the extent to which any such new risks and uncertainties or the extent to which the risks and uncertainties set forth below may adversely affect our business, results of operations, financial condition, our industry or the trading price of our common stock.

Our settlement with government agencies in connection with violations by us of the U.S. Foreign Corrupt Practices Act could have a material adverse effect on our business, results of operations and financial condition.

As previously disclosed, we entered into a non-prosecution agreement (NPA) with the U.S. Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) and consented to the entry of an Order by the SEC (SEC Order), effective November 3, 2014, which actions resolved both the DOJ and the SEC investigations into our violations of the U.S. Foreign Corrupt Practices Act (FCPA). Under the terms of the NPA and the SEC Order, we agreed to pay a financial penalty and certain amounts in disgorgement and interest as well as to compliance, reporting and cooperation obligations to be performed for two years. On October 28, 2016, the DOJ and SEC informed Bio-Rad that they did not intend to extend the NPA after it expired November 2, 2016.

Whether by virtue of disclosure of the NPA and the SEC Order or otherwise, we may be subject to investigations by foreign governments or further claims by third parties arising from conduct subject to the investigation or our other international operations. For additional information regarding further claims by third parties, see Note 13, “Legal Proceedings” in the Notes to Condensed Consolidated Financial Statements of Part II, Item 8 of this Annual Report on Form 10-K. Many of our customers in our significant international operations are government agencies or state-owned or state-controlled universities, hospitals and laboratories. The disclosure of the NPA and the SEC Order could harm our reputation with these customers, which could materially adversely affect our business, results of operations and financial condition.


7



Our international operations expose us to additional costs and legal and regulatory risks, which could have a material adverse effect on our business, results of operations and financial condition.

We have significant international operations. We have direct distribution channels in over 35 countries outside the United States, and in 2016 our foreign subsidiaries generated 63% of our net sales. Compliance with complex foreign and U.S. laws and regulations that apply to our international operations increases our cost of doing business. These numerous and sometimes conflicting laws and regulations include, among others, data privacy requirements (including with respect to the invalidation of the U.S.-European Union safe harbor by the European Court of Justice, compliance with the EU-U.S. Privacy Shield recently adopted by the European Commission, and the upcoming requirements for compliance with the EU General Data Protection Regulation), labor relations laws, tax laws, anti-competition regulations, import and trade restrictions, export requirements, U.S. laws such as the FCPA and other U.S. federal laws and regulations established by the office of Foreign Asset Control, local laws such as the UK Bribery Act 2010 or other local laws which prohibit corrupt payments to governmental officials or certain payments or remunerations to customers.

Given the high level of complexity of these laws, there is a risk that we may inadvertently breach some provisions, for example, through fraudulent or negligent behavior of individual employees, our failure to comply with certain formal documentation requirements, or otherwise. Our success depends, in part, on our ability to anticipate these risks and manage these challenges through policies, procedures and internal controls. However, we have a dispersed international sales organization, and we use distributors and agents in many of our international operations. This structure makes it more difficult for us to ensure that our international selling operations comply with our global policies and procedures.

Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Violations of laws and regulations also could result in prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, or our business, results of operations and financial condition. See also our risk factor regarding government regulations below.

The industries and market segments in which we operate are highly competitive, and we may not be able to compete effectively.

The life science and clinical diagnostics markets are each highly competitive. Some of our competitors have merged, and some of our competitors have greater financial resources than we do and are less leveraged than we are, making them better equipped to license technologies and intellectual property from third parties or to fund research and development, manufacturing and marketing efforts. For more information about our competitors, see “Competition” in Part 1, Item 1 of this Annual Report. Moreover, competitive and regulatory conditions in many markets in which we operate restrict our ability to fully recover, through price increases, higher costs of acquired goods and services resulting from inflation and other drivers of cost increases. Many public tenders have become more competitive due to governments lengthening the commitments of their public tenders to multiple years, which reduce the number of tenders in which we can participate annually. Because the value of these multiple-year tenders is so high, our competitors have been more aggressive with their pricing. Our failure to compete effectively and/or pricing pressures resulting from competition could adversely affect our business, results of operations and financial condition. 

We may not be able to grow our business because of our failure to develop new or improved products.

Our future growth depends in part on our ability to continue to improve our product offerings and develop and introduce new product lines and extensions that integrate technological advances. In particular, we may not be able to keep up with changes in the clinical diagnostics industry, such as the trend toward molecular diagnostics or point-of-care tests. If we are unable to integrate technological advances into our product offerings or to design, develop,

8


manufacture and market new product lines and extensions successfully and in a timely manner, our business, results of operations and financial condition will be adversely affected. We have experienced product launch delays in the past, and may do so in the future. We cannot assure you that our product and process development efforts will be successful or that new products we introduce will achieve market acceptance. Failure to launch successful new products or improvements to existing products may cause our products to become obsolete, which could harm our business, results of operations and financial condition.
 
We are subject to foreign currency exchange fluctuations, which could have a material adverse effect on our results of operations and financial condition.

As stated above, a significant portion of our operations and sales are outside of the United States. When we make purchases and sales in currencies other than the U.S. dollars, we are exposed to fluctuations in foreign currencies relative to the U.S. dollar that may adversely affect our results of operations and financial condition. Our international sales are largely denominated in local currencies. As a result, the strengthening of the U.S. dollar negatively impacts our consolidated net sales expressed in U.S. dollars. Conversely, when the U.S. dollar weakens, our expenses at our international sites increase. In addition, the volatility of other currencies, such as the Swiss Franc, Brazilian Real and Russian Ruble, may negatively impact our operations outside of the United States and increase our costs to hedge against currency fluctuations. We cannot assure you that future shifts in currency exchange rates will not have a material adverse effect on our results of operations and financial condition. For further information regarding our foreign exchange risk, see “Foreign currency exchange gains and losses” in Part II, Item 7, and “Foreign Exchange Risk” in Part II, Item 7A of this Annual Report.

We may experience difficulties implementing our new global enterprise resource planning system.

We are engaged in a multi-year implementation of a new global enterprise resource planning system (ERP). The ERP is designed to efficiently maintain our books and records and provide information important to the operation of our business to our management team. The ERP will continue to require significant investment of human and financial resources. In implementing the ERP, we may experience significant delays, increased costs and other difficulties. Any significant disruption or deficiency in the design and implementation of the ERP could adversely affect our ability to process orders, ship product, send invoices and track payments, fulfill contractual obligations or otherwise operate our business. For example, we experienced system implementation issues in our Clinical Diagnostics segment during our first deployment that impacted invoicing and caused an increase in accounts receivable. In our second deployment, which we launched in July 2015, we experienced delays in manufacturing and logistics, which adversely impacted our sales. We may experience similar and other issues with our upcoming third deployment in Western Europe, which we expect to launch in April 2017. We anticipate that the third deployment will be more complex than our prior deployments due to its scope. While we have invested significant resources in planning, project management and training, additional and significant implementation issues may arise. In addition, our efforts to centralize various business processes and functions within our organization in connection with our ERP implementation may disrupt our operations and negatively impact our business, results of operations and financial condition.

Recent and planned changes to our organizational structure and executive management team could negatively impact our business.

We made significant changes to our organizational structure in 2014, 2015 and 2016. In 2014 and 2015, we functionalized our manufacturing and selling organizations globally and separated them from our marketing and research and development organizations. Specifically, we combined our international selling organization with our North American selling divisions into one global selling group and consolidated our manufacturing, procurement and logistics operations into one global supply chain group. We also created new management positions to head each of these groups. In addition, we appointed new executives to head each of our Life Science and Clinical Diagnostics segments, and we appointed a Chief Operating Officer. We also restructured our Life Science segment based on functional groups rather than product line divisions. In 2016, we began implementing the reorganization of the structure of our European organization. These changes may have unintended consequences, such as

9


distraction of our management and employees, business disruption, attrition of our workforce, inability to attract or retain key employees, and reduced employee morale or productivity.

Our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline.

Maintaining effective internal control over financial reporting is necessary for us to produce reliable financial statements. As previously disclosed, in connection with our assessment of the effectiveness of internal control over financial reporting and the preparation of our financial statements for the year ended December 31, 2013, we identified a material weakness in the design of monitoring controls over operations at certain of our locations both within the United States and overseas, as well as a lack of documentation required to operate these controls appropriately. Although we remediated this material weakness as of December 31, 2014, we cannot assure you that additional material weaknesses in our internal control over financial reporting will not be identified in the future. For example, we previously identified different material weaknesses in internal controls at December 31, 2012 and December 31, 2010, both of which have been remediated.

Such material weaknesses have adversely affected us in the past and could affect us in the future, and the results of our periodic management evaluations and annual auditor attestation reports regarding the effectiveness of our internal control over financial reporting required by Section 404 of the Sarbanes-Oxley Act of 2002. Any failure to maintain new and more precise monitoring controls and improved detection and communication of financial misstatements across all levels of the organization could result in additional material weaknesses, result in material misstatements in our financial statements and cause us to fail to meet our reporting obligations. This could cause us to lose public confidence, and could cause the trading price of our common stock to decline. For further information regarding our controls and procedures, see Part II, Item 9A of this Annual Report.

Breaches of our information systems could have material adverse effect on our business and results of operations.

Through our sales and eCommerce channels, we collect and store confidential information that customers provide to, among other things, purchase products or services, enroll in promotional programs and register on our Web site. We also acquire and retain information about suppliers and employees in the normal course of business. We also create and maintain proprietary information that is critical to our business, such as our product designs and manufacturing processes. Despite recent initiatives to improve our technology systems, such as our enterprise resource planning implementation and the centralization of our global information technology organization, we could experience a significant data security breach. Computer hackers may attempt to penetrate our or our vendors’ information systems and, if successful, misappropriate confidential customer, supplier, employee or other business information, such as our intellectual property. Third parties could also gain control of our systems and use them for criminal purposes while appearing to be us. As a result, we could lose existing customers, have difficulty attracting new customers, be exposed to claims from customers, financial institutions, payment card associations, employees and other persons, have regulatory sanctions or penalties imposed, incur additional expenses or lose revenues as a result of a data privacy breach, or suffer other adverse consequences. Our operations and ability to process sales orders, particularly through our eCommerce channels, could also be disrupted. Any significant breakdown, intrusion, interruption, corruption, or destruction of our systems, as well as any data breaches, could have a material adverse effect on our business and results of operations. See also our risk factors regarding our ERP implementation above and our information technology systems below.

Risks relating to intellectual property rights may negatively impact our business.

We rely on a combination of copyright, trade secret, patent and trademark laws and third-party nondisclosure agreements to protect our intellectual property rights and products.  However, we cannot assure you that our intellectual property rights will not be challenged, invalidated, circumvented or rendered unenforceable, or that meaningful protection or adequate remedies will be available to us.  For instance, unauthorized third parties have

10


attempted to copy our intellectual property, reverse engineer or obtain and use information that we regard as proprietary, or have developed equivalent technologies independently, and may do so in the future.  Additionally, third parties have asserted patent, copyright and other intellectual property rights to technologies that are important to us, and may do so in the future. If we are unable to license or otherwise access protected technology used in our products, or if we lose our rights under any existing licenses, we could be prohibited from manufacturing and marketing such products. From time to time, we also must enforce our patents or other intellectual property rights or defend ourselves against claimed infringement of the rights of others through litigation. As a result, we could incur substantial costs, be forced to redesign our products, or be required to pay damages to an infringed party.  Any of the foregoing matters could adversely impact our business, results of operations and financial condition.

Global economic conditions could continue to adversely affect our operations.

In recent years, we have been faced with very challenging global economic conditions. Further deterioration in the global economic environment may result in decreased demand for our products, increased competition, downward pressure on the prices for our products and longer sales cycles. A weakening of macroeconomic conditions may also adversely affect our suppliers, which could result in interruptions in supply in the future. We have also experienced delays in collecting receivables in certain countries in Western Europe, and we may experience similar delays in these and other countries or regions experiencing liquidity problems. As of December 31, 2016, we had accounts receivable, net of allowance for doubtful accounts, in Spain, Italy, Greece and Portugal of $32.7 million. In addition, a slowing of growth in the Chinese economy and in emerging markets, especially those oil-producing countries that have been affected by the decline in oil prices, could adversely affect our business, results of operations or financial condition. We also are monitoring developments following the recent referendum in the United Kingdom to leave the European Union to determine if there will be any potential impact on our business.

Reductions in government funding and the capital spending programs of our customers could have a material adverse effect on our business, results of operations or financial condition.

Our customers include universities, clinical diagnostics laboratories, government agencies, hospitals and pharmaceutical, biotechnology and chemical companies.  The capital spending programs of these institutions and companies have a significant effect on the demand for our products.  Such programs are based on a wide variety of factors, including the resources available to make such purchases, the availability of funding from grants by governments or government agencies, the spending priorities for various types of equipment and the policies regarding capital expenditures during industry downturns or recessionary periods.  If government funding to our customers were to decrease, or if our customers were to decrease or reallocate their budgets in a manner adverse to us, our business, results of operations or financial condition could be materially and adversely affected. For more information on our customers, see "Sales and Marketing" in Part I, Item 1 of this Annual Report.

Changes in the healthcare industry could have an adverse effect on our business, results of operations and financial condition.

There have been, and will continue to be, significant changes in the healthcare industry in an effort to reduce costs. These changes include:

•
The trend towards managed care, together with healthcare reform of the delivery system in the United States and efforts to reform in Europe, has resulted in increased pressure on healthcare providers and other participants in the healthcare industry to reduce selling prices.  Consolidation among healthcare providers has resulted in fewer, more powerful groups, whose purchasing power gives them cost containment leverage.  In particular, there has been a consolidation of blood transfusion centers, as well as an industry decline in the number of blood transfusions. These industry trends and competitive forces place constraints on the levels of overall pricing, and thus could have a material adverse effect on our gross margins for products we sell in clinical diagnostic markets.


11


•
Third party payors, such as Medicare and Medicaid in the United States, have reduced their reimbursements for certain medical products and services. Our Clinical Diagnostics business is impacted by the level of reimbursement available for clinical tests from third party payors. In the United States payment for many diagnostic tests furnished to Medicare fee-for-service beneficiaries is made based on the Medicare Clinical Laboratory Fee Schedule (CLFS), a fee schedule established and adjusted from time to time by the Centers for Medicare and Medicaid Services (CMS). Some commercial payors are guided by the CLFS in establishing their reimbursement rates. Clinicians may decide not to order clinical diagnostic tests if third party payments are inadequate, and we cannot predict whether third party payors will offer adequate reimbursement for tests utilizing our products to make them commercially attractive. Legislation, such as the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (PPACA) and the Middle Class Tax Relief and Job Creation Act of 2012, has reduced the payments for clinical laboratory services paid under the CLFS. In addition, the Protecting Access to Medicare Act of 2014 will make significant changes to the way Medicare will pay for clinical laboratory services, which will further reduce reimbursement rates.

•
The PPACA has also imposed a 2.3% excise tax on the sales of certain medical devices in the U.S., which we are required to pay on most of our United States Clinical Diagnostic sales. However, the Consolidated Appropriations Act, 2016 (Pub. L. 114-113), signed into law on December 18, 2015, includes a two year moratorium on the medical device excise tax during the period beginning on January 1, 2016, and ending on December 31, 2017.

To the extent that the healthcare industry seeks to address the need to contain costs stemming from reform measures such as those contained in the PPACA and the Protecting Access to Medicare Act of 2014, or in future legislation, by limiting the number of clinical tests being performed or the amount of reimbursement available for such tests, our business, results of operations and financial condition could be adversely affected.  If these changes in the healthcare markets in the United States and Europe continue, we could be forced to alter our approach in selling, marketing, distributing and servicing our products.

We are subject to substantial government regulation, and any changes in regulation or violations of regulations by us could adversely affect our business, prospects, results of operations or financial condition.

Some of our products (primarily our Clinical Diagnostic products), production processes and marketing are subject to U.S. federal, state and local, and foreign regulation, including by the FDA in the United States and its foreign counterparts.  The FDA regulates our Clinical Diagnostic products as medical devices, and we are subject to significant regulatory clearances or approvals to market our Clinical Diagnostic products and other requirements including, for example, recordkeeping and reporting requirements, such as the FDA’s medical device reporting regulations and reporting of corrections and removals. The FDA has broad regulatory and enforcement powers. If the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions ranging from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals, seizure or recall of our products, total or partial shutdown of production, withdrawal of approvals or clearances already granted, and criminal prosecution.

The FDA can also require us to repair, replace or refund the cost of devices that we manufactured or distributed.
In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our products or impact our ability to modify our currently approved or cleared products on a timely basis. Changes in the FDA’s review of certain clinical diagnostic products referred to as laboratory developed tests, which are tests developed by a single laboratory for use only in that laboratory, could affect some of our customers who use our Life Science instruments for laboratory developed tests. In the past, the FDA has chosen to not enforce applicable regulations and has not reviewed such tests for approval. However, the FDA has issued draft guidance that it may begin enforcing its medical device requirements, including premarket submission requirements, to such tests. Any delay in, or failure to receive or maintain, clearance or approval for our products could prevent us from generating revenue from these products and adversely affect our business operations and financial results. Additionally, the FDA and other regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased

12


scrutiny on us, could affect the perceived safety and efficacy of our products and dissuade our customers from using our products.

Many foreign governments have similar rules and regulations regarding the importation, registration, labeling, sale and use of our products. Such agencies may also impose new requirements that may require us to modify or re-register products already on the market or otherwise impact our ability to market our products in those countries. For example, Europe published draft regulations in June 2016 that include broad changes to its regulations regarding in vitro diagnostic devices and medical devices, including stricter product labeling requirements, Russia has recently enacted more stringent medical product registration and labeling regulations, China has enacted stricter labeling requirements, and we expect other countries, such as Brazil and India, to impose more regulations that impact our product registrations. Due to these evolving and diverse requirements, we face uncertain product approval timelines, additional time and effort to comply, reduced sales and potential fines for noncompliance. Increasing protectionism in such countries also impedes our ability to compete with local companies. For example, we may not be able to participate in certain public tenders in Russia because of increasing measures to restrict access to such tenders for companies without local manufacturing capabilities. Specifically, a resolution passed by Russia in February 2015 prohibited the procurement of certain types of medical devices by Russian state entities from foreign companies provided there are a sufficient number of Russian manufacturers submitting tenders. In December 2016, Russia continued its focus on import substitution by passing a resolution that added to the list of certain medical devices which participate in state procurement on a restricted basis. Such regulations could adversely affect our business, results of operations and financial condition.

We are also subject to government regulation of the use and handling of a number of materials and controlled substances.  The U.S. Drug Enforcement Administration establishes registration, security, recordkeeping, reporting, storage, distribution and other requirements for controlled substances pursuant to the Controlled Substances Act of 1970. Failure to comply with present or future laws and regulations could result in substantial liability to us, suspension or cessation of our operations, restrictions on our ability to expand at our present locations or require us to make significant capital expenditures or incur other significant expenses.

We cannot assure you that we will be able to integrate acquired companies, products or technologies into our company successfully, or we may not be able to realize the anticipated benefits from the acquisitions.

As part of our overall business strategy, we pursue acquisitions of and investments in complementary companies, products and technologies. In order to be successful in these activities, we must, among other things:
•
assimilate the operations and personnel of acquired companies;
•
retain acquired business customers;
•
minimize potential disruption to our ongoing business;
•
retain key technical and management personnel;
•
integrate acquired companies into our strategic and financial plans;
•
accurately assess the value of target companies, products and technologies;
•
comply with new regulatory requirements;
•
harmonize standards, controls, procedures and policies;
•
minimize the impact to our relationships with our employees and customers; and
•
assess, document and remediate any deficiencies in disclosure controls and procedures and internal control over financial reporting.

The benefits of any acquisition may prove to be less than anticipated and may not outweigh the costs reported in our financial statements.  Completing any potential future acquisitions could cause significant diversion of our management’s time and resources.  If we acquire new companies, products or technologies, we may be required to assume contingent liabilities or record impairment charges for goodwill and other intangible assets over time. We cannot assure you that we will successfully overcome these risks or any other problems we encounter in connection with any acquisitions, and any such acquisitions could adversely affect our business, results of operations and financial condition.


13


Product quality and liability issues could harm our reputation and negatively impact our business, results of operations and financial condition.

We must adequately address quality issues associated with our products, including defects in our engineering, design and manufacturing processes, as well as defects in third-party components included in our products. Our instruments, reagents and consumables are complex, and identifying the root cause of quality issues, especially those affecting reagents or third-party components, is difficult. We may incur significant costs and expend substantial time in researching and remediating such issues. Quality issues could also delay our launching or manufacturing of new products. In addition, quality issues, unapproved uses of our products, or inadequate disclosure of risks related to our products, could result in product recalls or product liability or other claims being brought against us. These issues could harm our reputation, impair our relationship with existing customers and harm our ability to attract new customers, which could negatively impact our business, results of operations and financial condition.

Lack of key personnel could hurt our business.

Our products are very technical in nature. In general, only highly qualified and well-trained scientists have the necessary skills to develop, market and sell our products, and many of our manufacturing positions require very specialized knowledge and skills.  In addition, the global nature of our business also requires that we have sophisticated and experienced staff to comply with increasingly complex international laws and regulations. We face intense competition for these professionals from our competitors, customers, marketing partners and other companies throughout our industry. In particular, the job market in Northern California, where many of our employees are located, is very competitive. If we do not offer competitive compensation and benefits, we may fail to retain or attract a sufficient number of qualified personnel, which could impair our ability to properly run our business.

In some cases we rely on temporary personnel or consultants, and we may do so in the future. Such temporary personnel or consultants may lack the knowledge and/or specific skills necessary for our business, require time to train without benefiting us through extended employment and increase our costs. In addition, as noted above, our strategic initiatives, such as our internal restructuring and ERP implementation, may be burdensome and disruptive and lead to employee dissatisfaction and attrition.

A reduction or interruption in the supply of components and raw materials could adversely affect our manufacturing operations and related product sales.

The manufacture of many of our products requires the timely delivery of sufficient amounts of quality components and materials. We manufacture our products in numerous manufacturing facilities around the world. We acquire our components and materials from many suppliers in various countries. We work closely with our suppliers to ensure the continuity of supply but we cannot guarantee these efforts will always be successful. Further, while we seek to diversify our sources of components and materials, in certain instances we acquire components and materials from a sole supplier. In addition, due to the regulatory environment in which we operate, we may be unable to quickly establish additional or replacement sources for some components or materials. If our supply is reduced or interrupted or of poor quality, and we are unable to develop alternative sources for such supply, our ability to manufacture our products in a timely or cost-effective manner could be adversely affected, which would adversely affect our ability to sell our products.

If our information technology systems are disrupted, or if we fail to successfully implement, manage and integrate our information technology and reporting systems, our business, results of operations and financial condition could be harmed.

Our information technology (IT) systems are an integral part of our business, and a serious disruption of our IT systems could have a material adverse effect on our business, results of operations and financial condition. We depend on our IT systems to process orders, manage inventory and collect accounts receivable.  Our IT systems also allow us to efficiently purchase products from our suppliers and ship products to our customers on a timely basis,

14


maintain cost-effective operations and provide customer service.  We may experience disruption of our IT systems due to redundancy issues with our network servers. We cannot assure you that our contingency plans will allow us to operate at our current level of efficiency.

Our ability to implement our business plan in a rapidly evolving market requires effective planning, reporting and analytical processes.  We expect that we will need to continue to improve and further integrate our IT systems, reporting systems and operating procedures by training and educating our employees with respect to these improvements and integrations on an ongoing basis in order to effectively run our business.  We may suffer interruptions in service, loss of data or reduced functionality when we upgrade or change systems. If we fail to successfully manage and integrate our IT systems, reporting systems and operating procedures, it could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our ERP implementation and data security above and events beyond our control below.

Natural disasters, terrorist attacks, acts of war or other events beyond our control may cause damage or disruption to us and our employees, facilities, information systems, security systems, vendors and customers, which could significantly impact our business, results of operations and financial condition.

We have significant manufacturing and distribution facilities, including in the western United States, France, Switzerland, Germany and Singapore.  In particular, the western United States has experienced a number of earthquakes, wildfires, floods, landslides and other natural disasters in recent years.  These occurrences could damage or destroy our facilities which may result in interruptions to our business and losses that exceed our insurance coverage. In addition, strikes or other labor unrest at any of our sites or surrounding areas could cause disruption to our business.

Acts of terrorism, bioterrorism, violence or war could also affect the markets in which we operate, our business operations and strategic plans. Political unrest may affect our sales in certain regions, such as in Southeast Asia, the Middle East and Eastern Europe. In particular, the political turmoil in Ukraine, along with the response of the Russian and U.S. governments to this situation, has the potential to impact our operations in Russia. Any of these events could adversely affect our business, results of operations and financial condition.

Environmental, health and safety regulations and enforcement proceedings may negatively impact our business, results of operations and financial condition.

Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissions to air and discharges to water, as well as handling and disposal practices for solid, hazardous and medical wastes.  In addition to environmental laws that regulate our operations, we are also subject to environmental laws and regulations that create liability and clean-up responsibility for spills, disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise impacting real property that we own or operate.  The environmental laws and regulations also subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of our properties. We must also comply with various health and safety regulations in the United States and abroad in connection with our operations.

We may in the future incur capital and operating costs to comply with currently existing laws and regulations, and possible new statutory enactments, and these expenditures may be significant.  We have incurred, and may in the future incur, fines related to environmental matters and/or liability for costs or damages related to spills or other releases of hazardous substances into the environment at sites where we have operated, or at off-site locations where we have sent hazardous substances for disposal.  We cannot assure you, however, that such matters or any future obligations to comply with environmental or health and safety laws and regulations will not adversely affect our business, results of operations or financial condition.


15


We may be subject to additional tax liabilities.

We are subject to income taxes in the United States and many foreign jurisdictions. We calculate our provision for income taxes in each jurisdiction in which we operate. Significant judgment is required in determining our worldwide provision for income taxes and in the ordinary course of business, there are many tax positions taken where the ultimate resolution is uncertain. We are subject to the examination of our tax positions in the United States and foreign jurisdictions. Taxing authorities have disagreed with our judgment in the past and may disagree with positions we take in the future resulting in assessments of additional taxes. Economic and political pressures to increase tax revenues in various jurisdictions may make resolving tax disputes more difficult. For example, in recent years, the tax authorities in Europe have disagreed with our tax positions related to hybrid debt, research and development credits, transfer pricing and indirect taxes, among others. We regularly assess the likelihood of the outcome resulting from these examinations to determine the adequacy of our provision for income taxes. Although we believe our tax estimates are reasonable, the final determination of tax audits and any related litigation could be materially different from our historical income tax provisions and accruals. The results of an audit or litigation could have a material effect on our consolidated financial statements in the period or periods for which that determination is made. Changes in factors outside of our control, such as changes in tax laws or rates, changes in the interpretation of tax laws or changes in the jurisdictional mix of our earnings could adversely affect our financial position and results of operations.

Our debt may restrict our future operations.

We have substantial debt and have the ability to incur additional debt. As of December 31, 2016, we had approximately $434.5 million of outstanding indebtedness. In addition, we have a revolving credit facility that provides for up to $200.0 million, $0.8 million of which has been utilized for domestic standby letters of credit. Our incurrence of substantial amounts of debt may have important consequences.  For instance, it could:

•
make it more difficult for us to satisfy our financial obligations, including those relating to our outstanding debt;
•
require us to dedicate a substantial portion of our cash flow from operations to the payment of interest and principal due under our debt, which will reduce funds available for other business purposes;
•
increase our vulnerability to general adverse economic and industry conditions;
•
limit our flexibility in planning for, or reacting to, changes in our business and the industries in which we operate;
•
place us at a competitive disadvantage compared with some of our competitors that have less debt; and
•
limit our ability to obtain additional financing required to fund working capital and capital expenditures and for other general corporate purposes.

Our existing credit facility and the terms of our other debt instruments, including agreements we may enter in the future, contain or will contain covenants imposing significant restrictions on our business.  These restrictions may affect our ability to operate our business and may limit our ability to take advantage of potential business opportunities as they arise.  These covenants place restrictions on our ability to, among other things: incur additional debt; acquire other businesses or assets through merger or purchase; create liens; make investments; enter into transactions with affiliates; sell assets; in the case of some of our subsidiaries, guarantee debt; and declare or pay dividends, redeem stock or make other distributions to stockholders. Our existing credit facility also requires that we comply with certain financial ratios, including a maximum consolidated leverage ratio test and a minimum consolidated interest coverage ratio test.

Our ability to comply with these covenants may be affected by events beyond our control, including prevailing economic, financial and industry conditions.  The breach of any of these restrictions could result in a default.  An event of default under our debt agreements would permit some of our lenders to declare all amounts borrowed from them to be due and payable, together with accrued and unpaid interest. In addition, acceleration of our other indebtedness may cause us to be unable to make interest payments on our outstanding notes and repay the principal

16


amount of our outstanding notes or may cause the future subsidiary guarantors, if any, to be unable to make payments under the guarantees.

We are subject to healthcare fraud and abuse laws and regulations and could face substantial penalties if we are unable to fully comply with such laws.

We are subject to healthcare fraud and abuse regulation and enforcement by both the U.S. federal government and the U.S. states and foreign governments in which we conduct our business. These healthcare laws and regulations include, for example:

•
the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from soliciting, receiving, offering or providing remuneration, directly or indirectly, in return for or to induce either the referral of an individual for, or the purchase order or recommendation of, any item or services for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs;

•
U.S. federal false claims laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent. In addition, the U.S. federal government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes;

•
the U.S. Physician Payment Sunshine Act, which requires certain manufacturers of drugs, biologics, devices and medical supplies to record any transfers of value to U.S. physicians and U.S. teaching hospitals;

•
the Health Insurance Portability and Accountability Act ("HIPAA"), as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and

•
state or foreign law equivalents of each of the U.S. federal laws above, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers.

These laws will continue to impose administrative, cost and compliance burdens on us. The shifting compliance environment and the need to build and maintain robust systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may violate one or more of these requirements. In addition, any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business, results of operations and financial condition.


17



We may incur losses in future periods due to write-downs in the value of financial instruments.
We have positions in a variety of financial instruments including asset backed securities and other similar instruments. Financial markets are quite volatile and the markets for these securities can be illiquid.  The value of these securities will continue to be impacted by external market factors including default rates, changes in the value of the underlying property, such as residential or commercial real estate, rating agency actions, the prices at which observable market transactions occur and the financial strength of various entities, such as financial guarantors who provide insurance for the securities. Should we need to convert these positions to cash, we may not be able to sell these instruments without significant losses due to current debtor financial conditions or other market considerations.

Regulations related to “conflict minerals” could adversely impact our business.
As part of the Dodd-Frank Wall Street Reform and Consumer Protection Act, the SEC adopted disclosure requirements regarding the use of certain minerals, known as conflict minerals, which are mined from the Democratic Republic of Congo (DRC) and adjoining countries, as well as procedures regarding a manufacturer's efforts to identify the sourcing of such minerals and metals produced from those minerals. In November 2016, the EU institutions agreed on the text of a conflict minerals regulation. After formal approval by the European Parliament and European Council, the regulation will be published and enter into force 20 days later. We have incurred, and will continue to incur, additional costs in order to comply with the SEC’s disclosure requirements. In addition, we might incur further costs due to possible changes to our products, processes, or sources of supply as a consequence of our due diligence activities. As our supply chain is complex, we may not be able to sufficiently verify the origins of the specified minerals used in our products through our due diligence procedures, which may harm our reputation. In addition, we may encounter challenges to satisfy those customers who require that all of the components of our products be certified as “DRC conflict free”, which could place us at a competitive disadvantage if we do not do so. We filed our report for the calendar year 2015 with the SEC on May 27, 2016.

Risks related to our common stock
 
A significant majority of our voting stock is held by the Schwartz family, which could lead to conflicts of interest.
We have two classes of voting stock: Class A Common Stock and Class B Common Stock. With a few exceptions, holders of Class A and Class B Common Stock vote as a single class.  When voting as a single class, each share of Class A Common Stock is entitled to one-tenth of a vote, while each share of Class B Common Stock has one vote. In the election or removal of directors, the classes vote separately and the holders of Class A Common Stock are entitled to elect 25% of the Board of Directors, with holders of Class B Common Stock electing the remaining directors.

As a result of the Schwartz family's ownership of our Class A and Class B Common Stock, they are able to elect a majority of our directors, effect fundamental changes in our direction and control matters affecting us, including the determination of business opportunities that may be suitable for our company.  The Schwartz family may exercise its control over us according to interests that are different from other investors’ or debtors’ interests. In particular, this concentration of ownership and voting power may have the effect of delaying or preventing a change in control of our company.


ITEM 1B.  UNRESOLVED STAFF COMMENTS
None.

18



 
ITEM 2.  PROPERTIES

We own our corporate headquarters located in Hercules, California.  The principal manufacturing and research locations for each segment are as follows:

 
 
 
Segment
Location
Owned/Leased
 
 
 
Life Science
Greater San Francisco Bay Area, California
Owned/Leased
 
Greater Boston Area, Massachusetts
Leased
 
Singapore, Singapore
Leased
 
Oxford, England
Leased
 
 
 
Clinical
 
 
Diagnostics
Greater San Francisco Bay Area, California

Owned/Leased
 
Irvine, California
Leased
 
Greater Seattle Area, Washington
Leased
 
Greater Boston Area, Massachusetts
Leased
 
Lille, France
Owned
 
Greater Paris Area, France
Leased
 
Nazareth-Eke, Belgium
Leased
 
Cressier, Switzerland
Owned/Leased
 
Dreieich, Germany
Owned/Leased

Most manufacturing and research facilities also house administration, sales and distribution activities.  In addition, we lease office and warehouse facilities in a variety of locations around the world.  The facilities are used principally for sales, service, distribution and administration for both segments.
 
ITEM 3.  LEGAL PROCEEDINGS  

On January 23, 2015, the City of Riviera Beach General Employees’ Retirement System filed a shareholder derivative lawsuit in the Superior Court of California, Contra Costa County, against three of our current directors and one former director. We are also named as a nominal defendant. In the complaint, the plaintiff alleges that our directors breached their fiduciary duty of loyalty by failing to ensure that we had sufficient internal controls and systems for compliance with the Foreign Corrupt Practices Act ("FCPA"); that we failed to provide adequate training on the FCPA; and that based on these actions, the directors have been unjustly enriched. Purportedly seeking relief on our behalf, the plaintiff seeks an award of restitution and unspecified damages, costs and expenses (including attorneys’ fees). On April 23, 2015, we and the individual defendants filed a demurrer requesting dismissal of the complaint in this case. The demurrer was heard on August 6, 2015, and the Court granted the demurrer for failure to make a demand on our Board of Directors on August 17, 2015, but provided leave to amend. On September 4, 2015, the plaintiff filed an amended complaint and simultaneously served a litigation demand letter on our Board of Directors ("Board") via its counsel in this action. The letter demanded that we investigate and bring appropriate legal action against certain individuals, including the defendants in the City of Riviera Beach case and six current and former employees. The plaintiff also moved for a temporary stay in the proceedings, purportedly to enable the Board to respond to the demand. The Board formed a Demand Review Committee to respond to the demand. On February 24, 2016, the Demand Review Committee reported to the Board that it had

19


concluded its investigation and unanimously determined that it is not in the best interests of the Company and its stockholders to pursue litigation against any individuals named in the City of Riviera Beach’s litigation demand letter. On October 6, 2015, we and the individual defendants filed a second demurrer, seeking to dismiss the case for failure to make a timely pre-suit demand. The case was stayed pending mediation. The caption is City of Riviera Beach General Employees’ Retirement System v. Schwartz et al., Case No. C-15-00140. The lawsuit and demand letter are referred to collectively as the “California Action”.

On August 13, 2015 and August 18, 2015, respectively, each of International Brotherhood of Electrical Workers Local 38 Pension Fund and Wayne County Employees’ Retirement System filed a stockholder derivative complaint in the Delaware Court of Chancery against four of our current directors and one former director. We are named as a nominal defendant in the complaints. The complaints allege that the defendants failed to cause us to develop internal controls sufficient to ensure our compliance with the FCPA. The plaintiffs assert claims for breach of fiduciary duty and unjust enrichment and request an award of the damages we sustained as a result of the alleged violations, among other relief. The two lawsuits were consolidated on August 27, 2015.  The case was stayed pending mediation. The caption of the consolidated case is In re Bio-Rad Laboratories, Inc. Stockholder Litigation, Consol. C.A. No. 11387-VCN (Del. Ch.). The cases filed in the Delaware Court of Chancery, together with the California Action, are referred to collectively as the “Derivative Actions”.

The parties filed a Stipulation dated November 4, 2016 with the Superior Court of California for Contra Costa County that sets forth the terms of a proposed settlement of the Derivative Actions. The proposed settlement includes the dismissal with prejudice of all claims asserted in the Derivative Actions, an agreed-upon set of revised corporate procedures, and no monetary payment other than an award of attorneys’ fees and costs to the plaintiffs’ counsel. We and the other defendants do not admit any liability or fault in connection with the proposed settlement. On December 22, 2016 the Superior Court of California for Contra Costa County issued an order granting preliminary approval of this proposed settlement. Pursuant to the order, the Court will hold a hearing for final approval of the settlement on March 2, 2017, and any objections to the settlement were required to be filed in writing with the Court on or before February 15, 2017.

On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The parties engaged in mediation of the case on April 19, 2016 and on September 14, 2016. The mediations did not result in a settlement. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million, plus prejudgment interest of $141,608, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. We are considering an appeal of the judgment.

Bio-Rad received three notices of violations from the Bay Area Air Quality Management District (“District”). The District alleges that we operated three (3) power generation units without appropriate monitoring and recordkeeping and exceeded permissible levels of emissions during those operations. We are cooperating with the District and are investigating the allegations. No formal proceeding has been initiated by the District.
 

20


 
We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.

 
ITEM 4.  MINE SAFETY DISCLOSURES  

Not applicable.

PART II.


ITEM 5.   MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER
MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Information Concerning Common Stock

Bio-Rad’s Class A and Class B Common Stock are listed on the New York Stock Exchange with the symbols BIO and BIO.B, respectively.  The following sets forth, for the periods indicated, the high and low intraday sales prices for our Class A and Class B Common Stock.

 
 
Class A
 
Class B
 
 
High
 
Low
 
High
 
Low
2016
 
 
 
 
 
 
 
 
Fourth Quarter
 
$
184.89


$
154.89


$
194.15


$
154.05

Third Quarter
 
164.45


140.53


171.12


140.69

Second Quarter
 
150.00


135.02


150.04


134.86

First Quarter
 
139.63


122.03


146.41


123.43

2015
 
 
 
 
 
 
 
 
Fourth Quarter
 
$
142.48


$
132.49


$
141.77


$
134.08

Third Quarter
 
152.38


131.25


152.57


131.83

Second Quarter
 
151.97


133.38


151.93


123.31

First Quarter
 
137.23


112.51


137.23


113.32


On February 14, 2017, we had 275 holders of record of Class A Common Stock and 126 holders of record of Class B Common Stock.  Bio-Rad has never paid a cash dividend and has no present plans to pay cash dividends.

See Item 12 of Part III of this report for the security ownership of certain beneficial owners and management and for securities authorized for issuance under equity compensation plans.

21



Stock Performance Graph

The following graph compares the cumulative stockholder returns over the past five years for our Class A Common Stock, the S&P 400 MidCap Index and a selected peer group, assuming $100 invested on December 31, 2011, and reinvestment of dividends if paid:             
    
    a10k123115_chart-30568a01.jpg        
(1)  The Peer Group consists of the following public companies: Danaher, Becton Dickinson, Thermo Fisher Scientific, Meridian Bioscience and PerkinElmer. Companies in our peer group reflect our participation in two different markets: life science research products and clinical diagnostics. No single public or private company has a comparable mix of products which serve the same markets. In many cases, only one division of a peer-group company competes in the same market as we do. Collectively, however, our peer group reflects products and markets similar to those of Bio-Rad.

This stock performance graph shall not be deemed incorporated by reference by any general statement incorporating by reference into any filing under the Securities Act or the Exchange Act, and shall not otherwise be deemed filed under these Acts.


22



ITEM 6.  SELECTED FINANCIAL DATA

BIO-RAD LABORATORIES, INC.
 
 
 
 
 
 
Selected Financial Data
 
 
 
 
 
 
(in thousands, except per share data)
 
 
 
 
 
 
 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
 
2013
 
2012
 
 
 
 
 
 
 
 
 
 
 
Net sales
 
$
2,068,172

 
$
2,019,441

 
$
2,175,044

 
$
2,132,694

 
$
2,069,235

Cost of goods sold
 
930,085

 
897,771

 
996,527

 
954,216

 
914,077

Gross profit
 
1,138,087

 
1,121,670

 
1,178,517

 
1,178,478

 
1,155,158

Selling, general and administrative expense
 
816,724

 
761,990

 
808,200

 
798,070

 
681,778

Research and development expense
 
205,864

 
192,972

 
220,333

 
210,952

 
209,204

Impairment losses on goodwill and long-lived assets
 
62,305

 
—

 
—

 
—

 
—

Interest expense
 
21,942

 
21,692

 
22,131

 
61,271

 
51,112

Foreign exchange losses, net
 
4,542

 
10,249

 
9,305

 
8,566

 
5,040

Other (income) expense, net
 
(14,850
)
 
(11,080
)
 
(13,009
)
 
(12,766
)
 
(21,883
)
Income before income taxes
 
41,560

 
145,847

 
131,557

 
112,385

 
229,907

Provision for income taxes
 
(13,435
)
 
(32,754
)
 
(42,712
)
 
(34,574
)
 
(64,361
)
Net income attributable to noncontrolling interests
 
—

 
—

 
—

 
(21
)
 
(69
)
Net income attributable to Bio-Rad
 
$
28,125

 
$
113,093

 
$
88,845

 
$
77,790

 
$
165,477

 
 
 
 
 
 
 
 
 
 
 
Basic earnings per share
 
$
0.96

 
$
3.87

 
$
3.08

 
$
2.72

 
$
5.85

Diluted earnings per share
 
$
0.95

 
$
3.85

 
$
3.05

 
$
2.69

 
$
5.78

Cash dividends paid per common share
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

Total assets
 
$
3,850,504

 
$
3,709,718

 
$
3,341,278

 
$
3,388,790

 
$
3,443,503

Long-term debt, net of current maturities
 
$
434,186

 
$
433,883

 
$
435,710

 
$
435,615

 
$
732,414



ITEM 7.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This discussion should be read in conjunction with the information contained in our consolidated financial statements and the accompanying notes which are an integral part of the statements.

Overview.  We are a multinational manufacturer and worldwide distributor of our own life science research and clinical diagnostics products.  Our business is organized into two primary segments, Life Science and Clinical Diagnostics, with the mission to provide scientists with specialized products needed for biological research and clinical diagnostics.  

We sell more than 8,000 products and services to a diverse client base comprised of scientific research, healthcare, education and government customers worldwide. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

We manufacture and supply our customers with a range of reagents, apparatus and equipment to separate complex chemical and biological materials and to identify, analyze and purify components.  Because our customers require standardization for their experiments and test results, much of our revenues are recurring.  

We are impacted by the support of many governments for both research and healthcare. The current global economic outlook is still uncertain as the need to control government social spending by many governments limits

23


opportunities for growth. Adding to this uncertainty was the recent referendum in the United Kingdom to withdraw from the European Union, and a change in the U.S. executive branch of government. Approximately 37% of our 2016 consolidated net sales are derived from the United States and approximately 63% are derived from international locations, with Europe being our largest international region.  The international sales are largely denominated in local currencies such as the Euro, Swiss Franc, Japanese Yen, Chinese Yuan and British Sterling.  As a result, our consolidated net sales expressed in dollars benefit when the U.S. dollar weakens and suffer when the dollar strengthens.  When the U.S. dollar strengthens, we benefit from lower cost of sales from our own international manufacturing sites as well as non-U.S. suppliers, and from lower international operating expenses. We regularly discuss our changes in revenue and expense categories in terms of both changing foreign exchange rates and in terms of a currency neutral basis, if notable, to explain the impact currency has on our results.

On February 15, 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately $87 million including certain assumed net liabilities. Cash payments at closing were $82.9 million. The acquisition will be included in our Life Science segment’s results of operations from the acquisition date and will be accounted for as a business combination. RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. We believe that RainDance's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital™ PCR, offering customers with solutions for a wide range of nucleic acid detection applications. See Note 17 to the consolidated financial statements.

During the fourth quarter of 2016, we fully impaired goodwill and in-process research and development in the amounts of $13.5 million and $46.4 million, respectively, associated with our 2014 acquisition of GnuBIO, Inc.

In May 2016, we announced the elimination or relocation of various positions as part of restructuring plans approved by management. In connection with this announcement, for the year ended December 31, 2016, we recorded $12.5 million in restructuring charges related to severance and other employee benefits, of which $9.0 million is anticipated to be paid through 2019. These restructuring actions are primarily intended to reduce, eliminate or relocate our global workforce in order to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions are aligned with the creation and evolution of our organization structure and coordinated with the implementation of our single instance ERP platform. In the future, we may take additional restructuring actions to gain operating efficiencies or reduce our operating expenses, while simultaneously implementing additional cost containment measures and expense control programs. Such restructuring actions are subject to significant risks, including delays in implementing expense control programs or workforce reductions and the failure to meet operational targets due to the loss of employees or a decrease in employee morale, any of which would impair our ability to achieve anticipated cost reductions. If we do not achieve the anticipated cost reductions, our business could be harmed. See Note 15 to the consolidated financial statements.

In January 2016, we acquired a high performance analytical flow cytometer platform from Propel Labs (Propel) that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. This asset acquisition was accounted for as a business combination and is included in our Life Science segment's results of operations from the acquisition date. The fair values of the net assets acquired from Propel as of the acquisition date were determined to be $32.7 million of definite-lived intangible assets and $0.1 million of goodwill, after the effects of a calculation revision that were reflected in the fourth quarter of 2016. This revision reduced goodwill/intangibles and contingent consideration by the same amount and had no significant impact on our Consolidated Income Statement.

The fair value of the consideration as of the acquisition date was $32.8 million as revised, which included $9.5 million paid in cash at the closing date and $23.3 million in contingent consideration potentially payable to Propel. The contingent consideration was based on a probability-weighted income approach related to the achievement of

24


sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount through December 31, 2020. The contingent consideration was recognized at its estimated fair value of $25.4 million as of December 31, 2016.

As previously disclosed, in May 2010 we voluntarily disclosed to the U.S. Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) certain likely or potential violations of the U.S. Foreign Corrupt Practices Act (FCPA). Effective November 3, 2014, we entered into a non-prosecution agreement (NPA) with the DOJ and consented to the entry of an Order by the SEC (SEC Order), which actions resolve both the DOJ and SEC investigations. As a result of the settlements with the DOJ and the SEC, during the fourth quarter of 2014 we paid a total of $55.1 million that included a penalty of $14.4 million, $35.1 million in disgorgement, and $5.6 million in interest. On October 28, 2016, the DOJ and SEC informed Bio-Rad that they did not intend to extend the NPA after it expired on November 2, 2016.


Critical Accounting Policies and Estimates

The accompanying discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (GAAP).  The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and contingencies as of the date of the financial statements and reported amounts of revenues and expenses during the reporting periods.  We evaluate our estimates on an on-going basis.  We base our estimates on historical experience and on other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. However, future events may cause us to change our assumptions and estimates, which may require adjustment. Actual results could differ from these estimates. We have determined that for the periods reported in this Annual Report on Form 10-K the following accounting policies and estimates are critical in understanding our financial condition and results of operations.

Accounting for Income Taxes.  Management is required to make estimates related to our income tax provision in each of the jurisdictions in which we operate.  This process involves estimating our current tax exposures, as well as making judgments regarding the recoverability of deferred tax assets in each jurisdiction. Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Management assesses the likelihood that the deferred tax assets will be recovered from future taxable income and to the extent management believes that recovery is not likely, a valuation allowance must be established.  To the extent management establishes a valuation allowance or increases this allowance in a period, an increase to expense within the Provision for income taxes in the Consolidated Statements of Income may result.

We have recorded a valuation allowance of $66.4 million and $58.3 million as of December 31, 2016 and 2015, respectively, due to uncertainties related to our ability to utilize some of the deferred tax assets, primarily consisting of certain foreign net operating losses carried forward.  The valuation allowance is based on management’s current estimates of taxable income for the jurisdictions in which we operate and the period over which the deferred tax assets will be recoverable.  In the event that actual results differ from these estimates, or these estimates are adjusted in future periods, an additional valuation allowance may need to be established, which would increase the tax provision, lowering income and impacting our financial position.  Should realization of these deferred tax assets for which a valuation allowance has been provided occur, the provision for income taxes may decrease, raising income and positively impacting Bio-Rad’s financial position.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax

25


law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in income tax expense. Our overall effective tax rate is subject to fluctuations because of changes in the geographic mix of earnings, changes to statutory tax rates and tax laws, and because of the impact of various tax audits and assessments, as well as generation of tax credits.

Valuation of Goodwill and Long-lived Assets.  Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses. Goodwill amounts are assigned to reporting units at the time of acquisition and are adjusted for any subsequent significant transfers of business between reporting units. We assess the impairment of goodwill annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. We perform the impairment tests of goodwill at our reporting unit level, which is one level below our operating segments. The goodwill impairment test consists of a two-step process. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit to its carrying value, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required. The second step, if required, compares the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit. If the carrying amount of the reporting unit's goodwill exceeds its implied fair value, an impairment charge is recognized in an amount equal to that excess.

We use a projected discounted cash flow model to determine the fair value of a reporting unit. This discounted cash flow method for determining goodwill may be different from the fair value that would result from an actual transaction between a willing buyer and a willing seller. Projections such as discounted cash flow models are inherently uncertain and accordingly, actual future cash flows may differ materially from projected cash flows. Management judgment is required in developing the assumptions for the discounted cash flow model. These assumptions include revenue growth rates, profit margins, future capital expenditures, working capital needs, expected foreign currency rates, discount rates and terminal values. We estimate future cash flows using current and longer-term financial forecasts. These forecasts take into account the current economic environment. The discount rates used are compiled using independent sources, current trends in similar businesses and other observable market data. Changes to these rates might result in material changes in the valuation and determination of the recoverability of goodwill. For example, an increase in the discount rate used to discount cash flows will decrease the computed fair value.

Impairment tests are highly sensitive to changes in assumptions and minor changes to assumptions that could result in impairment losses. Our forecasts utilized in our 2016 impairment test assumed, among other things, sales growth from executing our sales and marketing programs, new product introductions, successful product development and timely registration of our products when required, while controlling costs. In addition, external factors, such as currency, inflation rates and cost of capital, could affect the determination of fair value of our reporting units. Aside from our GnuBIO, Inc. reporting unit, which reflected a carrying value that exceeded its fair value, our impairment tests resulted in excessive fair value over book value ranging from 22% to more than 400% for our various reporting units. If the initiatives mentioned above do not achieve the desired results, or external factors change detrimentally, future impairment losses may occur.

To validate the reasonableness of the reporting unit fair values, we reconcile the aggregate fair values of the reporting units to the enterprise market capitalization. In performing the reconciliation we may, depending on the volatility of the market value of our stock price, use either the stock price on the valuation date or the average stock price over a range of dates around the valuation date.

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. We assess the impairment of long-lived assets (including identifiable

26


intangibles) whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors that we consider important that could trigger an impairment review include:

•
significant reporting unit under-performance relative to expected, historical or projected future operating results;
•
significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;
•
a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of before the end of its previously estimated useful life; and
•
significant negative industry, legal, regulatory or economic trends.

When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method. Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets. We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If this is the case, an impairment loss would be recognized. The impairment loss recognized is the amount by which the carrying amount exceeds the fair value. In 2016, we fully impaired goodwill and in-process research and development in the amounts of $13.5 million and $46.4 million, respectively, associated with our 2014 acquisition of GnuBIO, Inc. The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows. Also in 2016, we impaired intellectual property in the amount of $2.4 million associated with the termination of a research and development project. There were no impairment losses recorded in 2015. In 2014, we impaired licenses of a discontinued product line in the amount of $6.4 million. This impairment charge included $5.8 million in Cost of goods sold and $0.6 million in Research and development expense in the accompanying Consolidated Statements of Income.

We early adopted ASU 2017-04, "Simplifying the Test for Goodwill Impairment," on January 1, 2017, which removes Step 2 of the goodwill impairment test for any impairments after January 1, 2017. See Note 1 to the consolidated financial statements.

Valuation of Inventories.   We value inventory at the lower of the actual cost to purchase and/or manufacture the inventory, or the current estimated net realizable value of the inventory.  We review inventory quantities on hand and reduce the cost basis of excess and obsolete inventory based primarily on an estimated forecast of product demand, production requirements and the quality, efficacy and potency of raw materials.  This review is done on a quarterly basis or, if warranted by the circumstances, more frequently.  In addition, our industry is characterized by technological change, frequent new product development and product obsolescence that could result in an increase in the amount of obsolete inventory quantities on hand.  Our estimates of future product demand may prove to be inaccurate, and if too high, we may have overstated the carrying value of our inventory. In the future, if inventory is determined to be overvalued, we would be required to write down the value of inventory to market and recognize such costs in our cost of goods sold at the time of such determination.  Therefore, although we make efforts to ensure the accuracy of our forecasts of future product demand and perform procedures to safeguard overall inventory quality, any significant unanticipated changes in demand, technological developments, regulations, storage conditions, or other economic or environmental factors affecting biological materials, could have a significant impact on the value of our inventory and reported results of operations.

We adopted ASU 2015-11, "Simplifying the Measurement of Inventory," on January 1, 2017, which requires inventory measurement at the lower of cost and net realizable value. See Note 1 to the consolidated financial statements.

Valuation of Investments.   We regularly review our investments for factors that may indicate that a decline in the fair value of an investment below its carrying value is other-than-temporary.  Some factors considered in evaluating whether or not a decline in fair value is other-than-temporary include our ability and intent to retain the investment

27


for a period of time sufficient to allow for a recovery in value, the duration and extent to which the fair value has been less than cost and the financial condition and prospects of the issuer.  Such reviews are inherently uncertain in that the value of the investment may not fully recover or may decline further in future periods resulting in realized losses.

Warranty Reserves.   We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon delivery and on acceptance of that equipment, we establish, as part of cost of goods sold, a provision for the expected costs of such warranty repairs based on historical experience, specific warranty terms and customer feedback.   A review is performed on a quarterly basis to assess the adequacy of our warranty reserve and it is adjusted if necessary.  The warranty reserve is based on actual experience and expected future costs to be incurred.  Should realized costs be higher than expected costs, cost of goods sold would be lower in the period of estimation and higher when realized.

Allowance for Doubtful Accounts.   We maintain an allowance for doubtful accounts for estimated losses resulting from the collectability of our customer accounts.  The amount of the allowance is determined by analyzing known uncollectible accounts, the age of our receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ general credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.  Uncertainty in the current economic environment, if prolonged, could result in greater amounts becoming uncollectible in the future.  Should the estimates of losses be higher than the actual uncollectible accounts, we would report lower profitability when the estimates are made and higher profitability when the receivable is collected.

Litigation Accruals.   We record as liabilities in our Consolidated Balance Sheets estimated amounts for claims that are probable and can be reasonably estimated.  The likelihood of a material change in these estimated liabilities is dependent on the possible outcome of settlement negotiations, regulatory or judicial review and the development of facts and circumstances in extended litigation which could change claims or assessments when both the amount and range of loss on some outstanding litigation is uncertain.  We disclose in the footnotes of the financial statements when we are unable to make a reasonable estimate of a material liability that could result from unfavorable outcomes in litigation.  As events occur, we will assess the potential liability related to our pending litigation and revise our estimates.  Such revisions could materially impact our results of operations.


Results of Operations - Sales, Gross Margins and Expenses

The following shows cost of goods sold, gross profit, expense items and net income as a percentage of net sales:

 
Year Ended December 31,
 
 
2016
 
2015
 
2014
 
Net sales
100.0
%
 
100.0
%
 
100.0
%
 
Cost of goods sold
45.0

 
44.5

 
45.8

 
Gross profit
55.0

 
55.5

 
54.2

 
Selling, general and administrative expense
39.5

 
37.7

 
37.2

 
Research and development expense
10.0

 
9.6

 
10.1

 
Net income attributable to Bio-Rad
1.4

 
5.6

 
4.1

 

Net sales

Net sales (sales) in 2016 were $2.07 billion, an increase of 2.4% compared to $2.02 billion in 2015. Excluding the impact of foreign currency, 2016 sales increased by approximately 4.0% compared to 2015. Currency neutral sales growth was primarily reflected in all regions except Europe.


28


The Life Science segment sales in 2016 were $730.7 million, an increase of 5.1% compared to 2015.  On a currency neutral basis, sales increased 6.5% compared to 2015. The currency neutral sales increase was primarily in our Droplet Digital™ PCR and process media products. The currency neutral sales increase was in all regions.

The Clinical Diagnostics segment sales in 2016 were $1.32 billion, an increase of 1.0% compared to 2015. On a currency neutral basis, sales increased 2.6% compared to 2015. The currency neutral sales increase was primarily attributable to growth in quality control, immunology, blood typing and diabetes product lines. On a geographic view, currency neutral sales in 2016 increased most notably in the Americas and Asia, while sales declined in Europe.

Sales in 2015 were $2.02 billion, a decrease of 7.2% compared to $2.18 billion in 2014. Excluding the impact of foreign currency, 2015 sales increased by approximately 1.6% compared to 2014. Currency neutral sales growth was primarily reflected in the United States and China.

The Life Science segment sales in 2015 were $695.0 million, a decrease of 4.6% compared to 2014.  On a currency neutral basis, sales increased 2.5% compared to 2014. The currency neutral sales increase was primarily in our Droplet Digital™ PCR, western blotting, process chromatography media and cell biology products. The currency neutral sales increase was primarily in the United States and Europe, partially offset by lower sales in Asia, excluding China.

The Clinical Diagnostics segment sales in 2015 were $1.31 billion, a decrease of 8.5% compared to 2014. On a currency neutral basis, sales increased 1.1% compared to 2014. The Clinical Diagnostics segment had currency neutral sales growth from quality controls and immunology products, partially offset by declines in blood typing and infectious disease products. Currency neutral sales growth was primarily in North America, China and Latin America, while European markets were still experiencing consolidation and pricing pressures.

Gross margin

Consolidated gross margins were 55.0% in 2016 compared to 55.5% in 2015. Life Science segment gross margins in 2016 decreased from 2015 by approximately 0.7 percentage points, primarily due to lower margins in protein quantification and cell biology, higher service costs, higher acquisition intangible amortization, and $0.7 million of restructuring costs, partially offset by higher margins in Droplet Digital™ PCR, process media products and antibody products. Clinical Diagnostics segment gross margins in 2016 decreased from 2015 by approximately
0.5 percentage points. The decrease compared to 2015 was primarily driven by sales mix and pricing pressures, along with higher period expenses, and $1.4 million of restructuring costs, partially offset by the suspension of the medical device tax.

Beginning in 2013, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (PPACA), among other initiatives, provided for a 2.3% annual excise tax on the sales of certain medical devices in the U.S. Bio-Rad has been paying this excise tax on most of our U.S. Clinical Diagnostic sales, which we accounted for as a period cost in Cost of goods sold. However, the Consolidated Appropriations Act, 2016 (Pub. L. 114-113), signed into law on December 18, 2015, includes a two year moratorium on the medical device excise tax during the period beginning on January 1, 2016, and ending on December 31, 2017.

Consolidated gross margins were 55.5% in 2015 compared to 54.2% in 2014. Life Science segment gross margins in 2015 increased from 2014 by approximately 0.9 percentage points, primarily due to sales of higher gross margin products including Droplet Digital™ PCR, gene expression and cell biology products. In addition, lower service costs in Europe and costs associated with the closing of a manufacturing plant in 2014 contributed to higher margins. Clinical Diagnostics segment gross margins in 2015 increased from 2014 by approximately
1.8 percentage points. The increase compared to 2014 was primarily due to the 2014 consolidation and closure of certain facilities and the discontinuation of an underperforming product line. Sales mix also contributed to the higher gross margins in 2015.

29



Selling, general and administrative expense

Consolidated selling, general and administrative expenses (SG&A) increased to $816.7 million or 39.5% of sales in 2016 compared to $762.0 million or 37.7% of sales in 2015.  Increases to SG&A primarily included employee-related expenses, our largest cost, which also included $10.4 million of restructuring costs, $21.0 million for various legal matters, including the Wadler judgment as discussed further in Note 13 to the consolidated financial statements, professional fees, software, the revaluation of contingent consideration primarily associated with the cell sorting system and to a lesser extent the analytical flow cytometer platform, travel, facilities and recruitment/relocation. Decreases to SG&A primarily included bad debt expense and a one-time distributor cost in 2015.

Consolidated SG&A decreased to $762.0 million or 37.7% of sales in 2015 compared to $808.2 million or 37.2% of sales in 2014.  Underlying the overall decrease in SG&A was the impact of foreign currency, an accrual of $19.5 million in 2014 associated with the SEC and DOJ investigations relating to the FCPA investigation for which a final settlement was reached in the fourth quarter of 2014, and a reduction of $4.2 million from the revaluations of contingent consideration. Currency neutral increases in SG&A were primarily employee-related expenses, our largest cost, facilities and professional fees, partially offset by travel. Other increases in SG&A included $2.3 million of bad debt expense and a one-time distributor termination cost of $1.9 million.

Research and development expense

Research and development expense increased to $205.9 million or 10.0% of sales in 2016 compared to $193.0 million or 9.6% of sales in 2015.  Life Science segment research and development expense increased in 2016 from 2015 primarily due to increased project activities in Droplet Digital™ PCR, protein quantification and cell biology. Clinical Diagnostics segment research and development expense increased in 2016 from 2015 primarily from increased spending associated with the GnuBIO business.

Research and development expense decreased to $193.0 million or 9.6% of sales in 2015 compared to $220.3 million or 10.1% of sales in 2014.  Life Science segment research and development expense decreased in 2015 from 2014 primarily due to headcount reductions, lower supplies and lower external product development spend. Clinical Diagnostics segment research and development expense decreased in 2015 from 2014 primarily due to the wind down of spending on projects as they approach launch and the discontinuation of an underperforming product line in 2014.

Results of Operations – Non-operating

Interest expense

Interest expense in 2016 increased 1.2% to $21.9 million, relatively flat compared to $21.7 million in 2015.

Interest expense in 2015 decreased 2.0% to $21.7 million compared to 2014 primarily due to $0.6 million in 2014 associated with our offer to settle the SEC and DOJ investigations relating to the FCPA investigation for which a final settlement was reached in the fourth quarter of 2014.
  
Foreign currency exchange gains and losses

Foreign currency exchange gains and losses consist of foreign currency transaction gains and losses on intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts used to manage our foreign currency exchange risk.  Net foreign currency exchange losses for 2016, 2015 and 2014 were $4.5 million, $10.2 million and $9.3 million, respectively.  The 2016, 2015 and 2014 net foreign currency exchange losses were attributable to market volatility, increasing costs to hedge and the result of the estimating process inherent in the timing of shipments and payments of intercompany debt, and our decision to reclassify a large percentage of our intercompany receivable from Brazil to long-term towards the end of 2015. All years are affected by the economic hedging program we employ to hedge our intercompany receivables and payables.

30



Other income and expense, net

Other income and expense, net includes investment and dividend income, generally interest income on our cash and cash equivalents, short-term investments and long term marketable securities.  Other (income) expense, net in 2016 increased to $14.9 million income compared to $11.1 million income in 2015. The increase was primarily due to higher dividend income in 2016 on the ordinary and preferred shares of our investment in Sartorius AG, and higher investment income.

Other (income) expense, net in 2015 decreased to $11.1 million income compared to $13.0 million income in 2014. The decrease was primarily due to lower interest and investment income primarily related to a weaker 2015 foreign currency exchange rate for ordinary and preferred dividends from our investment in Sartorius AG, and realized losses in 2015 compared to no realized losses in 2014.

Effective tax rate

Our effective tax rate was 32%, 22% and 32% in 2016, 2015 and 2014, respectively. The effective tax rates for 2016 and 2015 included tax benefits from the repatriation of foreign earnings. The effective tax rate for 2016 included additional tax liabilities for unrecognized tax benefits related to the non-deductibility of interest expense in our foreign jurisdictions. The effective tax rate for 2014 included nondeductible penalties and losses that were nonrecurring. Our foreign taxes result primarily from income earned in France and Switzerland. Many jurisdictions in which we operate, including Switzerland, Russia, the U.K. and Singapore, have statutory tax rates that are significantly lower than the U.S. statutory tax rate of 35%. Our effective tax rate may be impacted in the future, either favorably or unfavorably, by many factors including, but not limited to, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.

Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2013 and forward for the U.S., and the years 2010 and forward for certain foreign jurisdictions, including France, Switzerland and Germany. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.
We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.
As of December 31, 2016, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $3.5 million. Substantially all such amounts will impact our effective income tax rate.

During 2017 we expect to proceed with the implementation of our European Headquarters and related restructuring plans that could have a significant effect on our effective tax rate. Many of these plans are operational changes that may impact our jurisdictional mix of earnings in the future.

31



 

Liquidity and Capital Resources

Bio-Rad operates and conducts business globally, primarily through subsidiary companies established in the markets in which we trade.  Goods are manufactured in a small number of locations, and are then shipped to local distribution facilities around the world.  Our product mix is diversified, and certain products compete largely on product efficacy, while others compete on price.  Gross margins are generally sufficient to exceed normal operating costs, and funding for research and development of new products, as well as routine outflows of capital expenditures, interest and taxes.  In addition to the annual positive cash flow from operating activities, additional liquidity is readily available via the sale of short-term investments and access to our $200.0 million unsecured Credit Agreement that we entered into in June 2014.  Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of December 31, 2016, however, $0.8 million was utilized for domestic standby letters of credit that reduced our borrowing availability.  The Credit Agreement matures in June 2019.

At December 31, 2016, we had available $839.4 million in cash, cash equivalents and short-term investments, of which approximately 28% was held in our foreign subsidiaries. We believe that our holdings of cash, cash equivalents and short-term investments in the U.S. and in our foreign subsidiaries are sufficient to meet both the current and long-term needs of our global operations. The amount of funds held in the United States can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and foreign cash flows (both inflows and outflows). Repatriation of overseas funds will result in additional U.S. federal and state income tax payments. In general, it is our practice and intention to indefinitely reinvest the cash generated by our foreign subsidiaries in our foreign subsidiaries' operations.

Under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had $205.7 million available for borrowing and usage as of December 31, 2016, which was reduced by $5.4 million that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations. Management believes that this availability, together with cash flow from operations, will be adequate to meet our current objectives for operations, research and development, capital additions for manufacturing and distribution, plant and equipment, information technology systems and an acquisition of reasonable proportion to our existing total available capital.

While economic growth is somewhat improving, instability still exists in developed nations and in the U.S., such as the slowing rate of growth in the Chinese economy and in emerging markets, especially those oil-producing countries that have been affected by a decline in oil prices, which may adversely affect our future results of cash flows. Demand for our products and services could change more dramatically than in previous years based on activity, funding, reimbursement constraints and support levels from government, universities, hospitals and private industry, including diagnostic laboratories.  The need for certain sovereign nations with large annual deficits to curtail spending could lead to slower growth of, or even a decline in, our business. Sovereign nations either delaying payment for goods and services or renegotiating their debts could impact our liquidity. The situation in these sovereign nations is continuously evolving and we have no greater knowledge of the situation other than what is publicly reported. As of December 31, 2016 and December 31, 2015, we had accounts receivable, net of an allowance for doubtful accounts, in Spain, Italy, Greece and Portugal of $32.7 million and $40.7 million, respectively.

32





Cash Flows from Operations

Net cash provided by operations was $216.4 million, $186.2 million and $273.3 million in 2016, 2015, and 2014, respectively.  The net increase between 2016 and 2015 of $30.2 million primarily resulted from:

•
higher cash received from customers in 2016 primarily due to lower U.S. collections in the second half of 2015 from delays associated with the second phase of an ERP implementation, and
•
higher investment income received, partially offset by
•
more cash paid to suppliers and employees primarily related to higher payments to inventory suppliers as payments were delayed in the latter part of 2015 mostly associated with the second deployment of the ERP system, higher annual performance-based compensation payments in 2016, and higher legal and other professional fees,
•
higher net income tax payments than in 2015, and
•
net payments in 2016 compared to net cash received in 2015 for forward foreign exchange contracts.

The net decrease between 2015 and 2014 of $87.1 million primarily resulted from:
•
lower cash received from customers primarily due to the value of foreign currency denominated sales and subsequent collections that were affected by a strengthening in the U.S. dollar, disproportionately larger collections in 2014 from the Spanish government, lower U.S. collections in the second half of 2015 from delays associated with the second phase of an ERP implementation, and higher U.S. collections in 2014 resulting from delays caused by the first deployment of a new ERP system, partially offset by
•
less cash paid to suppliers and employees primarily related to a decrease in foreign exchange rates, and reductions in force, partially offset by higher performance-based compensation payments, and
•
a payment of $55.1 million for the settlement with the SEC and DOJ associated with the FCPA in the fourth quarter of 2014.

We regularly review past due receivables to assess the allowance for doubtful accounts and believe net accounts receivable are fully realizable. We also routinely review inventory for the impact of obsolescence and changes in market prices caused by the introduction of new products, technologies and in government reimbursement policies. Cash flows from operations during the first quarter have historically had larger payments for royalties, fourth quarter sales commissions to third parties and annual employee bonuses, and we expect this pattern to recur in the first quarter of 2017.

Cash Flows from Investing Activities

Net cash used in investing activities was $213.9 million, $166.9 million and $190.5 million for 2016, 2015 and 2014, respectively. Purchases, net of sales and maturities of marketable securities and investments had an overall decrease of $13.2 million in 2016 compared to 2015 primarily due to a decrease in maturities and securities sales, partially offset by a decrease in purchases. Purchases, net of sales and maturities of marketable securities and investments had an overall decrease of $35.4 million in 2015 compared to 2014 primarily due to an increase in purchases, partially offset by an increase in maturities and securities sales.

Short-term restricted investments of $4.56 million and $4.21 million in 2016 and 2015, respectively, represent a money market fund for collateral that secures worker's compensation and general liability insurance. Investment income accrues to us and is recorded in Investment proceeds and miscellaneous receipts, net in the Consolidated Statements of Cash Flows.

Our investment objective is to maintain liquidity to meet anticipated operational and other corporate requirements in which capital is preserved and increased through investing in low risk, high quality securities with commensurate returns, consistent with our risk tolerance level.

33



Purchases of intangible assets were higher in 2014 than in 2016 and 2015 primarily due to higher purchases of licenses. Payments for acquisitions, net of cash received, and long-term investments in 2016 and 2014 were primarily due to the following:

•
in January 2016, we acquired a high performance analytical flow cytometer platform from Propel for total consideration of $32.8 million, which included $9.5 million paid in cash at the closing date and $23.3 million in contingent consideration potentially payable to Propel, after the effects of a calculation revision that were reflected in the fourth quarter of 2016 , and
•
in April 2014, we acquired 100% of the issued and outstanding stock of GnuBIO for a total consideration of $50.4 million, which included $39.7 million paid in cash at the closing date and $10.7 million in contingent consideration potentially payable to GnuBIO's shareholders. The Level 3 contingent consideration was revalued to a fair value of $10.0 million as of December 31, 2016 and 2015.

We continue to review possible acquisitions to expand both our Life Science and Clinical Diagnostics segments, such as our acquisition of RainDance in February 2017. We routinely meet with the principals or brokers of the subject companies.  We are currently in discussion and assessing a few possible acquisitions in which we expect our current reported cash and cash equivalents to be sufficient for any cash consideration for these possible acquisitions. However, it is not certain at this time that any of these discussions involving material or significant acquisitions will advance to completion.

Capital expenditures in 2016 totaled $141.4 million, compared to $112.0 million and $121.0 million in 2015 and 2014, respectively. Capital expenditures represent the addition and replacement of production machinery and research equipment, ongoing manufacturing and facility additions for expansion, regulatory, environmental and compliance. Also included in capital expenditures are investments in business systems and data communication upgrades and enhancements.  All periods include equipment placed with Clinical Diagnostics segment customers who then contract to purchase our reagents for use. As we continue to implement the remaining phases of the ERP platform, we expect capital expenditures to moderate in 2017 and then decline over the next couple of years. Capital expenditures were lower in 2015 compared to 2016 as the second phase was implemented in July 2015 and the third phase of the ERP system ramped up in 2016. Capital expenditures were higher in 2014 than in 2015 as we were in the development stages (in which appropriate costs are capitalized) of implementing the second phase of a global single instance ERP platform. The current estimated future project cost for global implementation for the single instance ERP platform is projected to be $90 million to $130 million, and is estimated to take approximately the next two to three years to fully implement.

Cash Flows from Financing Activities

Net cash provided by financing activities was $9.0 million, $8.6 million and $11.7 million in 2016, 2015 and 2014, respectively.  Net cash provided by financing activities in 2016, 2015 and 2014 was primarily from proceeds from issuance of our common stock. Additionally in 2016, 2015 and 2014, there were payments of $3.5 million,
$3.0 million and $2.4 million, respectively, to Propel Labs' shareholders in contingent consideration for sales milestones that were associated with the valuation as of the 2012 acquisition date. In 2014, there was also the payment of a short-term borrowing.

We have outstanding Senior Notes of $425.0 million, which are not due until 2020. We believe the current cash is sufficient to meet normal operating costs, and funding for research and development of new products, as well as routine outflows of capital expenditures, interest and taxes.

The Board of Directors has authorized the repurchase of up to $18.0 million of Bio-Rad's common stock, of which $3.3 million has yet to be repurchased as of December 31, 2016. The Credit Agreement may limit our ability to repurchase our stock. In accordance with the terms of awards under the 2007 Incentive Award Plan, in June 2012, we withheld 122 shares of our Class A common stock and 917 shares of our Class B common stock to satisfy tax obligations due upon the vesting of restricted stock of certain of our employees, which is considered a repurchase of

34


our stock. All of the restricted stock vested as of December 31, 2013 and therefore we do not anticipate any repurchasing of shares for this purpose. We had no other repurchases of our stock during 2016, 2015 or 2014.

Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have had or are reasonably likely to have a current or future material effect on our financial condition, results of operations or liquidity.

Contractual Obligations

The following summarizes certain of our contractual obligations as of December 31, 2016 and the effect such obligations are expected to have on our cash flows in future periods (in millions):

 
 
Payments Due by Period
 
 
 
 
Less
Than
 
1-3
 
3-5
 
More
than
Contractual Obligations
 
Total
 
One Year
 
Years
 
Years
 
5 Years
Long-term debt, including current portion (1)
 
$
437.0

 
$
0.3

 
$
0.5

 
$
425.6

 
$
10.6

Interest payments (1)
 
81.6

 
20.7

 
41.4

 
19.5

 
—

Operating lease obligations (2)
 
158.0

 
42.1

 
56.7

 
33.5

 
25.7

Purchase obligations (3)
 
35.0

 
17.5

 
8.5

 
9.0

 
—

Long-term liabilities (4)
 
142.9

 
34.3

 
10.5

 
4.0

 
94.1

 
 
 
 
 
 
 
 
 
 
 
(1) These amounts represent expected cash payments, including capital lease obligations, which are included in our December 31, 2016 Consolidated Balance Sheet. Our debt is fixed and primarily consists of the 4.875% Notes. See Note 5 of the Consolidated Financial Statements for additional information about our debt.
 
 
 
(2) Operating lease obligations are described in Note 12 of the Consolidated Financial Statements.
 
 
 
(3) Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms.  Purchase obligations exclude agreements that are cancelable without penalty.
 
 
 
(4) Excluded from this table are tax liabilities for uncertain tax positions and contingencies in the amount of $16.4 million.  We are not able to reasonably estimate the timing of future cash flows of these tax liabilities, therefore, our income tax obligations are excluded from the table above.  See Note 6 of the Consolidated Financial Statements for additional information about our income taxes.
 
 
 

Recent Accounting Standards Updates

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective prospectively for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. ASU 2017-04 will provide a more stream-lined approach to evaluating future goodwill impairment and we early adopted on January 1, 2017. We have not assessed the impact that ASU 2017-04 will have on our consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017.

In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. ASU 2017-01 will be applied prospectively to any transactions occur

35


set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs.ring within the period of adoption. Early adoption is permitted, including for interim or annual periods in which the financial statements have not been issued or made available for issuance. We early adopted ASU 2017-01 on January 1, 2017. For our acquisition of RainDance Technologies, Inc., ASU 2017-01 did not affect the conclusion of it being a business combination (see Note 17 to the consolidated financial statements).

In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. We have had a limited amount of restricted cash of $2.0 million and $1.4 million as of December 31, 2016 and 2015, respectively, which was reclassified from cash to either Prepaid expenses, Other current assets or Other assets in the Consolidated Balance Sheets. At the time of adoption, we cannot assure whether these same restricted cash amounts will be held or what other restricted cash we may have, or that historically reported amounts will be similar.

In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements.  ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted as of the beginning of an annual reporting period for which financial statements have not been issued or made available for issuance. We do not plan to early adopt ASU 2016-16. We are currently evaluating the effect ASU 2016-16 will have on our consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the effect ASU 2016-15 will have on our consolidated statements of cash flows, if any.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for trade and other receivables, and instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also will allow an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods

36


within those fiscal years. We adopted ASU 2016-09 on January 1, 2017 and made a policy election to account for forfeitures as they occur. We do not expect ASU 2016-09 to have a material impact on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. ASU 2016-07 will be applied on a prospective basis and is effective for all entities for fiscal years beginning after December 15, 2016, and interim periods within those years. We adopted ASU 2016-07 on January 1, 2017 and do not expect it to materially affect our consolidated financial statements, unless our situation changes regarding our ability to influence the investee in the future as a result of our cost method investment in Sartorius AG (see Note 3 to the consolidated financial statements).

In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities.

In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the consolidated financial statements. At the time of adoption, we cannot assure whether these same equity securities will be held or what other equity securities we may have, or that historically reported changes will be similar.

In September 2015, the FASB issued ASU 2015-16, "Simplifying the Accounting for Measurement-Period Adjustments," which eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. Under ASU 2015-16, acquirers must recognize measurement-period adjustments during the period in which they determine the amounts, including the effect on earnings of any amounts they would have recorded in previous periods if the accounting had been completed at the acquisition date. The measurement period cannot exceed one year from the date of the acquisition. ASU 2015-16 was effective on January 1, 2016, and we adopted it at the same time as a change in accounting policy, which had no impact on our consolidated financial statements.

In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” ASU 2015-11 is effective prospectively for annual periods beginning after December 15, 2016, and interim periods

37


therein. We adopted ASU 2015-11 on January 1, 2017 and do not expect it to have a material impact to our consolidated financial statements.

In April 2015, the FASB issued ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs." ASU 2015-03 was issued to simplify the presentation of debt issuance costs by requiring debt issuance costs to be presented as a deduction from the corresponding debt liability. This makes the presentation of debt issuance costs consistent with the presentation of debt discounts or premiums. Under prior U.S. GAAP, debt issuance costs were reported on the balance sheet as assets and amortized as interest expense. Under ASU 2015-03, debt issuance costs will continue to be amortized to interest expense using the effective interest method. In August 2015, the FASB issued ASU 2015-15, "Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements" to clarify the SEC staff’s position that it would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, which is our current practice. We adopted ASU 2015-03 on January 1, 2016 on a retrospective basis as a change in accounting policy. The Condensed Consolidated Balance Sheet as of December 31, 2015 was retrospectively adjusted by decreasing Other assets and Long-term debt, net of current maturities, by $1.8 million, respectively.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 to defer the effective date for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted as of the original effective date in ASU 2014-09, which is annual reporting periods beginning after December 15, 2016, however, we will not early adopt. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectiblity, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method once we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. We have completed revenue recognition diagnostic surveys across all regions in our decentralized sales contracting process, which is based on local country commercial regulations and practices. We have begun assessing individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP, to determine the effect that these ASU’s will have on our consolidated financial statements and related disclosures.


38



ITEM 7A.  QUANTITIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Financial Risk Management

The main goal of Bio-Rad’s financial risk management program is to reduce the variance in expected cash flows arising from unexpected foreign exchange rate and interest rate changes.  Financial exposures are managed through operational means and by using various financial instruments, including cash and liquid resources, borrowings, and forward and spot foreign exchange contracts.  No derivative financial instruments are entered into for the purpose of trading or speculation.  Company policy requires that all derivative positions are undertaken to manage the risks arising from underlying business activities.  These derivative transactions do not qualify for hedge accounting treatment.  Derivative instruments used in these transactions are valued at fair value and changes in fair value are included in reported earnings.

Foreign Exchange Risk.  We operate and conduct business in many countries and are exposed to movements in foreign currency exchange rates.  We face transactional currency exposures that arise when we enter into transactions denominated in currencies other than U.S. dollars.  Additionally, our consolidated net equity is impacted by the conversion of the net assets of our international subsidiaries for which the functional currency is not the U.S. dollar.

Foreign currency exposures are managed on a centralized basis.  This allows for the netting of natural offsets and lowers transaction costs and net exposures.  Where possible, we seek to manage our foreign exchange risk in part through operational means, including matching same-currency revenues to same-currency costs, and same-currency assets to same-currency liabilities.  Moreover, weakening in one currency can often be offset by strengthening in another currency.  Foreign exchange risk is also managed through the use of forward foreign exchange contracts. Positions are primarily in Euro, Swiss Franc, British Sterling, Singapore Dollar, Brazilian Real and Japanese Yen. The majority of forward contracts are for periods of 90 days or less. We record the change in value of our foreign currency receivables and payables as a Foreign exchange (gain) loss on our Consolidated Statements of Income along with the change in fair market value of the forward exchange contract used as an economic hedge of those assets or liabilities.

Our forward contract holdings at year-end were analyzed to determine their sensitivity to fluctuations in foreign currency exchange rates.  All other variables were held constant.  Market risk associated with derivative holdings is the potential change in fair value of derivative positions arising from an adverse movement in foreign exchange rates.  A decline of 10% on quoted foreign exchange rates would result in an approximate net-present-value loss of $30 million on our derivative position as of December 31, 2016.  This impact of a change in exchange rates excludes the offset derived from the change in value of the underlying assets and liabilities, which could reduce the adverse effect significantly.

Interest Rate Risk of Debt Instruments.  Bio-Rad centrally manages the short-term cash surpluses and shortfalls of its subsidiaries.  Our holdings of variable rate debt instruments at year-end were analyzed to determine their sensitivity to movements in interest rates.  Due to the relatively small amount of short-term variable rate debt we have outstanding, there would not be a material impact to earnings or cash flows if interest rates moved adversely by 10%.  Our long-term debt consists primarily of fixed-rate instruments, and is thus insulated from interest rate changes.  As of December 31, 2016, the overall interest rate risk associated with our debt was not significant.

39






ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 
 
 
Index to Consolidated Financial Statements
 
 
Page
 
 
 
Reports of Independent Registered Public Accounting Firm
 
41-42

Consolidated Balance Sheets at December 31, 2016 and 2015
 
43-44
Consolidated Statements of Income for each of the three years in the period ended
 
 
December 31, 2016
 
45
Consolidated Statements of Comprehensive Income for each of the three years in the period
 
 
December 31, 2016
 
46
Consolidated Statements of Cash Flows for each of the three years in the period ended
 
 
December 31, 2016
 
47
Consolidated Statements of Changes in Stockholders’ Equity for each of the three years
 
 
in the period ended December 31, 2016
 
48
Notes to Consolidated Financial Statements
 
49-85
 
 
 



40


Report of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders
Bio-Rad Laboratories, Inc.:
We have audited the accompanying consolidated balance sheets of Bio-Rad Laboratories, Inc. and subsidiaries (the Company) as of December 31, 2016 and 2015, and the related consolidated statements of income, comprehensive income, stockholders’ equity, and cash flows for each of the years in the three‑year period ended December 31, 2016. In connection with our audits of the consolidated financial statements, we also have audited the financial statement schedule. These consolidated financial statements and financial statement schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements and financial statement schedule based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Bio-Rad Laboratories, Inc. and subsidiaries as of December 31, 2016 and 2015, and the results of their operations and their cash flows for each of the years in the three‑year period ended December 31, 2016, in conformity with U.S. generally accepted accounting principles. Also in our opinion, the related financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, present fairly, in all material respects, the information set forth therein.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Bio-Rad Laboratories, Inc.’s internal control over financial reporting as of December 31, 2016, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated February 28, 2017 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.
 
                                                                                          /s/ KPMG LLP
 
San Francisco, California
February 28, 2017
 

41


Report of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders
Bio‑Rad Laboratories, Inc.:

We have audited Bio-Rad Laboratories, Inc.’s (the Company) internal control over financial reporting as of December 31, 2016, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Bio-Rad Laboratories Inc.’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting (Item 9A(b)). Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
In our opinion, Bio-Rad Laboratories, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2016, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Bio-Rad Laboratories, Inc. and subsidiaries as of December 31, 2016 and 2015, and the related consolidated statements of operations, comprehensive income, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2016, and our report dated February 28, 2017 expressed an unqualified opinion on those consolidated financial statements and financial statement schedule.

 
                                                                                          /s/ KPMG LLP
 
San Francisco, California
February 28, 2017

42




BIO-RAD LABORATORIES, INC.
Consolidated Balance Sheets
(In thousands, except share data)
 
December 31,
 
2016
 
2015
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
456,264

 
$
457,549

Short-term investments
383,176

 
328,718

Restricted investments
4,560

 
4,210

Accounts receivable, less allowance for doubtful accounts of $23,367 at 2016 and $24,418 at 2015
372,348

 
391,485

 
 
 
 
Inventories:
 
 
 
Raw materials
116,540

 
109,928

Work in process
125,982

 
114,438

Finished goods
282,439

 
265,858

Total inventories
524,961

 
490,224

 
 
 
 
Prepaid expenses
91,014

 
94,369

Other current assets
12,201

 
11,041

Total current assets
1,844,524

 
1,777,596

 
 
 
 
Property, plant and equipment:
 
 
 
   Land and improvements
17,895

 
17,823

   Buildings and leasehold improvements
290,367

 
276,070

   Equipment
919,126

 
823,193

     Total property, plant and equipment
1,227,388

 
1,117,086

Less: accumulated depreciation and amortization
(738,774
)
 
(679,396
)
Property, plant and equipment, net
488,614

 
437,690

 
 
 
 
Goodwill, net
477,115

 
495,948

Purchased intangibles, net
161,609

 
214,026

Other investments
830,790

 
719,840

Other assets
47,852

 
64,618

Total assets
$
3,850,504

 
$
3,709,718

 
 
 
 

The accompanying notes are an integral part of these consolidated financial statements.

 43



BIO-RAD LABORATORIES, INC.
Consolidated Balance Sheets
(continued)
(In thousands, except share data)

 
December 31,
 
2016
 
2015
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
  Accounts payable
$
133,109

 
$
122,391

  Accrued payroll and employee benefits
163,364

 
157,857

  Notes payable and current maturities of long-term debt
334

 
298

  Income and other taxes payable
28,124

 
29,339

  Deferred revenue
31,003

 
29,683

  Other current liabilities
115,388

 
101,783

Total current liabilities
471,322

 
441,351

 
 
 
 
Long-term debt, net of current maturities
434,186

 
433,883

Deferred income taxes
222,919

 
233,475

Other long-term liabilities
135,318

 
110,506

Total liabilities
1,263,745

 
1,219,215

 
 
 
 
Commitments and contingent liabilities


 


 
 
 
 
Stockholders’ equity:
 
 
 
Preferred stock, $0.0001 par value, 7,500,000 shares authorized; issued and outstanding - none
—

 
—

  Class A common stock, $0.0001 par value; 80,000,000 shares authorized; shares issued - 24,454,048 and 24,230,448 at 2016 and 2015, respectively; shares outstanding - 24,453,926 and 24,230,326 at 2016 and 2015, respectively
2

 
2

  Class B common stock, $0.0001 par value; 20,000,000 shares authorized; shares issued - 5,123,883 and 5,130,558 at 2016 and 2015, respectively; shares outstanding - 5,122,966 and 5,129,641 at 2016 and 2015, respectively
1

 
1

Additional paid-in capital
332,911

 
300,408

  Class A treasury stock at cost, 122 shares at 2016 and 2015
(12
)
 
(12
)
  Class B treasury stock at cost, 917 shares at 2016 and 2015
(89
)
 
(89
)
Retained earnings
1,836,180

 
1,808,055

Accumulated other comprehensive income
417,766

 
382,138

Total stockholders’ equity
2,586,759

 
2,490,503

Total liabilities and stockholders’ equity
$
3,850,504

 
$
3,709,718

 
 
 
 



The accompanying notes are an integral part of these consolidated financial statements.

 44



BIO-RAD LABORATORIES, INC.
Consolidated Statements of Income
(In thousands, except per share data)


 
Year Ended December 31,
 
 
2016
 
2015
 
2014
 
 
 
 
 
 
 
 
Net sales
$
2,068,172

 
$
2,019,441

 
$
2,175,044

 
Cost of goods sold
930,085

 
897,771

 
996,527

 
Gross profit
1,138,087

 
1,121,670

 
1,178,517

 
Selling, general and administrative expense
816,724

 
761,990

 
808,200

 
Research and development expense
205,864

 
192,972

 
220,333

 
Impairment losses on goodwill and long-lived assets
62,305

 
—

 
—

 
Income from operations
53,194

 
166,708

 
149,984

 
Interest expense
21,942

 
21,692

 
22,131

 
Foreign exchange losses, net
4,542

 
10,249

 
9,305

 
Other (income) expense, net
(14,850
)
 
(11,080
)
 
(13,009
)
 
Income before income taxes
41,560

 
145,847

 
131,557

 
Provision for income taxes
(13,435
)
 
(32,754
)
 
(42,712
)
 
Net income
$
28,125

 
$
113,093

 
$
88,845

 
 
 
 
 
 
 
 
Basic earnings per share:
 
 
 
 
 
 
Net income per basic share
$
0.96

 
$
3.87

 
$
3.08

 
Weighted average common shares - basic
29,440

 
29,186

 
28,876

 
 
 
 
 
 
 
 
Diluted earnings per share:
 
 
 
 
 
 
Net income per diluted share
$
0.95

 
$
3.85

 
$
3.05

 
Weighted average common shares - diluted
29,646

 
29,409

 
29,133

 

The accompanying notes are an integral part of these consolidated financial statements. 


45


BIO-RAD LABORATORIES, INC.
Consolidated Statements of Comprehensive Income
(In thousands)


 
Year Ended December 31,
 
2016
 
2015
 
2014
Net income
$
28,125

 
$
113,093

 
$
88,845

Other comprehensive income (loss):
 
 
 
 
 
Foreign currency translation adjustments
(32,394
)
 
(37,536
)
 
(118,142
)
Foreign other post-employment benefits adjustments, net of income taxes
2,086

 
(4,403
)
 
(8,186
)
Net unrealized holding gains on available-for-sale (AFS) investments, net of income taxes
65,936

 
205,132

 
4,556

Other comprehensive income (loss), net of income taxes
35,628

 
163,193

 
(121,772
)
Comprehensive income (loss)
$
63,753

 
$
276,286

 
$
(32,927
)

Reclassification adjustments are calculated using the specific identification method.
The accompanying notes are an integral part of these consolidated financial statements.



46


BIO-RAD LABORATORIES, INC.
Consolidated Statements of Cash Flows
(In thousands)
 
Year Ended December 31,
 
2016
 
2015
 
2014
Cash flows from operating activities:
 
 
 
 
 
Cash received from customers
$
2,074,024

 
$
1,956,084

 
$
2,162,520

Cash paid to suppliers and employees
(1,810,844
)
 
(1,730,062
)
 
(1,806,526
)
Interest paid, net
(21,318
)
 
(20,793
)
 
(20,793
)
Income tax payments, net
(38,442
)
 
(31,715
)
 
(28,939
)
Settlement with the SEC and DOJ relating to the FCPA, including interest
—

 
—

 
(55,050
)
Investment proceeds and miscellaneous receipts, net
15,683

 
11,953

 
15,671

Excess tax benefits from share-based compensation
(1,506
)
 
(3,610
)
 
(1,349
)
(Payments for) proceeds from forward foreign exchange contracts, net
(1,164
)
 
4,353

 
7,778

Net cash provided by operating activities
216,433

 
186,210

 
273,312

Cash flows from investing activities:
 
 
 
 
 
Capital expenditures
(141,436
)
 
(112,000
)
 
(120,999
)
Proceeds from dispositions of property, plant and equipment
398

 
79

 
225

Payments for acquisition and long-term investment
(14,165
)
 
(4,356
)
 
(44,627
)
Payments for purchases of intangible assets
(135
)
 
(1,372
)
 
(15,479
)
Payments for purchases of restricted investment
(350
)
 
(4,210
)
 
—

Payments for purchases of marketable securities and investments
(278,071
)
 
(294,497
)
 
(205,746
)
Proceeds from sales of marketable securities and investments
76,859

 
78,664

 
75,725

Proceeds from maturities of marketable securities and investments
143,020

 
170,823

 
120,390

Net cash used in investing activities
(213,880
)
 
(166,869
)
 
(190,511
)
Cash flows from financing activities:
 
 
 
 
 
Net borrowings (payments) on line-of-credit arrangements and notes payable
37

 
—

 
(1,560
)
Payments on long-term borrowings
(303
)
 
(282
)
 
(253
)
Proceeds from issuances of common stock for share-based compensation
11,280

 
8,236

 
15,051

Payments of contingent consideration
(3,500
)
 
(2,983
)
 
(2,374
)
Debt issuance costs on long-term borrowings
—

 
—

 
(524
)
Excess tax benefits from share-based compensation
1,506

 
3,610

 
1,349

Net cash provided by financing activities
9,020

 
8,581

 
11,689

Effect of foreign exchange rate changes on cash
(12,858
)
 
16,376

 
(12,790
)
Net (decrease) increase in cash and cash equivalents
(1,285
)
 
44,298

 
81,700

Cash and cash equivalents at beginning of year
457,549

 
413,251

 
331,551

Cash and cash equivalents at end of year
$
456,264

 
$
457,549

 
$
413,251


The accompanying notes are an integral part of these consolidated financial statements.

47


BIO-RAD LABORATORIES, INC.
Consolidated Statements of Changes in Stockholders’ Equity
(In thousands)
 
 
Common
Stock
 
Additional Paid-in Capital
 
Treasury Stock
 
Retained
Earnings
 
Accumulated Other Comprehensive Income
 
Total Stockholders' Equity
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2013
 
$
3

 
$
239,986

 
$
(101
)
 
$
1,606,117

 
$
340,717

 
$
2,186,722

Net income
 
—

 
—

 
—

 
88,845

 
—

 
88,845

Other comprehensive loss, net of tax
 
—

 
—

 
—

 
—

 
(121,772
)
 
(121,772
)
Issuance of common stock
 
—

 
15,051

 
—

 
—

 
—

 
15,051

Stock compensation expense
 
—

 
14,888

 
—

 
—

 
—

 
14,888

Tax benefit-exercise stock options
 
—

 
1,421

 
—

 
—

 
—

 
1,421

Balance at December 31, 2014
 
3

 
271,346

 
(101
)
 
1,694,962

 
218,945

 
2,185,155

Net income
 
—

 
—

 
—

 
113,093

 
—

 
113,093

Other comprehensive income, net of tax
 
—

 
—

 
—

 
—

 
163,193

 
163,193

Issuance of common stock
 
—

 
8,236

 
—

 
—

 
—

 
8,236

Stock compensation expense
 
—

 
16,983

 
—

 
—

 
—

 
16,983

Tax benefit-exercise stock options
 
—

 
3,843

 
—

 
—

 
—

 
3,843

Balance at December 31, 2015
 
3

 
300,408

 
(101
)
 
1,808,055

 
382,138

 
2,490,503

Net income
 
—

 
—

 
—

 
28,125

 
—

 
28,125

Other comprehensive income, net of tax
 
—

 
—

 
—

 
—

 
35,628

 
35,628

Issuance of common stock
 
—

 
11,280

 
—

 
—

 
—

 
11,280

Stock compensation expense
 
—

 
19,730

 
—

 
—

 
—

 
19,730

Tax benefit-exercise stock options
 
—

 
1,493

 
—

 
—

 
—

 
1,493

Balance at December 31, 2016
 
$
3

 
$
332,911

 
$
(101
)
 
$
1,836,180

 
$
417,766

 
$
2,586,759



The accompanying notes are an integral part of these consolidated financial statements.

48


 
BIO-RAD LABORATORIES, INC.
Notes to Consolidated Financial Statements


1.SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value.

Short-term Restricted Investments

Short-term restricted investments of $4.56 million and $4.21 million at December 31, 2016 and 2015, respectively, represent a money market fund for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets.

Available-for-Sale Investments

Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale investments for other-than-temporary losses on a quarterly basis.  Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10).

Concentration of Credit Risk

Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and

49


investments are placed with various highly rated major financial institutions located in different geographic regions. Bio-Rad has not sustained significant losses from instruments held at financial institutions.

The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  However, we do not expect to record any losses as a result of counterparty default.

We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.

Accounts Receivable

We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.

Inventory

Inventories are valued at the lower of actual cost or market (net realizable value) and include material, labor and overhead costs.  The first-in, first-out method is used to relieve inventory for products sold.

Property, Plant and Equipment

Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  Buildings and leasehold improvements are amortized over 15-30 years or the term of the leases or life of the improvements, whichever is shorter.  With the exception of reagent rental equipment, which is amortized over a 1-5 year period, equipment and capitalized software is depreciated over 3-12 years.

Goodwill

Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.

The goodwill impairment test consists of a two-step process.  The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit to its carrying value, including goodwill.

50


We use a projected discounted cash flow model to determine the fair value of a reporting unit.  If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required.  The second step, if required, compares the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill.  The fair value of a reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit.  If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an impairment charge is recognized in an amount equal to that excess.

Long-Lived Assets

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:

•
significant under-performance relative to expected, historical or projected future operating results;
•
significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;
•
a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and
•
significant negative industry, legal, regulatory or economic trends.

When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.

Income Taxes
We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. To the extent we determine that we are able to realize our deferred income tax assets in the future in excess of their net recorded amount, we make an adjustment to the valuation allowance which may reduce the provision for income taxes. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit

51


that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes.

Revenue Recognition

Revenue is recognized when pervasive evidence of an arrangement exists, the price to the buyer is fixed or determinable, collectability is reasonably assured and title has passed to the customer or product has been delivered absent specific contractual specifications.  Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required contractually, has occurred.  At the time revenue is recognized, a provision is recognized for estimated product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement, or as services are performed if not under contract. Net sales are the actual selling price of products to customers. Any taxes billed to the customer (sales tax, value added tax, etc.) shall be credited to the tax liability accounts and excluded from net sales.

Reagent agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis.  We evaluate our reagent agreements and account for these contracts under the guidance pertaining to accounting for revenue arrangements with multiple deliverables.  Our reagent agreements represent one unit of accounting as the instrument and consumables are interdependent in producing a diagnostic result that neither has a stand-alone value with respect to these agreements. All revenues that we earn under our reagent agreements are recognized pursuant to the terms of each agreement and are based and entirely contingent upon either (i) when the consumables to conduct a fixed number of tests are delivered or (ii) as reported by the customer on a per test basis.

Shipping and Handling

We classify all freight costs billed to customers as Net sales.  Related freight costs are included in Cost of goods sold.

Warranty

We warrant certain equipment against defects in design, materials and workmanship, mostly for a period of one year.  Upon delivery of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

Changes in the warranty accrual, included in Other current liabilities and Other long-term liabilities, were as follows (in millions):
 
 
2016
 
2015
January 1
 
$
17.4

 
$
17.8

Provision for warranty
 
33.4

 
30.6

Actual warranty costs
 
(33.2
)
 
(31.0
)
December 31
 
$
17.6

 
$
17.4



Research and Development

Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.  

52



Foreign Currency

Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.

Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.

Forward Foreign Exchange Contracts

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.  

Share-Based Compensation Plans

Stock-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs net of estimated forfeitures over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  We estimated the forfeiture rate based on our historical experience.  These plans are described more fully in Note 9.

Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.


The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):
 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
Basic weighted average shares outstanding
 
29,440

 
29,186

 
28,876

Effect of potentially dilutive stock options
 
 
 
 
 
 
    and restricted stock awards
 
206

 
223

 
257

Diluted weighted average common shares
 
29,646

 
29,409

 
29,133

Anti-dilutive stock options and restricted stock awards
 
 
 
 
 
 
    excluded from the computation of diluted EPS
 
113

 
109

 
122





53


Fair Value of Financial Instruments

For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.

The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).

Recent Accounting Standards Updates

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective prospectively for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. ASU 2017-04 will provide a more stream-lined approach to evaluating future goodwill impairment and we early adopted on January 1, 2017. We have not assessed the impact that ASU 2017-04 will have on our consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017.

In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. ASU 2017-01 will be applied prospectively to any transactions occurring within the period of adoption. Early adoption is permitted, including for interim or annual periods in which the financial statements have not been issued or made available for issuance. We early adopted ASU 2017-01 on January 1, 2017. For our acquisition of RainDance Technologies, Inc., ASU 2017-01 did not affect the conclusion of it being a business combination (see Note 17 to the consolidated financial statements).

In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. We have had a limited amount of restricted cash of $2.0 million and $1.4 million as of December 31, 2016 and 2015, respectively, which was reclassified from cash to either Prepaid expenses, Other current assets or Other assets in the Consolidated Balance Sheets. At the time of adoption, we cannot assure whether these same restricted cash amounts will be held or what other restricted cash we may have, or that historically reported amounts will be similar.

In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted as of the beginning of an annual reporting period for which finan

54


inventory transfers.  Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements.  ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. cial statements have not been issued or made available for issuance. We do not plan to early adopt ASU 2016-16. We are currently evaluating the effect ASU 2016-16 will have on our consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the effect ASU 2016-15 will have on our consolidated statements of cash flows, if any.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for trade and other receivables, and instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also will allow an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. We adopted ASU 2016-09 on January 1, 2017 and made a policy election to account for forfeitures as they occur. We do not expect ASU 2016-09 to have a material impact on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. ASU 2016-07 will be applied on a prospective basis and is effective for all entities for fiscal years beginning after December 15, 2016, and interim periods within those years. We adopted ASU 2016-07 on January 1, 2017 and do not expect it to materially affect our consolidated financial statements, unless our situation changes regarding our ability to influence the investee in the future as a result of our cost method investment in Sartorius AG (see Note 3 to the consolidated financial statements).

In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods

55


presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities.

In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the consolidated financial statements. At the time of adoption, we cannot assure whether these same equity securities will be held or what other equity securities we may have, or that historically reported changes will be similar.
   
In September 2015, the FASB issued ASU 2015-16, "Simplifying the Accounting for Measurement-Period Adjustments," which eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. Under ASU 2015-16, acquirers must recognize measurement-period adjustments during the period in which they determine the amounts, including the effect on earnings of any amounts they would have recorded in previous periods if the accounting had been completed at the acquisition date. The measurement period cannot exceed one year from the date of the acquisition. ASU 2015-16 was effective on January 1, 2016, and we adopted it at the same time as a change in accounting policy, which had no impact on our consolidated financial statements.

In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” ASU 2015-11 is effective prospectively for annual periods beginning after December 15, 2016, and interim periods therein. We adopted ASU 2015-11 on January 1, 2017 and do not expect it to have a material impact to our consolidated financial statements.

In April 2015, the FASB issued ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs." ASU 2015-03 was issued to simplify the presentation of debt issuance costs by requiring debt issuance costs to be presented as a deduction from the corresponding debt liability. This makes the presentation of debt issuance costs consistent with the presentation of debt discounts or premiums. Under prior U.S. GAAP, debt issuance costs were reported on the balance sheet as assets and amortized as interest expense. Under ASU 2015-03, debt issuance costs will continue to be amortized to interest expense using the effective interest method. In August 2015, the FASB issued ASU 2015-15, "Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements" to clarify the SEC staff’s position that it would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, which is our current practice. We adopted ASU 2015-03 on January 1, 2016 on a retrospective basis as a change in accounting policy. The Condensed Consolidated Balance Sheet as of December 31, 2015 was retrospectively adjusted by decreasing Other assets and Long-term debt, net of current maturities, by $1.8 million, respectively.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 to defer the effective date for annual reporting periods

56


beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted as of the original effective date in ASU 2014-09, which is annual reporting periods beginning after December 15, 2016, however, we will not early adopt. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectiblity, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method once we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. We have completed revenue recognition diagnostic surveys across all regions in our decentralized sales contracting process, which is based on local country commercial regulations and practices. We have begun assessing individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP, to determine the effect that these ASU’s will have on our consolidated financial statements and related disclosures.


2.    ACQUISITIONS

Propel Labs, Inc.

In January 2016, we acquired a high performance analytical flow cytometer platform from Propel Labs (Propel) that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. This asset acquisition was accounted for as a business combination, as the new analytical flow cytometer platform represented an integrated set of activities and assets that is capable of being conducted and managed for the purpose of providing a return and therefore constitutes a business in accordance with GAAP. The amount of the acquisition-related cost was minimal as Bio-Rad primarily represented itself during the acquisition process. This business acquisition is included in our Life Science segment’s results of operations from the acquisition date.

The fair value of the consideration as of the acquisition date was $32.8 million, which included $9.5 million paid in cash at the closing date and $23.3 million in contingent consideration potentially payable to Propel, after the effects of a calculation revision that were reflected in the fourth quarter of 2016. This revision reduced goodwill/intangibles and contingent consideration by the same amount and had no significant impact on our Consolidated Income Statement. The contingent consideration was based on a probability-weighted income approach related to the achievement of certain sales milestones, and was recognized at its estimated fair value of $25.4 million as of December 31, 2016 (see Note 3, "Fair Value Measurements").

The fair values of the net assets acquired from Propel as of the acquisition date were determined to be $32.7 million of definite-lived intangible assets and $0.1 million of goodwill. We expect the goodwill recorded to be deductible for income tax purposes. The acquired analytical flow cytometer platform fits well into Bio-Rad’s existing Life Science segment product offerings and may offer researchers greater access to this technology.

In addition, Bio-Rad contracted with Propel to provide development services concurrent with and included in the purchase agreement. Bio-Rad is receiving future manufacturing, engineering and marketing support from Propel on which payments will be made upon the successful completion of all contracted services. As a result, these services are not included in the total purchase consideration and a majority will be expensed in future periods.

57





3. FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

•
Level 1: Quoted prices in active markets for identical instruments
•
Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
•
Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)

Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2016 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents (a):
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
14.1

 
$
—

 
$
14.1

Foreign time deposits
11.8

 
—

 
—

 
11.8

Domestic time deposits
—

 
20.0

 
—

 
20.0

U.S. government sponsored agencies
—

 
1.1

 
—

 
1.1

Money market funds
5.9

 
—

 
—

 
5.9

Total cash equivalents
17.7

 
35.2

 
—

 
52.9

Restricted investment:
4.6

 
—

 
—

 
4.6

Available-for-sale investments (b):
 
 
 
 
 
 
 
Corporate debt securities
—

 
179.4

 
—

 
179.4

U.S. government sponsored agencies
—

 
82.5

 
—

 
82.5

Foreign government obligations
—

 
4.4

 
—

 
4.4

Brokered certificates of deposit
—

 
3.6

 
—

 
3.6

Municipal obligations
—

 
15.4

 
—

 
15.4

Marketable equity securities
767.8

 
—

 
—

 
767.8

Asset-backed securities
—

 
62.5

 
—

 
62.5

Total available-for-sale investments
767.8

 
347.8

 
—

 
1,115.6

Forward foreign exchange contracts (c)
—

 
0.6

 
—

 
0.6

Total financial assets carried at fair value
$
790.1

 
$
383.6

 
$
—

 
$
1,173.7

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
     Forward foreign exchange contracts (d)
$
—

 
$
1.3

 
$
—

 
$
1.3

     Contingent consideration (e)
—

 
—

 
38.5

 
38.5

Total financial liabilities carried at fair value
$
—

 
$
1.3

 
$
38.5

 
$
39.8



Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2015 are classified in the hierarchy as follows (in millions):

58



 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents (a):
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
33.2

 
—

 
$
33.2

Foreign government obligations
—

 
0.6

 
—

 
0.6

Foreign time deposits
11.9

 
—

 
—

 
11.9

U.S. government sponsored agencies
—

 
14.6

 
—

 
14.6

Money market funds
11.3

 
—

 
—

 
11.3

Total cash equivalents
23.2

 
48.4

 
—

 
71.6

Restricted investment:
4.2

 
—

 
—

 
4.2

Available-for-sale investments (b):
 
 
 
 
 
 
 
Corporate debt securities
—

 
156.9

 
—

 
156.9

U.S. government sponsored agencies
—

 
74.8

 
—

 
74.8

Foreign government obligations
—

 
4.6

 
—

 
4.6

Municipal obligations
—

 
6.4

 
—

 
6.4

Marketable equity securities
660.1

 
—

 
—

 
660.1

Asset-backed securities
—

 
54.8

 
—

 
54.8

Total available-for-sale investments
660.1

 
297.5

 
—

 
957.6

Forward foreign exchange contracts (c)
—

 
0.9

 
—

 
0.9

Total financial assets carried at fair value
$
687.5

 
$
346.8

 
—

 
$
1,034.3

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (d)
$
—

 
$
1.1

 
—

 
$
1.1

 Contingent consideration (e)
—

 
—

 
19.1

 
19.1

Total financial liabilities carried at fair value
$
—

 
$
1.1

 
$
19.1

 
$
20.2


(a)
Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.

(b)
Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31,
2016
 
December 31, 2015
 
 
 
 
Short-term investments
$
383.2

 
$
328.7

Other investments
732.4

 
628.9

Total
$
1,115.6

 
$
957.6



(c)
Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.

(d)
Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.

(e)
Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):

59


 
December 31, 2016
 
December 31, 2015
 
 
 
 
Other current liabilities
$
14.5

 
$
13.5

Other long-term liabilities
24.0

 
5.6

   Total
$
38.5

 
$
19.1




In 2012, we recognized a contingent consideration liability for certain milestones of $44.6 million upon our acquisition of a new cell sorting system from Propel. Since 2012, we have paid $28.9 million upon reaching the milestones and have reduced the valuation of the milestones by $12.6 million to its estimated fair value of $3.1 million as of December 31, 2016. The remaining liability was paid in February 2017.

During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a new high performance analytical flow cytometer platform from Propel. At the acquisition date, the contingent consideration was based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount through December 31, 2020. The fair value of the contingent consideration as of the acquisition date was $23.3 million, after the effects of a calculation revision that were reflected in the fourth quarter of 2016. The contingent consideration was recognized at its estimated fair value of $25.4 million as of December 31, 2016.

The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value based on original valuations and updated quarterly for the year ended December 31, 2016 (in millions):

 
2016
 
 
January 1
$
9.1

Cell sorting system:
 
Payment of sales milestone
(3.5
)
Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense
(2.5
)
 
 
Analytical flow cytometer platform:
 
Acquisition of high performance analytical flow cytometer platform
23.3

Increase in estimated fair value of contingent consideration included in Selling, general and administrative expense
2.1

December 31
$
28.5




The following table provides quantitative information about Level 3 inputs for fair value measurement of analytical flow cytometer platform contingent consideration liability as of December 31, 2016. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.

60


 
 
 
Range
 
Valuation Technique
Unobservable Input
From
To
Analytical flow cytometer platform
Probability-weighted income approach
Sales milestones:
 
 
 
 
Discount rate
10
%
 
 
 
Cost of debt
4.7
%
 



In 2014, we recognized a contingent consideration liability upon our acquisition of GnuBIO, Inc.. The contingent consideration for the milestones was valued at $10.7 million at the acquisition date based on assumptions regarding the probability of achieving the milestones, with such amounts discounted to present value. The Level 3 contingent consideration was revalued to a fair value of $10.0 million as of December 31, 2016 and 2015.

To estimate the fair value of Level 2 debt securities as of December 31, 2016 and 2015, our primary pricing provider uses S&P Capital IQ as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. The chosen pricing hierarchy for our Level 2 securities, other than certificates of deposit and commercial paper, is S&P Capital IQ as the primary pricing source and then our custodian as the secondary pricing source. If S&P Capital IQ does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing.

For commercial paper as of December 31, 2016 and 2015, pricing is determined by a straight-line calculation, starting with the purchase price on the date of purchase and increasing to par at maturity. Interest bearing certificates of deposit and commercial paper are priced at par.

Our primary pricing provider performs daily reasonableness testing of S&P Capital IQ prices. Price changes of 5% or greater are investigated and resolved. In addition, we perform a quarterly testing of the S&P Capital IQ prices to custodian reported prices. Prices outside a tolerable variance of approximately 1% are investigated and resolved.

Available-for-sale investments consist of the following (in millions):

 
December 31, 2016
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
179.7

 
$
0.2

 
$
(0.5
)
 
$
179.4

Brokered certificates of deposit
3.6

 
—

 
—

 
3.6

Municipal obligations
15.5

 
—

 
(0.1
)
 
15.4

Asset-backed securities
62.2

 
0.1

 
(0.1
)
 
62.2

U.S. government sponsored agencies
83.1

 
0.1

 
(0.7
)
 
82.5

Foreign government obligations
4.4

 
—

 
—

 
4.4

Marketable equity securities
32.4

 
3.7

 
(0.4
)
 
35.7

 
380.9

 
4.1

 
(1.8
)
 
383.2

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
677.6

 
—

 
732.1

Asset-backed securities
0.3

 
—

 
—

 
0.3

 
54.8

 
677.6

 
—

 
732.4

Total
$
435.7

 
$
681.7

 
$
(1.8
)
 
$
1,115.6


61



 
December 31, 2015
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
157.2

 
$
0.1

 
$
(0.4
)
 
$
156.9

Municipal obligations
6.4

 
—

 
—

 
6.4

Asset-backed securities
54.8

 
—

 
(0.2
)
 
54.6

U.S. government sponsored agencies
74.9

 
0.1

 
(0.2
)
 
74.8

Foreign government obligations
4.6

 
—

 
—

 
4.6

Marketable equity securities
29.4

 
2.7

 
(0.7
)
 
31.4

 
327.3

 
2.9

 
(1.5
)
 
328.7

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
574.2

 
—

 
628.7

Asset-backed securities
0.3

 
—

 
(0.1
)
 
0.2

 
54.8

 
574.2

 
(0.1
)
 
628.9

Total
$
382.1

 
$
577.1

 
$
(1.6
)
 
$
957.6



The unrealized gains of our long-term marketable equity securities are primarily due to our investment in Sartorius AG preferred shares.

The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):

 
December 31,
2016
 
December 31, 2015
 
 
 
 
Fair value of investments in a loss position 12 months or more
$
11.8

 
$
10.4

Fair value of investments in a loss position less than 12 months
$
160.5

 
$
204.0

Gross unrealized losses for investments in a loss position 12 months or more
$
0.3

 
$
0.4

Gross unrealized losses for investments in a loss position less than 12 months
$
1.5

 
$
1.2



The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at December 31, 2016 or at December 31, 2015.

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of December 31, 2016 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains

62


or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign exchange losses, net in the Consolidated Statements of Income.

The following is a summary of our forward foreign currency exchange contracts (in millions):
 
December 31,
 
2016
Contracts maturing in January through March 2017 to sell foreign currency:
 
Notional value
$
16.9

Unrealized loss
$
0.1

Contracts maturing in January through March 2017 to purchase foreign currency:
 
Notional value
$
328.3

Unrealized loss
$
0.6



The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31, 2016 by contractual maturity date (in millions):

 
Amortized
Cost
 
Estimated Fair
Value
 
 
 
 
Mature in less than one year
$
156.1

 
$
156.1

Mature in one to five years
141.0

 
140.7

Mature in more than five years
51.7

 
51.0

Total
$
348.8

 
$
347.8



The estimated fair value of financial instruments that are not recognized at fair value in the Consolidated Balance Sheets and are included in Other investments, are presented in the table below. Fair value has been determined using significant observable inputs, including quoted prices in active markets for similar instruments.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value.  Other investments include financial instruments, the majority of which has fair value based on similar, actively traded stock adjusted for various discounts, including a discount for marketability.  Long-term debt, excluding leases and current maturities, has an estimated fair value based on quoted market prices for the same or similar issues.

The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):


 
December 31, 2016
 
December 31, 2015
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
Other investments
$
92.8

 
$
984.2

 
2
 
$
86.5

 
$
843.2

 
2
Total long-term debt, excluding leases
and current maturities
$
422.5

 
$
454.2

 
2
 
$
421.9

 
$
454.3

 
2


63



We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries.  We own over 35% of the outstanding voting shares (excluding treasury shares) of Sartorius as of December 31, 2016.  The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius’ board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. We account for this investment using the cost method.  The carrying value of this investment is included in Other investments in our Consolidated Balance Sheets. As the stock is thinly traded and in conjunction with the valuation method discussed above, we have classified the estimated fair value as Level 2. The Level 2 classification is appropriate given the valuation method employed, which incorporates an observable input of the fair value of the Sartorius’ actively traded preferred stock.


4.    GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):
 
 
2016
 
 
2015
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
$
207.2

 
$
316.9

 
$
524.1

 
 
$
207.7

 
$
320.9

 
$
528.6

Accumulated impairment losses and write-offs
 
(27.2
)
 
(1.0
)
 
(28.2
)
 
 
(27.2
)
 
(1.0
)
 
(28.2
)
Goodwill, net
 
180.0

 
315.9

 
495.9

 
 
180.5

 
319.9

 
500.4

Acquisitions
 
0.1

 
—

 
0.1

 
 
—

 
—

 
—

Impairment
 
—

 
(13.5
)
 
(13.5
)
 
 
—

 
—

 
—

Currency fluctuations
 
(0.2
)
 
(5.2
)
 
(5.4
)
 
 
(0.5
)
 
(4.0
)
 
(4.5
)
Balances as of December 31:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
207.1

 
311.7

 
518.8

 
 
207.2

 
316.9

 
524.1

Accumulated impairment losses and write-offs
 
(27.2
)
 
(14.5
)
 
(41.7
)
 
 
(27.2
)
 
(1.0
)
 
(28.2
)
Goodwill, net
 
$
179.9

 
$
297.2

 
$
477.1

 
 
$
180.0

 
$
315.9

 
$
495.9



In conjunction with the purchase of certain assets from Propel in January 2016 (see Note 2, "Acquisitions"), we recorded $0.1 million of goodwill and $32.7 million of definite-lived intangible assets: $29.7 million of developed product technology and $3.0 million of covenants not to compete, after the effects of a calculation revision that were reflected in the fourth quarter of 2016.

Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):

64


 
December 31, 2016
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-8
 
$
84.4

 
$
(52.8
)
 
$
31.6

Know how
1-9
 
182.6

 
(136.9
)
 
45.7

Developed product technology
3-12
 
125.9

 
(56.3
)
 
69.6

Licenses
1-9
 
39.0

 
(30.6
)
 
8.4

Tradenames
4-8
 
3.5

 
(2.5
)
 
1.0

Covenants not to compete
2-9
 
7.8

 
(2.5
)
 
5.3

     Total definite-lived intangible assets
 
 
443.2

 
(281.6
)
 
161.6

In-process research and development
 
 
—

 
—

 
—

     Total purchased intangible assets
 
 
$
443.2

 
$
(281.6
)
 
$
161.6


 
December 31, 2015
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
2-10
 
$
84.7

 
$
(46.8
)
 
$
37.9

Know how
1-10
 
184.0

 
(121.6
)
 
62.4

Developed product technology
4-12
 
101.3

 
(48.9
)
 
52.4

Licenses
3-10
 
39.2

 
(28.5
)
 
10.7

Tradenames
5-9
 
3.5

 
(2.4
)
 
1.1

Covenants not to compete
3-7
 
4.8

 
(1.7
)
 
3.1

     Total definite-lived intangible assets
 
 
417.5

 
(249.9
)
 
167.6

In-process research and development
 
 
46.4

 
—

 
46.4

     Total purchased intangible assets
 
 
$
463.9

 
$
(249.9
)
 
$
214.0



In 2016, we fully impaired goodwill and in-process research and development in the amounts of $13.5 million and $46.4 million, respectively, associated with our 2014 acquisition of GnuBIO, Inc. The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows. There were no impairment losses recorded in 2015.

Amortization expense related to purchased intangible assets for the years ended December 31, 2016, 2015 and 2014 was $35.2 million, $36.5 million and $47.8 million, respectively.  Estimated future amortization expense (based on existing purchased intangible assets) for the years ending December 31, 2017, 2018, 2019, 2020, 2021 and thereafter is $27.2 million, $24.2 million, $21.4 million, $19.4 million, $18.4 million, and $51.0 million, respectively.


5.NOTES PAYABLE AND LONG-TERM DEBT


Under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had $205.7 million available for borrowing and usage as of December 31, 2016, which was reduced by $5.4 million that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations.

The principal components of long-term debt are as follows (in millions):

65


 
December 31,
2016
 
December 31, 2015
 
 
 
 
4.875% Senior Notes due 2020, net of discount
$
425.0

 
$
425.0

Less unamortized discount and debt issuance costs
(2.5
)
 
(3.1
)
Long-term debt less unamortized discount and debt issuance costs
422.5

 
421.9

Capital leases and other debt
12.0

 
12.3

 
434.5

 
434.2

Less current maturities
(0.3
)
 
(0.3
)
Long-term debt
$
434.2

 
$
433.9



Senior Notes due 2020

In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due 2020 (4.875% Notes).  The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946%.  The 4.875% Notes pay a fixed rate of interest of 4.875% per year.  We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date.  Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness.  Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. We were in compliance with these covenants as of December 31, 2016. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.
 
Credit Agreement

In June 2014, Bio-Rad entered into a $200.0 million unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of December 31, 2016 or 2015, however, $0.8 million was utilized for domestic standby letters of credit that reduced our borrowing availability. The Credit Agreement matures in June 2019. If we had borrowed against our Credit Agreement, the borrowing rate would have been 2.25% at December 31, 2016.

The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of December 31, 2016.

Maturities of long-term debt at December 31, 2016 are as follows: 2017 - $0.3 million; 2018 - $0.3 million; 2019 - $0.2 million; 2020 - $425.3 million; 2021 - $0.3 million; thereafter - $10.6 million.


66



6. INCOME TAXES

The U.S. and international components of income before taxes are as follows (in millions):

 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
U.S.
 
$
(38.5
)
 
$
48.4

 
$
30.6

International
 
80.1

 
97.4

 
101.0

Income before taxes
 
$
41.6

 
$
145.8

 
$
131.6



The provision for income taxes consists of the following (in millions):

 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
Current tax expense:
 
 

 
 

 
 

U.S. Federal
 
$
16.1

 
$
8.7

 
$
9.6

State
 
3.1

 
1.7

 
3.8

International
 
30.3

 
34.1

 
35.6

Current tax expense
 
49.5

 
44.5

 
49.0

Deferred tax (benefit) expense:
 
 

 
 
 
 

U.S. Federal
 
(42.4
)
 
(0.2
)
 
1.5

State
 
(2.8
)
 
1.2

 
(0.2
)
International
 
(6.0
)
 
(7.1
)
 
(7.3
)
Deferred tax benefit
 
(51.2
)
 
(6.1
)
 
(6.0
)
Non-current tax expense (benefit)
 
15.1

 
(5.6
)
 
(0.3
)
Provision for income taxes
 
$
13.4

 
$
32.8

 
$
42.7



The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:


67


 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
U.S. statutory tax rate
 
35
 %
 
35
 %
 
35
 %
Impact of foreign operations
 
(15
)
 
(4
)
 
(4
)
Foreign dividends, net
 
(40
)
 
(4
)
 
—

Research tax credits
 
(9
)
 
(2
)
 
(3
)
Nontaxable subsidies
 
(4
)
 
(1
)
 
(2
)
Tax settlements and changes to unrecognized tax benefits
 
42

 
(4
)
 
(1
)
Goodwill impairment
 
11

 
—

 
—

Domestic manufacturing deduction
 
(4
)
 
(2
)
 
—

Stock-based compensation
 
3

 
1

 
1

Nondeductible executive compensation
 
3

 
1

 
1

Fines and penalties
 
2

 
—

 
3

Prior period adjustments
 
4

 
1

 
2

U.S. taxation on foreign income
 
2

 
—

 
—

Other
 
2

 
1

 
—

Provision for income taxes
 
32
 %
 
22
 %
 
32
 %


Our effective income tax rate was 32%, 22% and 32% in 2016, 2015 and 2014, respectively. The effective tax rates for 2016 and 2015 included tax benefits from the repatriation of foreign earnings. The effective tax rate for 2016 included additional tax liabilities for unrecognized tax benefits related to the non-deductibility of interest expense
in our foreign jurisdictions.  The effective tax rate for 2014 included nondeductible penalties and losses that were nonrecurring.
  
Our foreign taxes result primarily from income earned in France and Switzerland. Many jurisdictions in which we operate, including Switzerland, Russia, the U.K. and Singapore, have statutory tax rates that are significantly lower than the U.S. statutory tax rate of 35%. Our effective tax rate may be impacted in the future, either favorably or unfavorably, by many factors including, but not limited to, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.

Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):


68


 
 
December 31,
 
 
2016
 
2015
Deferred tax assets:
 
 

 
 

Bad debt, inventory and warranty accruals
 
$
28.4

 
$
26.3

Other post-employment benefits, vacation and other reserves
 
26.3

 
28.1

Tax credit and net operating loss carryforwards
 
96.4

 
80.2

Other
 
35.7

 
23.2

    Total gross deferred tax assets
 
186.8

 
157.8

Valuation allowance
 
(66.4
)
 
(58.3
)
       Total deferred tax assets
 
120.4

 
99.5

Deferred tax liabilities:
 
 
 
 
Property and equipment
 
22.5

 
30.2

Investments and intangible assets
 
287.8

 
271.8

        Total deferred tax liabilities
 
310.3

 
302.0

Net deferred tax liabilities
 
$
(189.9
)
 
$
(202.5
)


At December 31, 2016, Bio-Rad’s international subsidiaries had combined net operating loss carryforwards of $141.3 million.  Of these loss carryforwards, $140.8 million have no expiration date.  We believe that it is more likely than not that the benefit from most of these net operating loss carryforwards will not be realized. We have provided a valuation allowance of $29.6 million relating to these net operating loss carryforwards.

At December 31, 2016, Bio-Rad had U.S. Federal net operating loss carryforwards of approximately $1.9 million as a result of acquisitions. These carryforwards are subject to limitation on their utilization and will expire between 2028 and 2033. At December 31, 2016, Bio-Rad had U.S. Federal foreign tax credit carryforwards of $27.6 million and U.S. Federal research tax credit carryforwards of $3.6 million, $0.4 million of which are subject to limitations on their utilization.

At December 31, 2016, Bio-Rad had approximately $53 million of California net operating loss carryforwards related to the acquisition of QuantaLife. We believe that it is more likely than not that the benefit from these net operating loss carryforwards will not be realized and have recorded a full valuation allowance against these losses. At December 31, 2016, Bio-Rad had a deferred tax asset of $25.9 million relating to California research tax credit carryforwards, including $2.0 million from the acquisition of QuantaLife, which may be carried forward indefinitely.  Based on our judgment and consistent with prior years, we have recorded a full valuation allowance against the deferred tax asset.

We believe that it is more likely than not that certain of these deferred tax assets described above will not be realized in the foreseeable future. If or when recognized, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets at December 31, 2016 will be recognized as a reduction of income tax expense.

Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2013 and forward for the U.S., and the years 2010 and forward for certain foreign jurisdictions, including France, Switzerland and Germany. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

69



The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):
 
 
2016
 
2015
 
2014
Unrecognized tax benefits – January 1
 
$
8.9

 
$
14.2

 
$
16.2

Additions to tax positions related to prior years
 
10.4

 
0.7

 
1.7

Reductions to tax positions related to prior years
 
—

 
(0.2
)
 
(1.5
)
Additions to tax positions related to the current year
 
1.4

 
1.5

 
1.6

Settlements
 
(2.4
)
 
(0.5
)
 
(0.4
)
Lapse of statute of limitations
 
(2.3
)
 
(6.3
)
 
(2.6
)
Currency translation
 
0.1

 
(0.5
)
 
(0.8
)
Unrecognized tax benefits – December 31
 
$
16.1

 
$
8.9

 
$
14.2




Bio-Rad recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. Related to the unrecognized tax benefits noted above, Bio-Rad has accrued interest and penalties of $11.5 million, $3.0 million and $3.8 million as of December 31, 2016, 2015 and 2014, respectively. The total unrecognized tax benefits and interest and penalties of $27.6 million in 2016 was partially offset by prepaid taxes of $12.7 million, for a net amount of $14.9 million.

As of December 31, 2016, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $3.5 million. Substantially all such amounts will impact our effective income tax rate if recognized.

In general, it is our practice and intention to reinvest the earnings of our non-U.S. subsidiaries in their operations. As of December 31, 2016, Bio-Rad had not made a provision for U.S. or additional foreign withholding taxes on approximately $447 million of the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries that are essentially permanent in duration.  Generally, such amounts become subject to U.S. taxation upon remittance of dividends and under certain other circumstances.  If these earnings were repatriated to the U.S., the deferred tax liability associated with these temporary differences would be approximately $47 million.


7.    STOCKHOLDERS' EQUITY

Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B).  Each share of Class A and Class B participates equally in the earnings of Bio-Rad, and is identical in all respects except as follows. Class A has limited voting rights.  Each share of Class A is entitled to one tenth of a vote on most matters, and each share of Class B is entitled to one vote.  Additionally, Class A stockholders are entitled to elect 25% of the Board of Directors and Class B stockholders are entitled to elect 75% of the directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares but no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares.  Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.  The founders of Bio-Rad, the Schwartz family, collectively hold a majority of Bio-Rad’s voting stock.  As a result, the Schwartz family is able to exercise significant influence over Bio-Rad.

Changes to Bio-Rad's issued common stock shares are as follows (in thousands):

70


 
Class A Shares
 
Class B Shares
Balance at January 1, 2014
23,681

 
5,097

B to A conversions
5

 
(5
)
Issuance of common stock
286

 
7

Balance at December 31, 2014
23,972

 
5,099

B to A conversions
18

 
(18
)
Issuance of common stock
240

 
50

Balance at December 31, 2015
24,230

 
5,131

B to A conversions
13

 
(13
)
Issuance of common stock
211

 
6

Balance at December 31, 2016
24,454

 
5,124


Treasury Shares

The Board of Directors has authorized the repurchase of up to $18.0 million of Bio-Rad's common stock, of which $3.3 million has yet to be repurchased in the open market as of December 31, 2016. The Amended and Restated Credit Agreement (Credit Agreement) limits our ability to repurchase our stock. In accordance with the terms of awards under the 2007 Incentive Award Plan, in June 2012, we withheld 122 shares of our Class A common stock and 917 shares of our Class B common stock to satisfy the minimum statutory tax obligations due upon the vesting of restricted stock of certain of our employees, which is considered a repurchase of our stock. All of the restricted stock vested as of December 31, 2013, and therefore we do not anticipate any repurchasing of shares for this purpose. We had no other repurchases of our stock during 2016 or 2015.



71


8.    ACCUMULATED OTHER COMPREHENSIVE INCOME

Accumulated other comprehensive income included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):
 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains on available-for-sale investments
Total Accumulated other comprehensive income
Balances as of January 1, 2015
$
71.2

$
(16.3
)
$
164.0

$
218.9

Other comprehensive (loss) income, before reclassifications
(37.5
)
(6.8
)
325.4

281.1

Amounts reclassified from Accumulated other comprehensive income
—

1.1

(0.9
)
0.2

Income tax effects
—

1.3

(119.4
)
(118.1
)
Other comprehensive (loss) income, net of income taxes
(37.5
)
(4.4
)
205.1

163.2

Balances as of December 31, 2015
$
33.7

$
(20.7
)
$
369.1

$
382.1

Other comprehensive (loss) income, before reclassifications
(32.4
)
0.5

105.1

73.2

Amounts reclassified from Accumulated other comprehensive income
—

2.5

(0.8
)
1.7

Income tax effects
—

(0.9
)
(38.4
)
(39.3
)
Other comprehensive (loss) income, net of income taxes
(32.4
)
2.1

65.9

35.6

Balances as of December 31, 2016
$
1.3

$
(18.6
)
$
435.0

$
417.7



The increases in 2016 and 2015 for net unrealized holding gains on available-for-sale investments were primarily from our ownership in the preferred shares of Sartorius.

The amounts reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:
Income before taxes impact (in millions):
 
 
December 31,
 
 
Components of Comprehensive income
 
2016
2015
 
Location
 
Amortization of foreign other post-employment benefit items
 
$
(2.5
)
$
(1.1
)
 
Selling, general and administrative expense
 
Net holding gains on available for sale investments
 
$
0.8

$
0.9

 
Other (income) expense, net
 

Reclassification adjustments are calculated using the specific identification method.

72





9. SHARE-BASED COMPENSATION/STOCK OPTION AND PURCHASE PLANS

Description of Share-Based Compensation Plans

We believe our share-based compensation plans align the interests of our employees with those of our shareholders.

Stock Option and Award Plans
We have two stock option plans for officers and certain other employees: the 2003 Stock Option Plan (2003 Plan) and the 2007 Incentive Award Plan (2007 Plan).  The 2003 Plan authorized the grant of incentive stock options and non-qualified stock options to employees. The 2007 Plan authorizes the grant of stock options, restricted stock, restricted stock units, stock appreciation rights and other types of equity awards to employees.  We no longer grant stock option grants under the 2003 Plan. Since 2007, all share-based compensation grants have been from the 2007 Plan. A total of 2,250,360 shares have been reserved for issuance of equity awards under the 2007 Plan and may be of either Class A or Class B common stock as specified within the plan.  At December 31, 2016, there were 587,509 shares available to be granted in the future.

Under the above plans, Class A and Class B options are granted at prices not less than fair market value of the underlying common stock on the date of grant.  Generally, options granted have a term of 10 years and vest in increments of 20% per year over a five-year period on the yearly anniversary date of the grant.  Stock awards issued under the 2007 Plan generally vest in increments of 20% per year over a five-year period on the yearly anniversary date of the grant.

Employee Stock Purchase Plans
Our 2011 Employee Stock Purchase Plan (2011 ESPP) provides that eligible employees may contribute up to 10% of their compensation up to $25,000 annually toward the quarterly purchase of our Class A common stock.  The employees’ purchase price is 85% of the lesser of the fair market value of the stock on the first business day or the last business day of each calendar quarter.  

The 2011 ESPP includes two components: a Code Section 423 Component that we intend to qualify as an “employee stock purchase plan” under Section 423 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and a Non-423 Component, which authorizes the grant of purchase rights that does not qualify as an “employee stock purchase plan” under Section 423 of the Code. We have authorized the sale of 600,000 shares of Class A common stock under the 2011 ESPP.

Share-Based Compensation Expense

Included in our share-based compensation expense is the cost related to stock option grants, ESPP stock purchases and restricted stock unit awards.  Share-based compensation expense is allocated to Cost of goods sold, Research and development expense, and Selling, general and administrative expense in the Consolidated Statements of Income.

For 2016, 2015 and 2014, we recognized share-based compensation expense of $19.7 million, $17.0 million and $14.9 million, respectively.  We did not capitalize any share-based compensation expense in inventory.

For options and awards, we amortize the fair value on a straight-line basis.  All stock compensation awards are amortized over the requisite service periods of the awards, which are generally the vesting periods.

73



Stock Options
The following table summarizes stock option activity:

 
 
Shares
 
Weighted-
Average
Exercise Price
 
Weighted-
Average
Remaining
Contractual
Term (in years)
 
Aggregate
Intrinsic
Value
(in millions)
Outstanding, January 1, 2014
 
629,643

 
$
78.72

 
 
 
 
Granted
 
54,000

 
$
119.71

 
 
 
 
Exercised
 
(91,387
)
 
$
63.66

 
 
 
 
Forfeited/expired
 
(10,450
)
 
$
100.29

 
 
 
 
Outstanding, December 31, 2014
 
581,806

 
$
84.50

 
 
 
 
Granted
 
40,500

 
$
139.56

 
 
 
 
Exercised
 
(195,221
)
 
$
61.29

 
 
 
 
Forfeited/expired
 
(380
)
 
$
62.47

 
 
 
 
Outstanding, December 31, 2015
 
426,705

 
$
100.36

 
 
 
 
Granted
 
45,000

 
$
159.37

 
 
 
 
Exercised
 
(15,285
)
 
$
80.70

 
 
 
 
Forfeited/expired
 
(6,850
)
 
$
127.65

 
 
 
 
Outstanding, December 31, 2016
 
449,570

 
$
106.52

 
5.15
 
$
34.1

Vested and expected to vest,
 
 
 
 
 
 
 
 
December 31, 2016
 
437,350

 
$
105.39

 
5.04
 
$
33.6

Exercisable, December 31, 2016
 
314,330

 
$
93.78

 
3.80
 
$
27.8




Intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic value on the date of exercise of stock options exercised during 2016, 2015 and 2014 was approximately $1 million, $13 million and $5 million, respectively. The total grant date fair value of options vested during 2016, 2015 and 2014 was $2.1 million, $2.2 million and $2.1 million, respectively.

Cash received from stock options exercised during 2016, 2015 and 2014 was $1.2 million, $2.9 million and $5.8 million, respectively.  The actual tax benefit realized for the tax deductions from stock options exercised totaled $6.0 million, $9.3 million and $5.3 million in 2016, 2015 and 2014, respectively.

As of December 31, 2016, there was $4.9 million of total unrecognized compensation cost from stock options. This amount is expected to be recognized in the future over a weighted-average period of approximately 3 years.

The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
Expected volatility
 
21
%
 
23
%
 
25
%
Risk-free interest rate
 
1.35
%
 
1.90
%
 
2.35
%
Expected life (in years)
 
7.4

 
7.7

 
8.7

Expected dividend
 
—

 
—

 
—

Weighted-average fair value of options granted
 
$
42.40

 
$
42.74

 
$
43.96




74


Volatility is based on the historical volatilities of our common stock for a period equal to the stock option’s expected life.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the number of years that we estimate, based primarily on historical experience, that the options will be outstanding prior to exercise.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.

Restricted Stock Units
Restricted stock units, which are rights to receive shares of company stock, were granted from 2009 through 2016 under the 2007 Plan.  The fair value of a restricted stock unit is the market value as determined by the closing price of the stock on the day of grant.

The following table summarizes restricted stock unit activity:
 
 

Restricted Stock
Units
 
Weighted-
Average
Grant-Date
Fair Value
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic Value
(in millions)
Outstanding, January 1, 2014
 
375,430

 
$
105.44

 
 
 
 
Granted
 
145,695

 
$
119.56

 
 
 
 
Vested
 
(107,557
)
 
$
98.52

 
 
 
 
Forfeited
 
(36,203
)
 
$
108.17

 
 
 
 
Outstanding, December 31, 2014
 
377,365

 
$
112.60

 
 
 
 
Granted
 
177,110

 
$
139.56

 
 
 
 
Vested
 
(113,347
)
 
$
107.62

 
 
 
 
Forfeited
 
(28,706
)

$
116.19

 
 
 
 
Outstanding, December 31, 2015
 
412,422

 
$
125.30

 
 
 
 
Granted
 
193,025

 
$
159.32

 
 
 
 
Vested
 
(117,203
)
 
$
119.33

 
 
 
 
Forfeited
 
(39,422
)

$
129.80

 
 
 
 
Outstanding, December 31, 2016
 
448,822

 
$
141.09

 
2.16
 
$
81.8



The total grant date fair value of restricted stock units vested in 2016, 2015 and 2014 was $14.0 million, $12.2 million and $10.6 million, respectively. As of December 31, 2016, there was approximately $46.8 million of total unrecognized compensation cost related to restricted stock units.  This amount is expected to be recognized over a remaining weighted-average period of approximately 4 years.

Employee Stock Purchase Plans
The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:

 
Year Ended December 31,
 
2016
 
 
 
2015
 
 
 
2014
Expected volatility
20
%
 
 
 
18
%
 
 
 
15
%
Risk-free interest rate
0.26
%
 
 
 
0.02
%
 
 
 
0.04
%
Expected life (in years)
0.25

 
 
 
0.25

 
 
 
0.25

Expected dividend
—

 
 
 
—

 
 
 
—

Weighted-average fair value
 
 
 
 
 
 
 
 
 
of purchase rights
$
27.36

 
 
 
$
25.08

 
 
 
$
21.88



The major assumptions are primarily based on historical data.  Volatility is based on the historical volatilities of our common stock for a period equal to the expected life of the purchase rights.  The risk-free interest rate is based on

75


the U.S. Treasury yield curve in effect at the time of the grant.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.

We sold 93,605 shares for $11.5 million, 96,634 shares for $10.8 million and 102,222 shares for $10.2 million under the 2011 ESPP to employees in 2016, 2015 and 2014, respectively.  At December 31, 2016, 96,121 shares remain authorized and available for issuance under the 2011 ESPP.

We currently issue new shares to satisfy stock option exercises, restricted stock issuances and ESPP stock purchases.



10. OTHER INCOME AND EXPENSE, NET

Other (income) expense, net includes the following components (in millions):
 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
 
 
 
 
 
 
 
Interest and investment income
 
$
(14.7
)
 
$
(10.1
)
 
$
(13.5
)
Net realized gains on investments
 
(0.8
)
 
(1.6
)
 
—

Other-than-temporary impairment losses on investments
 
0.6

 
0.6

 
0.4

Miscellaneous other (income) expense items, net
 
—

 
—

 
0.1

Other (income) expense, net
 
$
(14.9
)
 
$
(11.1
)
 
$
(13.0
)


Other-than-temporary impairment losses on investments were recorded in 2016, 2015 and 2014 on certain of our available-for-sale investments and a certain equity investment in light of the continuing declines in their market prices at that time.



76


11. SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net income to net cash provided by operating activities is as follows (in millions):

 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
Net income
 
$
28.1

 
$
113.1

 
$
88.8

Adjustments to reconcile net income
 
 

 
 

 
 

to net cash provided by operating activities
 
 

 
 

 
 

Depreciation and amortization
 
142.9

 
131.8

 
149.9

Share-based compensation
 
19.7

 
17.0

 
14.9

(Gains) losses on dispositions of securities
 
(0.2
)
 
(1.0
)
 
0.3

Losses on dispositions of fixed assets
 
0.6

 
0.3

 
0.4

Excess tax benefits from share-based compensation
 
(1.5
)
 
(3.6
)
 
(1.3
)
Changes in fair value of contingent consideration
 
(0.4
)
 
(5.6
)
 
(1.4
)
Decrease (increase) in accounts receivable, net
 
12.5

 
(39.0
)
 
11.1

(Increase) decrease in inventories, net
 
(57.1
)
 
(54.2
)
 
5.8

(Increase) decrease in other current assets
 
(6.6
)
 
0.1

 
(5.7
)
Increase (decrease) in accounts payable
 


 


 


and other current liabilities
 
30.1

 
28.6

 
(9.9
)
Increase in income taxes payable
 
10.7

 
12.7

 
20.4

Decrease in deferred income taxes
 
(51.4
)
 
(6.4
)
 
(6.3
)
Decrease in other long term assets
 
12.7

 
0.3

 
3.6

Increase (decrease) in other long term liabilities
 
8.3

 
(12.2
)
 
(1.3
)
Impairment losses on goodwill and long-lived assets
 
62.3

 
—

 
—

Other
 
5.7

 
4.3

 
4.0

Net cash provided by operating activities
 
$
216.4

 
$
186.2

 
$
273.3

 
 
 
 
 
 
 
Non-cash investing activities:
 
 
 
 
 
 
   Purchased intangible assets
 
$
—

 
$
—

 
$
0.2

   Purchased marketable securities and investments
 
$
0.6

 
$
2.2

 
$
—





77


12. COMMITMENTS AND CONTINGENT LIABILITIES

Rents and Leases

Rental expense under operating leases was $44.4 million, $45.0 million and $46.9 million in 2016, 2015 and 2014, respectively.  Leases are principally for facilities and automobiles. We had no sublease income.

Annual future minimum lease payments at December 31, 2016 under operating leases are as follows: 2017 - $42.1 million; 2018 - $32.1 million; 2019 - $24.7 million; 2020 - $20.4 million; and 2021 and beyond - $38.8 million.

Deferred Profit Sharing Retirement Plan

We have a profit sharing plan covering substantially all U.S. employees.  Contributions are made at the discretion of the Board of Directors.  Bio-Rad has no liability other than for the current year’s contribution.  Contribution expense was $15.1 million, $14.7 million and $13.7 million in 2016, 2015 and 2014, respectively.

Other Post-Employment Benefits

In several foreign locations we are statutorily required to provide a lump sum severance or termination indemnity to our employees.  Under these plans, the vested benefit obligation at December 31, 2016 and 2015 was $68.0 million and $68.6 million, respectively, and has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets.  Most plans are not required to be funded, and as such, there is no trust or other device used to accumulate assets to settle these obligations. However, some of these plans require funding based on local laws in which there is a trust or other device used to accumulate assets to assist in settling these obligations.

Purchase Obligations

As of December 31, 2016, we had obligations that have been recognized on our balance sheet of $142.9 million, which include purchases of goods and services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty. These obligations also include other post-employment benefits in some of our foreign locations as indicated above.

The annual future fixed and determinable portion of our purchase obligations that have been recognized on our balance sheet as of December 31, 2016 are as follows: 2017 - $34.3 million, 2018 - $7.3 million, 2019 - $3.1 million, 2020 - $2.5 million, 2021 - $1.6 million and after 2021 - $94.1 million.

As of December 31, 2016, we had purchase obligations that have not been recognized on our balance sheet of $35.0 million, which include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty.

The annual future fixed and determinable portion of our purchase obligations that have not been recognized on our balance sheet as of December 31, 2016 are as follows: 2017 - $17.5 million, 2018 - $5.0 million, 2019 - $3.5 million, 2020 - $3.5 million, 2021 - $5.5 million and after 2021 - $0 million.

Letters of Credit/Guarantees

In the ordinary course of business, we are at times required to post letters of credit/guarantees.  The letters of credit/guarantees are issued by financial institutions to guarantee our obligations to various parties. We were contingently liable for $5.4 million of standby letters of credit/guarantees with financial institutions as of December 31, 2016.

78



Contingent Consideration

During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a new high performance analytical flow cytometer platform from Propel. At the acquisition date, the contingent consideration was based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount through December 31, 2020. The fair value of the contingent consideration as of the acquisition date was $23.3 million, after the effects of a calculation revision that were reflected in the fourth quarter of 2016. The contingent consideration was recognized at its estimated fair value of $25.4 million as of December 31, 2016.

In 2014, we recognized a contingent consideration liability upon our acquisition of GnuBIO, Inc. The contingent consideration for the milestones was valued at $10.7 million at the acquisition date based on assumptions regarding the probability of achieving the milestones, with such amounts discounted to present value. The Level 3 contingent consideration was revalued to a fair value of $10.0 million as of December 31, 2016 and 2015.

In 2012, we recognized a contingent consideration liability for certain milestones of $44.6 million upon our acquisition of a new cell sorting system from Propel. Since 2012, we have paid $28.9 million upon reaching the milestones and have reduced the valuation of the milestones by $12.6 million to its estimated fair value of $3.1 million as of December 31, 2016. The remaining liability was paid in February 2017.

Concentrations of Labor Subject to Collective Bargaining Agreements

At December 31, 2016, approximately seven percent of Bio-Rad's approximately 3,300 U.S. employees were covered by a collective bargaining agreement, which will expire on November 7, 2019.  Many of Bio-Rad's non-U.S. full-time employees, especially in France, are covered by collective bargaining agreements.


13.    LEGAL PROCEEDINGS

On January 23, 2015, the City of Riviera Beach General Employees’ Retirement System filed a shareholder derivative lawsuit in the Superior Court of California, Contra Costa County, against three of our current directors and one former director. We are also named as a nominal defendant. In the complaint, the plaintiff alleges that our directors breached their fiduciary duty of loyalty by failing to ensure that we had sufficient internal controls and systems for compliance with the Foreign Corrupt Practices Act ("FCPA"); that we failed to provide adequate training on the FCPA; and that based on these actions, the directors have been unjustly enriched. Purportedly seeking relief on our behalf, the plaintiff seeks an award of restitution and unspecified damages, costs and expenses (including attorneys’ fees). On April 23, 2015, we and the individual defendants filed a demurrer requesting dismissal of the complaint in this case. The demurrer was heard on August 6, 2015, and the Court granted the demurrer for failure to make a demand on our Board of Directors on August 17, 2015, but provided leave to amend. On September 4, 2015, the plaintiff filed an amended complaint and simultaneously served a litigation demand letter on our Board of Directors ("Board") via its counsel in this action. The letter demanded that we investigate and bring appropriate legal action against certain individuals, including the defendants in the City of Riviera Beach case and six current and former employees. The plaintiff also moved for a temporary stay in the proceedings, purportedly to enable the Board to respond to the demand. The Board formed a Demand Review Committee to respond to the demand. On February 24, 2016, the Demand Review Committee reported to the Board that it had concluded its investigation and unanimously determined that it is not in the best interests of the Company and its stockholders to pursue litigation against any individuals named in the City of Riviera Beach’s litigation demand letter. On October 6, 2015, we and the individual defendants filed a second demurrer, seeking to dismiss the case for failure to make a timely pre-suit demand. The case was stayed pending mediation. The caption is City of Riviera Beach General Employees’ Retirement System v. Schwartz et al., Case No. C-15-00140. The lawsuit and demand letter are referred to collectively as the “California Action”.

79



On August 13, 2015 and August 18, 2015, respectively, each of International Brotherhood of Electrical Workers Local 38 Pension Fund and Wayne County Employees’ Retirement System filed a stockholder derivative complaint in the Delaware Court of Chancery against four of our current directors and one former director. We are named as a nominal defendant in the complaints. The complaints allege that the defendants failed to cause us to develop internal controls sufficient to ensure our compliance with the FCPA. The plaintiffs assert claims for breach of fiduciary duty and unjust enrichment and request an award of the damages we sustained as a result of the alleged violations, among other relief. The two lawsuits were consolidated on August 27, 2015.  The case was stayed pending mediation. The caption of the consolidated case is In re Bio-Rad Laboratories, Inc. Stockholder Litigation, Consol. C.A. No. 11387-VCN (Del. Ch.). The cases filed in the Delaware Court of Chancery, together with the California Action, are referred to collectively as the “Derivative Actions”.

The parties filed a Stipulation dated November 4, 2016 with the Superior Court of California for Contra Costa County that sets forth the terms of a proposed settlement of the Derivative Actions. The proposed settlement includes the dismissal with prejudice of all claims asserted in the Derivative Actions, an agreed-upon set of revised corporate procedures, and no monetary payment other than an award of attorneys’ fees and costs to the plaintiffs’ counsel. We and the other defendants do not admit any liability or fault in connection with the proposed settlement. On December 22, 2016 the Superior Court of California for Contra Costa County issued an order granting preliminary approval of this proposed settlement. Pursuant to the order, the Court will hold a hearing for final approval of the settlement on March 2, 2017, and any objections to the settlement were required to be filed in writing with the Court on or before February 15, 2017.

On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The parties engaged in mediation of the case on April 19, 2016 and on September 14, 2016. The mediations did not result in a settlement. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million, plus prejudgment interest of $141,608, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. We are considering an appeal of the judgment.

Bio-Rad received three notices of violations from the Bay Area Air Quality Management District (“District”). The District alleges that we operated three (3) power generation units without appropriate monitoring and recordkeeping and exceeded permissible levels of emissions during those operations. We are cooperating with the District and are investigating the allegations. No formal proceeding has been initiated by the District.

We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.


80



14. SEGMENT INFORMATION

Bio-Rad is a multinational manufacturer and worldwide distributor of its own life science research products and clinical diagnostics products.  We have two reportable segments:  Life Science and Clinical Diagnostics.  These reportable segments are strategic business lines that offer more than 8,000 different products and services and require different marketing strategies. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research.  These products are sold to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories and government and industrial research facilities.

The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market.  These products are sold to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories and insurance and forensic testing laboratories.

Other Operations include the remainder of our Analytical Instruments segment.

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. The accounting policies of the segments are the same as those described in Significant Accounting Policies (see Note 1).  Segment profit or loss includes an allocation of corporate expense based upon sales and an allocation of interest expense based upon accounts receivable and inventories.  The difference between total segment allocated interest expense, depreciation and amortization, and capital expenditures and the corresponding consolidated amounts is attributable to our corporate headquarters.  Segments are expected to manage only assets completely under their control.  Accordingly, segment assets include primarily accounts receivable, inventories and gross machinery and equipment.  Goodwill balances have been included in corporate for segment reporting purposes.

Information regarding industry segments at December 31, 2016, 2015, and 2014 and for the years then ended is as follows (in millions):


81


 
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
Segment net sales 
2016
 
$
730.7

 
$
1,323.3

 
$
14.2

 
2015
 
695.0

 
1,310.4

 
14.0

 
2014
 
728.3

 
1,432.3

 
14.4

 
 
 
 
 
 
 
 
Allocated interest expense
2016
 
$
6.4

 
$
15.5

 
$
—

 
2015
 
6.1

 
15.4

 
0.1

 
2014
 
5.5

 
15.9

 
0.1

 
 
 
 
 
 
 
 
Depreciation and amortization
2016
 
$
31.7

 
$
80.5

 
$
—

 
2015
 
30.7

 
77.8

 
0.1

 
2014
 
33.2

 
95.8

 
—

 
 
 
 
 
 
 
 
Segment (loss) profit
2016
 
$
(19.2
)
 
$
57.0

 
$
0.9

 
2015
 
(0.7
)
 
152.4

 
0.7

 
2014
 
(14.7
)
 
167.1

 
1.2

 
 
 
 
 
 
 
 
Segment assets
2016
 
$
381.4

 
$
918.0

 
$
4.9

 
2015
 
390.5

 
878.3

 
4.4

 
 
 
 
 
 
 
 
Capital expenditures
2016
 
$
14.3

 
$
67.1

 
$
—

 
2015
 
8.2

 
51.3

 
0.1

Net corporate operating expense consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. In 2014, this included the accrual of $20.1 million associated with the U.S. Securities and Exchange Commission and Department of Justice investigations relating to the U.S. Foreign Corrupt Practices Act, for which a final settlement was reached in the fourth quarter of 2014. The following reconciles total segment profit to consolidated income before taxes (in millions):
 
 
 
Year Ended December 31,
 
2016
 
2015
 
2014
Total segment profit
$
38.7

 
$
152.4

 
$
153.6

Foreign exchange losses
(4.5
)
 
(10.2
)
 
(9.3
)
Net corporate operating, interest and other expense, net not allocated to segments
(7.5
)
 
(7.5
)
 
(25.7
)
Other income (expense), net
14.9

 
11.1

 
13.0

Consolidated income before taxes
$
41.6

 
$
145.8

 
$
131.6




The following reconciles total segment assets to consolidated total assets (in millions):


82


 
 
December 31,
 
 
2016
 
2015
Total segment assets
 
$
1,304.3

 
$
1,273.2

Cash and other current assets
 
980.3

 
926.9

Property, plant and equipment, net, excluding
 

 

  segment specific gross machinery and equipment
 
81.6

 
46.1

Goodwill, net
 
477.1

 
495.9

Other long-term assets
 
1,007.2

 
967.6

Total assets
 
$
3,850.5

 
$
3,709.7




The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):

 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
Europe
 
$
742.2

 
$
763.7

 
$
901.7

Pacific Rim
 
427.1

 
392.2

 
417.5

United States
 
770.6

 
735.0

 
704.9

Other (primarily Canada and Latin America)
 
128.3

 
128.5

 
150.9

Total net sales
 
$
2,068.2

 
$
2,019.4

 
$
2,175.0


The following presents Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):

 
 
December 31,
 
 
2016
 
2015
Europe
 
$
221.1

 
$
204.4

Pacific Rim
 
16.1

 
15.1

United States  
 
1,084.7

 
962.6

Other (primarily Canada and Latin America)
 
12.3

 
9.1

Total Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes
 
$
1,334.2

 
$
1,191.2




15.    RESTRUCTURING COSTS

For the year ended December 31, 2016, we recorded $12.5 million related to restructuring actions that include the elimination or relocation of various positions. These actions are generally intended to streamline and focus our efforts and more properly align our cost structure with projected future revenue streams.
 
The following table summarizes the activity of our restructuring reserves for severance (in millions):


83


 
 
Life Science
 
Clinical Diagnostics
 
Total
Balance at December 31, 2015
 
$
—

 
$
—

 
$
—

Charged to expense
 
4.1

 
7.6

 
11.7

Adjustment to expense
 
0.3

 
0.5

 
0.8

Cash payments
 
(1.0
)
 
(2.0
)
 
(3.0
)
Foreign currency translation gains
 
(0.2
)
 
(0.3
)
 
(0.5
)
Balance at December 31, 2016
 
$
3.2

 
$
5.8

 
$
9.0



In May 2016, management announced that it will take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance ERP platform, are expected to be incurred through 2019. As a result, we recorded approximately $12.5 million in restructuring charges related to severance and other employee benefits for the year ended December 31, 2016, of which $9.0 million is anticipated to be paid through 2019. The liability of $9.0 million as of December 31, 2016 encompassed a short-term liability of $6.4 million and a long-term liability of $2.6 million. The amounts recorded were reflected in Cost of goods sold of $2.1 million, and in Selling, general and administrative expense of $10.4 million in the Consolidated Statements of Income for the year ended December 31, 2016. The amounts adjusted were primarily for additional positions identified for elimination, partially offset by employees finding other positions within Bio-Rad or leaving prematurely.


16. QUARTERLY FINANCIAL DATA (UNAUDITED)

Summarized quarterly financial data for 2016 and 2015 are as follows (in millions, except per share data):

 
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2016
 
 
 
 
 
 
 
 
Net sales
 
$
471.2

 
$
516.8

 
$
508.7

 
$
571.5

Gross profit
 
264.0

 
280.2

 
279.5

 
314.4

Net income (loss)
 
12.3

 
18.0

 
18.4

 
(20.6
)
Basic earnings (loss) per share
 
$
0.42

 
$
0.61

 
$
0.63

 
$
(0.70
)
Diluted earnings (loss) per share
 
$
0.42

 
$
0.61

 
$
0.62

 
$
(0.70
)
 
 
 
 
 
 
 
 
 
2015
 
 
 
 
 
 
 
 
Net sales
 
$
472.8

 
$
506.1

 
$
470.0

 
$
570.6

Gross profit
 
270.1

 
279.6

 
263.5

 
308.5

Net income
 
17.8

 
28.4

 
17.4

 
49.5

Basic earnings per share
 
$
0.61

 
$
0.98

 
$
0.59

 
$
1.69

Diluted earnings per share
 
$
0.61

 
$
0.97

 
$
0.59

 
$
1.68




Note: As a result of the net loss for the three months ended December 31, 2016,
all potentially issuable common shares have been excluded from the diluted shares
used in the computation of earnings per share as their effect was anti-dilutive.


84



17. SUBSEQUENT EVENT

On February 15, 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately $87 million including certain assumed net liabilities. Cash payments at closing were $82.9 million. The acquisition will be included in our Life Science segment’s results of operations from the acquisition date and will be accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill to be recorded will not be deductible for income tax purposes.
We are presently unable to report the purchase price allocation or the evaluation of the transaction, as more time is needed to complete the information transfer from the seller and include all information into a valuation of individual assets and liabilities.

RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. We believe that RainDance's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital™ PCR, offering customers with solutions for a wide range of nucleic acid detection applications.


ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

Not applicable.



ITEM 9A.  CONTROLS AND PROCEDURES

(a)
Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
 
Subject to the limitations noted above, our management, with the participation of our CEO and CFO, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the year covered by this Annual Report on Form 10-K. Based on that evaluation, the CEO and CFO have concluded that, as of such date, our disclosure controls and procedures were effective to meet the objective for which they were designed and operate at the reasonable assurance level.


85


(b) Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company as defined in Rule 13a-15(f) or 15d-15(f) of the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Our management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2016 using the criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO"). Based on this assessment and those criteria, management concluded that our internal control over financial reporting was effective as of December 31, 2016. Our internal control over financial reporting has been audited by KPMG LLP, an independent registered public accounting firm, as stated in their report, which appears in Part II, Item 8 of this Form 10-K.


ITEM 9B.  OTHER INFORMATION

None.


PART III.

ITEM 10.  DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Part of the information required to be furnished pursuant to this item is incorporated by reference from portions of Bio-Rad’s definitive proxy statement to be mailed to stockholders in connection with our 2017 annual meeting of stockholders (the “2017 Proxy Statement”) under “Election of Directors,” “Committees of the Board of Directors” and “Section 16(a) Beneficial Ownership Reporting Compliance.”

Bio-Rad’s Board of Directors has determined that Mr. Louis Drapeau is an “audit committee financial expert,” as defined in Item 407(d)(5) of Regulation S-K.  Mr. Drapeau is also an “independent” director, as determined in accordance with the independence standards set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and Section 303A.02 of the New York Stock Exchange (NYSE) Listed Company Manual.

We have adopted a code of business ethics and conduct that applies to our principal executive officer, principal financial officer, controller and all other employees and is available through the Corporate Governance section of our website (www.bio-rad.com).  We will also provide a copy of the code of ethics to any person, without charge, upon request, by writing to us at “Bio-Rad Laboratories, Inc., Investor Relations, 1000 Alfred Nobel Drive, Hercules, CA  94547.” We intend to satisfy any disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of the code of ethics by posting such information on the Corporate Governance section of our website (www.bio-rad.com).

86




ITEM 11.  EXECUTIVE COMPENSATION

The information required to be furnished pursuant to this item is incorporated by reference from portions of the 2017 Proxy Statement under “Compensation Discussion and Analysis,” “Summary Compensation Table,” “Grants of Plan-Based Awards,” “Outstanding Equity Awards at Fiscal Year-End,” “Option Exercises and Stock Vested Table,” “Pension Benefits,” “Nonqualified Defined Contribution and Other Nonqualified Deferred Compensation Plans,” “Potential Payments on Termination or Change in Control,” “Director Compensation” and “Compensation Committee Interlocks and Insider Participation.”  In addition, the information from a portion of the 2017 Proxy Statement under “Compensation Committee Report” is incorporated herein by reference and furnished on this Form 10-K and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933.



ITEM 12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Part of the information required to be furnished pursuant to this item is incorporated by reference from a portion of the 2017 Proxy Statement under “Principal and Management Stockholders.”

Equity Compensation Plan Information as of December 31, 2016
Plan category
 
Number of securities
to be issued
upon exercise of outstanding options,
warrants and rights
 
Weighted-average exercise price of
outstanding options,
warrants and rights
 
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
 
 
(a)
 
(b)(3)
 
(c)
Equity compensation plans approved by
 
 
 
 
 
 
 
 
security holders (1)
 
898,392

 
$
106.52

 
683,630

 
(2)
Equity compensation plans not approved by
 
 
 
 
 
 
 
 
security holders
 
—

 
—

 
—

 
 
Total
 
898,392

 
$
106.52

 
683,630

 
 

(1)
Consists of the 2003 Stock Option Plan of Bio-Rad Laboratories, Inc., the Bio-Rad Laboratories, Inc. 2007 Incentive Award Plan, and the Bio-Rad Laboratories, Inc. 2011 Employee Stock Purchase Plan.
(2)
Consists of 587,509 shares available under the Bio-Rad Laboratories, Inc. 2007 Incentive Award Plan and 96,121 shares available under the Bio-Rad Laboratories, Inc. 2011 Employee Stock Purchase Plan.
(3)
Excludes Restricted Stock Units.


ITEM 13.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE

The information required to be furnished pursuant to this item is incorporated by reference from portions of the 2017 Proxy Statement under “Transactions with Related Persons” and “Committees of the Board of Directors.”


ITEM 14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required to be furnished by this item is incorporated by reference from a portion of the 2017 Proxy Statement under “Report of the Audit Committee of the Board of Directors.”

87



PART IV.

ITEM 15.  EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
 
 
 
(a)1
Index to Financial Statements – See Item 8 of Part II of this report “Financial Statements and
 
Supplementary Data" on page 40 for a list of financial statements.
 
 
 
2
Schedule II Valuation and Qualifying Accounts
 
 
 
 
All other financial statement schedules are omitted because they are not required or the required information is included in the consolidated financial statements or the notes thereto.
 
3
Index to Exhibits
 
 
The exhibits listed in the accompanying Index to Exhibits on pages 90 through 92 of this report are filed or incorporated by reference as part of this report.
 

BIO-RAD LABORATORIES, INC.
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
Years Ended December 31, 2016, 2015, and 2014
(in thousands)


Allowance for doubtful accounts receivable
 
 
Balance at
Beginning
of Year
 
Additions
Charged to Costs
and Expenses
 
Deductions
 
Balance at
End of Year
2016
 
$
24,418

 
$
3,785

 
$
(4,836
)
 
$
23,367

2015
 
$
27,973

 
$
8,783

 
$
(12,338
)
 
$
24,418

2014
 
$
32,471

 
$
7,164

 
$
(11,662
)
 
$
27,973




Valuation allowance for current and long-term deferred tax assets*
 
 
Balance at
Beginning
of Year
 
Additions Charged
(Credited) to Income
Tax Expense
 
Deductions
 
Balance at 
End of Year 
2016
 
$
58,277

 
$
8,126

 
$
—

 
$
66,403

2015
 
$
58,615

 
$
(338
)
 
$
—

 
$
58,277

2014
 
$
64,011

 
$
(5,396
)
 
$
—

 
$
58,615

*2014 is the only year presented that has current and long-term valuation allowances for deferred tax assets due to the adoption of ASU 2015-17 in 2015 on a prospective basis. Therefore, for the years 2016 and 2015, the valuation allowance is long-term for deferred tax assets.


88




SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIO-RAD LABORATORIES, INC.
 
 
By:
/s/ Christine A. Tsingos
 
Christine A. Tsingos
 
Executive Vice President, Chief Financial Officer
 
 
Date:
February 28, 2017

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 
 
 
Principal Executive Officer:
Chairman of the Board, President
 
/s/ Norman Schwartz
and Chief Executive Officer
February 28, 2017
(Norman Schwartz)
 
 
 
 
 
Principal Financial Officer:
 
 
/s/ Christine A. Tsingos
Executive Vice President,
 
(Christine A. Tsingos)
Chief Financial Officer
February 28, 2017
 
 
 
Principal Accounting Officer:
 
 
/s/ James R. Stark
Vice President, Corporate Controller
February 28, 2017
(James R. Stark)
 
 
 
 
 
Other Directors:
 
 
/s/ Louis Drapeau
Director
February 28, 2017
(Louis Drapeau)
 
 
 
 
 
/s/ Robert M. Malchione
Director
February 28, 2017
(Robert M. Malchione)
 
 
 
 
 
/s/ Joel McComb
Director
February 28, 2017
(Joel McComb)
 
 
 
 
 
/s/ Deborah J. Neff 
Director
February 28, 2017
(Deborah J. Neff)
 
 
 
 
 
/s/ Alice N. Schwartz
Director
February 28, 2017
(Alice N. Schwartz)
 
 


89


 
BIO-RAD LABORATORIES, INC.
INDEX TO EXHIBITS ITEM 15(a)3
 
Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed under the Securities Exchange Act of 1934.”
 
Exhibit No.
 
 
 
3.1

Restated Certificate of Incorporation of Bio-Rad Laboratories, Inc. (1)
 
 
3.1.1

Certificate of Amendment to Restated Certificate of Incorporation of Bio-Rad Laboratories, Inc. (1)
 
 
3.2

Amended and Restated Bylaws of Bio-Rad Laboratories, Inc. (2)
 
 
4.1

Indenture dated as of December 9, 2010 for 4.875% Senior Notes due 2020 among Bio-Rad Laboratories, Inc.,
 
as Issuer, and Wilmington Trust FSB, as Trustee.  (3)
 
 
10.1

Credit Agreement, dated as of June 20, 2014, by and among Bio-Rad Laboratories, Inc., the lenders referred to therein, JPMorgan Chase Bank, N.A., as administrative agent, Union Bank of California, N.A. and Wells Fargo Bank, N.A. as co-syndication agents, and Bank of America, N.A. and HSBC Bank USA, National Association, as co-documentation agents. (4)
 
 
10.2

Bio-Rad Laboratories, Inc. 2011 Employee Stock Purchase Plan. (5)
 
 
10.3

Employees’ Deferred Profit Sharing Retirement Plan (Amended and Restated effective January 1, 1997). (6)
 
 
10.4

2003 Stock Option Plan. (7)
 
 
10.4.1

Amendment to the 2003 Stock Option Plan of Bio-Rad Laboratories, Inc. (8)
 
 
10.4.2


Second Amendment to the 2003 Stock Option Plan of Bio-Rad Laboratories, Inc., dated March 1, 2012. (9)

10.5

2007 Incentive Award Plan. (10)
 
 
10.5.1

Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2007
 
Incentive Award Plan. (11)
 
 
10.5.2

Amendment to the Bio-Rad Laboratories, Inc. 2007 Incentive Award Plan. (12)
 
 
10.6

Form of Indemnification Agreement. (13)
 
 
10.7

Settlement Agreement and General Release. (14)
 
 
10.8

Non-Prosecution Agreement effective November 3, 2014 between the U.S. Department of Justice and Bio-Rad
 
Laboratories, Inc. (15)
 
 
10.9

Securities and Exchange Commission Order effective November 3, 2014. (15)
 
 

90


 
 
Exhibit No.
 
 
 
21.1

Listing of Subsidiaries.
 
 
23.1

Consent of Independent Registered Public Accounting Firm.
 
 
31.1

Certification of Chief Executive Officer Required by Rule 13a-14(a) (17CFR 240.13a-14(a)).
 
 
31.2

Certification of Chief Financial Officer Required by Rule 13a-14(a) (17CFR 240.13a-14(a)).
 
 
32.1

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
 
906 of the Sarbanes-Oxley Act of 2002.
 
 
32.2

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
 
906 of the Sarbanes-Oxley Act of 2002.
 
 
101.INS
The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCH
XBRL Taxonomy Extension Schema Document
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
XBRL Taxonomy Extension Labels Linkbase Document
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
(1
)
Incorporated by reference to the Exhibits to Bio-Rad’s Form 10-K filing for the fiscal year ended
 
December 31, 2010.
 
 
(2
)
Incorporated by reference to the Exhibit to Bio-Rad’s Form 8-K filing, dated March 31, 2014.
 
 
(3
)
Incorporated by reference to Exhibit 4.1 to Bio-Rad’s Form 8-K filing, dated December 9, 2010.
 
 
(4
)
Incorporated by reference to the Exhibits to Bio-Rad’s 8-K filing, dated June 26, 2014.
 
 
(5
)
Incorporated by reference to Exhibit 10.9 to Bio-Rad's June 30, 2011 Form 10-Q filing, dated August 4, 2011.
 
 
(6
)
Incorporated by reference to Exhibit 10.6 to Bio-Rad’s September 30, 1997 Form 10-Q filing, dated
 
November 13, 1997.
 
 
(7
)
Incorporated by reference to Exhibit 10.7 to Bio-Rad’s March 31, 2003 Form 10-Q filing, dated
 
May 13, 2003.
 
 
(8
)
Incorporated by reference to Exhibit 10.7.1 to Bio-Rad’s March 31, 2007 Form 10-Q filing, dated May 4, 2007.
 
 
(9
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s June 30, 2012 Form 10-Q filing, dated August 9, 2012.
 
 
(10
)
Incorporated by reference to Exhibit 4.1 to Bio-Rad’s Form S-8 filing, dated July 30, 2007.

91


 
 
(11
)
Incorporated by reference to Exhibit 10.8.1 to Bio-Rad’s September 30, 2009 Form 10-Q filing, dated November 4, 2009.
 
 
(12
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s March 31, 2014 Form 10-Q filing, dated May 8, 2014.
 
 
(13
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 8-K filing, dated June 28, 2011.
 
 
(14
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated November 7, 2014.
 
 
(15
)
Incorporated by reference to the Exhibits to Bio-Rad’s Form 10-K filing for the fiscal year ended December 31, 2014.


92
 EX-21.1 2 ex211123116.htm EXHIBIT 21.1 Exhibit


Exhibit 21.1
LISTING OF SUBSIDIARIES
 
 
 
 
 
JURISDICTION OF
SUBSIDIARY
 
ORGANIZATION
 
 
 
Bio-Rad Laboratories Pty. Limited
 
Australia
Bio-Rad Laboratories Ges.m.b.H.
 
Austria
DiaMed Österreich G.m.b.H.
 
Austria
Bio-Rad Laboratories N.V.
 
Belgium
Research Specialties for Laboratories N.V.
 
Belgium
DiaMed Benelux, N.V.
 
Belgium
Bio-Rad Laboratorios Brasil Ltda.
 
Brazil
DiaMed Latino America S.A.
 
Brazil
Bio-Metrics Properties, Limited
 
California, USA
Bio-Rad Laboratories (Israel) Inc.
 
California, USA
Bio-Rad Pacific Limited
 
California, USA
Bio-Rad Laboratories (Canada) Co., Limited
 
Canada
Bio-Rad Laboratories (Shanghai) Co., Limited
 
China
Bio-Rad (Shanghai) Life Science R&D Co. Ltd.
 
China
Bio-Rad Spol. S.R.O.
 
Czech Republic
Bio-Rad Export LLC
 
Delaware, USA
Bio-Metrics Ltd.
 
Delaware, USA
Bio-Rad QL, Inc.
 
Delaware, USA
GnuBIO Inc.
 
Delaware, USA
DiaMed Fennica Oy
 
Finland
Bio-Rad France Holding SAS
 
France
Bio-Rad Innovations SAS
 
France
Bio-Rad Laboratories SAS
 
France
Bio-Rad
 
France
Bio-Rad 2
 
France
Bio-Rad Services France
 
France
DiaMed France SA
 
France
Bio-Rad Laboratories G.m.b.H.
 
Germany
Bio-Rad German Holding G.m.b.H.
 
Germany
DiaMed Diagnostika Deutschland G.m.b.H.
 
Germany
Bio-Rad Medical Diagnostics G.m.b.H.
 
Germany
Bio-Rad AbD Serotec GmbH
 
Germany
Bio-Rad Laboratories Logistik GmbH
 
Germany
 
 
 
 
 
 
 
 
 

1


LISTING OF SUBSIDIARIES- continued
 
 
 
 
 
JURISDICTION OF
SUBSIDIARY
 
ORGANIZATION
 
 
 
Bio-Rad Laboratories M E.P.E.
 
Greece
Bio-Rad China Ltd.
 
Hong Kong
Bio-Rad Hungary Trading Ltd.
 
Hungary
IMV Medical Information Division, Inc.
 
Illinois, USA
Bio-Rad Laboratories (India) Private Limited
 
India
Bio-Rad Haifa Ltd.
 
Israel
Bio-Rad Laboratories S.r.l.
 
Italy
Bio-Rad Laboratories K.K.
 
Japan
Bio-Rad Korea Limited
 
Korea
Bio-Rad Luxembourg S.à.r.l.
 
Luxembourg
International Marketing Ventures, Limited
 
Maryland, USA
Bio-Rad S.A.
 
Mexico
Bio-Rad Laboratories B.V.
 
The Netherlands
Bio-Rad Polska Sp. z o.o.
 
Poland
Bio-Rad Laboratoires-Aparelhos e Reagentes Hospitalares, LDA
 
Portugal
Bio-Rad Laboratorii OOO
 
Russia
Bio-Rad Laboratories (Singapore) Pte. Limited
 
Singapore
Bio-Rad Laboratories (Pty) Limited
 
South Africa
Bio-Rad Laboratories S.A.
 
Spain
Distr. de Analitica para Medicina Iberica S.A.
 
Spain
Bio-Rad Laboratories AB
 
Sweden
DiaMed Holding G.m.b.H.
 
Switzerland
DiaMed (Schweiz) G.m.b.H.
 
Switzerland
DiaMed G.m.b.H.
 
Switzerland
Bio-Rad Laboratories AG
 
Switzerland
Bio-Rad Laboratories Limited
 
Thailand
DiaMed South East Asia Ltd.
 
Thailand
Bio-Rad Ltd.
 
United Kingdom
Bio-Rad Laboratories Limited
 
United Kingdom
DiaMed (G.B.) Limited
 
United Kingdom
Bio-Rad AbD Serotec Ltd
 
United Kingdom
Bio-Rad Services UK Limited
 
United Kingdom
 
 
 
 
 
 
 
 
 


2
 EX-23.1 3 ex231123116.htm EXHIBIT 23.1 Exhibit


Exhibit 23.1




Consent of Independent Registered Public Accounting Firm




The Board of Directors
Bio-Rad Laboratories, Inc.

We consent to the incorporation by reference in the registration statement on Form S-3 (No. 333‑170981) and on Forms S-8 (Nos. 333-144962, 333-133507, 333-124187, 333-53335, 333-53337, 333-179876, 333-197979 and 333-206885) of Bio-Rad Laboratories, Inc. of our reports dated February 28, 2017, with respect to the consolidated balance sheets of Bio-Rad Laboratories, Inc. and subsidiaries (the Company) as of December 31, 2016 and 2015, and the related consolidated statements of income, comprehensive income, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2016, and financial statement schedule, and the effectiveness of internal control over financial reporting as of December 31, 2016, which reports appear in the December 31, 2016 annual report on Form 10‑K of Bio-Rad Laboratories, Inc.

                            /s/ KPMG LLP
San Francisco, California
February 28, 2017



EX-31.1 4 ex311123116.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1

Certification of Chief Executive Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Norman Schwartz, certify that:

1.
I have reviewed this annual report on Form 10-K of Bio-Rad Laboratories, Inc.

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:
February 28, 2017
 
/s/ Norman Schwartz
 
 
 
Norman Schwartz, Chairman of the Board, President and
 
 
 
    Chief Executive Officer



 EX-31.2 5 ex312123116.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2

Certification of Chief Financial Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Christine A. Tsingos, certify that:

1.
I have reviewed this annual report on Form 10-K of Bio-Rad Laboratories, Inc.

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date:
February 28, 2017
 
/s/ Christine A.Tsingos
 
 
 
Christine A. Tsingos, Executive Vice President,
 
 
 
   Chief Financial Officer


 EX-32.1 6 ex321123116.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1




Certification of Periodic Report


I, Norman Schwartz, Chief Executive Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Saran's-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)
the Annual Report on Form 10-K of the Company for the year ended December 31, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:
February 28, 2017
 
/s/ Norman Schwartz
 
 
 
Norman Schwartz, Chairman of the Board, President and
 
 
 
    Chief Executive Officer


The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Annual Report or as a separate disclosure document.


 EX-32.2 7 ex322123116.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2




Certification of Periodic Report


I, Christine A. Tsingos, Chief Financial Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)
the Annual Report on Form 10-K of the Company for the year ended December 31, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date:
February 28, 2017
 
/s/ Christine A. Tsingos
 
 
 
Christine A. Tsingos, Executive Vice President,
 
 
 
   Chief Financial Officer

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Annual Report or as a separate disclosure document.



 EX-101.SCH 8 bio-20161231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2114100 - Disclosure - 10. Other Income and Expenses link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - 10. Other Income and Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - 10. Other Income and Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - 11. Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - 11. Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - 11. Supplemental Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - 12. Commitments & Contingent Liabilities link:presentationLink link:calculationLink link:definitionLink 2416401 - Disclosure - 12. Commitments & Contingent Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - 12. Commitments & Contingent Liabilities Period Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - 13. Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 2421401 - Disclosure - 13. Legal Proceedings Legal Proceedings (Details) link:presentationLink link:calculationLink link:definitionLink 2424404 - Disclosure - 14. Segment Information Segment Asset Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2424405 - Disclosure - 14. Segment Information Segment Information by Geographical Location (Details) link:presentationLink link:calculationLink link:definitionLink 2424403 - Disclosure - 14. Segment Information Segment Profit Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2124100 - Disclosure - 14. Segment Reporting link:presentationLink link:calculationLink link:definitionLink 2424402 - Disclosure - 14. Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 2324301 - Disclosure - 14. Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 2425402 - Disclosure - 15. Restructuring Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2125100 - Disclosure - 15. Restructuring Costs (Notes) link:presentationLink link:calculationLink link:definitionLink 2325301 - Disclosure - 15. Restructuring Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 2127100 - Disclosure - 16. Quarterly Financial Data link:presentationLink link:calculationLink link:definitionLink 2427402 - Disclosure - 16. Quarterly Financial Data (Details) link:presentationLink link:calculationLink link:definitionLink 2327301 - Disclosure - 16. Quarterly Financial Data (Tables) link:presentationLink link:calculationLink link:definitionLink 2429402 - Disclosure - 17. Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink 2129100 - Disclosure - 17. Subsequent Event (Notes) link:presentationLink link:calculationLink link:definitionLink 2329301 - Disclosure - 17. Subsequent Event (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - 1. Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401406 - Disclosure - 1. Significant Accounting Policies Details (Details) link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - 1. Significant Accounting Policies Earnings per share (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - 1. Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - 1. Significant Accounting Policies Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - 1. Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - 1. Significant Accounting Policies Warranty rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - 2. Acquisitions link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - 2. Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2403407 - Disclosure - 3. Fair Value Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - 3. Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - 3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2403408 - Disclosure - 3. Fair Value Measurements Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - 3. Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - 3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - 3. Fair Value Measurements Foreign Exchange Forward Contracts (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - 3. Fair Value Measurements Short-term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - 3. Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - 4. Intangible Assets, Goodwill and Other link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - 4. Intangible Assets, Goodwill and Other (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - 5. Notes Payable and Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - 5. Notes Payable and Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - 5. Notes Payable and Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - 6. Income Taxes link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - 6. Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - 6. Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - 6. Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - 7. Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - 7. Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - 7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - 7. Stockholders' Equity Treasury Shares (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - 8. Accumulated Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - 8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - 8. Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - 9. Share-based Compensation link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - 9. Share-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - 9. Share-based Compensation Restricted Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - 9. Share-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Consolidated Balance Sheets (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2128100 - Disclosure - Schedule II - Valuation and Qualifying Accoutns link:presentationLink link:calculationLink link:definitionLink 2428401 - Disclosure - Schedule II - Valuation and Qualifying Accoutns (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 bio-20161231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 bio-20161231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 bio-20161231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Segment Reporting Information, Profit (Loss) [Abstract] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] NonAllocated Expense Loss Contingency [Member] NonAllocated Expense Loss Contingency [Member] NonAllocated Expense Loss Contingency [Member] Foreign Currency Gain (Loss) [Member] Foreign Currency Gain (Loss) [Member] Other Nonoperating Income (Expense) [Member] Other Nonoperating Income (Expense) [Member] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Operating Segments [Member] Operating Segments [Member] Segment Reconciling Items [Member] Segment Reconciling Items [Member] Corporate, Non-Segment [Member] Corporate, Non-Segment [Member] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Segments, Geographical Areas [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Geographical [Axis] Geographical [Domain] Europe [Member] Europe [Member] Pacific Rim [Member] Asia Pacific [Member] UNITED STATES UNITED STATES Other (primarily Canada and Latin America) [Member] Americas [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Net sales Revenue, Net Other assets and property, plant and equipment, net Long-Lived Assets Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Statement, Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Foreign currency translation adjustments [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Other Postretirement Benefit Plan [Member] Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Net Unrealized Investment Gain (Loss) [Member] Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Parent [Member] Parent [Member] Accumulated Other Comprehensive Income (Loss) [Member] AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax Other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax Accounting Policies [Abstract] Schedule of Product Warranty Liability Schedule of Product Warranty Liability [Table Text Block] Schedule of Weighted Average Number of Shares Schedule of Weighted Average Number of Shares [Table Text Block] Fair Value Disclosures [Abstract] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Short-term Investments [Member] Other Long-term Investments [Member] Other Long-term Investments [Member] Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Domain] Corporate Debt Securities [Member] Corporate Debt Securities [Member] Interest-bearing Deposits [Member] Interest-bearing Deposits [Member] Domestic Time Deposit [Member] Certificates of Deposit [Member] Municipal Obligations [Member] Municipal Bonds [Member] Asset-backed Securities [Member] Asset-backed Securities [Member] Marketable Equity Securities [Member] Equity Securities [Member] Available-for-sale Securities [Member] Available-for-sale Securities [Member] US Government Sponsored Agencies [Member] US Treasury and Government [Member] Foreign Government Obligations [Member] Foreign Government Debt Securities [Member] Schedule of Available-for-sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Amortized Cost Available-for-sale Securities, Amortized Cost Basis Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Estimated Fair Value Available-for-sale Securities Commitments and Contingencies Disclosure [Abstract] Letters of Credit Outstanding, Amount Letters of Credit Outstanding, Amount Operating Leases, Rent Expense, Net Operating Leases, Rent Expense, Net Contribution expense Deferred Compensation Arrangement with Individual, Employer Contribution Restructuring Costs [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Segments [Axis] Segments [Axis] Segment [Domain] Segments [Domain] Life Science [Member] Life Science [Member] Life Sciences [Member] Clinical Diagnostics [Member] Clinical Diagnostics [Member] Clinical Diagnostics [Member] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Employee Severance [Member] Employee Severance [Member] Cost of Goods, Total [Member] Cost of Goods, Total [Member] Selling, General and Administrative Expenses [Member] Selling, General and Administrative Expenses [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring Reserve Restructuring Reserve Restructuring Charges Restructuring Charges Restructuring Reserve, Accrual Adjustment Restructuring Reserve, Accrual Adjustment Payments for Restructuring Payments for Restructuring Restructuring Reserve, Foreign Currency Translation Gain (Loss) Restructuring Reserve, Foreign Currency Translation Gain (Loss) Restructuring Reserve, Current Restructuring Reserve, Current Restructuring Reserve, Noncurrent Restructuring Reserve, Noncurrent Research and Development Expense, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Basis of Presentation Consolidation, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Short-term Restricted Investments [Policy Text Block] Short-term Restricted Investments [Policy Text Block] Short-term Restricted Investments [Policy Text Block] Available-for-sale Investments Marketable Securities, Available-for-sale Securities, Policy [Policy Text Block] Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration Risk, Credit Risk, Policy [Policy Text Block] Accounts Receivable Trade and Other Accounts Receivable, Policy [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Shipping and Handling Shipping and Handling Cost, Policy [Policy Text Block] Warranty Standard Product Warranty, Policy [Policy Text Block] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Forward Foreign Exchange Contracts Derivatives, Policy [Policy Text Block] Noncontrolling Interests Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block] Share-based Compensation Plans Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Earnings Per Share Earnings Per Share, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Share-based Compensation [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Range of Exercise Prices, Group One [Member] Range of Exercise Prices, Group One [Member] Range of Exercise Prices, Group Two [Member] Range of Exercise Prices, Group Two [Member] Range of Exercise Prices, Group Three [Member] Range of Exercise Prices, Group Three [Member] Range of Exercise Prices, Group Four [Member] Range of Exercise Prices, Group Four [Member] Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis] Award Type [Axis] Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain] Equity Award [Domain] Stock Option and Award Plans [Member] Stock Option and Award Plans [Member] Stock Option and Award Plans [Member] 2011 Employee Stock Purchase Plan [Member] 2011 Employee Stock Purchase Plan [Member] 2011 Employee Stock Purchase Plan [Member] Stock Options [Member] Employee Stock Option [Member] Employee Stock [Member] Employee Stock [Member] Stock Options [Member] Employee Stock [Member] Stock Award Plans [Member] Stock Award Plans [Member] Stock Award Plans [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Incentive Award Plan (2007) [Member] Incentive Award Plan (2007) [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Options Granted Term Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award Weighted Average Remaining Contractual Term (in years) - Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (in millions) - Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Options - Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options Granted - Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options Exercised - Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options Forfeitured/expired - Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Options - Shares Vested and Expected to Vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Options Vested and Expected to Vest - Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Options Vested and Expected to Vest - Weighted Average Remaining Contractual Term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Options Vested and Expected to Vest - Aggregate Intrinsic Value (in millions) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Weighted Average Exercise Price - Options Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) - Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Options Exercisable Aggregate Intrinsic Value (in millions) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Options, Exercises in Period, Total Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Cash Received from Exercise of Stock Options Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options Tax Benefit Realized from Exercise of Stock Options Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options Total unrecognized compensation cost from stock options Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Restricted Stock Units - Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Options Number Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Stock Issued During Period, Shares, Employee Stock Purchase Plans Stock Issued During Period, Shares, Employee Stock Purchase Plans Options Vesting Period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Employee Contribution Rate - Maximum Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount Employee Purchase Price Discount from Market Price Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date Share-based Compensation Expense Allocated Share-based Compensation Expense Weighted average fair value of options granted, period for recognition Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Expected Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Risk Free Interest Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected dividend Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend Weighted average fair value of options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Options - Shares Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Options - Shares Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options - Shares Forfeitures/expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Outstanding end of period Basic weighted average shares outstanding Weighted Average Number of Shares Outstanding, Basic Effect of potentially dilutive stock options and restricted stock awards Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Diluted weighted average common shares Weighted Average Number of Shares Outstanding, Diluted Anti-dilutive shares excluded from the computation of diluted EPS Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Legal Proceedings [Abstract] -- None. No documentation exists for this element. -- Loss Contingency, Damages Awarded, Value Loss Contingency, Damages Awarded, Value Litigation Settlement Interest Litigation Settlement Interest Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Adjustments for New Accounting Pronouncement [Member] Adjustments for New Accounting Pronouncement [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Property, Plant and Equipment by Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Software [Member] Computer Software, Intangible Asset [Member] Building and Building Improvements [Member] Building and Building Improvements [Member] Reagent Rental Equipment [Member] Reagent Rental Equipment [Member] Reagent Rental Equipment [Member] Equipment [Member] Equipment [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Useful Life Restricted Cash and Cash Equivalents Restricted Cash and Cash Equivalents Other assets Other Assets Long-term Debt and Capital Lease Obligations Long-term Debt and Capital Lease Obligations Purchase Commitment, Excluding Long-term Commitment [Table] Purchase Commitment, Excluding Long-term Commitment [Table] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Sales milestone percentage of annual invoices [Member] Sales milestone percentage of annual invoices [Member] Sales milestone percentage of annual invoices [Member] Sales milestone percentage of annual invoices low [Member] Sales milestone percentage of annual invoices low [Member] Sales milestone percentage of annual invoices low [Member] Sales milestone minimum amount [Member] Sales milestone minimum amount [Member] Sales milestone minimum amount [Member] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Scenario, Forecast [Member] Scenario, Forecast [Member] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Employee Location [Axis] Employee Location [Axis] Employee Location [Axis] Employee Location [Domain] Employee Location [Domain] [Domain] for Employee Location [Axis] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Analytical Flow Cytometer Platform [Member] Analytical Flow Cytometer Platform [Member] Analytical Flow Cytometer Platform GnuBIO [Member] GnuBIO [Member] GnuBIO [Member] QuantaLife [Member] QuantaLife [Member] QuantaLife [Member] CellSorter [Member] CellSorter [Member] CellSorter [Member] [Member] Purchase Commitment, Excluding Long-term Commitment [Line Items] Purchase Commitment, Excluding Long-term Commitment [Line Items] Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Operating leases, due next twelve months Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating leases, due in two years Operating Leases, Future Minimum Payments, Due in Two Years Operating leases, due in three years Operating Leases, Future Minimum Payments, Due in Three Years Operating leases, due in four years Operating Leases, Future Minimum Payments, Due in Four Years Operating leases, due thereafter Operating Leases, Future Minimum Payments, Due Thereafter Post-Employment Benefits Liability Postemployment Benefits Liability Recorded Unconditional Purchase Obligation Recorded Unconditional Purchase Obligation Recorded Unconditional Purchase Obligation Due in Next Twelve Months Recorded Unconditional Purchase Obligation Due in Next Twelve Months Recorded Unconditional Purchase Obligation Due in Second Year Recorded Unconditional Purchase Obligation Due in Second Year Recorded Unconditional Purchase Obligation Due in Third Year Recorded Unconditional Purchase Obligation Due in Third Year Recorded Unconditional Purchase Obligation Due in Fourth Year Recorded Unconditional Purchase Obligation Due in Fourth Year Recorded Unconditional Purchase Obligation Due in Fifth Year Recorded Unconditional Purchase Obligation Due in Fifth Year Recorded Unconditional Purchase Obligation Due after Fifth Year Recorded Unconditional Purchase Obligation Due after Fifth Year Unrecorded Unconditional Purchase Obligation Unrecorded Unconditional Purchase Obligation Unrecorded Unconditional Purchase Obligation, Due in Twelve Months Unrecorded Unconditional Purchase Obligation, Due in Next Twelve Months Unrecorded Unconditional Purchase Obligation, Due within Two Years Unrecorded Unconditional Purchase Obligation, Due within Two Years Unrecorded Unconditional Purchase Obligation, Due within Three Years Unrecorded Unconditional Purchase Obligation, Due within Three Years Unrecorded Unconditional Purchase Obligation, Due within Four Years Unrecorded Unconditional Purchase Obligation, Due within Four Years Unrecorded Unconditional Purchase Obligation, Due within Five Years Unrecorded Unconditional Purchase Obligation, Due within Five Years Unrecorded Unconditional Purchase Obligation, Due after Five Years Unrecorded Unconditional Purchase Obligation, Due after Five Years Letters of Credit Outstanding Amount Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Employees Covered By Collective Bargaining Agreements U.S., Percentage Employees Covered By Collective Bargaining Agreements U.S., Percentage Employees covered by collective bargaining agreements, percentage Entity Number of Employees Entity Number of Employees Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Business Acquisition, Contingent Consideration, Potential Percentage Payout Business Acquisition, Contingent Consideration, Potential Percentage Payout business acquisition contingent consideration percentage payout Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Movement in Standard Product Warranty Accrual [Roll Forward] Warranty accrual, beginning of period Standard and Extended Product Warranty Accrual Provision for warranty Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Actual warranty costs Standard and Extended Product Warranty Accrual, Decrease for Payments Warranty accrual, end of period Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure Goodwill and Intangible Assets Disclosure [Text Block] Supplemental Cash Flow Information [Abstract] Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Mature in less than one year Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis Mature in one to five years Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis Mature in more than five years Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Amortized Cost Basis Total Amortized Cost Available-for-sale Debt Securities, Amortized Cost Basis Mature in less than one year Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value Mature in one to five years Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value Mature in more than five years Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Fair Value Estimated Fair Value Available-for-sale Securities, Debt Securities Other Income and Expenses [Abstract] Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Interest and investment income Investment Income, Interest and Dividend Net realized (gains) losses on investments Realized Investment Gains (Losses) Other-than-temporary impairment losses on investments Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net Nonoperating Income (Expense) Nonoperating Income (Expense) Other (income) expense, net Other Nonoperating Income (Expense) Fair Value Measurements Fair Value Disclosures [Text Block] Statement of Stockholders' Equity [Abstract] Common Stock [Member] Additional Paid-in Capital [Member] Treasury Stock [Member] Treasury Stock [Member] Retained Earnings [Member] Total Bio Rad [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance Stockholders' Equity Attributable to Parent Net income Net Income (Loss) Attributable to Parent Other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Issuance of common stock Proceeds from Issuance of Common Stock Stock compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Tax benefit-exercise stock options Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation Balance Derivative [Table] Derivative [Table] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Derivative, Notional Amount Derivative, Notional Amount Loss on foreign currency derivative instruments not designated as hedging instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Valuation and Qualifying Accounts [Abstract] Valuation and Qualifying Accounts Disclosure [Table] Valuation and Qualifying Accounts Disclosure [Table] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves [Domain] Valuation Allowances and Reserves [Domain] Valuation Allowance of Deferred Tax Assets [Member] Allowance for Doubtful Accounts [Member] Valuation and Qualifying Accounts Disclosure [Line Items] Valuation and Qualifying Accounts Disclosure [Line Items] Valuation Allowances and Reserves, Period Increase (Decrease) Valuation Allowances and Reserves, Period Increase (Decrease) Valuation Allowances and Reserves, Additions for Charges to Cost and Expense Valuation Allowances and Reserves, Additions for Charges to Cost and Expense Movement in Valuation Allowances and Reserves [Roll Forward] Valuation Allowances and Reserves, Balance Period Start Valuation Allowances and Reserves, Balance Deductions Valuation Allowances and Reserves, Deductions Other Valuation Allowances and Reserves, Reserves of Businesses Acquired Valuation Allowances and Reserves, Balance Period End Document and Entity Information -- None. No documentation exists for this element. -- Entities [Table] Entities [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Class A [Member] Common Class A [Member] Common Class B [Member] Common Class B [Member] Entity Registrant Name Entity Registrant Name Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Filer Category Entity Filer Category Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Public Float Entity Public Float Segment Reporting [Abstract] Reconciliation of Assets from Segment to Consolidated [Table] Reconciliation of Assets from Segment to Consolidated [Table] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Other Current Assets [Member] Other Current Assets [Member] Property, Plant and Equipment excluding segment specific [Member] Property, Plant and Equipment excluding segment specific [Member] Property, Plant and Equipment excluding segment specific [Member] -- excludes segment specific gross machinery and equipment Goodwill [Member] Goodwill [Member] Other Noncurrent Assets [Member] Other Noncurrent Assets [Member] Segment Reporting, Asset Reconciling Item [Line Items] Segment Reporting, Asset Reconciling Item [Line Items] Total assets Assets Restructuring and Related Costs [Table Text Block] Restructuring and Related Costs [Table Text Block] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Acquired Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Customer Relationships [Member] Customer Relationships [Member] Know how [Member] Know How [Member] Know how [Member] Developed Technology Rights [Member] Developed Technology Rights [Member] Licensing Agreements [Member] Licensing Agreements [Member] Trade Names [Member] Trade Names [Member] Noncompete Agreements [Member] Noncompete Agreements [Member] Other Intangible Assets [Member] Other Intangible Assets [Member] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Finite-lived Intangible Assets Acquired Finite-lived Intangible Assets Acquired Finite-Lived Intangible Assets, Remaining Amortization Period Finite-Lived Intangible Assets, Remaining Amortization Period Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Future Amortization Expense, Year One Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months Future Amortization Expense, Year Two Finite-Lived Intangible Assets, Amortization Expense, Year Two Future Amortization Expense, Year Three Finite-Lived Intangible Assets, Amortization Expense, Year Three Future Amortization Expense, Year Four Finite-Lived Intangible Assets, Amortization Expense, Year Four Future Amortization Expense, Year Five Finite-Lived Intangible Assets, Amortization Expense, Year Five Finite-Lived Intangible Assets, Amortization Expense, after Year Five Finite-Lived Intangible Assets, Amortization Expense, after Year Five Finite-Lived Intangible Assets, Net [Abstract] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Carrying Amount Finite-Lived Intangible Assets, Net Amortization [Abstract] Amortization expense Amortization of Intangible Assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets (Excluding Goodwill) Impairment losses on goodwill and long-lived assets Asset Impairment Charges Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Intangible Assets, Gross (Excluding Goodwill) Intangible Assets, Gross (Excluding Goodwill) Intangible Assets, Net (Excluding Goodwill) Intangible Assets, Net (Excluding Goodwill) Segment Information Segment Reporting Disclosure [Text Block] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Goodwill [Line Items] Goodwill [Line Items] Goodwill [Roll Forward] Goodwill period start Goodwill, Gross Accumulated impairment loss period start Goodwill, Impaired, Accumulated Impairment Loss Goodwill, net period start Goodwill Goodwill, Acquired During Period Goodwill, Acquired During Period Goodwill, Impairment Loss Goodwill, Impairment Loss Currency fluctuations Goodwill, Foreign Currency Translation Gain (Loss) Goodwill period end Accumulated impairment loss period end Goodwill, net period end Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Business Combination, Consideration Transferred Business Combination, Consideration Transferred Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired Subsequent Events [Text Block] Subsequent Events [Text Block] Other Significant Noncash Transactions [Table] Other Significant Noncash Transactions [Table] Other Significant Noncash Transaction [Axis] Other Significant Noncash Transaction [Axis] Other Significant Noncash Transaction, Name [Domain] Other Significant Noncash Transaction, Name [Domain] Other Significant Noncash Transactions [Line Items] Other Significant Noncash Transactions [Line Items] Net Income (Loss) Attributable to Parent Depreciation and amortization Depreciation, Depletion and Amortization Share-based compensation Share-based Compensation (Gain) loss on disposition of securities Gain (Loss) on Sale of Securities, Net Loss on disposition of fixed assets Gain (Loss) on Disposition of Property Plant Equipment Excess tax benefits from share-based compensation Excess Tax Benefit from Share-based Compensation, Operating Activities Changes in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Decrease (increase) in accounts receivable, net Increase (Decrease) in Accounts Receivable (Increase) decrease in inventories, net Increase (Decrease) in Inventories (Increase) decrease in Other Current Assets Increase (Decrease) in Other Current Assets Increase (decrease) in accounts payable and other current liabilities Increase (Decrease) in Accounts Payable and Other Operating Liabilities Increase in Income Taxes Payable Increase (Decrease) in Income Taxes Payable Decrease in deferred income taxes Increase (Decrease) in Deferred Income Taxes Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Decrease in other long term assets Increase (Decrease) in Other Noncurrent Assets Increase (Decrease) in Other Long Term Liabilities Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Noncash purchased intangible assets Noncash or Part Noncash Acquisition, Intangible Assets Acquired Noncash Purchased Marketable Securities and Investments Noncash or Part Noncash Acquisition, Investments Acquired accumulated other comprehensive income [Text Block] accumulated other comprehensive income [Text Block] accumulated other comprehensive income [Text Block] Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Goodwill Quarterly Financial Data [Abstract] Schedule of Quarterly Financial Data [Table Text Block] Quarterly Financial Information [Table Text Block] Disclosure of Compensation Related Costs, Share-based Payments Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stockholders' Equity Attributable to Parent [Abstract] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Treasury Class-A [Member] Treasury Class-A [Member] Treasury Class A [Member] Treasury Class B [Member] Treasury Class B [Member] Treasury Class B [Member] Class of Stock [Line Items] Shares, Issued Shares, Issued Stock Issued During Period, Shares, Conversion of Convertible Securities Stock Issued During Period, Shares, Conversion of Convertible Securities Stock Issued During Period, Shares, New Issues Stock Issued During Period, Shares, New Issues Treasury Stock, Shares, Acquired Treasury Stock, Shares, Acquired Common Stock, Voting Rights Common Stock, Voting Rights Election Percentage for Board of Directors Election Percentage for Board of Directors Election Percentage for Board of Directors Restricted Stock [Member] Restricted Stock Units (RSUs) [Member] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Total unrecognized compensation cost from restricted stock Nonvested shares - Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Restricted Stock Units Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Units - Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Restricted Stock Units - Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Weighted Average Grant Date Fair Value - Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Restricted Stock Units Vested - Weighted-Average Grant-Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Resticted Stock Units Cancelled/forfeited - Weighted-Average Grant-Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Resticted Stock Units Outstanding Aggregate Intrinsic Value (in millions) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition Debt Disclosure [Abstract] Notes Payable and Long-term Debt Long-term Debt [Text Block] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Estimate of Fair Value, Fair Value Disclosure [Member] Estimate of Fair Value Measurement [Member] Carrying (Reported) Amount, Fair Value Disclosure [Member] Reported Value Measurement [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Other Investments Other Investments Total long-term debt, excluding leases and current maturities Long-term Debt, Fair Value Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Information regarding industry segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Reconciliation of segment profit to consolidated income before taxes Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Reconciliation of Assets from Segment to Consolidated Reconciliation of Assets from Segment to Consolidated [Table Text Block] Net sales and assets to external customers by geographic area Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Discount rate [Member] Discount rate [Member] Discount rate [Member] Sales [Member] Sales [Member] Credit Adjusted Discount Rates Lower [Member] Credit Adjusted Discount Rates Lower [Member] Credit Adjusted Discount Rates Lower [Member] Credit Adjusted Discount Rate Higher [Member] Credit Adjusted Discount Rate Higher [Member] Credit Adjusted Discount Rate Higher [Member] Cost of debt [Member] Cost of debt [Member] Cost of debt [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Additional performance period Additional performance period Additional performance period Net (decrease) increase in estimated fair value of contingent consideration included in selling, general and administrative expense Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Fair Value Inputs, Discount Rate Fair Value Inputs, Discount Rate Other Income and Other Expense Disclosure Other Income and Other Expense Disclosure [Text Block] Other Current Liabilities [Member] Other Current Liabilities [Member] Other Investments [Member] Other Investments [Member] Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 3 [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Foreign Time Deposits [Member] Bank Time Deposits [Member] Money Market Funds [Member] Commercial Paper [Member] Commercial Paper [Member] Cash Equivalents [Member] Cash Equivalents [Member] Money Market Funds [Member] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Restricted Investments, at Fair Value Restricted Investments, at Fair Value Available-for-sale investments Forward foreign exchange contracts, Asset Foreign Currency Contract, Asset, Fair Value Disclosure Financial Assets Carried at Fair Value Assets, Fair Value Disclosure Forward foreign exchange contracts, Liability Foreign Currency Contracts, Liability, Fair Value Disclosure Liabilities, Fair Value Disclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure Statement of Cash Flows [Abstract] Statement, Scenario [Axis] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Cash received from customers Proceeds from Customers Cash paid to suppliers and employees Payments to Suppliers and Employees Interest paid Interest Paid Income tax payments Income Taxes Paid, Net Settlement with the SEC and DOJ relating to the FCPA, including interest Settlement with the SEC and DOJ relating to the FCPA, including interest Settlement with the SEC and DOJ relating to the FCPA, including interest Investment proceeds and miscellaneous receipts, net Proceeds from Other Operating Activities (Payments for) proceeds from forward foreign exchange contracts, net Proceeds from derivative instruments, operating activities Proceeds from derivative instruments, operating activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Capital expenditures Payments to Acquire Property, Plant, and Equipment Proceeds from dispositions of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Payments for acquisitions, net of cash received, and long-term investments Payments to Acquire Assets, Investing Activities Payments for purchases of intangible assets Payments to Acquire Intangible Assets Payments for purchases of restricted investment Payments to Acquire Restricted Investments Payments for purchases of marketable securities and investments Payments to Acquire Investments Proceeds from sales of marketable securities and investments Proceeds from Sale of Available-for-sale Securities Proceeds from maturities of marketable securities and investments Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net borrowings on (payments for) line-of-credit arrangements and notes payable Proceeds from (Repayments of) Lines of Credit Payments on long-term borrowings Repayments of Long-term Debt Proceeds from issuance of common stock Payments of contingent consideration Payments of contingent consideration Payments of contingent consideration Debt issuance costs on long-term borrowings Payments of Debt Issuance Costs Excess tax benefits from share-based compensation Excess Tax Benefit from Share-based Compensation, Financing Activities Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of foreign exchange rate changes on cash Effect of Exchange Rate on Cash and Cash Equivalents Net (decrease) increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of year Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of year Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Fair Value Inputs, Liabilities, Quantitative Information [Table] Fair Value Inputs, Liabilities, Quantitative Information [Table] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Valuation Technique [Axis] Valuation Technique [Axis] Valuation Technique [Domain] Valuation Technique [Domain] Fair Value Inputs, Liabilities, Quantitative Information [Line Items] Fair Value Inputs, Liabilities, Quantitative Information [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block] Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block] Schedule of Derivative Instruments [Table Text Block] Schedule of Derivative Instruments [Table Text Block] Financial assets and liabilities carried at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of available-for-sale investments Available-for-sale Securities [Table Text Block] Summary of investments with gross unrealized losses and the associated fair value Schedule of Unrealized Loss on Investments [Table Text Block] Summary of amortized cost and estimated fair value of debt securities by contractual maturity date Investments Classified by Contractual Maturity Date [Table Text Block] Estimated fair value of financial instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Schedule of Long-term Debt Instruments [Table] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Unsecured Debt [Member] Capital Lease Obligations [Member] Line of Credit [Member] Standby Letters of Credit [Member] Standby Letters of Credit [Member] Debt Instrument [Axis] Debt Instrument, Name [Domain] Senior Notes 4.875% due 2020 [Member] Senior Notes 4.875% due 2020 [Member] Senior Notes 4.875% [Member] Capital Leases and Other Debt [Member] Capital Leases and Other Debt [Member] Capital Leases and Other Debt [Member] Performance Guarantee [Member] Performance Guarantee [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Unsecured Debt Unsecured Debt Long-term debt Long-term Debt Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Long-term Debt and Capital Lease Obligations, Including Current Maturities Long-term Debt and Capital Lease Obligations, Including Current Maturities Debt and Capital Lease Obligations Debt and Capital Lease Obligations Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, Effective Percentage Face amount of debt sold Debt Instrument, Face Amount Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Maturities of Long-term Debt [Abstract] Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months Long-term Debt, Maturities, Repayments of Principal in Year Two Long-term Debt, Maturities, Repayments of Principal in Year Two Long-term Debt, Maturities, Repayments of Principal in Year Three Long-term Debt, Maturities, Repayments of Principal in Year Three Long-term Debt, Maturities, Repayments of Principal in Year Four Long-term Debt, Maturities, Repayments of Principal in Year Four Long-term Debt, Maturities, Repayments of Principal in Year Five Long-term Debt, Maturities, Repayments of Principal in Year Five Long-term Debt, Maturities, Repayments of Principal after Year Five Long-term Debt, Maturities, Repayments of Principal after Year Five Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Amount Outstanding Long-term Line of Credit Line of Credit Facility, Remaining Borrowing Capacity Line of Credit Facility, Current Borrowing Capacity Line of Credit Facility, Interest Rate at Period End Line of Credit Facility, Interest Rate at Period End Principal components of long-term debt [Table Text Block] Schedule of Long-term Debt Instruments [Table Text Block] Cash Flow, Supplemental Disclosures [Text Block] Cash Flow, Supplemental Disclosures [Text Block] Stock Options Activity Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Stock Options Outstanding Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Stock Options Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Resticted Stock Activity Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Employee Stock Purchase Plan, Valuation Assumptions Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Changes to goodwill by segment Schedule of Goodwill [Table Text Block] Schedule of Finite-Lived Intangible Assets by Major-Class Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Fair Value Hierarchy [Domain] Price Change Debt Security Price Change Debt Security Price Change Debt Security Tolerable variance Level 2 debt security pricing Tolerable variance Level 2 debt security pricing Tolerable variance Level 2 debt security pricing Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Gross unrealized losses for investments in a loss position 12 months or more Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss Gross unrealized losses for investments in a loss position less than 12 months Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss Cost Method Investment, Percentage Owned Cost Method Investment, Percentage Owned Cost Method Investments, Percentage Owned Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] All Other Segments [Member] Other Segments [Member] Number Of Products And Services Number Of Products And Services Number Of Products And Services Interest expense Interest Expense Segment profit Operating Income (Loss) Payments to Acquire Property, Plant, and Equipment New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Restricted investments Restricted Investments, Current Legal Matters and Contingencies Legal Matters and Contingencies [Text Block] Class of Stock [Line Items] Schedule of Stock by Class [Table Text Block] Schedule of Stock by Class [Table Text Block] Business Combination Disclosure [Text Block] Business Combination Disclosure [Text Block] Balance Sheet Parenthetical [Abstract] Balance Sheet Parenthetical [Abstract] Common Stock [Member] Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Current Preferred stock par value Preferred Stock, Par or Stated Value Per Share Preferred stock authorized Preferred Stock, Shares Authorized Preferred stock issued Preferred Stock, Shares Issued Preferred stock outstanding Preferred Stock, Shares Outstanding Common stock par value Common Stock, Par or Stated Value Per Share Common stock authorized Common Stock, Shares Authorized Common stock issued Common Stock, Shares, Issued Common stock outstanding Common Stock, Shares, Outstanding Treasury Stock, Shares Treasury Stock, Shares Income Tax Disclosure [Abstract] Income Taxes [Text Block] Income Tax Disclosure [Text Block] Restructuring and Related Activities Disclosure [Text Block] Restructuring and Related Activities Disclosure [Text Block] Income Statement [Abstract] Cost of goods sold Cost of Goods Sold Gross profit Gross Profit Selling, general and administrative expense Selling, General and Administrative Expense Research and development expense Research and Development Expense Income from operations Foreign exchange losses, net Foreign Currency Transaction Gain (Loss), before Tax Other (income) expense, net Income before income taxes Provision for income taxes Income Tax Expense (Benefit) Net Income (Loss) Attributable to Parent Basic earnings per share: Earnings Per Share, Basic [Abstract] Net income per share basic attributable to Bio-Rad Earnings Per Share, Basic Weighted average common shares - basic Diluted earnings per share: Earnings Per Share, Diluted [Abstract] Net income per share diluted attributable to Bio-Rad Earnings Per Share, Diluted Weighted average common shares - diluted Income Tax Contingency [Table] Income Tax Contingency [Table] Net of prepaid taxes [Axis] Net of prepaid taxes [Axis] Net of prepaid taxes [Axis] Net of prepaid taxes [Domain] Net of prepaid taxes [Domain] [Domain] for Net of prepaid taxes [Axis] Net of prepaid taxes [Member] Net of prepaid taxes [Member] Net of prepaid taxes [Member] Dividends [Axis] Dividends [Axis] Dividends [Domain] Dividends [Domain] Foreign Tax Authority [Member] Foreign Tax Authority [Member] Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Foreign Tax Credit Carryforward [Member] Foreign Tax Credit Carryforward [Member] Foreign Tax Credit Carryforward [Member] Research Tax Credit Carryforward [Member] Limitations On Use Limitations On Use [Member] Limitations On Use [Member] Including accrued interest and penalties [Axis] Including accrued interest and penalties [Axis] Including accrued interest and penalties [Domain] Including accrued interest and penalties [Domain] Including accrued interest and penalties [Domain] Including accrued interest and penalties [Member] Including accrued interest and penalties [Member] Including accrued interest and penalties [Member] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Domestic Tax Authority [Member] State and Local Jurisdiction [Member] State and Local Jurisdiction [Member] Income Taxes [Line Items] Income Tax Contingency [Line Items] Prepaid Taxes Prepaid Taxes U.S. Income (Loss) from Continuing Operations before Income Taxes, Domestic International Income (Loss) from Continuing Operations before Income Taxes, Foreign U.S. Federal Current Federal Tax Expense (Benefit) State Current State and Local Tax Expense (Benefit) International Current Foreign Tax Expense (Benefit) Current Income Tax Expense (Benefit) Current Income Tax Expense (Benefit) U.S. Federal Deferred Federal Income Tax Expense (Benefit) State Deferred State and Local Income Tax Expense (Benefit) International Deferred Foreign Income Tax Expense (Benefit) Deferred tax benefit Deferred Income Tax Expense (Benefit) Non-current tax expense (benefit) Non Current Income Tax Expense Non Current Income Tax Expense Provision for income taxes U.S. statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Impact of foreign operations Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Foreign dividends, net Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent Research tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Nontaxable subsidies Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent Tax settlements and changes to unrecognized tax benefits Effective Income Tax Rate Reconciliation, Tax Settlement, Percent Goodwill impairment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent Domestic manufacturing deduction Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent Nondeductible executive compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Fines and penalties Effective Income Tax Rate Reconciliation, Fines and Penalties, Percent Effective Income Tax Rate Reconciliation, Fines and Penalties, Percent Prior period adjustments Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent U.S. taxation on foreign income Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Provision for income taxes Effective Income Tax Rate Reconciliation, Percent Bad debt, inventory and warranty accruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves Legal reserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies Other post-employment benefits, vacation and other reserves Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other Tax credit and net operating loss carryforwards Deferred Tax Assets, Tax Credit Carryforwards Other Deferred Tax Assets, Other Total gross deferred tax assets Deferred Tax Assets, Gross Valuation allowance Deferred Tax Assets, Valuation Allowance Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Investments and intangible assets Deferred Tax Liabilities, Other Finite-Lived Assets Total deferred tax liabilities Deferred Tax Liabilities, Gross Net deferred tax liabilities Deferred Tax Liabilities, Net Unrecognized tax benefits period start Unrecognized Tax Benefits Additions to tax positions related to prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Reductions to tax positions related to prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Additions to tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Lapse of statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation Acquisitions Unrecognized Tax Benefits, Increase Resulting from Acquisition Currency translation Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation Unrecognized tax benefits period end Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Operating Loss Carryforwards, Expiration Dates Operating Loss Carryforwards, Expiration Date Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Deferred Tax Liabilities, Undistributed Foreign Earnings Deferred Tax Liabilities, Undistributed Foreign Earnings Deferred Tax Liability Not Recognized, Cumulative Amount of Temporary Difference Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries Tax Credit Carryforward, Amount Tax Credit Carryforward, Amount Tax Credit Carryforward, Limitations on Use Tax Credit Carryforward, Limitations on Use Deferred Tax Assets, Tax Credit Carryforwards, Research Deferred Tax Assets, Tax Credit Carryforwards, Research Operating Loss Carryforward, Valuation Allowance Operating Loss Carryforwards, Valuation Allowance Operating Loss Carryforward With No Expiration Date Operating Loss Carryforward With No Expiration Date Operating Loss Carryforward With No Expiration Date Operating Loss Carryforwards Operating Loss Carryforwards Class of Treasury Stock [Table] Class of Treasury Stock [Table] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Statement of Financial Position [Abstract] Common Class A [Member] Common Class B [Member] ASSETS: Assets [Abstract] Cash and cash equivalents Short-term investments Short-term Investments Accounts receivable, less allowance for doubtful accounts Accounts Receivable, Net, Current Inventories: Inventory, Net [Abstract] Raw materials Inventory, Raw Materials, Gross Work in process Inventory, Work in Process, Gross Finished goods Inventory, Finished Goods, Gross Total inventories Inventory, Net Prepaid expenses Prepaid Expense, Current Other current assets Other Assets, Current Total current assets Assets, Current Property, plant and equipment: Property, Plant and Equipment, Gross [Abstract] Land and improvements Land Buildings and leasehold improvements Buildings and Improvements, Gross Equipment Machinery and Equipment, Gross Total property, plant and equipment Property, Plant and Equipment, Gross Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, net Property, Plant and Equipment, Net Goodwill, net Purchased intangibles, net Other investments Long-term Investments Long-term deferred tax assets Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Total assets LIABILITIES AND STOCKHOLDERS' EQUITY: Liabilities and Equity [Abstract] Accounts payable Accounts Payable, Current Accrued payroll and employee benefits Employee-related Liabilities, Current Notes payable and current maturities of long-term debt Notes and Loans Payable, Current Income and other taxes payable Taxes Payable, Current Accrued royalties Accrued Royalties, Current Deferred revenue Deferred Revenue, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Long-term debt, net of current maturities Deferred income taxes Deferred Tax Liabilities, Net, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingent liabilities Commitments and Contingencies Stockholders' equity: Preferred stock Preferred Stock, Value, Issued Common stock Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Treasury Stock, Value Treasury Stock, Value Retained earnings Retained Earnings (Accumulated Deficit) Total stockholders' equity Total liabilities and stockholders' equity Liabilities and Equity Equity [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Disclosure [Text Block] Schedule of other income (expense), net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Quarterly Financial Data [Text Block] Quarterly Financial Information [Text Block] Gross profit Basic earnings per share Diluted earnings per share Statement of Comprehensive Income [Abstract] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other post-employment benefits adjustments, net of tax Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent Net unrealized holding gains on available-for-sale investments, net of tax Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Comprehensive income attributable to Bio-Rad Comprehensive Income (Loss), Net of Tax, Attributable to Parent U.S. and international components of income before taxes [Table Text Block] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Provision for income taxes [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Reconcilation of effective tax rate on inocme before taxes and statutory rate [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Significant components of deferred tax assets and liabilities [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Summary of income tax years currently under audit or open to examinations [Table Text Block] Summary of Income Tax Examinations [Table Text Block] Tabular reconcilation of total amounts of unrecognized tax benefits [Table Text Block] Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income [Member] Reclassification out of Accumulated Other Comprehensive Income [Member] Selling, general and administrative expense Other Nonoperating Income (Expense) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] EX-101.PRE 12 bio-20161231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 a10k123115_chart-30568a01.jpg STOCK PERFORMANCE GRAPH begin 644 a10k123115_chart-30568a01.jpg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end XML 14 a10k123116_htm.xml IDEA: XBRL DOCUMENT 0000012208 2016-01-01 2016-12-31 0000012208 us-gaap:CommonClassAMember 2015-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2015-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2015-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 bio:TreasuryClassBMember 2015-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2015-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2015-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 bio:TreasuryClassAMember 2015-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2015-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2015-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2015-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 bio:TreasuryClassBMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2015-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 bio:TreasuryClassAMember 2016-12-31 0000012208 bio:CellsorterMember 2012-09-30 2016-12-31 0000012208 bio:CellsorterMember 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoicesMember 2016-12-31 0000012208 bio:GnuBIOMember 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoiceslowMember 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestoneminimumamountMember 2016-12-31 0000012208 bio:GnuBIOMember 2014-04-10 0000012208 bio:CellsorterMember 2012-09-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:DiscountrateMember 2016-01-01 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:CostofdebtMember 2016-01-01 2016-12-31 0000012208 2014-01-01 2014-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2016-12-31 0000012208 2015-01-01 2015-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 bio:CellsorterMember 2016-01-01 2016-12-31 0000012208 bio:CellsorterMember 2015-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-01-01 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 2013-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 2014-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 2016-06-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 bio:GnuBIOMember 2015-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-12-31 0000012208 bio:LifeScienceMember 2014-12-31 0000012208 bio:LifeScienceMember 2016-12-31 0000012208 bio:ClinicalDiagnosticsMember 2015-12-31 0000012208 bio:LifeScienceMember 2015-12-31 0000012208 bio:ClinicalDiagnosticsMember 2014-12-31 0000012208 bio:LifeScienceMember 2016-01-01 2016-12-31 0000012208 bio:ClinicalDiagnosticsMember 2016-12-31 0000012208 bio:LifeScienceMember 2015-01-01 2015-12-31 0000012208 bio:ClinicalDiagnosticsMember 2016-01-01 2016-12-31 0000012208 bio:ClinicalDiagnosticsMember 2015-01-01 2015-12-31 0000012208 us-gaap:RetainedEarningsMember 2014-01-01 2014-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2016-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2016-12-31 0000012208 bio:KnowHowMember 2016-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2016-12-31 0000012208 us-gaap:TradeNamesMember 2016-12-31 0000012208 us-gaap:LicensingAgreementsMember 2016-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2015-12-31 0000012208 bio:KnowHowMember 2015-12-31 0000012208 us-gaap:LicensingAgreementsMember 2015-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2015-12-31 0000012208 us-gaap:CommonStockMember 2015-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2015-12-31 0000012208 us-gaap:TradeNamesMember 2015-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember us-gaap:NoncompeteAgreementsMember 2016-01-01 2016-03-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember us-gaap:DevelopedTechnologyRightsMember 2016-01-01 2016-03-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0000012208 bio:KnowHowMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0000012208 bio:KnowHowMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0000012208 bio:KnowHowMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:TradeNamesMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0000012208 us-gaap:TradeNamesMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0000012208 us-gaap:TradeNamesMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 bio:KnowHowMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0000012208 us-gaap:TradeNamesMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2015-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2015-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2016-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2016-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2010-12-31 0000012208 us-gaap:StandbyLettersOfCreditMember 2016-12-31 0000012208 us-gaap:PerformanceGuaranteeMember 2016-12-31 0000012208 us-gaap:LineOfCreditMember 2014-06-30 0000012208 us-gaap:TreasuryStockMember 2014-12-31 0000012208 us-gaap:LineOfCreditMember 2016-12-31 0000012208 us-gaap:DomesticCountryMember 2016-01-01 2016-12-31 0000012208 us-gaap:DomesticCountryMember 2014-01-01 2014-12-31 0000012208 us-gaap:DomesticCountryMember 2015-01-01 2015-12-31 0000012208 us-gaap:StateAndLocalJurisdictionMember 2016-12-31 0000012208 us-gaap:ForeignCountryMember 2016-12-31 0000012208 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2016-12-31 0000012208 bio:NetofprepaidtaxesMember 2016-12-31 0000012208 us-gaap:DomesticCountryMember 2016-12-31 0000012208 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2016-12-31 0000012208 us-gaap:RetainedEarningsMember 2013-12-31 0000012208 us-gaap:DomesticCountryMember bio:LimitationsOnUseMember 2016-12-31 0000012208 bio:QuantalifeMember us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2016-12-31 0000012208 bio:IncludingaccruedinterestandpenaltiesMember 2016-12-31 0000012208 us-gaap:DomesticCountryMember bio:ForeignTaxCreditCarryforwardMember 2016-12-31 0000012208 bio:TreasuryClassAMember 2012-04-01 2012-06-30 0000012208 us-gaap:CommonClassAMember 2016-01-01 2016-12-31 0000012208 us-gaap:CommonClassBMember 2016-01-01 2016-12-31 0000012208 bio:TreasuryClassBMember 2012-04-01 2012-06-30 0000012208 us-gaap:CommonClassBMember 2014-01-01 2014-12-31 0000012208 us-gaap:CommonClassAMember 2014-12-31 0000012208 us-gaap:CommonClassBMember 2017-02-14 0000012208 us-gaap:CommonStockMember 2014-12-31 0000012208 us-gaap:CommonClassAMember 2013-12-31 0000012208 us-gaap:CommonClassAMember 2014-01-01 2014-12-31 0000012208 us-gaap:CommonClassAMember 2015-01-01 2015-12-31 0000012208 us-gaap:CommonClassBMember 2014-12-31 0000012208 us-gaap:CommonClassBMember 2015-01-01 2015-12-31 0000012208 us-gaap:CommonClassBMember 2013-12-31 0000012208 us-gaap:ParentMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2015-01-01 2015-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:ParentMember 2015-01-01 2015-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-01-01 2015-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2014-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-01-01 2015-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000012208 us-gaap:ParentMember 2015-12-31 0000012208 us-gaap:ParentMember 2014-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2014-12-31 0000012208 us-gaap:ParentMember 2016-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-01-01 2015-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-01-01 2015-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2016-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2014-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2015-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2013-12-31 0000012208 us-gaap:EmployeeStockMember 2014-01-01 2014-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-12-31 0000012208 us-gaap:EmployeeStockMember 2015-01-01 2015-12-31 0000012208 us-gaap:RetainedEarningsMember 2016-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2014-01-01 2014-12-31 0000012208 bio:StockOptionAndAwardPlansMember bio:IncentiveAwardPlan2007Member 2016-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-12-31 0000012208 us-gaap:EmployeeStockMember 2016-01-01 2016-12-31 0000012208 us-gaap:EmployeeStockMember 2016-12-31 0000012208 bio:StockAwardPlansMember bio:IncentiveAwardPlan2007Member 2016-01-01 2016-12-31 0000012208 bio:A2011EmployeeStockPurchasePlanMember 2016-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2014-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2013-12-31 0000012208 us-gaap:CommonStockMember 2013-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2015-12-31 0000012208 us-gaap:EmployeeStockMember 2014-12-31 0000012208 us-gaap:EmployeeStockMember 2015-12-31 0000012208 country:US 2016-12-31 0000012208 us-gaap:EuropeMember 2015-12-31 0000012208 us-gaap:AmericasMember 2015-12-31 0000012208 us-gaap:AmericasMember 2016-12-31 0000012208 country:US 2016-12-31 0000012208 us-gaap:AsiaPacificMember 2015-12-31 0000012208 us-gaap:EuropeMember 2016-12-31 0000012208 us-gaap:TreasuryStockMember 2013-12-31 0000012208 country:US 2015-12-31 0000012208 us-gaap:AsiaPacificMember 2016-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2014-01-01 2014-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2014-01-01 2014-12-31 0000012208 us-gaap:OperatingSegmentsMember 2016-01-01 2016-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2016-01-01 2016-12-31 0000012208 us-gaap:OperatingSegmentsMember 2014-01-01 2014-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2015-01-01 2015-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2014-01-01 2014-12-31 0000012208 us-gaap:TreasuryStockMember 2015-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2015-01-01 2015-12-31 0000012208 us-gaap:OperatingSegmentsMember 2015-01-01 2015-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2015-01-01 2015-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-01-01 2016-12-31 0000012208 bio:ClinicalDiagnosticsMember 2014-01-01 2014-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2014-01-01 2014-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2016-12-31 0000012208 bio:LifeScienceMember 2014-01-01 2014-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2015-01-01 2015-12-31 0000012208 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2015-12-31 0000012208 us-gaap:AmericasMember 2014-01-01 2014-12-31 0000012208 us-gaap:EuropeMember 2016-01-01 2016-12-31 0000012208 us-gaap:AmericasMember 2015-01-01 2015-12-31 0000012208 us-gaap:EuropeMember 2014-01-01 2014-12-31 0000012208 us-gaap:AsiaPacificMember 2015-01-01 2015-12-31 0000012208 us-gaap:AsiaPacificMember 2014-01-01 2014-12-31 0000012208 country:US 2014-01-01 2014-12-31 0000012208 us-gaap:EuropeMember 2015-01-01 2015-12-31 0000012208 country:US 2015-01-01 2015-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000012208 us-gaap:AmericasMember 2016-01-01 2016-12-31 0000012208 us-gaap:AsiaPacificMember 2016-01-01 2016-12-31 0000012208 country:US 2016-01-01 2016-12-31 0000012208 us-gaap:CorporateNonSegmentMember bio:NonAllocatedExpenseLossContingencyMember 2014-01-01 2014-12-31 0000012208 us-gaap:GoodwillMember us-gaap:MaterialReconcilingItemsMember 2015-12-31 0000012208 bio:PropertyPlantandEquipmentexcludingsegmentspecificMember us-gaap:MaterialReconcilingItemsMember 2016-12-31 0000012208 us-gaap:OtherNoncurrentAssetsMember us-gaap:MaterialReconcilingItemsMember 2015-12-31 0000012208 bio:PropertyPlantandEquipmentexcludingsegmentspecificMember us-gaap:MaterialReconcilingItemsMember 2015-12-31 0000012208 us-gaap:OtherNoncurrentAssetsMember us-gaap:MaterialReconcilingItemsMember 2016-12-31 0000012208 us-gaap:OperatingSegmentsMember 2016-12-31 0000012208 us-gaap:CommonClassAMember 2017-02-14 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000012208 us-gaap:OtherCurrentAssetsMember us-gaap:MaterialReconcilingItemsMember 2016-12-31 0000012208 us-gaap:OperatingSegmentsMember 2015-12-31 0000012208 us-gaap:GoodwillMember us-gaap:MaterialReconcilingItemsMember 2016-12-31 0000012208 us-gaap:OtherCurrentAssetsMember us-gaap:MaterialReconcilingItemsMember 2015-12-31 0000012208 us-gaap:EmployeeSeveranceMember 2016-01-01 2016-12-31 0000012208 us-gaap:CostOfGoodsTotalMember 2016-01-01 2016-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-12-31 0000012208 2015-01-01 2015-03-31 0000012208 2015-07-01 2015-09-30 0000012208 2016-04-01 2016-06-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000012208 2016-10-01 2016-12-31 0000012208 2015-04-01 2015-06-30 0000012208 2015-10-01 2015-12-31 0000012208 2016-07-01 2016-09-30 0000012208 2016-01-01 2016-03-31 0000012208 us-gaap:SubsequentEventMember 2017-02-15 2017-02-15 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2015-01-01 2015-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-01-01 2016-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2015-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2014-01-01 2014-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-01-01 2014-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2013-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2014-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2014-01-01 2014-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2014-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2015-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2016-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2013-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2015-01-01 2015-12-31 0000012208 us-gaap:RetainedEarningsMember 2014-12-31 0000012208 us-gaap:RetainedEarningsMember 2015-12-31 0000012208 us-gaap:TreasuryStockMember 2016-12-31 0000012208 us-gaap:CommonStockMember 2016-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000012208 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:EquipmentMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 2015-12-31 0000012208 bio:ReagentRentalEquipmentMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:EquipmentMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2015-12-31 0000012208 bio:ReagentRentalEquipmentMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2016-12-31 0000012208 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:ComputerSoftwareIntangibleAssetMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:ComputerSoftwareIntangibleAssetMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-01-06 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-01-01 2016-03-31 0000012208 us-gaap:CommonClassBMember 2015-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2016-01-01 2016-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2016-12-31 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2016-12-31 0000012208 2016-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2016-01-01 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2015-12-31 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2015-12-31 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2015-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2015-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2015-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2015-12-31 0000012208 us-gaap:CommonClassAMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2015-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2015-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2015-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2015-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2015-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2015-12-31 0000012208 us-gaap:CommonClassBMember 2016-12-31 0000012208 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2015-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2015-12-31 0000012208 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2015-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-12-31 iso4217:USD shares iso4217:USD pure shares 0.07 false --12-31 FY 2016 2016-12-31 10-K 0000012208 24460068 5116824 Yes Large Accelerated Filer 3001889921 BIO RAD LABORATORIES INC No Yes 24418000 23367000 10000000 0.0001 0.0001 0.0001 0.0001 80000000 20000000 80000000 20000000 24230448 5130558 24454048 5123883 24230326 5129641 24453926 5122966 .10 1 P10Y P1Y P10Y P2Y P12Y P4Y P10Y P3Y P7Y P3Y P0Y P0Y P9Y P5Y P9Y P1Y P8Y P1Y P12Y P3Y P9Y P1Y P9Y P2Y P0Y P0Y P8Y P4Y 0 1800000 0.0001 0.0001 7500000 7500000 0 0 0 0 P12Y P3Y P5Y P5Y 0 0 122 917 122 917 456264000 457549000 383176000 328718000 4560000 4210000 372348000 391485000 116540000 109928000 125982000 114438000 282439000 265858000 524961000 490224000 91014000 94369000 12201000 11041000 1844524000 1777596000 17895000 17823000 290367000 276070000 919126000 823193000 1227388000 1117086000 738774000 679396000 488614000 437690000 477115000 495948000 161609000 214026000 830790000 719840000 47852000 64618000 3850504000 3709718000 133109000 122391000 163364000 157857000 334000 298000 28124000 29339000 31003000 29683000 115388000 101783000 471322000 441351000 434186000 433883000 222919000 233475000 135318000 110506000 1263745000 1219215000 0 0 2000 2000 1000 1000 332911000 300408000 12000 12000 89000 89000 1836180000 1808055000 417766000 382138000 2586759000 2490503000 3850504000 3709718000 2068172000 2019441000 2175044000 930085000 897771000 996527000 1138087000 1121670000 1178517000 816724000 761990000 808200000 205864000 192972000 220333000 62305000 0 0 53194000 166708000 149984000 21942000 21692000 22131000 -4542000 -10249000 -9305000 14850000 11080000 13009000 41560000 145847000 131557000 13435000 32754000 42712000 28125000 113093000 88845000 0.96 3.87 3.08 29440000 29186000 28876000 0.95 3.85 3.05 29646000 29409000 29133000 28125000 113093000 88845000 -32394000 -37536000 -118142000 -2086000 4403000 8186000 65936000 205132000 4556000 35628000 163193000 -121772000 63753000 276286000 -32927000 2074024000 1956084000 2162520000 1810844000 1730062000 1806526000 21318000 20793000 20793000 38442000 31715000 28939000 0 0 55050000 15683000 11953000 15671000 1506000 3610000 1349000 -1164000 4353000 7778000 216433000 186210000 273312000 141436000 112000000 120999000 398000 79000 225000 14165000 4356000 44627000 135000 1372000 15479000 350000 4210000 0 278071000 294497000 205746000 76859000 78664000 75725000 143020000 170823000 120390000 -213880000 -166869000 -190511000 37000 0 -1560000 303000 282000 253000 11280000 8236000 15051000 3500000 2983000 2374000 0 0 524000 1506000 3610000 1349000 9020000 8581000 11689000 -12858000 16376000 -12790000 -1285000 44298000 81700000 457549000 413251000 331551000 456264000 457549000 413251000 3000 239986000 -101000 1606117000 340717000 2186722000 88845000 88845000 -121772000 -121772000 15051000 15051000 14888000 14888000 1421000 1421000 3000 271346000 -101000 1694962000 218945000 2185155000 113093000 113093000 163193000 163193000 8236000 8236000 16983000 16983000 3843000 3843000 3000 300408000 -101000 1808055000 382138000 2490503000 28125000 28125000 35628000 35628000 11280000 11280000 19730000 19730000 1493000 1493000 3000 332911000 -101000 1836180000 417766000 2586759000 1.<span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">SIGNIFICANT ACCOUNTING POLICIES</span><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Cash and Cash Equivalents</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Short-term Restricted Investments</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term restricted investments of </span><span style="font-family:inherit;font-size:11pt;"><span>$4.56 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$4.21 million</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2015</span><span style="font-family:inherit;font-size:11pt;">, respectively, represent a money market fund for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Available-for-Sale Investments</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale investments for other-than-temporary losses on a quarterly basis. </span><span style="font-family:inherit;font-size:11pt;color:#007f00;"> </span><span style="font-family:inherit;font-size:11pt;">Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10).</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Concentration of Credit Risk</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">investments are placed with various highly rated major financial institutions located in different geographic regions. Bio-Rad has not sustained significant losses from instruments held at financial institutions.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  However, we do not expect to record any losses as a result of counterparty default.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Accounts Receivable</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Inventory</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Inventories are valued at the lower of actual cost or market (net realizable value) and include material, labor and overhead costs.  The first-in, first-out method is used to relieve inventory for products sold.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Property, Plant and Equipment</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  Buildings and leasehold improvements are amortized over </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>15</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>30</span></span><span style="font-family:inherit;font-size:11pt;"> years or the term of the leases or life of the improvements, whichever is shorter.  With the exception of reagent rental equipment, which is amortized over a </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>1</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>5</span></span><span style="font-family:inherit;font-size:11pt;"> year period, equipment and capitalized software is depreciated over </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>3</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>12</span></span><span style="font-family:inherit;font-size:11pt;"> years.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The goodwill impairment test consists of a two-step process.  The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit to its carrying value, including goodwill. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We use a projected discounted cash flow model to determine the fair value of a reporting unit.  If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required.  The second step, if required, compares the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill.  The fair value of a reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit.  If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an impairment charge is recognized in an amount equal to that excess.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Long-Lived Assets</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant under-performance relative to expected, historical or projected future operating results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant negative industry, legal, regulatory or economic trends.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Income Taxes </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. To the extent we determine that we are able to realize our deferred income tax assets in the future in excess of their net recorded amount, we make an adjustment to the valuation allowance which may reduce the provision for income taxes. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Revenue is recognized when pervasive evidence of an arrangement exists, the price to the buyer is fixed or determinable, collectability is reasonably assured and title has passed to the customer or product has been delivered absent specific contractual specifications.  Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required contractually, has occurred.  At the time revenue is recognized, a provision is recognized for estimated product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement, or as services are performed if not under contract. Net sales are the actual selling price of products to customers. Any taxes billed to the customer (sales tax, value added tax, etc.) shall be credited to the tax liability accounts and excluded from net sales.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reagent agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis.  We evaluate our reagent agreements and account for these contracts under the guidance pertaining to accounting for revenue arrangements with multiple deliverables.  Our reagent agreements represent one unit of accounting as the instrument and consumables are interdependent in producing a diagnostic result that neither has a stand-alone value with respect to these agreements. All revenues that we earn under our reagent agreements are recognized pursuant to the terms of each agreement and are based and entirely contingent upon either (i) when the consumables to conduct a fixed number of tests are delivered or (ii) as reported by the customer on a per test basis.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Shipping and Handling</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We classify all freight costs billed to customers as Net sales.  Related freight costs are included in Cost of goods sold.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Warranty</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We warrant certain equipment against defects in design, materials and workmanship, mostly for a period of one year.  Upon delivery of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in the warranty accrual, included in Other current liabilities and Other long-term liabilities, were as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:425px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:237px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:76px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:76px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for warranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>33.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Actual warranty costs</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(33.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(31.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Foreign Currency</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward Foreign Exchange Contracts</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Share-Based Compensation Plans</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Stock-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs net of estimated forfeitures over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  We estimated the forfeiture rate based on our historical experience.  These plans are described more fully in Note 9.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Earnings Per Share</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:372px;"/><td style="width:5px;"/><td style="width:93px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:93px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:92px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic weighted average shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,186</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28,876</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effect of potentially dilutive stock options</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    and restricted stock awards</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>206</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted weighted average common shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,646</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,409</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,133</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Anti-dilutive stock options and restricted stock awards </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    excluded from the computation of diluted EPS</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>122</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Recent Accounting Standards Updates</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-size:11pt;">In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective prospectively for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. ASU 2017-04 will provide a more stream-lined approach to evaluating future goodwill impairment and we early adopted on January 1, 2017. We have not assessed the impact that ASU 2017-04 will have on our consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017. </span><span style="font-size:12pt;"> </span><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs.</span><span> </span><span style="font-size:11pt;">Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. ASU 2017-01 will be applied prospectively to any transactions occurring within the period of adoption. Early adoption is permitted, including for interim or annual periods in which the financial statements have not been issued or made available for issuance. We early adopted ASU 2017-01 on January 1, 2017. For our acquisition of RainDance Technologies, Inc., ASU 2017-01 did not affect the conclusion of it being a business combination (see Note 17 to the consolidated financial statements). </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. We have had a limited amount of r</span><span style="font-family:inherit;font-size:10pt;">e</span><span style="font-family:inherit;font-size:11pt;">stricted cash of </span><span style="font-family:inherit;font-size:11pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of December 31, 2016 and 2015, respectively, which was reclassified from cash to either Prepaid expenses, Other current assets or Other assets in the Consolidated Balance Sheets. At the time of adoption, we cannot assure whether these same restricted cash amounts will be held or what other restricted cash we may have, or that historically reported amounts will be similar. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than </span><span> </span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-size:11pt;">ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted as of the beginning of an annual reporting period for which finan</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">inventory transfers.  Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements.  ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. </span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-size:11pt;">cial statements have not been issued or made available for issuance. We do not plan to early adopt ASU 2016-16. We are currently evaluating the effect ASU 2016-16 will have on our consolidated financial statements.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In August 2016, the FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the effect ASU 2016-15 will have on our consolidated statements of cash flows, if any.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for trade and other receivables, and instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also will allow an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. We adopted ASU 2016-09 on January 1, 2017 and made a policy election to account for forfeitures as they occur. We do not expect ASU 2016-09 to have a material impact on our consolidated financial statements.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. ASU 2016-07 will be applied on a prospective basis and is effective for all entities for fiscal years beginning after December 15, 2016, and interim periods within those years. We adopted ASU 2016-07 on January 1, 2017 and do not expect it to materially affect our consolidated financial statements, unless our situation changes regarding our ability to influence the investee in the future as a result of our cost method investment in Sartorius AG (see Note 3 to the consolidated financial statements). </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-size:11pt;">In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. </span><span style="font-size:12pt;"> </span><span style="font-size:11pt;">For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the consolidated financial statements. At the time of adoption, we cannot assure whether these same equity securities will be held or what other equity securities we may have, or that historically reported changes will be similar.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In September 2015, the FASB issued ASU 2015-16, "Simplifying the Accounting for Measurement-Period Adjustments," which eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. Under ASU 2015-16, acquirers must recognize measurement-period adjustments during the period in which they determine the amounts, including the effect on earnings of any amounts they would have recorded in previous periods if the accounting had been completed at the acquisition date. The measurement period cannot exceed one year from the date of the acquisition. ASU 2015-16 was effective on January 1, 2016, and we adopted it at the same time as a change in accounting policy, which had no impact on our consolidated financial statements. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” ASU 2015-11 is effective prospectively for annual periods beginning after December 15, 2016, and interim periods therein. We adopted ASU 2015-11 on January 1, 2017 and do not expect it to have a material impact to our consolidated financial statements. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In April 2015, the FASB issued ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs." ASU 2015-03 was issued to simplify the presentation of debt issuance costs by requiring debt issuance costs to be presented as a deduction from the corresponding debt liability. This makes the presentation of debt issuance costs consistent with the presentation of debt discounts or premiums. Under prior U.S. GAAP, debt issuance costs were reported on the balance sheet as assets and amortized as interest expense. Under ASU 2015-03, debt issuance costs will continue to be amortized to interest expense using the effective interest method. In August 2015, the FASB issued ASU 2015-15, "Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements" to clarify the SEC staff’s position that it would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, which is our current practice. We adopted ASU 2015-03 on January 1, 2016 on a retrospective basis as a change in accounting policy. The Condensed Consolidated Balance Sheet as of December 31, 2015 was retrospectively adjusted by decreasing Other assets and Long-term debt, net of current maturities, by </span><span style="font-family:inherit;font-size:11pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 to defer the effective date for annual reporting periods </span></div><span style="font-size:11pt;">beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted as of the original effective date in ASU 2014-09, which is annual reporting periods beginning after December 15, 2016, however, we will not early adopt. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectiblity, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method once we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. We have completed revenue recognition diagnostic surveys across all regions in our decentralized sales contracting process, which is based on local country commercial regulations and practices. We have begun assessing individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP, to determine the effect that these ASU’s will have on our consolidated financial statements and related disclosures.</span> Basis of Presentation<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions. Cash and Cash Equivalents<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value. Short-term Restricted Investments<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">Short-term restricted investments of </span><span style="font-family:inherit;font-size:11pt;"><span>$4.56 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$4.21 million</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2015</span>, respectively, represent a money market fund for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets. 4560000 4210000 Available-for-Sale Investments<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale investments for other-than-temporary losses on a quarterly basis. </span><span style="font-family:inherit;font-size:11pt;color:#007f00;"> </span>Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10). Concentration of Credit Risk<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">investments are placed with various highly rated major financial institutions located in different geographic regions. Bio-Rad has not sustained significant losses from instruments held at financial institutions.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  However, we do not expect to record any losses as a result of counterparty default.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.</span></div><br/> Accounts Receivable<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance. Inventory<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Inventories are valued at the lower of actual cost or market (net realizable value) and include material, labor and overhead costs.  The first-in, first-out method is used to relieve inventory for products sold. Property, Plant and Equipment<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  Buildings and leasehold improvements are amortized over </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>15</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>30</span></span><span style="font-family:inherit;font-size:11pt;"> years or the term of the leases or life of the improvements, whichever is shorter.  With the exception of reagent rental equipment, which is amortized over a </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>1</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>5</span></span><span style="font-family:inherit;font-size:11pt;"> year period, equipment and capitalized software is depreciated over </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>3</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>12</span></span> years. P15Y0M0D P30Y0M0D P1Y0M0D P5Y0M0D P3Y0M0D P12Y0M0D Goodwill<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The goodwill impairment test consists of a two-step process.  The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit to its carrying value, including goodwill. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We use a projected discounted cash flow model to determine the fair value of a reporting unit.  If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required.  The second step, if required, compares the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill.  The fair value of a reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit.  If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an impairment charge is recognized in an amount equal to that excess.</span></div><br/> Long-Lived Assets<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant under-performance relative to expected, historical or projected future operating results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant negative industry, legal, regulatory or economic trends.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value. Income Taxes <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. To the extent we determine that we are able to realize our deferred income tax assets in the future in excess of their net recorded amount, we make an adjustment to the valuation allowance which may reduce the provision for income taxes. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit </span></div><span style="font-family:inherit;font-size:11pt;">that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax</span><span style="font-family:inherit;font-size:11pt;"> </span>benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes. Revenue Recognition<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Revenue is recognized when pervasive evidence of an arrangement exists, the price to the buyer is fixed or determinable, collectability is reasonably assured and title has passed to the customer or product has been delivered absent specific contractual specifications.  Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required contractually, has occurred.  At the time revenue is recognized, a provision is recognized for estimated product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement, or as services are performed if not under contract. Net sales are the actual selling price of products to customers. Any taxes billed to the customer (sales tax, value added tax, etc.) shall be credited to the tax liability accounts and excluded from net sales.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Reagent agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis.  We evaluate our reagent agreements and account for these contracts under the guidance pertaining to accounting for revenue arrangements with multiple deliverables.  Our reagent agreements represent one unit of accounting as the instrument and consumables are interdependent in producing a diagnostic result that neither has a stand-alone value with respect to these agreements. All revenues that we earn under our reagent agreements are recognized pursuant to the terms of each agreement and are based and entirely contingent upon either (i) when the consumables to conduct a fixed number of tests are delivered or (ii) as reported by the customer on a per test basis. <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Shipping and Handling</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>We classify all freight costs billed to customers as Net sales.  Related freight costs are included in Cost of goods sold. <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Warranty</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We warrant certain equipment against defects in design, materials and workmanship, mostly for a period of one year.  Upon delivery of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in the warranty accrual, included in Other current liabilities and Other long-term liabilities, were as follows (in millions):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:425px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:237px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:76px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:76px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for warranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>33.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Actual warranty costs</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(33.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(31.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><br/> <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in the warranty accrual, included in Other current liabilities and Other long-term liabilities, were as follows (in millions):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:425px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:237px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:76px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:76px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for warranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>33.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Actual warranty costs</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(33.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(31.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><br/> 17400000 17800000 33400000 30600000 33200000 31000000.0 17600000 17400000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed. <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Foreign Currency</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction. <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward Foreign Exchange Contracts</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income. <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Share-Based Compensation Plans</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Stock-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs net of estimated forfeitures over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  We estimated the forfeiture rate based on our historical experience.  These plans are described more fully in Note 9. <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Earnings Per Share</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:372px;"/><td style="width:5px;"/><td style="width:93px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:93px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:92px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic weighted average shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,186</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28,876</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effect of potentially dilutive stock options</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    and restricted stock awards</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>206</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted weighted average common shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,646</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,409</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,133</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Anti-dilutive stock options and restricted stock awards </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    excluded from the computation of diluted EPS</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>122</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:372px;"/><td style="width:5px;"/><td style="width:93px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:93px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:92px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic weighted average shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,186</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28,876</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effect of potentially dilutive stock options</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    and restricted stock awards</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>206</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted weighted average common shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,646</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,409</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,133</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Anti-dilutive stock options and restricted stock awards </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    excluded from the computation of diluted EPS</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>122</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 29440000 29186000 28876000 206000 223000 257000 29646000 29409000 29133000 113000 109000 122000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3). Recent Accounting Standards Updates<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-size:11pt;">In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective prospectively for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. ASU 2017-04 will provide a more stream-lined approach to evaluating future goodwill impairment and we early adopted on January 1, 2017. We have not assessed the impact that ASU 2017-04 will have on our consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017. </span><span style="font-size:12pt;"> </span><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs.</span><span> </span><span style="font-size:11pt;">Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. ASU 2017-01 will be applied prospectively to any transactions occurring within the period of adoption. Early adoption is permitted, including for interim or annual periods in which the financial statements have not been issued or made available for issuance. We early adopted ASU 2017-01 on January 1, 2017. For our acquisition of RainDance Technologies, Inc., ASU 2017-01 did not affect the conclusion of it being a business combination (see Note 17 to the consolidated financial statements). </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. We have had a limited amount of r</span><span style="font-family:inherit;font-size:10pt;">e</span><span style="font-family:inherit;font-size:11pt;">stricted cash of </span><span style="font-family:inherit;font-size:11pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of December 31, 2016 and 2015, respectively, which was reclassified from cash to either Prepaid expenses, Other current assets or Other assets in the Consolidated Balance Sheets. At the time of adoption, we cannot assure whether these same restricted cash amounts will be held or what other restricted cash we may have, or that historically reported amounts will be similar. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than </span><span> </span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-size:11pt;">ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted as of the beginning of an annual reporting period for which finan</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">inventory transfers.  Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements.  ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. </span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-size:11pt;">cial statements have not been issued or made available for issuance. We do not plan to early adopt ASU 2016-16. We are currently evaluating the effect ASU 2016-16 will have on our consolidated financial statements.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In August 2016, the FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the effect ASU 2016-15 will have on our consolidated statements of cash flows, if any.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for trade and other receivables, and instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also will allow an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. We adopted ASU 2016-09 on January 1, 2017 and made a policy election to account for forfeitures as they occur. We do not expect ASU 2016-09 to have a material impact on our consolidated financial statements.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. ASU 2016-07 will be applied on a prospective basis and is effective for all entities for fiscal years beginning after December 15, 2016, and interim periods within those years. We adopted ASU 2016-07 on January 1, 2017 and do not expect it to materially affect our consolidated financial statements, unless our situation changes regarding our ability to influence the investee in the future as a result of our cost method investment in Sartorius AG (see Note 3 to the consolidated financial statements). </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-size:11pt;">In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. </span><span style="font-size:12pt;"> </span><span style="font-size:11pt;">For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the consolidated financial statements. At the time of adoption, we cannot assure whether these same equity securities will be held or what other equity securities we may have, or that historically reported changes will be similar.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In September 2015, the FASB issued ASU 2015-16, "Simplifying the Accounting for Measurement-Period Adjustments," which eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. Under ASU 2015-16, acquirers must recognize measurement-period adjustments during the period in which they determine the amounts, including the effect on earnings of any amounts they would have recorded in previous periods if the accounting had been completed at the acquisition date. The measurement period cannot exceed one year from the date of the acquisition. ASU 2015-16 was effective on January 1, 2016, and we adopted it at the same time as a change in accounting policy, which had no impact on our consolidated financial statements. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” ASU 2015-11 is effective prospectively for annual periods beginning after December 15, 2016, and interim periods therein. We adopted ASU 2015-11 on January 1, 2017 and do not expect it to have a material impact to our consolidated financial statements. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In April 2015, the FASB issued ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs." ASU 2015-03 was issued to simplify the presentation of debt issuance costs by requiring debt issuance costs to be presented as a deduction from the corresponding debt liability. This makes the presentation of debt issuance costs consistent with the presentation of debt discounts or premiums. Under prior U.S. GAAP, debt issuance costs were reported on the balance sheet as assets and amortized as interest expense. Under ASU 2015-03, debt issuance costs will continue to be amortized to interest expense using the effective interest method. In August 2015, the FASB issued ASU 2015-15, "Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements" to clarify the SEC staff’s position that it would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, which is our current practice. We adopted ASU 2015-03 on January 1, 2016 on a retrospective basis as a change in accounting policy. The Condensed Consolidated Balance Sheet as of December 31, 2015 was retrospectively adjusted by decreasing Other assets and Long-term debt, net of current maturities, by </span><span style="font-family:inherit;font-size:11pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 to defer the effective date for annual reporting periods </span></div><span style="font-size:11pt;">beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted as of the original effective date in ASU 2014-09, which is annual reporting periods beginning after December 15, 2016, however, we will not early adopt. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectiblity, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method once we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. We have completed revenue recognition diagnostic surveys across all regions in our decentralized sales contracting process, which is based on local country commercial regulations and practices. We have begun assessing individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP, to determine the effect that these ASU’s will have on our consolidated financial statements and related disclosures.</span> 2000000.0 1400000 1800000 2.    ACQUISITIONS<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Propel Labs, Inc.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In January 2016, we acquired a high performance analytical flow cytometer platform from Propel Labs (Propel) that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. This asset acquisition was accounted for as a business combination, as the new analytical flow cytometer platform represented an integrated set of activities and assets that is capable of being conducted and managed for the purpose of providing a return and therefore constitutes a business in accordance with GAAP. The amount of the acquisition-related cost was minimal as Bio-Rad primarily represented itself during the acquisition process. This business acquisition is included in our Life Science segment’s results of operations from the acquisition date.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The fair value of the consideration as of the acquisition date was </span><span style="font-family:inherit;font-size:11pt;"><span>$32.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, which included </span><span style="font-family:inherit;font-size:11pt;"><span>$9.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> paid in cash at the closing date and </span><span style="font-family:inherit;font-size:11pt;"><span>$23.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> in contingent consideration potentially payable to Propel, after the effects of a calculation revision that were reflected in the fourth quarter of 2016. This revision reduced goodwill/intangibles and contingent consideration by the same amount and had no significant impact on our Consolidated Income Statement. The contingent consideration was based on a probability-weighted income approach related to the achievement of certain sales milestones, and was recognized at its estimated fair value of </span><span style="font-family:inherit;font-size:11pt;"><span>$25.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> (see Note 3, "Fair Value Measurements").</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The fair values of the net assets acquired from Propel as of the acquisition date were determined to be </span><span style="font-family:inherit;font-size:11pt;"><span>$32.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> of definite-lived intangible assets and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> of goodwill. We expect the goodwill recorded to be deductible for income tax purposes. The acquired analytical flow cytometer platform fits well into Bio-Rad’s existing Life Science segment product offerings and may offer researchers greater access to this technology.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>In addition, Bio-Rad contracted with Propel to provide development services concurrent with and included in the purchase agreement. Bio-Rad is receiving future manufacturing, engineering and marketing support from Propel on which payments will be made upon the successful completion of all contracted services. As a result, these services are not included in the total purchase consideration and a majority will be expensed in future periods. 32800000 9500000 23300000 25400000 32700000 100000 3. FAIR VALUE MEASUREMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1: Quoted prices in active markets for identical instruments</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents (a):</span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Domestic time deposits</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>52.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment:</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments (b):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>767.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>767.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>767.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>347.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,115.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (c)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>790.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>383.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,173.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Forward foreign exchange contracts (d)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Contingent consideration (e)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2015</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents (a):</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign time deposits</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>48.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>71.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment:</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments (b):</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>156.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>156.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>74.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>74.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>660.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>660.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>660.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>297.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>957.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (c)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>687.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>346.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,034.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> Contingent consideration (e)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>383.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>328.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>732.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>628.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,115.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>957.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(c)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(d)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(e)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2012, we recognized a contingent consideration liability for certain milestones of </span><span style="font-family:inherit;font-size:11pt;"><span>$44.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> upon our acquisition of a new cell sorting system from Propel. Since 2012, we have paid </span><span style="font-family:inherit;font-size:11pt;"><span>$28.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> upon reaching the milestones and have reduced the valuation of the milestones by </span><span style="font-family:inherit;font-size:11pt;"><span>$12.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> to its estimated fair value of </span><span style="font-family:inherit;font-size:11pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">. The remaining liability was paid in </span><span style="font-family:inherit;font-size:10pt;">February 2017</span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a new high performance analytical flow cytometer platform from Propel. At the acquisition date, the contingent consideration was based on a probability-weighted income approach related to the achievement of sales milestones, ranging from </span><span style="font-family:inherit;font-size:11pt;"><span>39%</span></span><span style="font-family:inherit;font-size:11pt;"> to </span><span style="font-family:inherit;font-size:11pt;"><span>20%</span></span><span style="font-family:inherit;font-size:11pt;"> for the calendar years </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> through </span><span style="font-family:inherit;font-size:11pt;">2020</span><span style="font-family:inherit;font-size:11pt;">. The sales milestones could potentially range from </span><span style="font-family:inherit;font-size:11pt;"><span>$0</span></span><span style="font-family:inherit;font-size:11pt;"> to an unlimited amount through </span><span style="font-family:inherit;font-size:11pt;">December 31, 2020</span><span style="font-family:inherit;font-size:11pt;">. The fair value of the contingent consideration as of the acquisition date was </span><span style="font-family:inherit;font-size:11pt;"><span>$23.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, after the effects of a calculation revision that were reflected in the fourth quarter of 2016. The contingent consideration was recognized at its estimated fair value of </span><span style="font-family:inherit;font-size:11pt;"><span>$25.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value based on original valuations and updated quarterly for the year ended </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cell sorting system:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Payment of sales milestone </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Analytical flow cytometer platform:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Acquisition of high performance analytical flow cytometer platform</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase in estimated fair value of contingent consideration included in Selling, general and administrative expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The following table provides quantitative information about Level 3 inputs for fair value measurement of analytical flow cytometer platform contingent consideration liability as of</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">.</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:16%;"/><td style="width:23%;"/><td style="width:36%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Range</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unobservable Input</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">From</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">To</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Analytical flow cytometer platform</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Probability-weighted income approach</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Sales milestones:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2014, we recognized a contingent consideration liability upon our acquisition of GnuBIO, Inc.. The contingent consideration for the milestones was valued at </span><span style="font-family:inherit;font-size:11pt;"><span>$10.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> at the acquisition date based on assumptions regarding the probability of achieving the milestones, with such amounts discounted to present value. The Level 3 contingent consideration was revalued to a fair value of </span><span style="font-family:inherit;font-size:11pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2015</span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">To estimate the fair value of Level 2 debt securities as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2015</span><span style="font-family:inherit;font-size:11pt;">, our primary pricing provider uses S&amp;P Capital IQ as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. The chosen pricing hierarchy for our Level 2 securities, other than certificates of deposit and commercial paper, is S&amp;P Capital IQ as the primary pricing source and then our custodian as the secondary pricing source. If S&amp;P Capital IQ does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing. </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For commercial paper as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2015</span><span style="font-family:inherit;font-size:11pt;">, pricing is determined by a straight-line calculation, starting with the purchase price on the date of purchase and increasing to par at maturity. Interest bearing certificates of deposit and commercial paper are priced at par.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our primary pricing provider performs daily reasonableness testing of S&amp;P Capital IQ prices. Price changes of </span><span style="font-family:inherit;font-size:11pt;"><span>5%</span></span><span style="font-family:inherit;font-size:11pt;"> or greater are investigated and resolved. In addition, we perform a quarterly testing of the S&amp;P Capital IQ prices to custodian reported prices. Prices outside a tolerable variance of approximately </span><span style="font-family:inherit;font-size:11pt;"><span>1%</span></span><span style="font-family:inherit;font-size:11pt;"> are investigated and resolved.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of the following (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>83.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>380.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.8</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>383.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>677.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>732.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>677.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>732.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>435.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>681.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,115.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>157.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>156.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>74.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>74.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>327.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>328.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>574.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>628.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>574.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>628.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>382.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>577.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>957.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The unrealized gains of our long-term marketable equity securities are primarily due to our investment in Sartorius AG preferred shares.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>160.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>204.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> or at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2015</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign exchange losses, net in the Consolidated Statements of Income. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of our forward foreign currency exchange contracts (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in January through March 2017 to sell foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in January through March 2017 to purchase foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>328.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of the amortized cost and estimated fair value of our debt securities at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> by contractual maturity date (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in less than one year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>156.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>156.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in one to five years</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>141.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>140.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in more than five years</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>51.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>51.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>348.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>347.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of financial instruments that are not recognized at fair value in the Consolidated Balance Sheets and are included in Other investments, are presented in the table below. Fair value has been determined using significant observable inputs, including quoted prices in active markets for similar instruments.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value.  Other investments include financial instruments, the majority of which has fair value based on similar, actively traded stock adjusted for various discounts, including a discount for marketability.  Long-term debt, excluding leases and current maturities, has an estimated fair value based on quoted market prices for the same or similar issues. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value Hierarchy Level</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value Hierarchy Level</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>92.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>984.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>86.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>843.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total long-term debt, excluding leases </span></div><div style="padding-left:12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">and current maturities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>422.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>454.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>421.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>454.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries.  We own over </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>35%</span></span><span style="font-family:inherit;font-size:11pt;"> of the outstanding voting shares (excluding treasury shares) of Sartorius as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span>.  The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius’ board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. We account for this investment using the cost method.  The carrying value of this investment is included in Other investments in our Consolidated Balance Sheets. As the stock is thinly traded and in conjunction with the valuation method discussed above, we have classified the estimated fair value as Level 2. The Level 2 classification is appropriate given the valuation method employed, which incorporates an observable input of the fair value of the Sartorius’ actively traded preferred stock. Financial assets and liabilities carried at fair value and measured on a recurring basis as of <span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents (a):</span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Domestic time deposits</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>52.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment:</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments (b):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>767.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>767.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>767.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>347.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,115.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (c)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>790.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>383.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,173.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Forward foreign exchange contracts (d)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Contingent consideration (e)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2015</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents (a):</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign time deposits</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>48.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>71.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment:</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments (b):</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>156.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>156.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>74.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>74.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>660.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>660.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>660.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>297.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>957.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (c)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>687.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>346.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,034.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> Contingent consideration (e)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>383.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>328.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>732.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>628.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,115.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>957.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(c)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(d)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(e)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 0 14100000 0 14100000 11800000 0 0 11800000 0 20000000.0 0 20000000.0 0 1100000 0 1100000 5900000 0 0 5900000 17700000 35200000 0 52900000 4600000 0 0 4600000 0 179400000 0 179400000 0 82500000 0 82500000 0 4400000 0 4400000 0 3600000 0 3600000 0 15400000 0 15400000 767800000 0 0 767800000 0 62500000 0 62500000 767800000 347800000 0 1115600000 0 600000 0 600000 790100000 383600000 0 1173700000 0 1300000 0 1300000 0 0 38500000 38500000 0 1300000 38500000 39800000 0 33200000 0 33200000 0 600000 0 600000 11900000 0 0 11900000 0 14600000 0 14600000 11300000 0 0 11300000 23200000 48400000 0 71600000 4200000 0 0 4200000 0 156900000 0 156900000 0 74800000 0 74800000 0 4600000 0 4600000 0 6400000 0 6400000 660100000 0 0 660100000 0 54800000 0 54800000 660100000 297500000 0 957600000 0 900000 0 900000 687500000 346800000 0 1034300000 0 1100000 0 1100000 0 0 19100000 19100000 0 1100000 19100000 20200000 383200000 328700000 732400000 628900000 1115600000 957600000 14500000 13500000 24000000.0 5600000 38500000 19100000 44600000 28900000 12600000 3100000 0.39 0.20 0 23300000 25400000 The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value based on original valuations and updated quarterly for the year ended <span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> (in millions):</span><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cell sorting system:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Payment of sales milestone </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Analytical flow cytometer platform:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Acquisition of high performance analytical flow cytometer platform</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase in estimated fair value of contingent consideration included in Selling, general and administrative expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 9100000 3500000 2500000 23300000 -2100000 28500000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The following table provides quantitative information about Level 3 inputs for fair value measurement of analytical flow cytometer platform contingent consideration liability as of</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">.</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:16%;"/><td style="width:23%;"/><td style="width:36%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Range</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unobservable Input</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">From</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">To</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Analytical flow cytometer platform</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Probability-weighted income approach</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Sales milestones:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 0.10 0.047 10700000 10000000.0 0.05 0.01 Available-for-sale investments consist of the following (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>83.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>380.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.8</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>383.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>677.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>732.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>677.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>732.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>435.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>681.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,115.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>157.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>156.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>74.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>74.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>327.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>328.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>574.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>628.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>574.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>628.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>382.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>577.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>957.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 179700000 200000 500000 179400000 3600000 0 0 3600000 15500000 0 100000 15400000 62200000 100000 100000 62200000 83100000 100000 700000 82500000 4400000 0 0 4400000 32400000 3700000 400000 35700000 380900000 4100000 1800000 383200000 54500000 677600000 0 732100000 300000 0 0 300000 54800000 677600000 0 732400000 435700000 681700000 1800000 1115600000 157200000 100000 400000 156900000 6400000 0 0 6400000 54800000 0 200000 54600000 74900000 100000 200000 74800000 4600000 0 0 4600000 29400000 2700000 700000 31400000 327300000 2900000 1500000 328700000 54500000 574200000 0 628700000 300000 0 100000 200000 54800000 574200000 100000 628900000 382100000 577100000 1600000 957600000 The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>160.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>204.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 11800000 10400000 160500000 204000000.0 300000 400000 1500000 1200000 The following is a summary of our forward foreign currency exchange contracts (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in January through March 2017 to sell foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in January through March 2017 to purchase foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>328.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 16900000 100000 328300000 600000 The following is a summary of the amortized cost and estimated fair value of our debt securities at <span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> by contractual maturity date (in millions):</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in less than one year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>156.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>156.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in one to five years</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>141.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>140.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in more than five years</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>51.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>51.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>348.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>347.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 156100000 156100000 141000000.0 140700000 51700000 51000000.0 348800000 347800000 The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value Hierarchy Level</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value Hierarchy Level</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>92.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>984.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>86.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>843.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total long-term debt, excluding leases </span></div><div style="padding-left:12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">and current maturities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>422.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>454.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>421.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>454.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr></table></div> 92800000 984200000 86500000 843200000 422500000 454200000 421900000 454300000 0.35 4.    GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes to goodwill by segment were as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:667px;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:244px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:58px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:61px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:41px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:58px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:61px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:41px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Life<br/>Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical<br/>Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Life<br/>Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical<br/>Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balances as of January 1:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>207.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>316.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>524.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>207.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>320.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>528.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated impairment losses and write-offs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(28.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(28.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>180.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>315.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>495.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>180.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>319.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>500.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquisitions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Impairment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(13.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(13.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Currency fluctuations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balances as of December 31:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>207.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>311.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>518.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>207.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>316.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>524.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated impairment losses and write-offs</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(14.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(41.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(28.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>179.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>297.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>477.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>180.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>315.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>495.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In conjunction with the purchase of certain assets from Propel in January 2016 (see Note 2, "Acquisitions"), we recorded </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> of goodwill and </span><span style="font-family:inherit;font-size:11pt;"><span>$32.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> of definite-lived intangible assets: </span><span style="font-family:inherit;font-size:11pt;"><span>$29.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> of developed product technology and </span><span style="font-family:inherit;font-size:11pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> of covenants not to compete, after the effects of a calculation revision that were reflected in the fourth quarter of 2016.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>84.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(52.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>182.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(136.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>45.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">3-12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>125.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(56.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>69.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(30.6</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>443.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(281.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>161.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In-process research and development</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total purchased intangible assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>443.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(281.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>161.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2-10</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>84.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(46.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>37.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-10</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>184.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(121.6</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4-12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>101.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(48.9</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>52.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">3-10</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(28.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">5-9</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.4</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">3-7</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.7</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>417.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(249.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>167.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In-process research and development</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>46.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>46.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total purchased intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>463.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(249.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>214.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2016, we fully impaired goodwill and in-process research and development in the amounts of </span><span style="font-family:inherit;font-size:11pt;"><span>$13.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$46.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, associated with our 2014 acquisition of GnuBIO, Inc. The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows. There were no impairment losses recorded in 2015.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">Amortization expense related to purchased intangible assets for the years ended December 31, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2014</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$35.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$36.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$47.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively.  Estimated future amortization expense (based on existing purchased intangible assets) for the years ending December 31, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2020</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2021</span><span style="font-family:inherit;font-size:11pt;"> and thereafter is </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$27.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$24.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$21.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$19.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$18.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;"><span>$51.0 million</span></span>, respectively. <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes to goodwill by segment were as follows (in millions):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:667px;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:244px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:58px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:61px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:41px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:58px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:61px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:41px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Life<br/>Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical<br/>Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Life<br/>Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical<br/>Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balances as of January 1:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>207.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>316.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>524.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>207.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>320.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>528.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated impairment losses and write-offs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(28.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(28.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>180.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>315.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>495.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>180.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>319.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>500.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquisitions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Impairment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(13.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(13.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Currency fluctuations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balances as of December 31:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>207.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>311.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>518.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>207.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>316.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>524.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated impairment losses and write-offs</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(14.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(41.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(28.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>179.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>297.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>477.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>180.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>315.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>495.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 207200000 316900000 524100000 207700000 320900000 528600000 27200000 1000000.0 28200000 27200000 1000000.0 28200000 180000000.0 315900000 495900000 180500000 319900000 500400000 100000 0 100000 0 0 0 0 13500000 13500000 0 0 0 -200000 -5200000 -5400000 -500000 -4000000.0 -4500000 207100000 311700000 518800000 207200000 316900000 524100000 27200000 14500000 41700000 27200000 1000000.0 28200000 179900000 297200000 477100000 180000000.0 315900000 495900000 100000 32700000 29700000 3000000.0 Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):<div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>84.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(52.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>182.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(136.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>45.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">3-12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>125.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(56.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>69.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(30.6</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>443.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(281.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>161.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In-process research and development</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total purchased intangible assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>443.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(281.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>161.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2-10</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>84.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(46.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>37.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-10</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>184.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(121.6</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4-12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>101.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(48.9</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>52.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">3-10</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(28.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">5-9</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.4</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">3-7</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.7</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>417.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(249.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>167.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In-process research and development</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>46.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>46.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total purchased intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>463.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(249.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>214.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><br/> 84400000 52800000 31600000 182600000 136900000 45700000 125900000 56300000 69600000 39000000.0 30600000 8400000 3500000 2500000 1000000.0 7800000 2500000 5300000 443200000 281600000 161600000 0 0 443200000 281600000 161600000 84700000 46800000 37900000 184000000.0 121600000 62400000 101300000 48900000 52400000 39200000 28500000 10700000 3500000 2400000 1100000 4800000 1700000 3100000 417500000 249900000 167600000 46400000 46400000 463900000 249900000 214000000.0 13500000 46400000 35200000 36500000 47800000 27200000 24200000 21400000 19400000 18400000 51000000.0 5.<span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">NOTES PAYABLE AND LONG-TERM DEBT</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had </span><span style="font-family:inherit;font-size:11pt;"><span>$205.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> available for borrowing and usage as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, which was reduced by </span><span style="font-family:inherit;font-size:11pt;"><span>$5.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The principal components of long-term debt are as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4.875% Senior Notes due 2020, net of discount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.1</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>422.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>421.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital leases and other debt</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less current maturities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>433.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Senior Notes due 2020</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In December 2010, Bio-Rad sold </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$425.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> principal amount of Senior Notes due 2020 (</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes).  The sale yielded net cash proceeds of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$422.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> at an effective rate of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.946%</span></span><span style="font-family:inherit;font-size:11pt;">.  The </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes pay a fixed rate of interest of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> per year.  We have the option to redeem any or all of the </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes) and accrued and unpaid interest thereon to the redemption date.  Our obligations under the </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness.  Certain covenants apply at each year end to the </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. We were in compliance with these covenants as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Credit Agreement</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In June 2014, Bio-Rad entered into a </span><span style="font-family:inherit;font-size:11pt;color:#000000;font-style:normal;text-decoration:none;"><span>$200.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> or </span><span style="font-family:inherit;font-size:11pt;">2015</span><span style="font-family:inherit;font-size:11pt;">, however, </span><span style="font-family:inherit;font-size:11pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> was utilized for domestic standby letters of credit that reduced our borrowing availability. The Credit Agreement matures in </span><span style="font-family:inherit;font-size:11pt;">June 2019</span><span style="font-family:inherit;font-size:11pt;">. If we had borrowed against our Credit Agreement, the borrowing rate would have been </span><span style="font-family:inherit;font-size:11pt;"><span>2.25%</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Maturities of long-term debt at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> are as follows: </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2020</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$425.3 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2021</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">thereafter</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$10.6 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><br/> 205700000 5400000 The principal components of long-term debt are as follows (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4.875% Senior Notes due 2020, net of discount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.1</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>422.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>421.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital leases and other debt</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less current maturities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>433.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 425000000.0 425000000.0 2500000 3100000 422500000 421900000 12000000.0 12300000 434500000 434200000 300000 300000 434200000 433900000 425000000.0 0.04875 422600000 0.04946 0.04875 0.04875 0.04875 0.04875 0.04875 0.04875 200000000.0 800000 0.0225 300000 300000 200000 425300000 300000 10600000 6. INCOME TAXES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The U.S. and international components of income before taxes are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S.</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(38.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>48.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>97.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>101.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income before taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>145.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>131.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The provision for income taxes consists of the following (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Current tax expense:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Current tax expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>44.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax (benefit) expense:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. Federal</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(42.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.1</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(51.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.0</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Non-current tax expense (benefit)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.6</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. statutory tax rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Impact of foreign operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign dividends, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research tax credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Nontaxable subsidies</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tax settlements and changes to unrecognized tax benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill impairment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Domestic manufacturing deduction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Nondeductible executive compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fines and penalties</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior period adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. taxation on foreign income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our effective income tax rate was </span><span style="font-family:inherit;font-size:11pt;"><span>32%</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>22%</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>32%</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2015</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2014</span><span style="font-family:inherit;font-size:11pt;">, respectively. The effective tax rates for 2016 and 2015 included tax benefits from the repatriation of foreign earnings. The effective tax rate for 2016 included additional tax liabilities for unrecognized tax benefits related to the non-deductibility of interest expense</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">in our foreign jurisdictions.  The effective tax rate for 2014 included nondeductible penalties and losses that were nonrecurring. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">  </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our foreign taxes result primarily from income earned in France and Switzerland. Many jurisdictions in which we operate, including Switzerland, Russia, the U.K. and Singapore, have statutory tax rates that are significantly lower than the U.S. statutory tax rate of </span><span style="font-family:inherit;font-size:11pt;"><span>35%</span></span><span style="font-family:inherit;font-size:11pt;">. Our effective tax rate may be impacted in the future, either favorably or unfavorably, by many factors including, but not limited to, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax assets:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bad debt, inventory and warranty accruals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other post-employment benefits, vacation and other reserves</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tax credit and net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>96.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    Total gross deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>186.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>157.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(66.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(58.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">       Total deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>120.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>99.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Investments and intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>287.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>271.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">        Total deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>310.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>302.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net deferred tax liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(189.9</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(202.5</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">At </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, Bio-Rad’s international subsidiaries had combined net operating loss carryforwards of </span><span style="font-family:inherit;font-size:11pt;"><span>$141.3 million</span></span><span style="font-family:inherit;font-size:11pt;">.  Of these loss carryforwards, </span><span style="font-family:inherit;font-size:11pt;"><span>$140.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> have no expiration date.  We believe that it is more likely than not that the benefit from most of these net operating loss carryforwards will not be realized. We have provided a valuation allowance of </span><span style="font-family:inherit;font-size:11pt;"><span>$29.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> relating to these net operating loss carryforwards.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">At </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, Bio-Rad had U.S. Federal net operating loss carryforwards of approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> as a result of acquisitions. These carryforwards are subject to limitation on their utilization and will expire between 2028 and 2033. At </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, Bio-Rad had U.S. Federal foreign tax credit carryforwards of </span><span style="font-family:inherit;font-size:11pt;"><span>$27.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> and U.S. Federal research tax credit carryforwards of </span><span style="font-family:inherit;font-size:11pt;"><span>$3.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> of which are subject to limitations on their utilization. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">At </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, Bio-Rad had approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$53 million</span></span><span style="font-family:inherit;font-size:11pt;"> of California net operating loss carryforwards related to the acquisition of QuantaLife. We believe that it is more likely than not that the benefit from these net operating loss carryforwards will not be realized and have recorded a full valuation allowance against these losses. At </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, Bio-Rad had a deferred tax asset of </span><span style="font-family:inherit;font-size:11pt;"><span>$25.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> relating to California research tax credit carryforwards, including </span><span style="font-family:inherit;font-size:11pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> from the acquisition of QuantaLife, which may be carried forward indefinitely.  Based on our judgment and consistent with prior years, we have recorded a full valuation allowance against the deferred tax asset.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We believe that it is more likely than not that certain of these deferred tax assets described above will not be realized in the foreseeable future. If or when recognized, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> will be recognized as a reduction of income tax expense.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2013 and forward for the U.S., and the years 2010 and forward for certain foreign jurisdictions, including France, Switzerland and Germany. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrecognized tax benefits – January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Additions to tax positions related to prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reductions to tax positions related to prior years</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Additions to tax positions related to the current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Settlements</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Lapse of statute of limitations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.6</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Currency translation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrecognized tax benefits – December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bio-Rad recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. Related to the unrecognized tax benefits noted above, Bio-Rad has accrued interest and penalties of </span><span style="font-family:inherit;font-size:11pt;"><span>$11.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$3.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2015</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2014</span><span style="font-family:inherit;font-size:11pt;">, respectively. The total unrecognized tax benefits and interest and penalties of </span><span style="font-family:inherit;font-size:11pt;"><span>$27.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> in 2016 was partially offset by prepaid taxes of </span><span style="font-family:inherit;font-size:11pt;"><span>$12.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, for a net amount of </span><span style="font-family:inherit;font-size:11pt;"><span>$14.9 million</span></span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:11pt;">. Substantially all such amounts will impact our effective income tax rate if recognized.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">In general, it is our practice and intention to reinvest the earnings of our non-U.S. subsidiaries in their operations. As of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, Bio-Rad had not made a provision for U.S. or additional foreign withholding taxes on approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$447 million</span></span><span style="font-family:inherit;font-size:11pt;"> of the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries that are essentially permanent in duration.  Generally, such amounts become subject to U.S. taxation upon remittance of dividends and under certain other circumstances.  If these earnings were repatriated to the U.S., the deferred tax liability associated with these temporary differences would be approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$47 million</span></span>. The U.S. and international components of income before taxes are as follows (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S.</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(38.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>48.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>97.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>101.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income before taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>145.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>131.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> -38500000 48400000 30600000 80100000 97400000 101000000.0 41600000 145800000 131600000 The provision for income taxes consists of the following (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Current tax expense:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Current tax expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>44.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax (benefit) expense:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. Federal</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(42.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.1</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(51.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.0</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Non-current tax expense (benefit)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.6</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 16100000 8700000 9600000 3100000 1700000 3800000 30300000 34100000 35600000 49500000 44500000 49000000.0 -42400000 -200000 1500000 -2800000 1200000 -200000 -6000000.0 -7100000 -7300000 -51200000 -6100000 -6000000.0 15100000 -5600000 -300000 13400000 32800000 42700000 The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. statutory tax rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Impact of foreign operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign dividends, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research tax credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Nontaxable subsidies</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tax settlements and changes to unrecognized tax benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill impairment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Domestic manufacturing deduction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Nondeductible executive compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fines and penalties</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior period adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. taxation on foreign income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td></tr></table></div> 0.35 0.35 0.35 -0.15 -0.04 -0.04 0.40 0.04 0 0.09 0.02 0.03 0.04 0.01 0.02 0.42 -0.04 -0.01 0.11 0 0 0.04 0.02 0 0.03 0.01 0.01 0.03 0.01 0.01 0.02 0 0.03 0.04 0.01 0.02 0.02 0 0 0.02 0.01 0 0.32 0.22 0.32 0.32 0.22 0.32 0.35 Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax assets:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bad debt, inventory and warranty accruals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other post-employment benefits, vacation and other reserves</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tax credit and net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>96.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    Total gross deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>186.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>157.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(66.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(58.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">       Total deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>120.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>99.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Investments and intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>287.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>271.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">        Total deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>310.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>302.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net deferred tax liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(189.9</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(202.5</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div> 28400000 26300000 26300000 28100000 96400000 80200000 35700000 23200000 186800000 157800000 66400000 58300000 120400000 99500000 22500000 30200000 287800000 271800000 310300000 302000000.0 189900000 202500000 141300000 140800000 29600000 1900000 27600000 3600000 400000 53000000 25900000 2000000.0 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrecognized tax benefits – January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Additions to tax positions related to prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reductions to tax positions related to prior years</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Additions to tax positions related to the current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Settlements</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Lapse of statute of limitations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.6</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Currency translation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrecognized tax benefits – December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 8900000 14200000 16200000 10400000 700000 1700000 0 200000 1500000 1400000 1500000 1600000 2400000 500000 400000 2300000 6300000 2600000 100000 500000 800000 16100000 8900000 14200000 11500000 3000000.0 3800000 27600000 12700000 14900000 3500000 447000000 47000000 7.    STOCKHOLDERS' EQUITY<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B).  Each share of Class A and Class B participates equally in the earnings of Bio-Rad, and is identical in all respects except as follows. Class A has limited voting rights.  Each share of Class A is entitled to one tenth of a vote on most matters, and each share of Class B is entitled to one vote.  Additionally, Class A stockholders are entitled to elect </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>25%</span></span><span style="font-family:inherit;font-size:11pt;"> of the Board of Directors and Class B stockholders are entitled to elect </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>75%</span></span><span style="font-family:inherit;font-size:11pt;"> of the directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares but no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares.  Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.  The founders of Bio-Rad, the Schwartz family, collectively hold a majority of Bio-Rad’s voting stock.  As a result, the Schwartz family is able to exercise significant influence over Bio-Rad.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes to Bio-Rad's issued common stock shares are as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.2265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:49%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Class A Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Class B Shares</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at January 1, 2014</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,681</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,097</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>286</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,972</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,099</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2015</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,230</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,131</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,454</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,124</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Treasury Shares</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">The Board of Directors has authorized the repurchase of up to </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$18.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> of Bio-Rad's common stock, of which </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$3.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> has yet to be repurchased in the open market as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">. The Amended and Restated Credit Agreement (Credit Agreement) limits our ability to repurchase our stock. In accordance with the terms of awards under the 2007 Incentive Award Plan, in June 2012, we withheld </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>122 shares</span></span><span style="font-family:inherit;font-size:11pt;"> of our Class A common stock and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>917 shares</span></span><span style="font-family:inherit;font-size:11pt;"> of our Class B common stock to satisfy the minimum statutory tax obligations due upon the vesting of restricted stock of certain of our employees, which is considered a repurchase of our stock. All of the restricted stock vested as of December 31, 2013, and therefore we do not anticipate any repurchasing of shares for this purpose. We had no other repurchases of our stock during </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> or </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span>. 0.25 0.75 Changes to Bio-Rad's issued common stock shares are as follows (in thousands):<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.2265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:49%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Class A Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Class B Shares</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at January 1, 2014</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,681</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,097</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>286</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,972</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,099</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2015</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,230</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,131</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,454</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,124</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><br/> 23681000 5097000 5000 -5000 286000 7000 23972000 5099000 18000 -18000 240000 50000 24230000 5131000 13000 -13000 211000 6000 24454000 5124000 18000000.0 3300000 122 917 8.    <span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">ACCUMULATED OTHER COMPREHENSIVE INCOME</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated other comprehensive income included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign other post-employment benefits adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized holding gains on available-for-sale investments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Accumulated other comprehensive income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of January 1, 2015</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>164.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>218.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(37.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>325.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(119.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(118.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(37.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>205.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>163.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of December 31, 2015</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>369.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(38.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of December 31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>435.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>417.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The increases in 2016 and 2015 for net unrealized holding gains on available-for-sale investments were primarily from our ownership in the preferred shares of Sartorius.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The amounts reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:43%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:23%;"/><td style="width:5%;"/><td style="width:5%;"/></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before taxes impact (in millions):</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of Comprehensive income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of foreign other post-employment benefit items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net holding gains on available for sale investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Reclassification adjustments are calculated using the specific identification method. Accumulated other comprehensive income included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign other post-employment benefits adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized holding gains on available-for-sale investments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Accumulated other comprehensive income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of January 1, 2015</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>164.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>218.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(37.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>325.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(119.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(118.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(37.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>205.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>163.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of December 31, 2015</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>369.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(38.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of December 31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>435.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>417.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 71200000 -16300000 164000000.0 218900000 -37500000 -6800000 325400000 281100000 0 1100000 -900000 200000 0 -1300000 119400000 118100000 -37500000 -4400000 205100000 163200000 33700000 -20700000 369100000 382100000 -32400000 500000 105100000 73200000 0 2500000 -800000 1700000 0 900000 38400000 39300000 -32400000 2100000 65900000 35600000 1300000 -18600000 435000000.0 417700000 reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:43%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:23%;"/><td style="width:5%;"/><td style="width:5%;"/></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before taxes impact (in millions):</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of Comprehensive income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of foreign other post-employment benefit items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net holding gains on available for sale investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Reclassification adjustments are calculated using the specific identification method. -2500000 -1100000 800000 900000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">9. SHARE-BASED COMPENSATION/STOCK OPTION AND PURCHASE PLANS</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Description of Share-Based Compensation Plans</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We believe our share-based compensation plans align the interests of our employees with those of our shareholders.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Stock Option and Award Plans</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We have two stock option plans for officers and certain other employees: the 2003 Stock Option Plan (2003 Plan) and the 2007 Incentive Award Plan (2007 Plan).  The 2003 Plan authorized the grant of incentive stock options and non-qualified stock options to employees. The 2007 Plan authorizes the grant of stock options, restricted stock, restricted stock units, stock appreciation rights and other types of equity awards to employees.  We no longer grant stock option grants under the 2003 Plan. Since 2007, all share-based compensation grants have been from the 2007 Plan. A total of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>2,250,360</span></span><span style="font-family:inherit;font-size:11pt;"> shares have been reserved for issuance of equity awards under the 2007 Plan and may be of either Class A or Class B common stock as specified within the plan.  At </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, there were </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>587,509</span></span><span style="font-family:inherit;font-size:11pt;"> shares available to be granted in the future.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Under the above plans, Class A and Class B options are granted at prices not less than fair market value of the underlying common stock on the date of grant.  Generally, options granted have a term of </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>10</span></span><span style="font-family:inherit;font-size:11pt;"> years and vest in increments of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>20%</span></span><span style="font-family:inherit;font-size:11pt;"> per year over a </span><span style="font-family:inherit;font-size:11pt;">five</span><span style="font-family:inherit;font-size:11pt;">-year period on the yearly anniversary date of the grant.  Stock awards issued under the 2007 Plan generally vest in increments of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>20%</span></span><span style="font-family:inherit;font-size:11pt;"> per year over a </span><span style="font-family:inherit;font-size:11pt;">five</span><span style="font-family:inherit;font-size:11pt;">-year period on the yearly anniversary date of the grant.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plans</span><span style="font-family:inherit;font-size:11pt;font-style:italic;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our 2011 Employee Stock Purchase Plan (2011 ESPP) provides that eligible employees may contribute up to </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>10%</span></span><span style="font-family:inherit;font-size:11pt;"> of their compensation up to </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$25,000</span></span><span style="font-family:inherit;font-size:11pt;"> annually toward the quarterly purchase of our Class A common stock.  The employees’ purchase price is </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>85%</span></span><span style="font-family:inherit;font-size:11pt;"> of the lesser of the fair market value of the stock on the first business day or the last business day of each calendar quarter.  </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The 2011 ESPP includes two components: a Code Section 423 Component that we intend to qualify as an “employee stock purchase plan” under Section 423 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and a Non-423 Component, which authorizes the grant of purchase rights that does not qualify as an “employee stock purchase plan” under Section 423 of the Code. We have authorized the sale of </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;text-decoration:none;"><span>600,000</span></span><span style="font-family:inherit;font-size:11pt;"> shares of Class A common stock under the 2011 ESPP.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Share-Based Compensation Expense</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Included in our share-based compensation expense is the cost related to stock option grants, ESPP stock purchases and restricted stock unit awards.  Share-based compensation expense is allocated to Cost of goods sold, Research and development expense, and Selling, general and administrative expense in the Consolidated Statements of Income.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2014</span><span style="font-family:inherit;font-size:11pt;">, we recognized share-based compensation expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$19.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$17.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$14.9 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively.  We did not capitalize any share-based compensation expense in inventory.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For options and awards, we amortize the fair value on a straight-line basis.  All stock compensation awards are amortized over the requisite service periods of the awards, which are generally the vesting periods.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Stock Options</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes stock option activity:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:678px;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:305px;"/><td style="width:5px;"/><td style="width:83px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:89px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:75px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intrinsic</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Value</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, January 1, 2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>629,643</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78.72</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,000</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119.71</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(91,387</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63.66</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited/expired</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,450</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.29</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>581,806</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84.50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,500</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139.56</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(195,221</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited/expired</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(380</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62.47</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>426,705</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,000</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159.37</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,285</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80.70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited/expired</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,850</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127.65</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>449,570</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.15</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest,</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>437,350</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105.39</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.04</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>314,330</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93.78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.80</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic value on the date of exercise of stock options exercised during </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2014</span><span style="font-family:inherit;font-size:11pt;"> was approximately </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$1 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$13 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$5 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively. The total grant date fair value of options vested during </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2014</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash received from stock options exercised during </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2014</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$5.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively.  The actual tax benefit realized for the tax deductions from stock options exercised totaled </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$6.0 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$9.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$5.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2014</span><span style="font-family:inherit;font-size:11pt;">, respectively.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, there was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$4.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> of total unrecognized compensation cost from stock options. This amount is expected to be recognized in the future over a weighted-average period of approximately </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>3</span></span><span style="font-family:inherit;font-size:11pt;"> years.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:340px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:83px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:94px;"/><td style="width:12px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.35</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.90</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.35</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected life (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected dividend</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-average fair value of options granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Volatility is based on the historical volatilities of our common stock for a period equal to the stock option’s expected life.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the number of years that we estimate, based primarily on historical experience, that the options will be outstanding prior to exercise.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Restricted Stock Units</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted stock units, which are rights to receive shares of company stock, were granted from 2009 through </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> under the 2007 Plan.  The fair value of a restricted stock unit is the market value as determined by the closing price of the stock on the day of grant.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes restricted stock unit activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:654px;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:186px;"/><td style="width:5px;"/><td style="width:106px;"/><td style="width:4px;"/><td style="width:10px;"/><td style="width:9px;"/><td style="width:96px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:110px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:96px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted Stock</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Grant-Date</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual Term</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intrinsic Value</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, January 1, 2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>375,430</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,695</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119.56</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(107,557</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36,203</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108.17</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>377,365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112.60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177,110</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139.56</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(113,347</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107.62</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28,706</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116.19</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>412,422</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>125.30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>193,025</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159.32</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(117,203</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119.33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39,422</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129.80</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>448,822</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.16</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The total grant date fair value of restricted stock units vested in </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2015</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2014</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;"><span>$14.0 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$12.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$10.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively. As of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, there was approximately </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$46.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> of total unrecognized compensation cost related to restricted stock units.  This amount is expected to be recognized over a remaining weighted-average period of approximately </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4</span></span><span style="font-family:inherit;font-size:11pt;"> years.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plans</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:529px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:245px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:33px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:33px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected volatility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Risk-free interest rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.26</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.02</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.04</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected life (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected dividend</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-average fair value</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">of purchase rights</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The major assumptions are primarily based on historical data.  Volatility is based on the historical volatilities of our common stock for a period equal to the expected life of the purchase rights.  The risk-free interest rate is based on </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">the U.S. Treasury yield curve in effect at the time of the grant.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We sold </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>93,605</span></span><span style="font-family:inherit;font-size:11pt;"> shares for </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$11.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>96,634</span></span><span style="font-family:inherit;font-size:11pt;"> shares for </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$10.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>102,222</span></span><span style="font-family:inherit;font-size:11pt;"> shares for </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$10.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> under the 2011 ESPP to employees in </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2014</span><span style="font-family:inherit;font-size:11pt;">, respectively.  At </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>96,121</span></span><span style="font-family:inherit;font-size:11pt;"> shares remain authorized and available for issuance under the 2011 ESPP.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>We currently issue new shares to satisfy stock option exercises, restricted stock issuances and ESPP stock purchases. 2250360 587509 P10Y0M0D 0.20 0.20 0.10 25000 0.85 600000 19700000 17000000.0 14900000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Stock Options</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes stock option activity:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:678px;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:305px;"/><td style="width:5px;"/><td style="width:83px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:89px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:75px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intrinsic</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Value</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, January 1, 2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>629,643</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78.72</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,000</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119.71</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(91,387</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63.66</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited/expired</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,450</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.29</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>581,806</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84.50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,500</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139.56</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(195,221</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited/expired</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(380</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62.47</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>426,705</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,000</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159.37</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,285</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80.70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited/expired</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,850</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127.65</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>449,570</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.15</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest,</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>437,350</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105.39</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.04</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>314,330</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93.78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.80</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 629643 78.72 54000 119.71 91387 63.66 10450 100.29 581806 84.50 40500 139.56 195221 61.29 380 62.47 426705 100.36 45000 159.37 15285 80.70 6850 127.65 449570 106.52 P5Y1M24D 34.1 437350 105.39 P5Y0M14D 33.6 314330 93.78 P3Y9M18D 27.8 1000000 13000000 5000000 2100000 2200000 2100000 1200000 2900000 5800000 6000000.0 9300000 5300000 4900000 P3Y0M0D <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:340px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:83px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:94px;"/><td style="width:12px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.35</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.90</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.35</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected life (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected dividend</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-average fair value of options granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 0.21 0.23 0.25 0.0135 0.0190 0.0235 P7Y4M24D P7Y8M12D P8Y8M12D 0 0 0 42.40 42.74 43.96 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes restricted stock unit activity:</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:654px;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:186px;"/><td style="width:5px;"/><td style="width:106px;"/><td style="width:4px;"/><td style="width:10px;"/><td style="width:9px;"/><td style="width:96px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:110px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:96px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted Stock</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Grant-Date</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual Term</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intrinsic Value</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, January 1, 2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>375,430</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,695</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119.56</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(107,557</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36,203</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108.17</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>377,365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112.60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177,110</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139.56</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(113,347</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107.62</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28,706</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116.19</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>412,422</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>125.30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>193,025</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159.32</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(117,203</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119.33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39,422</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129.80</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>448,822</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.16</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 375430 105.44 145695 119.56 107557 98.52 36203 108.17 377365 112.60 177110 139.56 113347 107.62 28706 116.19 412422 125.30 193025 159.32 117203 119.33 39422 129.80 448822 141.09 P2Y1M28D 81.8 14000000.0 12200000 10600000 46800000 P4Y0M0D The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:529px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:245px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:33px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:33px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected volatility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Risk-free interest rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.26</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.02</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.04</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected life (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected dividend</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-average fair value</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">of purchase rights</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 0.20 0.18 0.15 0.0026 0.0002 0.0004 P0M7D P0M7D P0M7D 0 0 0 27.36 25.08 21.88 93605 11500000 96634 10800000 102222 10200000 96121 10. OTHER INCOME AND EXPENSE, NET<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net includes the following components (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:401px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:79px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:72px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:75px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Interest and investment income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(14.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(13.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net realized gains on investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other-than-temporary impairment losses on investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Miscellaneous other (income) expense items, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(14.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">Other-than-temporary impairment losses on investments were recorded in </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2014</span> on certain of our available-for-sale investments and a certain equity investment in light of the continuing declines in their market prices at that time. Other (income) expense, net includes the following components (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:401px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:79px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:72px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:75px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Interest and investment income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(14.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(13.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net realized gains on investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other-than-temporary impairment losses on investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Miscellaneous other (income) expense items, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(14.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div> 14700000 10100000 13500000 800000 1600000 0 600000 600000 400000 0 0 -100000 11100000 13000000.0 11. SUPPLEMENTAL CASH FLOW INFORMATION<div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The reconciliation of net income to net cash provided by operating activities is as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:591px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:298px;"/><td style="width:9px;"/><td style="width:8px;"/><td style="width:77px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:77px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:77px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>113.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>88.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustments to reconcile net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">to net cash provided by operating activities </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>142.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>131.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>149.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Share-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Gains) losses on dispositions of securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses on dispositions of fixed assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Excess tax benefits from share-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in fair value of contingent consideration</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease (increase) in accounts receivable, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(39.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Increase) decrease in inventories, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(57.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(54.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Increase) decrease in other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase (decrease) in accounts payable</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">and other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase in income taxes payable</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in deferred income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(51.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in other long term assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase (decrease) in other long term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(12.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Impairment losses on goodwill and long-lived assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>216.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>186.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>273.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Non-cash investing activities:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Purchased intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Purchased marketable securities and investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 11. SUPPLEMENTAL CASH FLOW INFORMATION<div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The reconciliation of net income to net cash provided by operating activities is as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:591px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:298px;"/><td style="width:9px;"/><td style="width:8px;"/><td style="width:77px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:77px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:77px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>113.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>88.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustments to reconcile net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">to net cash provided by operating activities </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>142.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>131.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>149.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Share-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Gains) losses on dispositions of securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses on dispositions of fixed assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Excess tax benefits from share-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in fair value of contingent consideration</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease (increase) in accounts receivable, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(39.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Increase) decrease in inventories, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(57.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(54.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Increase) decrease in other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase (decrease) in accounts payable</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">and other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase in income taxes payable</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in deferred income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(51.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in other long term assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase (decrease) in other long term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(12.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Impairment losses on goodwill and long-lived assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>216.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>186.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>273.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Non-cash investing activities:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Purchased intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Purchased marketable securities and investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 28100000 113100000 88800000 142900000 131800000 149900000 19700000 17000000.0 14900000 200000 1000000.0 -300000 -600000 -300000 -400000 1500000 3600000 1300000 -400000 -5600000 -1400000 -12500000 39000000.0 -11100000 57100000 54200000 -5800000 6600000 -100000 5700000 30100000 28600000 -9900000 10700000 12700000 20400000 51400000 6400000 6300000 -12700000 -300000 -3600000 -8300000 12200000 1300000 62300000 0 0 -5700000 -4300000 -4000000.0 216400000 186200000 273300000 0 0 200000 600000 2200000 0 12. COMMITMENTS AND CONTINGENT LIABILITIES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Rents and Leases</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Rental expense under operating leases was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$44.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$45.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$46.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2014</span><span style="font-family:inherit;font-size:11pt;">, respectively.  Leases are principally for facilities and automobiles. We had no sublease income.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Annual future minimum lease payments at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> under operating leases are as follows: </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$42.1 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$32.1 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$24.7 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2020</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$20.4 million</span></span><span style="font-family:inherit;font-size:11pt;">; and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2021</span><span style="font-family:inherit;font-size:11pt;"> and beyond - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$38.8 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Deferred Profit Sharing Retirement Plan</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We have a profit sharing plan covering substantially all U.S. employees.  Contributions are made at the discretion of the Board of Directors.  Bio-Rad has no liability other than for the current year’s contribution.  Contribution expense was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$15.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$14.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$13.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2014</span><span style="font-family:inherit;font-size:11pt;">, respectively.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Other Post-Employment Benefits</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In several foreign locations we are statutorily required to provide a lump sum severance or termination indemnity to our employees.  Under these plans, the vested benefit obligation at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$68.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$68.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, and has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets.  Most plans are not required to be funded, and as such, there is no trust or other device used to accumulate assets to settle these obligations. However, some of these plans require funding based on local laws in which there is a trust or other device used to accumulate assets to assist in settling these obligations.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Purchase Obligations</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, we had obligations that have been recognized on our balance sheet of </span><span style="font-family:inherit;font-size:11pt;"><span>$142.9 million</span></span><span style="font-family:inherit;font-size:11pt;">, which include purchases of goods and services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty. These obligations also include other post-employment benefits in some of our foreign locations as indicated above. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The annual future fixed and determinable portion of our purchase obligations that have been recognized on our balance sheet as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> are as follows: </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$34.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$7.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2020</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2021</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> and after </span><span style="font-family:inherit;font-size:11pt;">2021</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$94.1 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, we had purchase obligations that have not been recognized on our balance sheet of </span><span style="font-family:inherit;font-size:11pt;"><span>$35.0 million</span></span><span style="font-family:inherit;font-size:11pt;">, which include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The annual future fixed and determinable portion of our purchase obligations that have not been recognized on our balance sheet as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> are as follows: </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$17.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:10pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2020</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2021</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$5.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> and after </span><span style="font-family:inherit;font-size:11pt;">2021</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$0 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Letters of Credit/Guarantees</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In the ordinary course of business, we are at times required to post letters of credit/guarantees.  The letters of credit/guarantees are issued by financial institutions to guarantee our obligations to various parties. We were contingently liable for </span><span style="font-family:inherit;font-size:11pt;"><span>$5.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> of standby letters of credit/guarantees with financial institutions as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Contingent Consideration</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a new high performance analytical flow cytometer platform from Propel. At the acquisition date, the contingent consideration was based on a probability-weighted income approach related to the achievement of sales milestones, ranging from </span><span style="font-family:inherit;font-size:11pt;"><span>39%</span></span><span style="font-family:inherit;font-size:11pt;"> to </span><span style="font-family:inherit;font-size:11pt;"><span>20%</span></span><span style="font-family:inherit;font-size:11pt;"> for the calendar years </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> through </span><span style="font-family:inherit;font-size:11pt;">2020</span><span style="font-family:inherit;font-size:11pt;">. The sales milestones could potentially range from </span><span style="font-family:inherit;font-size:11pt;"><span>$0</span></span><span style="font-family:inherit;font-size:11pt;"> to an unlimited amount through </span><span style="font-family:inherit;font-size:11pt;">December 31, 2020</span><span style="font-family:inherit;font-size:11pt;">. The fair value of the contingent consideration as of the acquisition date was </span><span style="font-family:inherit;font-size:11pt;"><span>$23.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, after the effects of a calculation revision that were reflected in the fourth quarter of 2016. The contingent consideration was recognized at its estimated fair value of </span><span style="font-family:inherit;font-size:11pt;"><span>$25.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2014, we recognized a contingent consideration liability upon our acquisition of GnuBIO, Inc. The contingent consideration for the milestones was valued at </span><span style="font-family:inherit;font-size:11pt;"><span>$10.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> at the acquisition date based on assumptions regarding the probability of achieving the milestones, with such amounts discounted to present value. The Level 3 contingent consideration was revalued to a fair value of </span><span style="font-family:inherit;font-size:11pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2015</span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2012, we recognized a contingent consideration liability for certain milestones of </span><span style="font-family:inherit;font-size:11pt;"><span>$44.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> upon our acquisition of a new cell sorting system from Propel. Since 2012, we have paid </span><span style="font-family:inherit;font-size:11pt;"><span>$28.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> upon reaching the milestones and have reduced the valuation of the milestones by </span><span style="font-family:inherit;font-size:11pt;"><span>$12.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> to its estimated fair value of </span><span style="font-family:inherit;font-size:11pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">. The remaining liability was paid in </span><span style="font-family:inherit;font-size:10pt;">February 2017</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Concentrations of Labor Subject to Collective Bargaining Agreements</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">At </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, approximately </span><span style="font-family:inherit;font-size:11pt;">seven</span><span style="font-family:inherit;font-size:11pt;"> percent of Bio-Rad's approximately </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>3,300</span></span> U.S. employees were covered by a collective bargaining agreement, which will expire on November 7, 2019.  Many of Bio-Rad's non-U.S. full-time employees, especially in France, are covered by collective bargaining agreements. 44400000 45000000.0 46900000 42100000 32100000 24700000 20400000 38800000 15100000 14700000 13700000 68000000.0 68600000 142900000 34300000 7300000 3100000 2500000 1600000 94100000 35000000.0 17500000 5000000.0 3500000 3500000 5500000 0 5400000 0.39 0.20 0 23300000 25400000 10700000 10000000.0 44600000 28900000 12600000 3100000 3300 13.    LEGAL PROCEEDINGS<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">On January 23, 2015, the City of Riviera Beach General Employees’ Retirement System filed a shareholder derivative lawsuit in the Superior Court of California, Contra Costa County, against three of our current directors and one former director. We are also named as a nominal defendant. In the complaint, the plaintiff alleges that our directors breached their fiduciary duty of loyalty by failing to ensure that we had sufficient internal controls and systems for compliance with the Foreign Corrupt Practices Act ("FCPA"); that we failed to provide adequate training on the FCPA; and that based on these actions, the directors have been unjustly enriched. Purportedly seeking relief on our behalf, the plaintiff seeks an award of restitution and unspecified damages, costs and expenses (including attorneys’ fees). On April 23, 2015, we and the individual defendants filed a demurrer requesting dismissal of the complaint in this case. The demurrer was heard on August 6, 2015, and the Court granted the demurrer for failure to make a demand on our Board of Directors on August 17, 2015, but provided leave to amend. On September 4, 2015, the plaintiff filed an amended complaint and simultaneously served a litigation demand letter on our Board of Directors ("Board") via its counsel in this action. The letter demanded that we investigate and bring appropriate legal action against certain individuals, including the defendants in the City of Riviera Beach case and six current and former employees. The plaintiff also moved for a temporary stay in the proceedings, purportedly to enable the Board to respond to the demand. The Board formed a Demand Review Committee to respond to the demand. On February 24, 2016, the Demand Review Committee reported to the Board that it had concluded its investigation and unanimously determined that it is not in the best interests of the Company and its stockholders to pursue litigation against any individuals named in the City of Riviera Beach’s litigation demand letter. On October 6, 2015, we and the individual defendants filed a second demurrer, seeking to dismiss the case for failure to make a timely pre-suit demand. The case was stayed pending mediation. The caption is City of Riviera Beach General Employees’ Retirement System v. Schwartz et al., Case No. C-15-00140. The lawsuit and demand letter are referred to collectively as the “California Action”.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">On August 13, 2015 and August 18, 2015, respectively, each of International Brotherhood of Electrical Workers Local 38 Pension Fund and Wayne County Employees’ Retirement System filed a stockholder derivative complaint in the Delaware Court of Chancery against four of our current directors and one former director. We are named as a nominal defendant in the complaints. The complaints allege that the defendants failed to cause us to develop internal controls sufficient to ensure our compliance with the FCPA. The plaintiffs assert claims for breach of fiduciary duty and unjust enrichment and request an award of the damages we sustained as a result of the alleged violations, among other relief. The two lawsuits were consolidated on August 27, 2015.  The case was stayed pending mediation. The caption of the consolidated case is In re Bio-Rad Laboratories, Inc. Stockholder Litigation, Consol. C.A. No. 11387-VCN (Del. Ch.). The cases filed in the Delaware Court of Chancery, together with the California Action, are referred to collectively as the “Derivative Actions”.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">The parties filed a Stipulation dated November 4, 2016 with the Superior Court of California for Contra Costa County that sets forth the terms of a proposed settlement of the Derivative Actions. The proposed settlement includes the dismissal with prejudice of all claims asserted in the Derivative Actions, an agreed-upon set of revised corporate procedures, and no monetary payment other than an award of attorneys’ fees and costs to the plaintiffs’ counsel. We and the other defendants do not admit any liability or fault in connection with the proposed settlement. On December 22, 2016 the Superior Court of California for Contra Costa County issued an order granting preliminary approval of this proposed settlement. Pursuant to the order, the Court will hold a hearing for final approval of the settlement on March 2, 2017, and any objections to the settlement were required to be filed in writing with the Court on or before February 15, 2017.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The parties engaged in mediation of the case on April 19, 2016 and on September 14, 2016. The mediations did not result in a settlement. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded </span><span style="font-family:inherit;font-size:11pt;"><span>$10.92 million</span></span><span style="font-family:inherit;font-size:11pt;">, plus prejudgment interest of </span><span style="font-family:inherit;font-size:11pt;"><span>$141,608</span></span><span style="font-family:inherit;font-size:11pt;">, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. We are considering an appeal of the judgment. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">Bio-Rad received three notices of violations from the Bay Area Air Quality Management District (“District”). The District alleges that we operated three (3) power generation units without appropriate monitoring and recordkeeping and exceeded permissible levels of emissions during those operations. We are cooperating with the District and are investigating the allegations. No formal proceeding has been initiated by the District. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><br/> 10920000 141608 14. SEGMENT INFORMATION<div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bio-Rad is a multinational manufacturer and worldwide distributor of its own life science research products and clinical diagnostics products.  We have two reportable segments:  Life Science and Clinical Diagnostics.  These reportable segments are strategic business lines that offer more than </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>8,000</span></span><span style="font-family:inherit;font-size:11pt;"> different products and services and require different marketing strategies. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research.  These products are sold to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories and government and industrial research facilities.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market.  These products are sold to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories and insurance and forensic testing laboratories.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other Operations include the remainder of our Analytical Instruments segment.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. The accounting policies of the segments are the same as those described in Significant Accounting Policies (see Note 1).  Segment profit or loss includes an allocation of corporate expense based upon sales and an allocation of interest expense based upon accounts receivable and inventories.  The difference between total segment allocated interest expense, depreciation and amortization, and capital expenditures and the corresponding consolidated amounts is attributable to our corporate headquarters.  Segments are expected to manage only assets completely under their control.  Accordingly, segment assets include primarily accounts receivable, inventories and gross machinery and equipment.  Goodwill balances have been included in corporate for segment reporting purposes.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Information regarding industry segments at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2014</span><span style="font-family:inherit;font-size:11pt;"> and for the years then ended is as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:81.0546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:33%;"/><td style="width:13%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operations</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net sales </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>730.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,323.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>695.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,310.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>728.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,432.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Allocated interest expense</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation and amortization</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>77.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>95.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment (loss) profit</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(19.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>152.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(14.7</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>167.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>381.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>918.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>390.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>878.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital expenditures</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>51.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net corporate operating expense consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. In 2014, this included the accrual of </span><span style="font-family:inherit;font-size:11pt;"><span>$20.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> associated with the U.S. Securities and Exchange Commission and Department of Justice investigations relating to the U.S. Foreign Corrupt Practices Act, for which a final settlement was reached in the fourth quarter of 2014. The following reconciles total segment profit to consolidated income before taxes (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.4296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>152.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>153.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign exchange losses</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.3</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net corporate operating, interest and other expense, net not allocated to segments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(25.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Consolidated income before taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>145.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>131.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following reconciles total segment assets to consolidated total assets (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:596px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:421px;"/><td style="width:8px;"/><td style="width:8px;"/><td style="width:68px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:68px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,304.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,273.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>980.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>926.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property, plant and equipment, net, excluding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">  segment specific gross machinery and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>81.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>46.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>477.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>495.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,007.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>967.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,850.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,709.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:647px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:317px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:96px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:96px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:84px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>742.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>763.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>901.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Pacific Rim</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>427.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>392.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>417.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>770.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>735.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>704.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>128.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>128.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>150.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,068.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,019.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,175.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following presents Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:583px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:374px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:85px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:85px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>221.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>204.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Pacific Rim</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,084.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>962.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,334.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,191.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 8000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Information regarding industry segments at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2014</span><span style="font-family:inherit;font-size:11pt;"> and for the years then ended is as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:81.0546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:33%;"/><td style="width:13%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operations</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net sales </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>730.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,323.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>695.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,310.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>728.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,432.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Allocated interest expense</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation and amortization</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>77.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>95.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment (loss) profit</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(19.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>152.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(14.7</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>167.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>381.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>918.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>390.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>878.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital expenditures</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>51.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> 730700000 1323300000 14200000 695000000.0 1310400000 14000000.0 728300000 1432300000 14400000 6400000 15500000 0 6100000 15400000 100000 5500000 15900000 100000 31700000 80500000 0 30700000 77800000 100000 33200000 95800000 0 -19200000 57000000.0 900000 -700000 152400000 700000 -14700000 167100000 1200000 381400000 918000000.0 4900000 390500000 878300000 4400000 14300000 67100000 0 8200000 51300000 100000 -20100000 he following reconciles total segment profit to consolidated income before taxes (in millions):<div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.4296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>152.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>153.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign exchange losses</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.3</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net corporate operating, interest and other expense, net not allocated to segments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(25.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Consolidated income before taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>145.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>131.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><br/> 38700000 152400000 153600000 -4500000 -10200000 -9300000 -7500000 -7500000 -25700000 14900000 11100000 13000000.0 41600000 145800000 131600000 The following reconciles total segment assets to consolidated total assets (in millions):<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:596px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:421px;"/><td style="width:8px;"/><td style="width:8px;"/><td style="width:68px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:68px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,304.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,273.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>980.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>926.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property, plant and equipment, net, excluding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">  segment specific gross machinery and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>81.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>46.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>477.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>495.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,007.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>967.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,850.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,709.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1304300000 1273200000 980300000 926900000 81600000 46100000 477100000 495900000 1007200000 967600000 3850500000 3709700000 The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:647px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:317px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:96px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:96px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:84px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>742.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>763.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>901.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Pacific Rim</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>427.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>392.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>417.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>770.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>735.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>704.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>128.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>128.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>150.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,068.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,019.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,175.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following presents Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:583px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:374px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:85px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:85px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>221.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>204.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Pacific Rim</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,084.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>962.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,334.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,191.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 742200000 763700000 901700000 427100000 392200000 417500000 770600000 735000000.0 704900000 128300000 128500000 150900000 2068200000 2019400000 2175000000.0 221100000 204400000 16100000 15100000 1084700000 962600000 12300000 9100000 1334200000 1191200000 RESTRUCTURING COSTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For the year ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, we recorded </span><span style="font-family:inherit;font-size:11pt;"><span>$12.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> related to restructuring actions that include the elimination or relocation of various positions. These actions are generally intended to streamline and focus our efforts and more properly align our cost structure with projected future revenue streams.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes the activity of our restructuring reserves for severance (in millions): </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.0703125%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:40%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance at December 31, 2015</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Charged to expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustment to expense</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation gains</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance at December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">In May 2016, management announced that it will take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance ERP platform, are expected to be incurred through 2019. As a result, we recorded approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$12.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> in restructuring charges related to severance and other employee benefits for the year ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, of which </span><span style="font-family:inherit;font-size:11pt;"><span>$9.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> is anticipated to be paid through 2019. The liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$9.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> encompassed a short-term liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$6.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and a long-term liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:11pt;">. The amounts recorded were reflected in Cost of goods sold of </span><span style="font-family:inherit;font-size:11pt;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, and in Selling, general and administrative expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$10.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> in the Consolidated Statements of Income for the year ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span>. The amounts adjusted were primarily for additional positions identified for elimination, partially offset by employees finding other positions within Bio-Rad or leaving prematurely. 12500000 The following table summarizes the activity of our restructuring reserves for severance (in millions): <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.0703125%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:40%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance at December 31, 2015</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Charged to expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustment to expense</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation gains</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance at December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 0 0 0 4100000 7600000 11700000 300000 500000 800000 1000000.0 2000000.0 3000000.0 200000 300000 500000 3200000 5800000 9000000.0 12500000 9000000.0 9000000.0 6400000 2600000 2100000 10400000 16. QUARTERLY FINANCIAL DATA (UNAUDITED)<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Summarized quarterly financial data for </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;"> are as follows (in millions, except per share data):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:673px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:253px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">First</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Second</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Third</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fourth</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>471.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>516.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>508.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>571.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>264.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>280.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>279.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>314.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(20.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings (loss) per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.70</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings (loss) per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.61</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.62</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.70</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>472.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>506.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>470.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>570.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>270.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>279.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>263.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>308.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.98</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.61</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.97</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.59</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.68</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Note: As a result of the net loss for the three months ended December 31, 2016, </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> all potentially issuable common shares have been excluded from the diluted shares</span></div> used in the computation of earnings per share as their effect was anti-dilutive. <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:673px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:253px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">First</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Second</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Third</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fourth</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>471.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>516.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>508.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>571.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>264.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>280.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>279.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>314.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(20.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings (loss) per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.70</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings (loss) per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.61</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.62</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.70</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>472.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>506.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>470.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>570.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>270.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>279.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>263.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>308.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.98</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.61</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.97</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.59</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.68</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 471200000 516800000 508700000 571500000 264000000.0 280200000 279500000 314400000 12300000 18000000.0 18400000 -20600000 0.42 0.61 0.63 -0.70 0.42 0.61 0.62 -0.70 472800000 506100000 470000000.0 570600000 270100000 279600000 263500000 308500000 17800000 28400000 17400000 49500000 0.61 0.98 0.59 1.69 0.61 0.97 0.59 1.68 17. SUBSEQUENT EVENT<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On February 15, 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$87 million</span></span><span style="font-family:inherit;font-size:11pt;"> including certain assumed net liabilities. Cash payments at closing were </span><span style="font-family:inherit;font-size:11pt;"><span>$82.9 million</span></span><span style="font-family:inherit;font-size:11pt;">. The acquisition will be included in our Life Science segment’s results of operations from the acquisition date and will be accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill to be recorded will not be deductible for income tax purposes.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We are presently unable to report the purchase price allocation or the evaluation of the transaction, as more time is needed to complete the information transfer from the seller and include all information into a valuation of individual assets and liabilities.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. We believe that RainDance's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital™ PCR, offering customers with solutions for a wide range of nucleic acid detection applications. 87000000 82900000 BIO-RAD LABORATORIES, INC.<div style="line-height:120%;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Years Ended </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2015</span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;">2014</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(in thousands)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Allowance for doubtful accounts receivable</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:561px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:109px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:95px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:95px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:95px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:95px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Charged to Costs</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and Expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">End of Year</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,418</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,785</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,836</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,367</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,973</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,783</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,338</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,418</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,471</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,164</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11,662</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,973</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Valuation allowance for current and long-term deferred tax assets*</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:561px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:109px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:95px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:95px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:95px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:95px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions Charged</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Credited) to Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax Expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">End of Year </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,277</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,126</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,403</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,615</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(338</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,011</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,396</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,615</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*2014 is the only year presented that has current and long-term valuation allowances for deferred tax assets due to the adoption of ASU 2015-17 in 2015 on a prospective basis. Therefore, for the years 2016 and 2015, the valuation allowance is long-term for deferred tax assets.</span></div><br/> 24418000 3785000 4836000 23367000 27973000 8783000 12338000 24418000 32471000 7164000 11662000 27973000 58277000 8126000 0 66403000 58615000 -338000 0 58277000 64011000 -5396000 0 58615000 Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets. Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions): December 31, 2016 December 31, 2015    Other current liabilities$14.5 $13.5Other long-term liabilities24.0 5.6   Total$38.5 $19.1 Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets. Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions): December 31, 2016 December 31, 2015    Short-term investments$383.2 $328.7Other investments732.4 628.9Total$1,115.6 $957.6 Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets. XML 15 R1.htm IDEA: XBRL DOCUMENT v3.6.0.2
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2016
Feb. 14, 2017
Jun. 30, 2016
Entity Registrant Name BIO RAD LABORATORIES INC    
Document Type 10-K    
Document Period End Date Dec. 31, 2016    
Amendment Flag false    
Entity Central Index Key 0000012208    
Current Fiscal Year End Date --12-31    
Entity Filer Category Large Accelerated Filer    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer Yes    
Document Fiscal Year Focus 2016    
Document Fiscal Period Focus FY    
Entity Public Float     $ 3,001,889,921
Common Class A [Member]      
Entity Common Stock, Shares Outstanding   24,460,068  
Common Class B [Member]      
Entity Common Stock, Shares Outstanding   5,116,824  
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
ASSETS:    
Cash and cash equivalents $ 456,264 $ 457,549
Short-term investments 383,176 328,718
Restricted investments 4,560 4,210
Accounts receivable, less allowance for doubtful accounts 372,348 391,485
Inventories:    
Raw materials 116,540 109,928
Work in process 125,982 114,438
Finished goods 282,439 265,858
Total inventories 524,961 490,224
Prepaid expenses 91,014 94,369
Other current assets 12,201 11,041
Total current assets 1,844,524 1,777,596
Property, plant and equipment:    
Land and improvements 17,895 17,823
Buildings and leasehold improvements 290,367 276,070
Equipment 919,126 823,193
Total property, plant and equipment 1,227,388 1,117,086
Less: accumulated depreciation and amortization (738,774) (679,396)
Property, plant and equipment, net 488,614 437,690
Goodwill, net 477,115 495,948
Purchased intangibles, net 161,609 214,026
Other investments 830,790 719,840
Other assets 47,852 64,618
Total assets 3,850,504 3,709,718
LIABILITIES AND STOCKHOLDERS' EQUITY:    
Accounts payable 133,109 122,391
Accrued payroll and employee benefits 163,364 157,857
Notes payable and current maturities of long-term debt 334 298
Income and other taxes payable 28,124 29,339
Deferred revenue 31,003 29,683
Other current liabilities 115,388 101,783
Total current liabilities 471,322 441,351
Long-term debt, net of current maturities 434,186 433,883
Deferred income taxes 222,919 233,475
Other long-term liabilities 135,318 110,506
Total liabilities 1,263,745 1,219,215
Commitments and contingent liabilities
Stockholders' equity:    
Preferred stock 0 0
Additional paid-in capital 332,911 300,408
Retained earnings 1,836,180 1,808,055
Accumulated other comprehensive income 417,766 382,138
Total stockholders' equity 2,586,759 2,490,503
Total liabilities and stockholders' equity 3,850,504 3,709,718
Common Class A [Member]    
Stockholders' equity:    
Common stock 2 2
Common Class B [Member]    
Stockholders' equity:    
Common stock 1 1
Treasury Class-A [Member]    
Stockholders' equity:    
Treasury Stock, Value (12) (12)
Treasury Class B [Member]    
Stockholders' equity:    
Treasury Stock, Value $ (89) $ (89)
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Balance Sheets (Parentheticals) - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Allowance for doubtful accounts $ 23,367 $ 24,418
Preferred stock par value $ 0.0001 $ 0.0001
Preferred stock authorized 7,500,000 7,500,000
Preferred stock issued 0 0
Preferred stock outstanding 0 0
Common Class A [Member]    
Common stock par value $ 0.0001 $ 0.0001
Common stock authorized 80,000,000 80,000,000
Common stock issued 24,454,048 24,230,448
Common stock outstanding 24,453,926 24,230,326
Common Class B [Member]    
Common stock par value $ 0.0001 $ 0.0001
Common stock authorized 20,000,000 20,000,000
Common stock issued 5,123,883 5,130,558
Common stock outstanding 5,122,966 5,129,641
Treasury Class-A [Member]    
Treasury Stock, Shares 122 122
Treasury Class B [Member]    
Treasury Stock, Shares 917 917
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Net sales $ 2,068,172 $ 2,019,441 $ 2,175,044
Cost of goods sold 930,085 897,771 996,527
Gross profit 1,138,087 1,121,670 1,178,517
Selling, general and administrative expense 816,724 761,990 808,200
Research and development expense 205,864 192,972 220,333
Impairment losses on goodwill and long-lived assets 62,305 0 0
Income from operations 53,194 166,708 149,984
Interest expense 21,942 21,692 22,131
Foreign exchange losses, net 4,542 10,249 9,305
Other (income) expense, net (14,850) (11,080) (13,009)
Income before income taxes 41,560 145,847 131,557
Provision for income taxes (13,435) (32,754) (42,712)
Net Income (Loss) Attributable to Parent $ 28,125 $ 113,093 $ 88,845
Basic earnings per share:      
Net income per share basic attributable to Bio-Rad $ 0.96 $ 3.87 $ 3.08
Weighted average common shares - basic 29,440 29,186 28,876
Diluted earnings per share:      
Net income per share diluted attributable to Bio-Rad $ 0.95 $ 3.85 $ 3.05
Weighted average common shares - diluted 29,646 29,409 29,133
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Cash flows from operating activities:      
Cash received from customers $ 2,074,024 $ 1,956,084 $ 2,162,520
Cash paid to suppliers and employees (1,810,844) (1,730,062) (1,806,526)
Interest paid (21,318) (20,793) (20,793)
Income tax payments (38,442) (31,715) (28,939)
Settlement with the SEC and DOJ relating to the FCPA, including interest 0 0 (55,050)
Investment proceeds and miscellaneous receipts, net 15,683 11,953 15,671
Excess tax benefits from share-based compensation (1,506) (3,610) (1,349)
(Payments for) proceeds from forward foreign exchange contracts, net (1,164) 4,353 7,778
Net cash provided by operating activities 216,433 186,210 273,312
Cash flows from investing activities:      
Capital expenditures (141,436) (112,000) (120,999)
Proceeds from dispositions of property, plant and equipment 398 79 225
Payments for acquisitions, net of cash received, and long-term investments (14,165) (4,356) (44,627)
Payments for purchases of intangible assets (135) (1,372) (15,479)
Payments for purchases of restricted investment (350) (4,210) 0
Payments for purchases of marketable securities and investments (278,071) (294,497) (205,746)
Proceeds from sales of marketable securities and investments 76,859 78,664 75,725
Proceeds from maturities of marketable securities and investments 143,020 170,823 120,390
Net cash used in investing activities (213,880) (166,869) (190,511)
Cash flows from financing activities:      
Net borrowings on (payments for) line-of-credit arrangements and notes payable 37 0 (1,560)
Payments on long-term borrowings (303) (282) (253)
Proceeds from issuance of common stock 11,280 8,236 15,051
Payments of contingent consideration (3,500) (2,983) (2,374)
Debt issuance costs on long-term borrowings 0 0 (524)
Excess tax benefits from share-based compensation 1,506 3,610 1,349
Net cash provided by financing activities 9,020 8,581 11,689
Effect of foreign exchange rate changes on cash (12,858) 16,376 (12,790)
Net (decrease) increase in cash and cash equivalents (1,285) 44,298 81,700
Cash and cash equivalents at beginning of year 457,549 413,251 331,551
Cash and cash equivalents at end of year $ 456,264 $ 457,549 $ 413,251
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Treasury Stock [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Balance at Dec. 31, 2013 $ 2,186,722 $ 3 $ 239,986 $ (101) $ 1,606,117 $ 340,717
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 88,845       88,845  
Other comprehensive income, net of tax           (121,772)
Issuance of common stock 15,051   15,051      
Stock compensation expense     14,888      
Tax benefit-exercise stock options     1,421      
Balance at Dec. 31, 2014 2,185,155 3 271,346 (101) 1,694,962 218,945
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 113,093       113,093  
Other comprehensive income, net of tax           163,193
Issuance of common stock 8,236   8,236      
Stock compensation expense     16,983      
Tax benefit-exercise stock options     3,843      
Balance at Dec. 31, 2015 2,490,503 3 300,408 (101) 1,808,055 382,138
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 28,125       28,125  
Other comprehensive income, net of tax           35,628
Issuance of common stock 11,280   11,280      
Stock compensation expense     19,730      
Tax benefit-exercise stock options     1,493      
Balance at Dec. 31, 2016 $ 2,586,759 $ 3 $ 332,911 $ (101) $ 1,836,180 $ 417,766
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Net Income (Loss) Attributable to Parent $ 28,125 $ 113,093 $ 88,845
Foreign currency translation adjustments (32,394) (37,536) (118,142)
Other post-employment benefits adjustments, net of tax 2,086 (4,403) (8,186)
Net unrealized holding gains on available-for-sale investments, net of tax 65,936 205,132 4,556
Other comprehensive income, net of tax 35,628 163,193 (121,772)
Comprehensive income attributable to Bio-Rad $ 63,753 $ 276,286 $ (32,927)
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.6.0.2
1. Significant Accounting Policies
 12 Months Ended
Dec. 31, 2016
Accounting Policies [Abstract]  
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies 1.SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value.

Short-term Restricted Investments

Short-term restricted investments of $4.56 million and $4.21 million at December 31, 2016 and 2015, respectively, represent a money market fund for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets.

Available-for-Sale Investments

Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale investments for other-than-temporary losses on a quarterly basis.  Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10).

Concentration of Credit Risk

Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and
investments are placed with various highly rated major financial institutions located in different geographic regions. Bio-Rad has not sustained significant losses from instruments held at financial institutions.

The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  However, we do not expect to record any losses as a result of counterparty default.

We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.

Accounts Receivable

We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.

Inventory

Inventories are valued at the lower of actual cost or market (net realizable value) and include material, labor and overhead costs.  The first-in, first-out method is used to relieve inventory for products sold.

Property, Plant and Equipment

Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  Buildings and leasehold improvements are amortized over 15-30 years or the term of the leases or life of the improvements, whichever is shorter.  With the exception of reagent rental equipment, which is amortized over a 1-5 year period, equipment and capitalized software is depreciated over 3-12 years.

Goodwill

Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.

The goodwill impairment test consists of a two-step process.  The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit to its carrying value, including goodwill.
We use a projected discounted cash flow model to determine the fair value of a reporting unit.  If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required.  The second step, if required, compares the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill.  The fair value of a reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit.  If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an impairment charge is recognized in an amount equal to that excess.

Long-Lived Assets

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:

•
significant under-performance relative to expected, historical or projected future operating results;
•
significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;
•
a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and
•
significant negative industry, legal, regulatory or economic trends.

When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.

Income Taxes
We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. To the extent we determine that we are able to realize our deferred income tax assets in the future in excess of their net recorded amount, we make an adjustment to the valuation allowance which may reduce the provision for income taxes. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit
that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes.

Revenue Recognition

Revenue is recognized when pervasive evidence of an arrangement exists, the price to the buyer is fixed or determinable, collectability is reasonably assured and title has passed to the customer or product has been delivered absent specific contractual specifications.  Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required contractually, has occurred.  At the time revenue is recognized, a provision is recognized for estimated product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement, or as services are performed if not under contract. Net sales are the actual selling price of products to customers. Any taxes billed to the customer (sales tax, value added tax, etc.) shall be credited to the tax liability accounts and excluded from net sales.

Reagent agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis.  We evaluate our reagent agreements and account for these contracts under the guidance pertaining to accounting for revenue arrangements with multiple deliverables.  Our reagent agreements represent one unit of accounting as the instrument and consumables are interdependent in producing a diagnostic result that neither has a stand-alone value with respect to these agreements. All revenues that we earn under our reagent agreements are recognized pursuant to the terms of each agreement and are based and entirely contingent upon either (i) when the consumables to conduct a fixed number of tests are delivered or (ii) as reported by the customer on a per test basis.

Shipping and Handling

We classify all freight costs billed to customers as Net sales.  Related freight costs are included in Cost of goods sold.

Warranty

We warrant certain equipment against defects in design, materials and workmanship, mostly for a period of one year.  Upon delivery of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

Changes in the warranty accrual, included in Other current liabilities and Other long-term liabilities, were as follows (in millions):
 
 
2016
 
2015
January 1
 
$
17.4

 
$
17.8

Provision for warranty
 
33.4

 
30.6

Actual warranty costs
 
(33.2
)
 
(31.0
)
December 31
 
$
17.6

 
$
17.4



Research and Development

Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.  

Foreign Currency

Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.

Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.

Forward Foreign Exchange Contracts

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.  

Share-Based Compensation Plans

Stock-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs net of estimated forfeitures over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  We estimated the forfeiture rate based on our historical experience.  These plans are described more fully in Note 9.

Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.


The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):
 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
Basic weighted average shares outstanding
 
29,440

 
29,186

 
28,876

Effect of potentially dilutive stock options
 
 
 
 
 
 
    and restricted stock awards
 
206

 
223

 
257

Diluted weighted average common shares
 
29,646

 
29,409

 
29,133

Anti-dilutive stock options and restricted stock awards
 
 
 
 
 
 
    excluded from the computation of diluted EPS
 
113

 
109

 
122




Fair Value of Financial Instruments

For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.

The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).

Recent Accounting Standards Updates

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective prospectively for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. ASU 2017-04 will provide a more stream-lined approach to evaluating future goodwill impairment and we early adopted on January 1, 2017. We have not assessed the impact that ASU 2017-04 will have on our consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017.

In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. ASU 2017-01 will be applied prospectively to any transactions occurring within the period of adoption. Early adoption is permitted, including for interim or annual periods in which the financial statements have not been issued or made available for issuance. We early adopted ASU 2017-01 on January 1, 2017. For our acquisition of RainDance Technologies, Inc., ASU 2017-01 did not affect the conclusion of it being a business combination (see Note 17 to the consolidated financial statements).

In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. We have had a limited amount of restricted cash of $2.0 million and $1.4 million as of December 31, 2016 and 2015, respectively, which was reclassified from cash to either Prepaid expenses, Other current assets or Other assets in the Consolidated Balance Sheets. At the time of adoption, we cannot assure whether these same restricted cash amounts will be held or what other restricted cash we may have, or that historically reported amounts will be similar.

In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted as of the beginning of an annual reporting period for which finan
inventory transfers.  Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements.  ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. cial statements have not been issued or made available for issuance. We do not plan to early adopt ASU 2016-16. We are currently evaluating the effect ASU 2016-16 will have on our consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the effect ASU 2016-15 will have on our consolidated statements of cash flows, if any.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for trade and other receivables, and instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also will allow an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. We adopted ASU 2016-09 on January 1, 2017 and made a policy election to account for forfeitures as they occur. We do not expect ASU 2016-09 to have a material impact on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. ASU 2016-07 will be applied on a prospective basis and is effective for all entities for fiscal years beginning after December 15, 2016, and interim periods within those years. We adopted ASU 2016-07 on January 1, 2017 and do not expect it to materially affect our consolidated financial statements, unless our situation changes regarding our ability to influence the investee in the future as a result of our cost method investment in Sartorius AG (see Note 3 to the consolidated financial statements).

In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods
presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities.

In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the consolidated financial statements. At the time of adoption, we cannot assure whether these same equity securities will be held or what other equity securities we may have, or that historically reported changes will be similar.
   
In September 2015, the FASB issued ASU 2015-16, "Simplifying the Accounting for Measurement-Period Adjustments," which eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. Under ASU 2015-16, acquirers must recognize measurement-period adjustments during the period in which they determine the amounts, including the effect on earnings of any amounts they would have recorded in previous periods if the accounting had been completed at the acquisition date. The measurement period cannot exceed one year from the date of the acquisition. ASU 2015-16 was effective on January 1, 2016, and we adopted it at the same time as a change in accounting policy, which had no impact on our consolidated financial statements.

In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” ASU 2015-11 is effective prospectively for annual periods beginning after December 15, 2016, and interim periods therein. We adopted ASU 2015-11 on January 1, 2017 and do not expect it to have a material impact to our consolidated financial statements.

In April 2015, the FASB issued ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs." ASU 2015-03 was issued to simplify the presentation of debt issuance costs by requiring debt issuance costs to be presented as a deduction from the corresponding debt liability. This makes the presentation of debt issuance costs consistent with the presentation of debt discounts or premiums. Under prior U.S. GAAP, debt issuance costs were reported on the balance sheet as assets and amortized as interest expense. Under ASU 2015-03, debt issuance costs will continue to be amortized to interest expense using the effective interest method. In August 2015, the FASB issued ASU 2015-15, "Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements" to clarify the SEC staff’s position that it would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, which is our current practice. We adopted ASU 2015-03 on January 1, 2016 on a retrospective basis as a change in accounting policy. The Condensed Consolidated Balance Sheet as of December 31, 2015 was retrospectively adjusted by decreasing Other assets and Long-term debt, net of current maturities, by $1.8 million, respectively.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 to defer the effective date for annual reporting periods
beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted as of the original effective date in ASU 2014-09, which is annual reporting periods beginning after December 15, 2016, however, we will not early adopt. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectiblity, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method once we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. We have completed revenue recognition diagnostic surveys across all regions in our decentralized sales contracting process, which is based on local country commercial regulations and practices. We have begun assessing individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP, to determine the effect that these ASU’s will have on our consolidated financial statements and related disclosures.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.6.0.2
2. Acquisitions
 12 Months Ended
Dec. 31, 2016
Business Combinations [Abstract]  
Business Combination Disclosure [Text Block] 2.    ACQUISITIONS

Propel Labs, Inc.

In January 2016, we acquired a high performance analytical flow cytometer platform from Propel Labs (Propel) that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. This asset acquisition was accounted for as a business combination, as the new analytical flow cytometer platform represented an integrated set of activities and assets that is capable of being conducted and managed for the purpose of providing a return and therefore constitutes a business in accordance with GAAP. The amount of the acquisition-related cost was minimal as Bio-Rad primarily represented itself during the acquisition process. This business acquisition is included in our Life Science segment’s results of operations from the acquisition date.

The fair value of the consideration as of the acquisition date was $32.8 million, which included $9.5 million paid in cash at the closing date and $23.3 million in contingent consideration potentially payable to Propel, after the effects of a calculation revision that were reflected in the fourth quarter of 2016. This revision reduced goodwill/intangibles and contingent consideration by the same amount and had no significant impact on our Consolidated Income Statement. The contingent consideration was based on a probability-weighted income approach related to the achievement of certain sales milestones, and was recognized at its estimated fair value of $25.4 million as of December 31, 2016 (see Note 3, "Fair Value Measurements").

The fair values of the net assets acquired from Propel as of the acquisition date were determined to be $32.7 million of definite-lived intangible assets and $0.1 million of goodwill. We expect the goodwill recorded to be deductible for income tax purposes. The acquired analytical flow cytometer platform fits well into Bio-Rad’s existing Life Science segment product offerings and may offer researchers greater access to this technology.

In addition, Bio-Rad contracted with Propel to provide development services concurrent with and included in the purchase agreement. Bio-Rad is receiving future manufacturing, engineering and marketing support from Propel on which payments will be made upon the successful completion of all contracted services. As a result, these services are not included in the total purchase consideration and a majority will be expensed in future periods.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.6.0.2
3. Fair Value Measurements
 12 Months Ended
Dec. 31, 2016
Fair Value Disclosures [Abstract]  
Fair Value Measurements 3. FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

•
Level 1: Quoted prices in active markets for identical instruments
•
Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
•
Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)

Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2016 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents (a):
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
14.1

 
$
—

 
$
14.1

Foreign time deposits
11.8

 
—

 
—

 
11.8

Domestic time deposits
—

 
20.0

 
—

 
20.0

U.S. government sponsored agencies
—

 
1.1

 
—

 
1.1

Money market funds
5.9

 
—

 
—

 
5.9

Total cash equivalents
17.7

 
35.2

 
—

 
52.9

Restricted investment:
4.6

 
—

 
—

 
4.6

Available-for-sale investments (b):
 
 
 
 
 
 
 
Corporate debt securities
—

 
179.4

 
—

 
179.4

U.S. government sponsored agencies
—

 
82.5

 
—

 
82.5

Foreign government obligations
—

 
4.4

 
—

 
4.4

Brokered certificates of deposit
—

 
3.6

 
—

 
3.6

Municipal obligations
—

 
15.4

 
—

 
15.4

Marketable equity securities
767.8

 
—

 
—

 
767.8

Asset-backed securities
—

 
62.5

 
—

 
62.5

Total available-for-sale investments
767.8

 
347.8

 
—

 
1,115.6

Forward foreign exchange contracts (c)
—

 
0.6

 
—

 
0.6

Total financial assets carried at fair value
$
790.1

 
$
383.6

 
$
—

 
$
1,173.7

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
     Forward foreign exchange contracts (d)
$
—

 
$
1.3

 
$
—

 
$
1.3

     Contingent consideration (e)
—

 
—

 
38.5

 
38.5

Total financial liabilities carried at fair value
$
—

 
$
1.3

 
$
38.5

 
$
39.8



Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2015 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents (a):
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
33.2

 
—

 
$
33.2

Foreign government obligations
—

 
0.6

 
—

 
0.6

Foreign time deposits
11.9

 
—

 
—

 
11.9

U.S. government sponsored agencies
—

 
14.6

 
—

 
14.6

Money market funds
11.3

 
—

 
—

 
11.3

Total cash equivalents
23.2

 
48.4

 
—

 
71.6

Restricted investment:
4.2

 
—

 
—

 
4.2

Available-for-sale investments (b):
 
 
 
 
 
 
 
Corporate debt securities
—

 
156.9

 
—

 
156.9

U.S. government sponsored agencies
—

 
74.8

 
—

 
74.8

Foreign government obligations
—

 
4.6

 
—

 
4.6

Municipal obligations
—

 
6.4

 
—

 
6.4

Marketable equity securities
660.1

 
—

 
—

 
660.1

Asset-backed securities
—

 
54.8

 
—

 
54.8

Total available-for-sale investments
660.1

 
297.5

 
—

 
957.6

Forward foreign exchange contracts (c)
—

 
0.9

 
—

 
0.9

Total financial assets carried at fair value
$
687.5

 
$
346.8

 
—

 
$
1,034.3

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (d)
$
—

 
$
1.1

 
—

 
$
1.1

 Contingent consideration (e)
—

 
—

 
19.1

 
19.1

Total financial liabilities carried at fair value
$
—

 
$
1.1

 
$
19.1

 
$
20.2


(a)
Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.

(b)
Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31,
2016
 
December 31, 2015
 
 
 
 
Short-term investments
$
383.2

 
$
328.7

Other investments
732.4

 
628.9

Total
$
1,115.6

 
$
957.6



(c)
Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.

(d)
Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.

(e)
Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2016
 
December 31, 2015
 
 
 
 
Other current liabilities
$
14.5

 
$
13.5

Other long-term liabilities
24.0

 
5.6

   Total
$
38.5

 
$
19.1




In 2012, we recognized a contingent consideration liability for certain milestones of $44.6 million upon our acquisition of a new cell sorting system from Propel. Since 2012, we have paid $28.9 million upon reaching the milestones and have reduced the valuation of the milestones by $12.6 million to its estimated fair value of $3.1 million as of December 31, 2016. The remaining liability was paid in February 2017.

During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a new high performance analytical flow cytometer platform from Propel. At the acquisition date, the contingent consideration was based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount through December 31, 2020. The fair value of the contingent consideration as of the acquisition date was $23.3 million, after the effects of a calculation revision that were reflected in the fourth quarter of 2016. The contingent consideration was recognized at its estimated fair value of $25.4 million as of December 31, 2016.

The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value based on original valuations and updated quarterly for the year ended December 31, 2016 (in millions):

 
2016
 
 
January 1
$
9.1

Cell sorting system:
 
Payment of sales milestone
(3.5
)
Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense
(2.5
)
 
 
Analytical flow cytometer platform:
 
Acquisition of high performance analytical flow cytometer platform
23.3

Increase in estimated fair value of contingent consideration included in Selling, general and administrative expense
2.1

December 31
$
28.5




The following table provides quantitative information about Level 3 inputs for fair value measurement of analytical flow cytometer platform contingent consideration liability as of December 31, 2016. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.
 
 
 
Range
 
Valuation Technique
Unobservable Input
From
To
Analytical flow cytometer platform
Probability-weighted income approach
Sales milestones:
 
 
 
 
Discount rate
10
%
 
 
 
Cost of debt
4.7
%
 



In 2014, we recognized a contingent consideration liability upon our acquisition of GnuBIO, Inc.. The contingent consideration for the milestones was valued at $10.7 million at the acquisition date based on assumptions regarding the probability of achieving the milestones, with such amounts discounted to present value. The Level 3 contingent consideration was revalued to a fair value of $10.0 million as of December 31, 2016 and 2015.

To estimate the fair value of Level 2 debt securities as of December 31, 2016 and 2015, our primary pricing provider uses S&P Capital IQ as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. The chosen pricing hierarchy for our Level 2 securities, other than certificates of deposit and commercial paper, is S&P Capital IQ as the primary pricing source and then our custodian as the secondary pricing source. If S&P Capital IQ does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing.

For commercial paper as of December 31, 2016 and 2015, pricing is determined by a straight-line calculation, starting with the purchase price on the date of purchase and increasing to par at maturity. Interest bearing certificates of deposit and commercial paper are priced at par.

Our primary pricing provider performs daily reasonableness testing of S&P Capital IQ prices. Price changes of 5% or greater are investigated and resolved. In addition, we perform a quarterly testing of the S&P Capital IQ prices to custodian reported prices. Prices outside a tolerable variance of approximately 1% are investigated and resolved.

Available-for-sale investments consist of the following (in millions):

 
December 31, 2016
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
179.7

 
$
0.2

 
$
(0.5
)
 
$
179.4

Brokered certificates of deposit
3.6

 
—

 
—

 
3.6

Municipal obligations
15.5

 
—

 
(0.1
)
 
15.4

Asset-backed securities
62.2

 
0.1

 
(0.1
)
 
62.2

U.S. government sponsored agencies
83.1

 
0.1

 
(0.7
)
 
82.5

Foreign government obligations
4.4

 
—

 
—

 
4.4

Marketable equity securities
32.4

 
3.7

 
(0.4
)
 
35.7

 
380.9

 
4.1

 
(1.8
)
 
383.2

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
677.6

 
—

 
732.1

Asset-backed securities
0.3

 
—

 
—

 
0.3

 
54.8

 
677.6

 
—

 
732.4

Total
$
435.7

 
$
681.7

 
$
(1.8
)
 
$
1,115.6


 
December 31, 2015
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
157.2

 
$
0.1

 
$
(0.4
)
 
$
156.9

Municipal obligations
6.4

 
—

 
—

 
6.4

Asset-backed securities
54.8

 
—

 
(0.2
)
 
54.6

U.S. government sponsored agencies
74.9

 
0.1

 
(0.2
)
 
74.8

Foreign government obligations
4.6

 
—

 
—

 
4.6

Marketable equity securities
29.4

 
2.7

 
(0.7
)
 
31.4

 
327.3

 
2.9

 
(1.5
)
 
328.7

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
574.2

 
—

 
628.7

Asset-backed securities
0.3

 
—

 
(0.1
)
 
0.2

 
54.8

 
574.2

 
(0.1
)
 
628.9

Total
$
382.1

 
$
577.1

 
$
(1.6
)
 
$
957.6



The unrealized gains of our long-term marketable equity securities are primarily due to our investment in Sartorius AG preferred shares.

The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):

 
December 31,
2016
 
December 31, 2015
 
 
 
 
Fair value of investments in a loss position 12 months or more
$
11.8

 
$
10.4

Fair value of investments in a loss position less than 12 months
$
160.5

 
$
204.0

Gross unrealized losses for investments in a loss position 12 months or more
$
0.3

 
$
0.4

Gross unrealized losses for investments in a loss position less than 12 months
$
1.5

 
$
1.2



The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at December 31, 2016 or at December 31, 2015.

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of December 31, 2016 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains
or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign exchange losses, net in the Consolidated Statements of Income.

The following is a summary of our forward foreign currency exchange contracts (in millions):
 
December 31,
 
2016
Contracts maturing in January through March 2017 to sell foreign currency:
 
Notional value
$
16.9

Unrealized loss
$
0.1

Contracts maturing in January through March 2017 to purchase foreign currency:
 
Notional value
$
328.3

Unrealized loss
$
0.6



The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31, 2016 by contractual maturity date (in millions):

 
Amortized
Cost
 
Estimated Fair
Value
 
 
 
 
Mature in less than one year
$
156.1

 
$
156.1

Mature in one to five years
141.0

 
140.7

Mature in more than five years
51.7

 
51.0

Total
$
348.8

 
$
347.8



The estimated fair value of financial instruments that are not recognized at fair value in the Consolidated Balance Sheets and are included in Other investments, are presented in the table below. Fair value has been determined using significant observable inputs, including quoted prices in active markets for similar instruments.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value.  Other investments include financial instruments, the majority of which has fair value based on similar, actively traded stock adjusted for various discounts, including a discount for marketability.  Long-term debt, excluding leases and current maturities, has an estimated fair value based on quoted market prices for the same or similar issues.

The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):


 
December 31, 2016
 
December 31, 2015
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
Other investments
$
92.8

 
$
984.2

 
2
 
$
86.5

 
$
843.2

 
2
Total long-term debt, excluding leases
and current maturities
$
422.5

 
$
454.2

 
2
 
$
421.9

 
$
454.3

 
2


We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries.  We own over 35% of the outstanding voting shares (excluding treasury shares) of Sartorius as of December 31, 2016.  The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius’ board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. We account for this investment using the cost method.  The carrying value of this investment is included in Other investments in our Consolidated Balance Sheets. As the stock is thinly traded and in conjunction with the valuation method discussed above, we have classified the estimated fair value as Level 2. The Level 2 classification is appropriate given the valuation method employed, which incorporates an observable input of the fair value of the Sartorius’ actively traded preferred stock.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.6.0.2
4. Intangible Assets, Goodwill and Other
 12 Months Ended
Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Disclosure 4.    GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):
 
 
2016
 
 
2015
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
$
207.2

 
$
316.9

 
$
524.1

 
 
$
207.7

 
$
320.9

 
$
528.6

Accumulated impairment losses and write-offs
 
(27.2
)
 
(1.0
)
 
(28.2
)
 
 
(27.2
)
 
(1.0
)
 
(28.2
)
Goodwill, net
 
180.0

 
315.9

 
495.9

 
 
180.5

 
319.9

 
500.4

Acquisitions
 
0.1

 
—

 
0.1

 
 
—

 
—

 
—

Impairment
 
—

 
(13.5
)
 
(13.5
)
 
 
—

 
—

 
—

Currency fluctuations
 
(0.2
)
 
(5.2
)
 
(5.4
)
 
 
(0.5
)
 
(4.0
)
 
(4.5
)
Balances as of December 31:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
207.1

 
311.7

 
518.8

 
 
207.2

 
316.9

 
524.1

Accumulated impairment losses and write-offs
 
(27.2
)
 
(14.5
)
 
(41.7
)
 
 
(27.2
)
 
(1.0
)
 
(28.2
)
Goodwill, net
 
$
179.9

 
$
297.2

 
$
477.1

 
 
$
180.0

 
$
315.9

 
$
495.9



In conjunction with the purchase of certain assets from Propel in January 2016 (see Note 2, "Acquisitions"), we recorded $0.1 million of goodwill and $32.7 million of definite-lived intangible assets: $29.7 million of developed product technology and $3.0 million of covenants not to compete, after the effects of a calculation revision that were reflected in the fourth quarter of 2016.

Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):
 
December 31, 2016
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-8
 
$
84.4

 
$
(52.8
)
 
$
31.6

Know how
1-9
 
182.6

 
(136.9
)
 
45.7

Developed product technology
3-12
 
125.9

 
(56.3
)
 
69.6

Licenses
1-9
 
39.0

 
(30.6
)
 
8.4

Tradenames
4-8
 
3.5

 
(2.5
)
 
1.0

Covenants not to compete
2-9
 
7.8

 
(2.5
)
 
5.3

     Total definite-lived intangible assets
 
 
443.2

 
(281.6
)
 
161.6

In-process research and development
 
 
—

 
—

 
—

     Total purchased intangible assets
 
 
$
443.2

 
$
(281.6
)
 
$
161.6


 
December 31, 2015
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
2-10
 
$
84.7

 
$
(46.8
)
 
$
37.9

Know how
1-10
 
184.0

 
(121.6
)
 
62.4

Developed product technology
4-12
 
101.3

 
(48.9
)
 
52.4

Licenses
3-10
 
39.2

 
(28.5
)
 
10.7

Tradenames
5-9
 
3.5

 
(2.4
)
 
1.1

Covenants not to compete
3-7
 
4.8

 
(1.7
)
 
3.1

     Total definite-lived intangible assets
 
 
417.5

 
(249.9
)
 
167.6

In-process research and development
 
 
46.4

 
—

 
46.4

     Total purchased intangible assets
 
 
$
463.9

 
$
(249.9
)
 
$
214.0



In 2016, we fully impaired goodwill and in-process research and development in the amounts of $13.5 million and $46.4 million, respectively, associated with our 2014 acquisition of GnuBIO, Inc. The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows. There were no impairment losses recorded in 2015.

Amortization expense related to purchased intangible assets for the years ended December 31, 2016, 2015 and 2014 was $35.2 million, $36.5 million and $47.8 million, respectively.  Estimated future amortization expense (based on existing purchased intangible assets) for the years ending December 31, 2017, 2018, 2019, 2020, 2021 and thereafter is $27.2 million, $24.2 million, $21.4 million, $19.4 million, $18.4 million, and $51.0 million, respectively.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.6.0.2
5. Notes Payable and Long-Term Debt
 12 Months Ended
Dec. 31, 2016
Debt Disclosure [Abstract]  
Notes Payable and Long-term Debt 5.NOTES PAYABLE AND LONG-TERM DEBT


Under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had $205.7 million available for borrowing and usage as of December 31, 2016, which was reduced by $5.4 million that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations.

The principal components of long-term debt are as follows (in millions):
 
December 31,
2016
 
December 31, 2015
 
 
 
 
4.875% Senior Notes due 2020, net of discount
$
425.0

 
$
425.0

Less unamortized discount and debt issuance costs
(2.5
)
 
(3.1
)
Long-term debt less unamortized discount and debt issuance costs
422.5

 
421.9

Capital leases and other debt
12.0

 
12.3

 
434.5

 
434.2

Less current maturities
(0.3
)
 
(0.3
)
Long-term debt
$
434.2

 
$
433.9



Senior Notes due 2020

In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due 2020 (4.875% Notes).  The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946%.  The 4.875% Notes pay a fixed rate of interest of 4.875% per year.  We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date.  Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness.  Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. We were in compliance with these covenants as of December 31, 2016. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.
 
Credit Agreement

In June 2014, Bio-Rad entered into a $200.0 million unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of December 31, 2016 or 2015, however, $0.8 million was utilized for domestic standby letters of credit that reduced our borrowing availability. The Credit Agreement matures in June 2019. If we had borrowed against our Credit Agreement, the borrowing rate would have been 2.25% at December 31, 2016.

The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of December 31, 2016.

Maturities of long-term debt at December 31, 2016 are as follows: 2017 - $0.3 million; 2018 - $0.3 million; 2019 - $0.2 million; 2020 - $425.3 million; 2021 - $0.3 million; thereafter - $10.6 million.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.6.0.2
6. Income Taxes
 12 Months Ended
Dec. 31, 2016
Income Tax Disclosure [Abstract]  
Income Taxes [Text Block] 6. INCOME TAXES

The U.S. and international components of income before taxes are as follows (in millions):

 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
U.S.
 
$
(38.5
)
 
$
48.4

 
$
30.6

International
 
80.1

 
97.4

 
101.0

Income before taxes
 
$
41.6

 
$
145.8

 
$
131.6



The provision for income taxes consists of the following (in millions):

 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
Current tax expense:
 
 

 
 

 
 

U.S. Federal
 
$
16.1

 
$
8.7

 
$
9.6

State
 
3.1

 
1.7

 
3.8

International
 
30.3

 
34.1

 
35.6

Current tax expense
 
49.5

 
44.5

 
49.0

Deferred tax (benefit) expense:
 
 

 
 
 
 

U.S. Federal
 
(42.4
)
 
(0.2
)
 
1.5

State
 
(2.8
)
 
1.2

 
(0.2
)
International
 
(6.0
)
 
(7.1
)
 
(7.3
)
Deferred tax benefit
 
(51.2
)
 
(6.1
)
 
(6.0
)
Non-current tax expense (benefit)
 
15.1

 
(5.6
)
 
(0.3
)
Provision for income taxes
 
$
13.4

 
$
32.8

 
$
42.7



The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:

 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
U.S. statutory tax rate
 
35
 %
 
35
 %
 
35
 %
Impact of foreign operations
 
(15
)
 
(4
)
 
(4
)
Foreign dividends, net
 
(40
)
 
(4
)
 
—

Research tax credits
 
(9
)
 
(2
)
 
(3
)
Nontaxable subsidies
 
(4
)
 
(1
)
 
(2
)
Tax settlements and changes to unrecognized tax benefits
 
42

 
(4
)
 
(1
)
Goodwill impairment
 
11

 
—

 
—

Domestic manufacturing deduction
 
(4
)
 
(2
)
 
—

Stock-based compensation
 
3

 
1

 
1

Nondeductible executive compensation
 
3

 
1

 
1

Fines and penalties
 
2

 
—

 
3

Prior period adjustments
 
4

 
1

 
2

U.S. taxation on foreign income
 
2

 
—

 
—

Other
 
2

 
1

 
—

Provision for income taxes
 
32
 %
 
22
 %
 
32
 %


Our effective income tax rate was 32%, 22% and 32% in 2016, 2015 and 2014, respectively. The effective tax rates for 2016 and 2015 included tax benefits from the repatriation of foreign earnings. The effective tax rate for 2016 included additional tax liabilities for unrecognized tax benefits related to the non-deductibility of interest expense
in our foreign jurisdictions.  The effective tax rate for 2014 included nondeductible penalties and losses that were nonrecurring.
  
Our foreign taxes result primarily from income earned in France and Switzerland. Many jurisdictions in which we operate, including Switzerland, Russia, the U.K. and Singapore, have statutory tax rates that are significantly lower than the U.S. statutory tax rate of 35%. Our effective tax rate may be impacted in the future, either favorably or unfavorably, by many factors including, but not limited to, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.

Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):

 
 
December 31,
 
 
2016
 
2015
Deferred tax assets:
 
 

 
 

Bad debt, inventory and warranty accruals
 
$
28.4

 
$
26.3

Other post-employment benefits, vacation and other reserves
 
26.3

 
28.1

Tax credit and net operating loss carryforwards
 
96.4

 
80.2

Other
 
35.7

 
23.2

    Total gross deferred tax assets
 
186.8

 
157.8

Valuation allowance
 
(66.4
)
 
(58.3
)
       Total deferred tax assets
 
120.4

 
99.5

Deferred tax liabilities:
 
 
 
 
Property and equipment
 
22.5

 
30.2

Investments and intangible assets
 
287.8

 
271.8

        Total deferred tax liabilities
 
310.3

 
302.0

Net deferred tax liabilities
 
$
(189.9
)
 
$
(202.5
)


At December 31, 2016, Bio-Rad’s international subsidiaries had combined net operating loss carryforwards of $141.3 million.  Of these loss carryforwards, $140.8 million have no expiration date.  We believe that it is more likely than not that the benefit from most of these net operating loss carryforwards will not be realized. We have provided a valuation allowance of $29.6 million relating to these net operating loss carryforwards.

At December 31, 2016, Bio-Rad had U.S. Federal net operating loss carryforwards of approximately $1.9 million as a result of acquisitions. These carryforwards are subject to limitation on their utilization and will expire between 2028 and 2033. At December 31, 2016, Bio-Rad had U.S. Federal foreign tax credit carryforwards of $27.6 million and U.S. Federal research tax credit carryforwards of $3.6 million, $0.4 million of which are subject to limitations on their utilization.

At December 31, 2016, Bio-Rad had approximately $53 million of California net operating loss carryforwards related to the acquisition of QuantaLife. We believe that it is more likely than not that the benefit from these net operating loss carryforwards will not be realized and have recorded a full valuation allowance against these losses. At December 31, 2016, Bio-Rad had a deferred tax asset of $25.9 million relating to California research tax credit carryforwards, including $2.0 million from the acquisition of QuantaLife, which may be carried forward indefinitely.  Based on our judgment and consistent with prior years, we have recorded a full valuation allowance against the deferred tax asset.

We believe that it is more likely than not that certain of these deferred tax assets described above will not be realized in the foreseeable future. If or when recognized, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets at December 31, 2016 will be recognized as a reduction of income tax expense.

Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2013 and forward for the U.S., and the years 2010 and forward for certain foreign jurisdictions, including France, Switzerland and Germany. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):
 
 
2016
 
2015
 
2014
Unrecognized tax benefits – January 1
 
$
8.9

 
$
14.2

 
$
16.2

Additions to tax positions related to prior years
 
10.4

 
0.7

 
1.7

Reductions to tax positions related to prior years
 
—

 
(0.2
)
 
(1.5
)
Additions to tax positions related to the current year
 
1.4

 
1.5

 
1.6

Settlements
 
(2.4
)
 
(0.5
)
 
(0.4
)
Lapse of statute of limitations
 
(2.3
)
 
(6.3
)
 
(2.6
)
Currency translation
 
0.1

 
(0.5
)
 
(0.8
)
Unrecognized tax benefits – December 31
 
$
16.1

 
$
8.9

 
$
14.2




Bio-Rad recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. Related to the unrecognized tax benefits noted above, Bio-Rad has accrued interest and penalties of $11.5 million, $3.0 million and $3.8 million as of December 31, 2016, 2015 and 2014, respectively. The total unrecognized tax benefits and interest and penalties of $27.6 million in 2016 was partially offset by prepaid taxes of $12.7 million, for a net amount of $14.9 million.

As of December 31, 2016, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $3.5 million. Substantially all such amounts will impact our effective income tax rate if recognized.

In general, it is our practice and intention to reinvest the earnings of our non-U.S. subsidiaries in their operations. As of December 31, 2016, Bio-Rad had not made a provision for U.S. or additional foreign withholding taxes on approximately $447 million of the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries that are essentially permanent in duration.  Generally, such amounts become subject to U.S. taxation upon remittance of dividends and under certain other circumstances.  If these earnings were repatriated to the U.S., the deferred tax liability associated with these temporary differences would be approximately $47 million.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.6.0.2
7. Stockholders' Equity
 12 Months Ended
Dec. 31, 2016
Stockholders' Equity Attributable to Parent [Abstract]  
Stockholders' Equity Note Disclosure [Text Block] 7.    STOCKHOLDERS' EQUITY

Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B).  Each share of Class A and Class B participates equally in the earnings of Bio-Rad, and is identical in all respects except as follows. Class A has limited voting rights.  Each share of Class A is entitled to one tenth of a vote on most matters, and each share of Class B is entitled to one vote.  Additionally, Class A stockholders are entitled to elect 25% of the Board of Directors and Class B stockholders are entitled to elect 75% of the directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares but no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares.  Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.  The founders of Bio-Rad, the Schwartz family, collectively hold a majority of Bio-Rad’s voting stock.  As a result, the Schwartz family is able to exercise significant influence over Bio-Rad.

Changes to Bio-Rad's issued common stock shares are as follows (in thousands):
 
Class A Shares
 
Class B Shares
Balance at January 1, 2014
23,681

 
5,097

B to A conversions
5

 
(5
)
Issuance of common stock
286

 
7

Balance at December 31, 2014
23,972

 
5,099

B to A conversions
18

 
(18
)
Issuance of common stock
240

 
50

Balance at December 31, 2015
24,230

 
5,131

B to A conversions
13

 
(13
)
Issuance of common stock
211

 
6

Balance at December 31, 2016
24,454

 
5,124


Treasury Shares

The Board of Directors has authorized the repurchase of up to $18.0 million of Bio-Rad's common stock, of which $3.3 million has yet to be repurchased in the open market as of December 31, 2016. The Amended and Restated Credit Agreement (Credit Agreement) limits our ability to repurchase our stock. In accordance with the terms of awards under the 2007 Incentive Award Plan, in June 2012, we withheld 122 shares of our Class A common stock and 917 shares of our Class B common stock to satisfy the minimum statutory tax obligations due upon the vesting of restricted stock of certain of our employees, which is considered a repurchase of our stock. All of the restricted stock vested as of December 31, 2013, and therefore we do not anticipate any repurchasing of shares for this purpose. We had no other repurchases of our stock during 2016 or 2015.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.6.0.2
8. Accumulated Other Comprehensive Income
 12 Months Ended
Dec. 31, 2016
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
accumulated other comprehensive income [Text Block] 8.    ACCUMULATED OTHER COMPREHENSIVE INCOME

Accumulated other comprehensive income included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):
 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains on available-for-sale investments
Total Accumulated other comprehensive income
Balances as of January 1, 2015
$
71.2

$
(16.3
)
$
164.0

$
218.9

Other comprehensive (loss) income, before reclassifications
(37.5
)
(6.8
)
325.4

281.1

Amounts reclassified from Accumulated other comprehensive income
—

1.1

(0.9
)
0.2

Income tax effects
—

1.3

(119.4
)
(118.1
)
Other comprehensive (loss) income, net of income taxes
(37.5
)
(4.4
)
205.1

163.2

Balances as of December 31, 2015
$
33.7

$
(20.7
)
$
369.1

$
382.1

Other comprehensive (loss) income, before reclassifications
(32.4
)
0.5

105.1

73.2

Amounts reclassified from Accumulated other comprehensive income
—

2.5

(0.8
)
1.7

Income tax effects
—

(0.9
)
(38.4
)
(39.3
)
Other comprehensive (loss) income, net of income taxes
(32.4
)
2.1

65.9

35.6

Balances as of December 31, 2016
$
1.3

$
(18.6
)
$
435.0

$
417.7



The increases in 2016 and 2015 for net unrealized holding gains on available-for-sale investments were primarily from our ownership in the preferred shares of Sartorius.

The amounts reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:
Income before taxes impact (in millions):
 
 
December 31,
 
 
Components of Comprehensive income
 
2016
2015
 
Location
 
Amortization of foreign other post-employment benefit items
 
$
(2.5
)
$
(1.1
)
 
Selling, general and administrative expense
 
Net holding gains on available for sale investments
 
$
0.8

$
0.9

 
Other (income) expense, net
 

Reclassification adjustments are calculated using the specific identification method.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.6.0.2
9. Share-based Compensation
 12 Months Ended
Dec. 31, 2016
Share-based Compensation [Abstract]  
Disclosure of Compensation Related Costs, Share-based Payments
9. SHARE-BASED COMPENSATION/STOCK OPTION AND PURCHASE PLANS

Description of Share-Based Compensation Plans

We believe our share-based compensation plans align the interests of our employees with those of our shareholders.

Stock Option and Award Plans
We have two stock option plans for officers and certain other employees: the 2003 Stock Option Plan (2003 Plan) and the 2007 Incentive Award Plan (2007 Plan).  The 2003 Plan authorized the grant of incentive stock options and non-qualified stock options to employees. The 2007 Plan authorizes the grant of stock options, restricted stock, restricted stock units, stock appreciation rights and other types of equity awards to employees.  We no longer grant stock option grants under the 2003 Plan. Since 2007, all share-based compensation grants have been from the 2007 Plan. A total of 2,250,360 shares have been reserved for issuance of equity awards under the 2007 Plan and may be of either Class A or Class B common stock as specified within the plan.  At December 31, 2016, there were 587,509 shares available to be granted in the future.

Under the above plans, Class A and Class B options are granted at prices not less than fair market value of the underlying common stock on the date of grant.  Generally, options granted have a term of 10 years and vest in increments of 20% per year over a five-year period on the yearly anniversary date of the grant.  Stock awards issued under the 2007 Plan generally vest in increments of 20% per year over a five-year period on the yearly anniversary date of the grant.

Employee Stock Purchase Plans
Our 2011 Employee Stock Purchase Plan (2011 ESPP) provides that eligible employees may contribute up to 10% of their compensation up to $25,000 annually toward the quarterly purchase of our Class A common stock.  The employees’ purchase price is 85% of the lesser of the fair market value of the stock on the first business day or the last business day of each calendar quarter.  

The 2011 ESPP includes two components: a Code Section 423 Component that we intend to qualify as an “employee stock purchase plan” under Section 423 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and a Non-423 Component, which authorizes the grant of purchase rights that does not qualify as an “employee stock purchase plan” under Section 423 of the Code. We have authorized the sale of 600,000 shares of Class A common stock under the 2011 ESPP.

Share-Based Compensation Expense

Included in our share-based compensation expense is the cost related to stock option grants, ESPP stock purchases and restricted stock unit awards.  Share-based compensation expense is allocated to Cost of goods sold, Research and development expense, and Selling, general and administrative expense in the Consolidated Statements of Income.

For 2016, 2015 and 2014, we recognized share-based compensation expense of $19.7 million, $17.0 million and $14.9 million, respectively.  We did not capitalize any share-based compensation expense in inventory.

For options and awards, we amortize the fair value on a straight-line basis.  All stock compensation awards are amortized over the requisite service periods of the awards, which are generally the vesting periods.

Stock Options
The following table summarizes stock option activity:

 
 
Shares
 
Weighted-
Average
Exercise Price
 
Weighted-
Average
Remaining
Contractual
Term (in years)
 
Aggregate
Intrinsic
Value
(in millions)
Outstanding, January 1, 2014
 
629,643

 
$
78.72

 
 
 
 
Granted
 
54,000

 
$
119.71

 
 
 
 
Exercised
 
(91,387
)
 
$
63.66

 
 
 
 
Forfeited/expired
 
(10,450
)
 
$
100.29

 
 
 
 
Outstanding, December 31, 2014
 
581,806

 
$
84.50

 
 
 
 
Granted
 
40,500

 
$
139.56

 
 
 
 
Exercised
 
(195,221
)
 
$
61.29

 
 
 
 
Forfeited/expired
 
(380
)
 
$
62.47

 
 
 
 
Outstanding, December 31, 2015
 
426,705

 
$
100.36

 
 
 
 
Granted
 
45,000

 
$
159.37

 
 
 
 
Exercised
 
(15,285
)
 
$
80.70

 
 
 
 
Forfeited/expired
 
(6,850
)
 
$
127.65

 
 
 
 
Outstanding, December 31, 2016
 
449,570

 
$
106.52

 
5.15
 
$
34.1

Vested and expected to vest,
 
 
 
 
 
 
 
 
December 31, 2016
 
437,350

 
$
105.39

 
5.04
 
$
33.6

Exercisable, December 31, 2016
 
314,330

 
$
93.78

 
3.80
 
$
27.8




Intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic value on the date of exercise of stock options exercised during 2016, 2015 and 2014 was approximately $1 million, $13 million and $5 million, respectively. The total grant date fair value of options vested during 2016, 2015 and 2014 was $2.1 million, $2.2 million and $2.1 million, respectively.

Cash received from stock options exercised during 2016, 2015 and 2014 was $1.2 million, $2.9 million and $5.8 million, respectively.  The actual tax benefit realized for the tax deductions from stock options exercised totaled $6.0 million, $9.3 million and $5.3 million in 2016, 2015 and 2014, respectively.

As of December 31, 2016, there was $4.9 million of total unrecognized compensation cost from stock options. This amount is expected to be recognized in the future over a weighted-average period of approximately 3 years.

The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
Expected volatility
 
21
%
 
23
%
 
25
%
Risk-free interest rate
 
1.35
%
 
1.90
%
 
2.35
%
Expected life (in years)
 
7.4

 
7.7

 
8.7

Expected dividend
 
—

 
—

 
—

Weighted-average fair value of options granted
 
$
42.40

 
$
42.74

 
$
43.96



Volatility is based on the historical volatilities of our common stock for a period equal to the stock option’s expected life.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the number of years that we estimate, based primarily on historical experience, that the options will be outstanding prior to exercise.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.

Restricted Stock Units
Restricted stock units, which are rights to receive shares of company stock, were granted from 2009 through 2016 under the 2007 Plan.  The fair value of a restricted stock unit is the market value as determined by the closing price of the stock on the day of grant.

The following table summarizes restricted stock unit activity:
 
 

Restricted Stock
Units
 
Weighted-
Average
Grant-Date
Fair Value
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic Value
(in millions)
Outstanding, January 1, 2014
 
375,430

 
$
105.44

 
 
 
 
Granted
 
145,695

 
$
119.56

 
 
 
 
Vested
 
(107,557
)
 
$
98.52

 
 
 
 
Forfeited
 
(36,203
)
 
$
108.17

 
 
 
 
Outstanding, December 31, 2014
 
377,365

 
$
112.60

 
 
 
 
Granted
 
177,110

 
$
139.56

 
 
 
 
Vested
 
(113,347
)
 
$
107.62

 
 
 
 
Forfeited
 
(28,706
)

$
116.19

 
 
 
 
Outstanding, December 31, 2015
 
412,422

 
$
125.30

 
 
 
 
Granted
 
193,025

 
$
159.32

 
 
 
 
Vested
 
(117,203
)
 
$
119.33

 
 
 
 
Forfeited
 
(39,422
)

$
129.80

 
 
 
 
Outstanding, December 31, 2016
 
448,822

 
$
141.09

 
2.16
 
$
81.8



The total grant date fair value of restricted stock units vested in 2016, 2015 and 2014 was $14.0 million, $12.2 million and $10.6 million, respectively. As of December 31, 2016, there was approximately $46.8 million of total unrecognized compensation cost related to restricted stock units.  This amount is expected to be recognized over a remaining weighted-average period of approximately 4 years.

Employee Stock Purchase Plans
The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:

 
Year Ended December 31,
 
2016
 
 
 
2015
 
 
 
2014
Expected volatility
20
%
 
 
 
18
%
 
 
 
15
%
Risk-free interest rate
0.26
%
 
 
 
0.02
%
 
 
 
0.04
%
Expected life (in years)
0.25

 
 
 
0.25

 
 
 
0.25

Expected dividend
—

 
 
 
—

 
 
 
—

Weighted-average fair value
 
 
 
 
 
 
 
 
 
of purchase rights
$
27.36

 
 
 
$
25.08

 
 
 
$
21.88



The major assumptions are primarily based on historical data.  Volatility is based on the historical volatilities of our common stock for a period equal to the expected life of the purchase rights.  The risk-free interest rate is based on
the U.S. Treasury yield curve in effect at the time of the grant.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.

We sold 93,605 shares for $11.5 million, 96,634 shares for $10.8 million and 102,222 shares for $10.2 million under the 2011 ESPP to employees in 2016, 2015 and 2014, respectively.  At December 31, 2016, 96,121 shares remain authorized and available for issuance under the 2011 ESPP.

We currently issue new shares to satisfy stock option exercises, restricted stock issuances and ESPP stock purchases.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.6.0.2
10. Other Income and Expenses
 12 Months Ended
Dec. 31, 2016
Other Income and Expenses [Abstract]  
Other Income and Other Expense Disclosure 10. OTHER INCOME AND EXPENSE, NET

Other (income) expense, net includes the following components (in millions):
 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
 
 
 
 
 
 
 
Interest and investment income
 
$
(14.7
)
 
$
(10.1
)
 
$
(13.5
)
Net realized gains on investments
 
(0.8
)
 
(1.6
)
 
—

Other-than-temporary impairment losses on investments
 
0.6

 
0.6

 
0.4

Miscellaneous other (income) expense items, net
 
—

 
—

 
0.1

Other (income) expense, net
 
$
(14.9
)
 
$
(11.1
)
 
$
(13.0
)


Other-than-temporary impairment losses on investments were recorded in 2016, 2015 and 2014 on certain of our available-for-sale investments and a certain equity investment in light of the continuing declines in their market prices at that time.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.6.0.2
11. Supplemental Cash Flow Information
 12 Months Ended
Dec. 31, 2016
Supplemental Cash Flow Information [Abstract]  
Cash Flow, Supplemental Disclosures [Text Block] 11. SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net income to net cash provided by operating activities is as follows (in millions):

 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
Net income
 
$
28.1

 
$
113.1

 
$
88.8

Adjustments to reconcile net income
 
 

 
 

 
 

to net cash provided by operating activities
 
 

 
 

 
 

Depreciation and amortization
 
142.9

 
131.8

 
149.9

Share-based compensation
 
19.7

 
17.0

 
14.9

(Gains) losses on dispositions of securities
 
(0.2
)
 
(1.0
)
 
0.3

Losses on dispositions of fixed assets
 
0.6

 
0.3

 
0.4

Excess tax benefits from share-based compensation
 
(1.5
)
 
(3.6
)
 
(1.3
)
Changes in fair value of contingent consideration
 
(0.4
)
 
(5.6
)
 
(1.4
)
Decrease (increase) in accounts receivable, net
 
12.5

 
(39.0
)
 
11.1

(Increase) decrease in inventories, net
 
(57.1
)
 
(54.2
)
 
5.8

(Increase) decrease in other current assets
 
(6.6
)
 
0.1

 
(5.7
)
Increase (decrease) in accounts payable
 


 


 


and other current liabilities
 
30.1

 
28.6

 
(9.9
)
Increase in income taxes payable
 
10.7

 
12.7

 
20.4

Decrease in deferred income taxes
 
(51.4
)
 
(6.4
)
 
(6.3
)
Decrease in other long term assets
 
12.7

 
0.3

 
3.6

Increase (decrease) in other long term liabilities
 
8.3

 
(12.2
)
 
(1.3
)
Impairment losses on goodwill and long-lived assets
 
62.3

 
—

 
—

Other
 
5.7

 
4.3

 
4.0

Net cash provided by operating activities
 
$
216.4

 
$
186.2

 
$
273.3

 
 
 
 
 
 
 
Non-cash investing activities:
 
 
 
 
 
 
   Purchased intangible assets
 
$
—

 
$
—

 
$
0.2

   Purchased marketable securities and investments
 
$
0.6

 
$
2.2

 
$
—
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.6.0.2
12. Commitments & Contingent Liabilities
 12 Months Ended
Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block] 12. COMMITMENTS AND CONTINGENT LIABILITIES

Rents and Leases

Rental expense under operating leases was $44.4 million, $45.0 million and $46.9 million in 2016, 2015 and 2014, respectively.  Leases are principally for facilities and automobiles. We had no sublease income.

Annual future minimum lease payments at December 31, 2016 under operating leases are as follows: 2017 - $42.1 million; 2018 - $32.1 million; 2019 - $24.7 million; 2020 - $20.4 million; and 2021 and beyond - $38.8 million.

Deferred Profit Sharing Retirement Plan

We have a profit sharing plan covering substantially all U.S. employees.  Contributions are made at the discretion of the Board of Directors.  Bio-Rad has no liability other than for the current year’s contribution.  Contribution expense was $15.1 million, $14.7 million and $13.7 million in 2016, 2015 and 2014, respectively.

Other Post-Employment Benefits

In several foreign locations we are statutorily required to provide a lump sum severance or termination indemnity to our employees.  Under these plans, the vested benefit obligation at December 31, 2016 and 2015 was $68.0 million and $68.6 million, respectively, and has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets.  Most plans are not required to be funded, and as such, there is no trust or other device used to accumulate assets to settle these obligations. However, some of these plans require funding based on local laws in which there is a trust or other device used to accumulate assets to assist in settling these obligations.

Purchase Obligations

As of December 31, 2016, we had obligations that have been recognized on our balance sheet of $142.9 million, which include purchases of goods and services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty. These obligations also include other post-employment benefits in some of our foreign locations as indicated above.

The annual future fixed and determinable portion of our purchase obligations that have been recognized on our balance sheet as of December 31, 2016 are as follows: 2017 - $34.3 million, 2018 - $7.3 million, 2019 - $3.1 million, 2020 - $2.5 million, 2021 - $1.6 million and after 2021 - $94.1 million.

As of December 31, 2016, we had purchase obligations that have not been recognized on our balance sheet of $35.0 million, which include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty.

The annual future fixed and determinable portion of our purchase obligations that have not been recognized on our balance sheet as of December 31, 2016 are as follows: 2017 - $17.5 million, 2018 - $5.0 million, 2019 - $3.5 million, 2020 - $3.5 million, 2021 - $5.5 million and after 2021 - $0 million.

Letters of Credit/Guarantees

In the ordinary course of business, we are at times required to post letters of credit/guarantees.  The letters of credit/guarantees are issued by financial institutions to guarantee our obligations to various parties. We were contingently liable for $5.4 million of standby letters of credit/guarantees with financial institutions as of December 31, 2016.

Contingent Consideration

During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a new high performance analytical flow cytometer platform from Propel. At the acquisition date, the contingent consideration was based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount through December 31, 2020. The fair value of the contingent consideration as of the acquisition date was $23.3 million, after the effects of a calculation revision that were reflected in the fourth quarter of 2016. The contingent consideration was recognized at its estimated fair value of $25.4 million as of December 31, 2016.

In 2014, we recognized a contingent consideration liability upon our acquisition of GnuBIO, Inc. The contingent consideration for the milestones was valued at $10.7 million at the acquisition date based on assumptions regarding the probability of achieving the milestones, with such amounts discounted to present value. The Level 3 contingent consideration was revalued to a fair value of $10.0 million as of December 31, 2016 and 2015.

In 2012, we recognized a contingent consideration liability for certain milestones of $44.6 million upon our acquisition of a new cell sorting system from Propel. Since 2012, we have paid $28.9 million upon reaching the milestones and have reduced the valuation of the milestones by $12.6 million to its estimated fair value of $3.1 million as of December 31, 2016. The remaining liability was paid in February 2017.

Concentrations of Labor Subject to Collective Bargaining Agreements

At December 31, 2016, approximately seven percent of Bio-Rad's approximately 3,300 U.S. employees were covered by a collective bargaining agreement, which will expire on November 7, 2019.  Many of Bio-Rad's non-U.S. full-time employees, especially in France, are covered by collective bargaining agreements.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.6.0.2
13. Legal Proceedings
 12 Months Ended
Dec. 31, 2016
Legal Proceedings [Abstract]  
Legal Matters and Contingencies 13.    LEGAL PROCEEDINGS

On January 23, 2015, the City of Riviera Beach General Employees’ Retirement System filed a shareholder derivative lawsuit in the Superior Court of California, Contra Costa County, against three of our current directors and one former director. We are also named as a nominal defendant. In the complaint, the plaintiff alleges that our directors breached their fiduciary duty of loyalty by failing to ensure that we had sufficient internal controls and systems for compliance with the Foreign Corrupt Practices Act ("FCPA"); that we failed to provide adequate training on the FCPA; and that based on these actions, the directors have been unjustly enriched. Purportedly seeking relief on our behalf, the plaintiff seeks an award of restitution and unspecified damages, costs and expenses (including attorneys’ fees). On April 23, 2015, we and the individual defendants filed a demurrer requesting dismissal of the complaint in this case. The demurrer was heard on August 6, 2015, and the Court granted the demurrer for failure to make a demand on our Board of Directors on August 17, 2015, but provided leave to amend. On September 4, 2015, the plaintiff filed an amended complaint and simultaneously served a litigation demand letter on our Board of Directors ("Board") via its counsel in this action. The letter demanded that we investigate and bring appropriate legal action against certain individuals, including the defendants in the City of Riviera Beach case and six current and former employees. The plaintiff also moved for a temporary stay in the proceedings, purportedly to enable the Board to respond to the demand. The Board formed a Demand Review Committee to respond to the demand. On February 24, 2016, the Demand Review Committee reported to the Board that it had concluded its investigation and unanimously determined that it is not in the best interests of the Company and its stockholders to pursue litigation against any individuals named in the City of Riviera Beach’s litigation demand letter. On October 6, 2015, we and the individual defendants filed a second demurrer, seeking to dismiss the case for failure to make a timely pre-suit demand. The case was stayed pending mediation. The caption is City of Riviera Beach General Employees’ Retirement System v. Schwartz et al., Case No. C-15-00140. The lawsuit and demand letter are referred to collectively as the “California Action”.

On August 13, 2015 and August 18, 2015, respectively, each of International Brotherhood of Electrical Workers Local 38 Pension Fund and Wayne County Employees’ Retirement System filed a stockholder derivative complaint in the Delaware Court of Chancery against four of our current directors and one former director. We are named as a nominal defendant in the complaints. The complaints allege that the defendants failed to cause us to develop internal controls sufficient to ensure our compliance with the FCPA. The plaintiffs assert claims for breach of fiduciary duty and unjust enrichment and request an award of the damages we sustained as a result of the alleged violations, among other relief. The two lawsuits were consolidated on August 27, 2015.  The case was stayed pending mediation. The caption of the consolidated case is In re Bio-Rad Laboratories, Inc. Stockholder Litigation, Consol. C.A. No. 11387-VCN (Del. Ch.). The cases filed in the Delaware Court of Chancery, together with the California Action, are referred to collectively as the “Derivative Actions”.

The parties filed a Stipulation dated November 4, 2016 with the Superior Court of California for Contra Costa County that sets forth the terms of a proposed settlement of the Derivative Actions. The proposed settlement includes the dismissal with prejudice of all claims asserted in the Derivative Actions, an agreed-upon set of revised corporate procedures, and no monetary payment other than an award of attorneys’ fees and costs to the plaintiffs’ counsel. We and the other defendants do not admit any liability or fault in connection with the proposed settlement. On December 22, 2016 the Superior Court of California for Contra Costa County issued an order granting preliminary approval of this proposed settlement. Pursuant to the order, the Court will hold a hearing for final approval of the settlement on March 2, 2017, and any objections to the settlement were required to be filed in writing with the Court on or before February 15, 2017.

On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The parties engaged in mediation of the case on April 19, 2016 and on September 14, 2016. The mediations did not result in a settlement. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million, plus prejudgment interest of $141,608, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. We are considering an appeal of the judgment.

Bio-Rad received three notices of violations from the Bay Area Air Quality Management District (“District”). The District alleges that we operated three (3) power generation units without appropriate monitoring and recordkeeping and exceeded permissible levels of emissions during those operations. We are cooperating with the District and are investigating the allegations. No formal proceeding has been initiated by the District.

We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.


XML 35 R21.htm IDEA: XBRL DOCUMENT v3.6.0.2
14. Segment Reporting
 12 Months Ended
Dec. 31, 2016
Segment Reporting [Abstract]  
Segment Information 14. SEGMENT INFORMATION

Bio-Rad is a multinational manufacturer and worldwide distributor of its own life science research products and clinical diagnostics products.  We have two reportable segments:  Life Science and Clinical Diagnostics.  These reportable segments are strategic business lines that offer more than 8,000 different products and services and require different marketing strategies. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research.  These products are sold to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories and government and industrial research facilities.

The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market.  These products are sold to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories and insurance and forensic testing laboratories.

Other Operations include the remainder of our Analytical Instruments segment.

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. The accounting policies of the segments are the same as those described in Significant Accounting Policies (see Note 1).  Segment profit or loss includes an allocation of corporate expense based upon sales and an allocation of interest expense based upon accounts receivable and inventories.  The difference between total segment allocated interest expense, depreciation and amortization, and capital expenditures and the corresponding consolidated amounts is attributable to our corporate headquarters.  Segments are expected to manage only assets completely under their control.  Accordingly, segment assets include primarily accounts receivable, inventories and gross machinery and equipment.  Goodwill balances have been included in corporate for segment reporting purposes.

Information regarding industry segments at December 31, 2016, 2015, and 2014 and for the years then ended is as follows (in millions):

 
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
Segment net sales 
2016
 
$
730.7

 
$
1,323.3

 
$
14.2

 
2015
 
695.0

 
1,310.4

 
14.0

 
2014
 
728.3

 
1,432.3

 
14.4

 
 
 
 
 
 
 
 
Allocated interest expense
2016
 
$
6.4

 
$
15.5

 
$
—

 
2015
 
6.1

 
15.4

 
0.1

 
2014
 
5.5

 
15.9

 
0.1

 
 
 
 
 
 
 
 
Depreciation and amortization
2016
 
$
31.7

 
$
80.5

 
$
—

 
2015
 
30.7

 
77.8

 
0.1

 
2014
 
33.2

 
95.8

 
—

 
 
 
 
 
 
 
 
Segment (loss) profit
2016
 
$
(19.2
)
 
$
57.0

 
$
0.9

 
2015
 
(0.7
)
 
152.4

 
0.7

 
2014
 
(14.7
)
 
167.1

 
1.2

 
 
 
 
 
 
 
 
Segment assets
2016
 
$
381.4

 
$
918.0

 
$
4.9

 
2015
 
390.5

 
878.3

 
4.4

 
 
 
 
 
 
 
 
Capital expenditures
2016
 
$
14.3

 
$
67.1

 
$
—

 
2015
 
8.2

 
51.3

 
0.1

Net corporate operating expense consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. In 2014, this included the accrual of $20.1 million associated with the U.S. Securities and Exchange Commission and Department of Justice investigations relating to the U.S. Foreign Corrupt Practices Act, for which a final settlement was reached in the fourth quarter of 2014. The following reconciles total segment profit to consolidated income before taxes (in millions):
 
 
 
Year Ended December 31,
 
2016
 
2015
 
2014
Total segment profit
$
38.7

 
$
152.4

 
$
153.6

Foreign exchange losses
(4.5
)
 
(10.2
)
 
(9.3
)
Net corporate operating, interest and other expense, net not allocated to segments
(7.5
)
 
(7.5
)
 
(25.7
)
Other income (expense), net
14.9

 
11.1

 
13.0

Consolidated income before taxes
$
41.6

 
$
145.8

 
$
131.6




The following reconciles total segment assets to consolidated total assets (in millions):

 
 
December 31,
 
 
2016
 
2015
Total segment assets
 
$
1,304.3

 
$
1,273.2

Cash and other current assets
 
980.3

 
926.9

Property, plant and equipment, net, excluding
 

 

  segment specific gross machinery and equipment
 
81.6

 
46.1

Goodwill, net
 
477.1

 
495.9

Other long-term assets
 
1,007.2

 
967.6

Total assets
 
$
3,850.5

 
$
3,709.7




The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):

 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
Europe
 
$
742.2

 
$
763.7

 
$
901.7

Pacific Rim
 
427.1

 
392.2

 
417.5

United States
 
770.6

 
735.0

 
704.9

Other (primarily Canada and Latin America)
 
128.3

 
128.5

 
150.9

Total net sales
 
$
2,068.2

 
$
2,019.4

 
$
2,175.0


The following presents Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):

 
 
December 31,
 
 
2016
 
2015
Europe
 
$
221.1

 
$
204.4

Pacific Rim
 
16.1

 
15.1

United States  
 
1,084.7

 
962.6

Other (primarily Canada and Latin America)
 
12.3

 
9.1

Total Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes
 
$
1,334.2

 
$
1,191.2
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.6.0.2
15. Restructuring Costs (Notes)
 12 Months Ended
Dec. 31, 2016
Restructuring Costs [Abstract]  
Restructuring and Related Activities Disclosure [Text Block] RESTRUCTURING COSTS

For the year ended December 31, 2016, we recorded $12.5 million related to restructuring actions that include the elimination or relocation of various positions. These actions are generally intended to streamline and focus our efforts and more properly align our cost structure with projected future revenue streams.
 
The following table summarizes the activity of our restructuring reserves for severance (in millions):

 
 
Life Science
 
Clinical Diagnostics
 
Total
Balance at December 31, 2015
 
$
—

 
$
—

 
$
—

Charged to expense
 
4.1

 
7.6

 
11.7

Adjustment to expense
 
0.3

 
0.5

 
0.8

Cash payments
 
(1.0
)
 
(2.0
)
 
(3.0
)
Foreign currency translation gains
 
(0.2
)
 
(0.3
)
 
(0.5
)
Balance at December 31, 2016
 
$
3.2

 
$
5.8

 
$
9.0



In May 2016, management announced that it will take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance ERP platform, are expected to be incurred through 2019. As a result, we recorded approximately $12.5 million in restructuring charges related to severance and other employee benefits for the year ended December 31, 2016, of which $9.0 million is anticipated to be paid through 2019. The liability of $9.0 million as of December 31, 2016 encompassed a short-term liability of $6.4 million and a long-term liability of $2.6 million. The amounts recorded were reflected in Cost of goods sold of $2.1 million, and in Selling, general and administrative expense of $10.4 million in the Consolidated Statements of Income for the year ended December 31, 2016. The amounts adjusted were primarily for additional positions identified for elimination, partially offset by employees finding other positions within Bio-Rad or leaving prematurely.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.6.0.2
16. Quarterly Financial Data
 12 Months Ended
Dec. 31, 2016
Quarterly Financial Data [Abstract]  
Quarterly Financial Data [Text Block] 16. QUARTERLY FINANCIAL DATA (UNAUDITED)

Summarized quarterly financial data for 2016 and 2015 are as follows (in millions, except per share data):

 
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2016
 
 
 
 
 
 
 
 
Net sales
 
$
471.2

 
$
516.8

 
$
508.7

 
$
571.5

Gross profit
 
264.0

 
280.2

 
279.5

 
314.4

Net income (loss)
 
12.3

 
18.0

 
18.4

 
(20.6
)
Basic earnings (loss) per share
 
$
0.42

 
$
0.61

 
$
0.63

 
$
(0.70
)
Diluted earnings (loss) per share
 
$
0.42

 
$
0.61

 
$
0.62

 
$
(0.70
)
 
 
 
 
 
 
 
 
 
2015
 
 
 
 
 
 
 
 
Net sales
 
$
472.8

 
$
506.1

 
$
470.0

 
$
570.6

Gross profit
 
270.1

 
279.6

 
263.5

 
308.5

Net income
 
17.8

 
28.4

 
17.4

 
49.5

Basic earnings per share
 
$
0.61

 
$
0.98

 
$
0.59

 
$
1.69

Diluted earnings per share
 
$
0.61

 
$
0.97

 
$
0.59

 
$
1.68




Note: As a result of the net loss for the three months ended December 31, 2016,
all potentially issuable common shares have been excluded from the diluted shares
used in the computation of earnings per share as their effect was anti-dilutive.
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.6.0.2
Schedule II - Valuation and Qualifying Accoutns
 12 Months Ended
Dec. 31, 2016
Valuation and Qualifying Accounts Disclosure [Line Items]  
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] BIO-RAD LABORATORIES, INC.
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
Years Ended December 31, 2016, 2015, and 2014
(in thousands)


Allowance for doubtful accounts receivable
 
 
Balance at
Beginning
of Year
 
Additions
Charged to Costs
and Expenses
 
Deductions
 
Balance at
End of Year
2016
 
$
24,418

 
$
3,785

 
$
(4,836
)
 
$
23,367

2015
 
$
27,973

 
$
8,783

 
$
(12,338
)
 
$
24,418

2014
 
$
32,471

 
$
7,164

 
$
(11,662
)
 
$
27,973




Valuation allowance for current and long-term deferred tax assets*
 
 
Balance at
Beginning
of Year
 
Additions Charged
(Credited) to Income
Tax Expense
 
Deductions
 
Balance at 
End of Year 
2016
 
$
58,277

 
$
8,126

 
$
—

 
$
66,403

2015
 
$
58,615

 
$
(338
)
 
$
—

 
$
58,277

2014
 
$
64,011

 
$
(5,396
)
 
$
—

 
$
58,615

*2014 is the only year presented that has current and long-term valuation allowances for deferred tax assets due to the adoption of ASU 2015-17 in 2015 on a prospective basis. Therefore, for the years 2016 and 2015, the valuation allowance is long-term for deferred tax assets.
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.6.0.2
17. Subsequent Event (Notes)
 12 Months Ended
Dec. 31, 2016
Subsequent Events [Abstract]  
Subsequent Events [Text Block] 17. SUBSEQUENT EVENT

On February 15, 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately $87 million including certain assumed net liabilities. Cash payments at closing were $82.9 million. The acquisition will be included in our Life Science segment’s results of operations from the acquisition date and will be accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill to be recorded will not be deductible for income tax purposes.
We are presently unable to report the purchase price allocation or the evaluation of the transaction, as more time is needed to complete the information transfer from the seller and include all information into a valuation of individual assets and liabilities.

RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. We believe that RainDance's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital™ PCR, offering customers with solutions for a wide range of nucleic acid detection applications.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.6.0.2
1. Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2016
Accounting Policies [Abstract]  
Research and Development Expense, Policy [Policy Text Block]
Research and Development

Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.
Basis of Presentation Basis of Presentation

The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions.
Cash and Cash Equivalents Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value.
Short-term Restricted Investments [Policy Text Block] Short-term Restricted Investments

Short-term restricted investments of $4.56 million and $4.21 million at December 31, 2016 and 2015, respectively, represent a money market fund for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets.
Available-for-sale Investments Available-for-Sale Investments

Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale investments for other-than-temporary losses on a quarterly basis.  Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10).
Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk

Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and
investments are placed with various highly rated major financial institutions located in different geographic regions. Bio-Rad has not sustained significant losses from instruments held at financial institutions.

The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  However, we do not expect to record any losses as a result of counterparty default.

We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.
Accounts Receivable Accounts Receivable

We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.
Inventory Inventory

Inventories are valued at the lower of actual cost or market (net realizable value) and include material, labor and overhead costs.  The first-in, first-out method is used to relieve inventory for products sold.
Property, Plant and Equipment Property, Plant and Equipment

Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  Buildings and leasehold improvements are amortized over 15-30 years or the term of the leases or life of the improvements, whichever is shorter.  With the exception of reagent rental equipment, which is amortized over a 1-5 year period, equipment and capitalized software is depreciated over 3-12 years.
Goodwill Goodwill

Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.

The goodwill impairment test consists of a two-step process.  The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit to its carrying value, including goodwill.
We use a projected discounted cash flow model to determine the fair value of a reporting unit.  If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required.  The second step, if required, compares the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill.  The fair value of a reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit.  If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an impairment charge is recognized in an amount equal to that excess.
Long-Lived Assets Long-Lived Assets

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:

•
significant under-performance relative to expected, historical or projected future operating results;
•
significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;
•
a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and
•
significant negative industry, legal, regulatory or economic trends.

When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.
Income Taxes Income Taxes
We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. To the extent we determine that we are able to realize our deferred income tax assets in the future in excess of their net recorded amount, we make an adjustment to the valuation allowance which may reduce the provision for income taxes. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit
that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes.
Revenue Recognition Revenue Recognition

Revenue is recognized when pervasive evidence of an arrangement exists, the price to the buyer is fixed or determinable, collectability is reasonably assured and title has passed to the customer or product has been delivered absent specific contractual specifications.  Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required contractually, has occurred.  At the time revenue is recognized, a provision is recognized for estimated product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement, or as services are performed if not under contract. Net sales are the actual selling price of products to customers. Any taxes billed to the customer (sales tax, value added tax, etc.) shall be credited to the tax liability accounts and excluded from net sales.

Reagent agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis.  We evaluate our reagent agreements and account for these contracts under the guidance pertaining to accounting for revenue arrangements with multiple deliverables.  Our reagent agreements represent one unit of accounting as the instrument and consumables are interdependent in producing a diagnostic result that neither has a stand-alone value with respect to these agreements. All revenues that we earn under our reagent agreements are recognized pursuant to the terms of each agreement and are based and entirely contingent upon either (i) when the consumables to conduct a fixed number of tests are delivered or (ii) as reported by the customer on a per test basis.
Shipping and Handling
Shipping and Handling

We classify all freight costs billed to customers as Net sales.  Related freight costs are included in Cost of goods sold.
Warranty
Warranty

We warrant certain equipment against defects in design, materials and workmanship, mostly for a period of one year.  Upon delivery of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

Changes in the warranty accrual, included in Other current liabilities and Other long-term liabilities, were as follows (in millions):
 
 
2016
 
2015
January 1
 
$
17.4

 
$
17.8

Provision for warranty
 
33.4

 
30.6

Actual warranty costs
 
(33.2
)
 
(31.0
)
December 31
 
$
17.6

 
$
17.4
Foreign Currency
Foreign Currency

Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.

Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.
Forward Foreign Exchange Contracts

Forward Foreign Exchange Contracts

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.
Share-based Compensation Plans
Share-Based Compensation Plans

Stock-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs net of estimated forfeitures over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  We estimated the forfeiture rate based on our historical experience.  These plans are described more fully in Note 9.
Earnings Per Share

Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.


The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):
 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
Basic weighted average shares outstanding
 
29,440

 
29,186

 
28,876

Effect of potentially dilutive stock options
 
 
 
 
 
 
    and restricted stock awards
 
206

 
223

 
257

Diluted weighted average common shares
 
29,646

 
29,409

 
29,133

Anti-dilutive stock options and restricted stock awards
 
 
 
 
 
 
    excluded from the computation of diluted EPS
 
113

 
109

 
122
Fair Value of Financial Instruments

Fair Value of Financial Instruments

For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.

The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).
New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Standards Updates

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective prospectively for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. ASU 2017-04 will provide a more stream-lined approach to evaluating future goodwill impairment and we early adopted on January 1, 2017. We have not assessed the impact that ASU 2017-04 will have on our consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017.

In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. ASU 2017-01 will be applied prospectively to any transactions occurring within the period of adoption. Early adoption is permitted, including for interim or annual periods in which the financial statements have not been issued or made available for issuance. We early adopted ASU 2017-01 on January 1, 2017. For our acquisition of RainDance Technologies, Inc., ASU 2017-01 did not affect the conclusion of it being a business combination (see Note 17 to the consolidated financial statements).

In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. We have had a limited amount of restricted cash of $2.0 million and $1.4 million as of December 31, 2016 and 2015, respectively, which was reclassified from cash to either Prepaid expenses, Other current assets or Other assets in the Consolidated Balance Sheets. At the time of adoption, we cannot assure whether these same restricted cash amounts will be held or what other restricted cash we may have, or that historically reported amounts will be similar.

In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted as of the beginning of an annual reporting period for which finan
inventory transfers.  Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements.  ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. cial statements have not been issued or made available for issuance. We do not plan to early adopt ASU 2016-16. We are currently evaluating the effect ASU 2016-16 will have on our consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the effect ASU 2016-15 will have on our consolidated statements of cash flows, if any.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for trade and other receivables, and instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also will allow an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. We adopted ASU 2016-09 on January 1, 2017 and made a policy election to account for forfeitures as they occur. We do not expect ASU 2016-09 to have a material impact on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. ASU 2016-07 will be applied on a prospective basis and is effective for all entities for fiscal years beginning after December 15, 2016, and interim periods within those years. We adopted ASU 2016-07 on January 1, 2017 and do not expect it to materially affect our consolidated financial statements, unless our situation changes regarding our ability to influence the investee in the future as a result of our cost method investment in Sartorius AG (see Note 3 to the consolidated financial statements).

In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods
presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities.

In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the consolidated financial statements. At the time of adoption, we cannot assure whether these same equity securities will be held or what other equity securities we may have, or that historically reported changes will be similar.
   
In September 2015, the FASB issued ASU 2015-16, "Simplifying the Accounting for Measurement-Period Adjustments," which eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. Under ASU 2015-16, acquirers must recognize measurement-period adjustments during the period in which they determine the amounts, including the effect on earnings of any amounts they would have recorded in previous periods if the accounting had been completed at the acquisition date. The measurement period cannot exceed one year from the date of the acquisition. ASU 2015-16 was effective on January 1, 2016, and we adopted it at the same time as a change in accounting policy, which had no impact on our consolidated financial statements.

In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” ASU 2015-11 is effective prospectively for annual periods beginning after December 15, 2016, and interim periods therein. We adopted ASU 2015-11 on January 1, 2017 and do not expect it to have a material impact to our consolidated financial statements.

In April 2015, the FASB issued ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs." ASU 2015-03 was issued to simplify the presentation of debt issuance costs by requiring debt issuance costs to be presented as a deduction from the corresponding debt liability. This makes the presentation of debt issuance costs consistent with the presentation of debt discounts or premiums. Under prior U.S. GAAP, debt issuance costs were reported on the balance sheet as assets and amortized as interest expense. Under ASU 2015-03, debt issuance costs will continue to be amortized to interest expense using the effective interest method. In August 2015, the FASB issued ASU 2015-15, "Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements" to clarify the SEC staff’s position that it would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, which is our current practice. We adopted ASU 2015-03 on January 1, 2016 on a retrospective basis as a change in accounting policy. The Condensed Consolidated Balance Sheet as of December 31, 2015 was retrospectively adjusted by decreasing Other assets and Long-term debt, net of current maturities, by $1.8 million, respectively.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 to defer the effective date for annual reporting periods
beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted as of the original effective date in ASU 2014-09, which is annual reporting periods beginning after December 15, 2016, however, we will not early adopt. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectiblity, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method once we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. We have completed revenue recognition diagnostic surveys across all regions in our decentralized sales contracting process, which is based on local country commercial regulations and practices. We have begun assessing individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP, to determine the effect that these ASU’s will have on our consolidated financial statements and related disclosures.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.6.0.2
1. Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2016
Accounting Policies [Abstract]  
Schedule of Product Warranty Liability
Changes in the warranty accrual, included in Other current liabilities and Other long-term liabilities, were as follows (in millions):
 
 
2016
 
2015
January 1
 
$
17.4

 
$
17.8

Provision for warranty
 
33.4

 
30.6

Actual warranty costs
 
(33.2
)
 
(31.0
)
December 31
 
$
17.6

 
$
17.4
Schedule of Weighted Average Number of Shares
The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):
 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
Basic weighted average shares outstanding
 
29,440

 
29,186

 
28,876

Effect of potentially dilutive stock options
 
 
 
 
 
 
    and restricted stock awards
 
206

 
223

 
257

Diluted weighted average common shares
 
29,646

 
29,409

 
29,133

Anti-dilutive stock options and restricted stock awards
 
 
 
 
 
 
    excluded from the computation of diluted EPS
 
113

 
109

 
122
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.6.0.2
3. Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2016
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value based on original valuations and updated quarterly for the year ended December 31, 2016 (in millions):

 
2016
 
 
January 1
$
9.1

Cell sorting system:
 
Payment of sales milestone
(3.5
)
Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense
(2.5
)
 
 
Analytical flow cytometer platform:
 
Acquisition of high performance analytical flow cytometer platform
23.3

Increase in estimated fair value of contingent consideration included in Selling, general and administrative expense
2.1

December 31
$
28.5
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]
The following table provides quantitative information about Level 3 inputs for fair value measurement of analytical flow cytometer platform contingent consideration liability as of December 31, 2016. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.
 
 
 
Range
 
Valuation Technique
Unobservable Input
From
To
Analytical flow cytometer platform
Probability-weighted income approach
Sales milestones:
 
 
 
 
Discount rate
10
%
 
 
 
Cost of debt
4.7
%
 
Schedule of Derivative Instruments [Table Text Block] The following is a summary of our forward foreign currency exchange contracts (in millions):
 
December 31,
 
2016
Contracts maturing in January through March 2017 to sell foreign currency:
 
Notional value
$
16.9

Unrealized loss
$
0.1

Contracts maturing in January through March 2017 to purchase foreign currency:
 
Notional value
$
328.3

Unrealized loss
$
0.6
Financial assets and liabilities carried at fair value on a recurring basis Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2016 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents (a):
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
14.1

 
$
—

 
$
14.1

Foreign time deposits
11.8

 
—

 
—

 
11.8

Domestic time deposits
—

 
20.0

 
—

 
20.0

U.S. government sponsored agencies
—

 
1.1

 
—

 
1.1

Money market funds
5.9

 
—

 
—

 
5.9

Total cash equivalents
17.7

 
35.2

 
—

 
52.9

Restricted investment:
4.6

 
—

 
—

 
4.6

Available-for-sale investments (b):
 
 
 
 
 
 
 
Corporate debt securities
—

 
179.4

 
—

 
179.4

U.S. government sponsored agencies
—

 
82.5

 
—

 
82.5

Foreign government obligations
—

 
4.4

 
—

 
4.4

Brokered certificates of deposit
—

 
3.6

 
—

 
3.6

Municipal obligations
—

 
15.4

 
—

 
15.4

Marketable equity securities
767.8

 
—

 
—

 
767.8

Asset-backed securities
—

 
62.5

 
—

 
62.5

Total available-for-sale investments
767.8

 
347.8

 
—

 
1,115.6

Forward foreign exchange contracts (c)
—

 
0.6

 
—

 
0.6

Total financial assets carried at fair value
$
790.1

 
$
383.6

 
$
—

 
$
1,173.7

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
     Forward foreign exchange contracts (d)
$
—

 
$
1.3

 
$
—

 
$
1.3

     Contingent consideration (e)
—

 
—

 
38.5

 
38.5

Total financial liabilities carried at fair value
$
—

 
$
1.3

 
$
38.5

 
$
39.8



Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2015 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents (a):
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
33.2

 
—

 
$
33.2

Foreign government obligations
—

 
0.6

 
—

 
0.6

Foreign time deposits
11.9

 
—

 
—

 
11.9

U.S. government sponsored agencies
—

 
14.6

 
—

 
14.6

Money market funds
11.3

 
—

 
—

 
11.3

Total cash equivalents
23.2

 
48.4

 
—

 
71.6

Restricted investment:
4.2

 
—

 
—

 
4.2

Available-for-sale investments (b):
 
 
 
 
 
 
 
Corporate debt securities
—

 
156.9

 
—

 
156.9

U.S. government sponsored agencies
—

 
74.8

 
—

 
74.8

Foreign government obligations
—

 
4.6

 
—

 
4.6

Municipal obligations
—

 
6.4

 
—

 
6.4

Marketable equity securities
660.1

 
—

 
—

 
660.1

Asset-backed securities
—

 
54.8

 
—

 
54.8

Total available-for-sale investments
660.1

 
297.5

 
—

 
957.6

Forward foreign exchange contracts (c)
—

 
0.9

 
—

 
0.9

Total financial assets carried at fair value
$
687.5

 
$
346.8

 
—

 
$
1,034.3

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (d)
$
—

 
$
1.1

 
—

 
$
1.1

 Contingent consideration (e)
—

 
—

 
19.1

 
19.1

Total financial liabilities carried at fair value
$
—

 
$
1.1

 
$
19.1

 
$
20.2


(a)
Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.

(b)
Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31,
2016
 
December 31, 2015
 
 
 
 
Short-term investments
$
383.2

 
$
328.7

Other investments
732.4

 
628.9

Total
$
1,115.6

 
$
957.6



(c)
Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.

(d)
Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.

(e)
Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2016
 
December 31, 2015
 
 
 
 
Other current liabilities
$
14.5

 
$
13.5

Other long-term liabilities
24.0

 
5.6

   Total
$
38.5

 
$
19.1
Schedule of available-for-sale investments Available-for-sale investments consist of the following (in millions):

 
December 31, 2016
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
179.7

 
$
0.2

 
$
(0.5
)
 
$
179.4

Brokered certificates of deposit
3.6

 
—

 
—

 
3.6

Municipal obligations
15.5

 
—

 
(0.1
)
 
15.4

Asset-backed securities
62.2

 
0.1

 
(0.1
)
 
62.2

U.S. government sponsored agencies
83.1

 
0.1

 
(0.7
)
 
82.5

Foreign government obligations
4.4

 
—

 
—

 
4.4

Marketable equity securities
32.4

 
3.7

 
(0.4
)
 
35.7

 
380.9

 
4.1

 
(1.8
)
 
383.2

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
677.6

 
—

 
732.1

Asset-backed securities
0.3

 
—

 
—

 
0.3

 
54.8

 
677.6

 
—

 
732.4

Total
$
435.7

 
$
681.7

 
$
(1.8
)
 
$
1,115.6


 
December 31, 2015
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
157.2

 
$
0.1

 
$
(0.4
)
 
$
156.9

Municipal obligations
6.4

 
—

 
—

 
6.4

Asset-backed securities
54.8

 
—

 
(0.2
)
 
54.6

U.S. government sponsored agencies
74.9

 
0.1

 
(0.2
)
 
74.8

Foreign government obligations
4.6

 
—

 
—

 
4.6

Marketable equity securities
29.4

 
2.7

 
(0.7
)
 
31.4

 
327.3

 
2.9

 
(1.5
)
 
328.7

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
574.2

 
—

 
628.7

Asset-backed securities
0.3

 
—

 
(0.1
)
 
0.2

 
54.8

 
574.2

 
(0.1
)
 
628.9

Total
$
382.1

 
$
577.1

 
$
(1.6
)
 
$
957.6
Summary of investments with gross unrealized losses and the associated fair value The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):

 
December 31,
2016
 
December 31, 2015
 
 
 
 
Fair value of investments in a loss position 12 months or more
$
11.8

 
$
10.4

Fair value of investments in a loss position less than 12 months
$
160.5

 
$
204.0

Gross unrealized losses for investments in a loss position 12 months or more
$
0.3

 
$
0.4

Gross unrealized losses for investments in a loss position less than 12 months
$
1.5

 
$
1.2
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31, 2016 by contractual maturity date (in millions):

 
Amortized
Cost
 
Estimated Fair
Value
 
 
 
 
Mature in less than one year
$
156.1

 
$
156.1

Mature in one to five years
141.0

 
140.7

Mature in more than five years
51.7

 
51.0

Total
$
348.8

 
$
347.8
Estimated fair value of financial instruments The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):


 
December 31, 2016
 
December 31, 2015
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
Other investments
$
92.8

 
$
984.2

 
2
 
$
86.5

 
$
843.2

 
2
Total long-term debt, excluding leases
and current maturities
$
422.5

 
$
454.2

 
2
 
$
421.9

 
$
454.3

 
2
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.6.0.2
4. Intangible Assets, Goodwill and Other (Tables)
 12 Months Ended
Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes to goodwill by segment
Changes to goodwill by segment were as follows (in millions):
 
 
2016
 
 
2015
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
$
207.2

 
$
316.9

 
$
524.1

 
 
$
207.7

 
$
320.9

 
$
528.6

Accumulated impairment losses and write-offs
 
(27.2
)
 
(1.0
)
 
(28.2
)
 
 
(27.2
)
 
(1.0
)
 
(28.2
)
Goodwill, net
 
180.0

 
315.9

 
495.9

 
 
180.5

 
319.9

 
500.4

Acquisitions
 
0.1

 
—

 
0.1

 
 
—

 
—

 
—

Impairment
 
—

 
(13.5
)
 
(13.5
)
 
 
—

 
—

 
—

Currency fluctuations
 
(0.2
)
 
(5.2
)
 
(5.4
)
 
 
(0.5
)
 
(4.0
)
 
(4.5
)
Balances as of December 31:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
207.1

 
311.7

 
518.8

 
 
207.2

 
316.9

 
524.1

Accumulated impairment losses and write-offs
 
(27.2
)
 
(14.5
)
 
(41.7
)
 
 
(27.2
)
 
(1.0
)
 
(28.2
)
Goodwill, net
 
$
179.9

 
$
297.2

 
$
477.1

 
 
$
180.0

 
$
315.9

 
$
495.9
Schedule of Finite-Lived Intangible Assets by Major-Class Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):
 
December 31, 2016
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-8
 
$
84.4

 
$
(52.8
)
 
$
31.6

Know how
1-9
 
182.6

 
(136.9
)
 
45.7

Developed product technology
3-12
 
125.9

 
(56.3
)
 
69.6

Licenses
1-9
 
39.0

 
(30.6
)
 
8.4

Tradenames
4-8
 
3.5

 
(2.5
)
 
1.0

Covenants not to compete
2-9
 
7.8

 
(2.5
)
 
5.3

     Total definite-lived intangible assets
 
 
443.2

 
(281.6
)
 
161.6

In-process research and development
 
 
—

 
—

 
—

     Total purchased intangible assets
 
 
$
443.2

 
$
(281.6
)
 
$
161.6


 
December 31, 2015
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
2-10
 
$
84.7

 
$
(46.8
)
 
$
37.9

Know how
1-10
 
184.0

 
(121.6
)
 
62.4

Developed product technology
4-12
 
101.3

 
(48.9
)
 
52.4

Licenses
3-10
 
39.2

 
(28.5
)
 
10.7

Tradenames
5-9
 
3.5

 
(2.4
)
 
1.1

Covenants not to compete
3-7
 
4.8

 
(1.7
)
 
3.1

     Total definite-lived intangible assets
 
 
417.5

 
(249.9
)
 
167.6

In-process research and development
 
 
46.4

 
—

 
46.4

     Total purchased intangible assets
 
 
$
463.9

 
$
(249.9
)
 
$
214.0
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.6.0.2
5. Notes Payable and Long-Term Debt (Tables)
 12 Months Ended
Dec. 31, 2016
Debt Disclosure [Abstract]  
Principal components of long-term debt [Table Text Block] The principal components of long-term debt are as follows (in millions):
 
December 31,
2016
 
December 31, 2015
 
 
 
 
4.875% Senior Notes due 2020, net of discount
$
425.0

 
$
425.0

Less unamortized discount and debt issuance costs
(2.5
)
 
(3.1
)
Long-term debt less unamortized discount and debt issuance costs
422.5

 
421.9

Capital leases and other debt
12.0

 
12.3

 
434.5

 
434.2

Less current maturities
(0.3
)
 
(0.3
)
Long-term debt
$
434.2

 
$
433.9
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.6.0.2
6. Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2016
Income Tax Disclosure [Abstract]  
U.S. and international components of income before taxes [Table Text Block] The U.S. and international components of income before taxes are as follows (in millions):

 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
U.S.
 
$
(38.5
)
 
$
48.4

 
$
30.6

International
 
80.1

 
97.4

 
101.0

Income before taxes
 
$
41.6

 
$
145.8

 
$
131.6
Provision for income taxes [Table Text Block] The provision for income taxes consists of the following (in millions):

 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
Current tax expense:
 
 

 
 

 
 

U.S. Federal
 
$
16.1

 
$
8.7

 
$
9.6

State
 
3.1

 
1.7

 
3.8

International
 
30.3

 
34.1

 
35.6

Current tax expense
 
49.5

 
44.5

 
49.0

Deferred tax (benefit) expense:
 
 

 
 
 
 

U.S. Federal
 
(42.4
)
 
(0.2
)
 
1.5

State
 
(2.8
)
 
1.2

 
(0.2
)
International
 
(6.0
)
 
(7.1
)
 
(7.3
)
Deferred tax benefit
 
(51.2
)
 
(6.1
)
 
(6.0
)
Non-current tax expense (benefit)
 
15.1

 
(5.6
)
 
(0.3
)
Provision for income taxes
 
$
13.4

 
$
32.8

 
$
42.7
Reconcilation of effective tax rate on inocme before taxes and statutory rate [Table Text Block] The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:

 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
U.S. statutory tax rate
 
35
 %
 
35
 %
 
35
 %
Impact of foreign operations
 
(15
)
 
(4
)
 
(4
)
Foreign dividends, net
 
(40
)
 
(4
)
 
—

Research tax credits
 
(9
)
 
(2
)
 
(3
)
Nontaxable subsidies
 
(4
)
 
(1
)
 
(2
)
Tax settlements and changes to unrecognized tax benefits
 
42

 
(4
)
 
(1
)
Goodwill impairment
 
11

 
—

 
—

Domestic manufacturing deduction
 
(4
)
 
(2
)
 
—

Stock-based compensation
 
3

 
1

 
1

Nondeductible executive compensation
 
3

 
1

 
1

Fines and penalties
 
2

 
—

 
3

Prior period adjustments
 
4

 
1

 
2

U.S. taxation on foreign income
 
2

 
—

 
—

Other
 
2

 
1

 
—

Provision for income taxes
 
32
 %
 
22
 %
 
32
 %
Significant components of deferred tax assets and liabilities [Table Text Block] Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):

 
 
December 31,
 
 
2016
 
2015
Deferred tax assets:
 
 

 
 

Bad debt, inventory and warranty accruals
 
$
28.4

 
$
26.3

Other post-employment benefits, vacation and other reserves
 
26.3

 
28.1

Tax credit and net operating loss carryforwards
 
96.4

 
80.2

Other
 
35.7

 
23.2

    Total gross deferred tax assets
 
186.8

 
157.8

Valuation allowance
 
(66.4
)
 
(58.3
)
       Total deferred tax assets
 
120.4

 
99.5

Deferred tax liabilities:
 
 
 
 
Property and equipment
 
22.5

 
30.2

Investments and intangible assets
 
287.8

 
271.8

        Total deferred tax liabilities
 
310.3

 
302.0

Net deferred tax liabilities
 
$
(189.9
)
 
$
(202.5
)
Tabular reconcilation of total amounts of unrecognized tax benefits [Table Text Block]
The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):
 
 
2016
 
2015
 
2014
Unrecognized tax benefits – January 1
 
$
8.9

 
$
14.2

 
$
16.2

Additions to tax positions related to prior years
 
10.4

 
0.7

 
1.7

Reductions to tax positions related to prior years
 
—

 
(0.2
)
 
(1.5
)
Additions to tax positions related to the current year
 
1.4

 
1.5

 
1.6

Settlements
 
(2.4
)
 
(0.5
)
 
(0.4
)
Lapse of statute of limitations
 
(2.3
)
 
(6.3
)
 
(2.6
)
Currency translation
 
0.1

 
(0.5
)
 
(0.8
)
Unrecognized tax benefits – December 31
 
$
16.1

 
$
8.9

 
$
14.2
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.6.0.2
7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables)
 12 Months Ended
Dec. 31, 2016
Class of Stock [Line Items]  
Schedule of Stock by Class [Table Text Block] Changes to Bio-Rad's issued common stock shares are as follows (in thousands):
 
Class A Shares
 
Class B Shares
Balance at January 1, 2014
23,681

 
5,097

B to A conversions
5

 
(5
)
Issuance of common stock
286

 
7

Balance at December 31, 2014
23,972

 
5,099

B to A conversions
18

 
(18
)
Issuance of common stock
240

 
50

Balance at December 31, 2015
24,230

 
5,131

B to A conversions
13

 
(13
)
Issuance of common stock
211

 
6

Balance at December 31, 2016
24,454

 
5,124
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.6.0.2
8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)
 12 Months Ended
Dec. 31, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Accumulated other comprehensive income included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):
 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains on available-for-sale investments
Total Accumulated other comprehensive income
Balances as of January 1, 2015
$
71.2

$
(16.3
)
$
164.0

$
218.9

Other comprehensive (loss) income, before reclassifications
(37.5
)
(6.8
)
325.4

281.1

Amounts reclassified from Accumulated other comprehensive income
—

1.1

(0.9
)
0.2

Income tax effects
—

1.3

(119.4
)
(118.1
)
Other comprehensive (loss) income, net of income taxes
(37.5
)
(4.4
)
205.1

163.2

Balances as of December 31, 2015
$
33.7

$
(20.7
)
$
369.1

$
382.1

Other comprehensive (loss) income, before reclassifications
(32.4
)
0.5

105.1

73.2

Amounts reclassified from Accumulated other comprehensive income
—

2.5

(0.8
)
1.7

Income tax effects
—

(0.9
)
(38.4
)
(39.3
)
Other comprehensive (loss) income, net of income taxes
(32.4
)
2.1

65.9

35.6

Balances as of December 31, 2016
$
1.3

$
(18.6
)
$
435.0

$
417.7
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.6.0.2
8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)
 12 Months Ended
Dec. 31, 2016
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]  
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:
Income before taxes impact (in millions):
 
 
December 31,
 
 
Components of Comprehensive income
 
2016
2015
 
Location
 
Amortization of foreign other post-employment benefit items
 
$
(2.5
)
$
(1.1
)
 
Selling, general and administrative expense
 
Net holding gains on available for sale investments
 
$
0.8

$
0.9

 
Other (income) expense, net
 

Reclassification adjustments are calculated using the specific identification method.
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.6.0.2
9. Share-based Compensation (Tables)
 12 Months Ended
Dec. 31, 2016
Share-based Compensation [Abstract]  
Stock Options Activity
Stock Options
The following table summarizes stock option activity:

 
 
Shares
 
Weighted-
Average
Exercise Price
 
Weighted-
Average
Remaining
Contractual
Term (in years)
 
Aggregate
Intrinsic
Value
(in millions)
Outstanding, January 1, 2014
 
629,643

 
$
78.72

 
 
 
 
Granted
 
54,000

 
$
119.71

 
 
 
 
Exercised
 
(91,387
)
 
$
63.66

 
 
 
 
Forfeited/expired
 
(10,450
)
 
$
100.29

 
 
 
 
Outstanding, December 31, 2014
 
581,806

 
$
84.50

 
 
 
 
Granted
 
40,500

 
$
139.56

 
 
 
 
Exercised
 
(195,221
)
 
$
61.29

 
 
 
 
Forfeited/expired
 
(380
)
 
$
62.47

 
 
 
 
Outstanding, December 31, 2015
 
426,705

 
$
100.36

 
 
 
 
Granted
 
45,000

 
$
159.37

 
 
 
 
Exercised
 
(15,285
)
 
$
80.70

 
 
 
 
Forfeited/expired
 
(6,850
)
 
$
127.65

 
 
 
 
Outstanding, December 31, 2016
 
449,570

 
$
106.52

 
5.15
 
$
34.1

Vested and expected to vest,
 
 
 
 
 
 
 
 
December 31, 2016
 
437,350

 
$
105.39

 
5.04
 
$
33.6

Exercisable, December 31, 2016
 
314,330

 
$
93.78

 
3.80
 
$
27.8
Stock Options Valuation Assumptions
The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
Expected volatility
 
21
%
 
23
%
 
25
%
Risk-free interest rate
 
1.35
%
 
1.90
%
 
2.35
%
Expected life (in years)
 
7.4

 
7.7

 
8.7

Expected dividend
 
—

 
—

 
—

Weighted-average fair value of options granted
 
$
42.40

 
$
42.74

 
$
43.96
Resticted Stock Activity
The following table summarizes restricted stock unit activity:
 
 

Restricted Stock
Units
 
Weighted-
Average
Grant-Date
Fair Value
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic Value
(in millions)
Outstanding, January 1, 2014
 
375,430

 
$
105.44

 
 
 
 
Granted
 
145,695

 
$
119.56

 
 
 
 
Vested
 
(107,557
)
 
$
98.52

 
 
 
 
Forfeited
 
(36,203
)
 
$
108.17

 
 
 
 
Outstanding, December 31, 2014
 
377,365

 
$
112.60

 
 
 
 
Granted
 
177,110

 
$
139.56

 
 
 
 
Vested
 
(113,347
)
 
$
107.62

 
 
 
 
Forfeited
 
(28,706
)

$
116.19

 
 
 
 
Outstanding, December 31, 2015
 
412,422

 
$
125.30

 
 
 
 
Granted
 
193,025

 
$
159.32

 
 
 
 
Vested
 
(117,203
)
 
$
119.33

 
 
 
 
Forfeited
 
(39,422
)

$
129.80

 
 
 
 
Outstanding, December 31, 2016
 
448,822

 
$
141.09

 
2.16
 
$
81.8
Employee Stock Purchase Plan, Valuation Assumptions The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:

 
Year Ended December 31,
 
2016
 
 
 
2015
 
 
 
2014
Expected volatility
20
%
 
 
 
18
%
 
 
 
15
%
Risk-free interest rate
0.26
%
 
 
 
0.02
%
 
 
 
0.04
%
Expected life (in years)
0.25

 
 
 
0.25

 
 
 
0.25

Expected dividend
—

 
 
 
—

 
 
 
—

Weighted-average fair value
 
 
 
 
 
 
 
 
 
of purchase rights
$
27.36

 
 
 
$
25.08

 
 
 
$
21.88
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.6.0.2
10. Other Income and Expenses (Tables)
 12 Months Ended
Dec. 31, 2016
Other Income and Expenses [Abstract]  
Schedule of other income (expense), net Other (income) expense, net includes the following components (in millions):
 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
 
 
 
 
 
 
 
Interest and investment income
 
$
(14.7
)
 
$
(10.1
)
 
$
(13.5
)
Net realized gains on investments
 
(0.8
)
 
(1.6
)
 
—

Other-than-temporary impairment losses on investments
 
0.6

 
0.6

 
0.4

Miscellaneous other (income) expense items, net
 
—

 
—

 
0.1

Other (income) expense, net
 
$
(14.9
)
 
$
(11.1
)
 
$
(13.0
)
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.6.0.2
11. Supplemental Cash Flow Information (Tables)
 12 Months Ended
Dec. 31, 2016
Supplemental Cash Flow Information [Abstract]  
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] 11. SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net income to net cash provided by operating activities is as follows (in millions):

 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
Net income
 
$
28.1

 
$
113.1

 
$
88.8

Adjustments to reconcile net income
 
 

 
 

 
 

to net cash provided by operating activities
 
 

 
 

 
 

Depreciation and amortization
 
142.9

 
131.8

 
149.9

Share-based compensation
 
19.7

 
17.0

 
14.9

(Gains) losses on dispositions of securities
 
(0.2
)
 
(1.0
)
 
0.3

Losses on dispositions of fixed assets
 
0.6

 
0.3

 
0.4

Excess tax benefits from share-based compensation
 
(1.5
)
 
(3.6
)
 
(1.3
)
Changes in fair value of contingent consideration
 
(0.4
)
 
(5.6
)
 
(1.4
)
Decrease (increase) in accounts receivable, net
 
12.5

 
(39.0
)
 
11.1

(Increase) decrease in inventories, net
 
(57.1
)
 
(54.2
)
 
5.8

(Increase) decrease in other current assets
 
(6.6
)
 
0.1

 
(5.7
)
Increase (decrease) in accounts payable
 


 


 


and other current liabilities
 
30.1

 
28.6

 
(9.9
)
Increase in income taxes payable
 
10.7

 
12.7

 
20.4

Decrease in deferred income taxes
 
(51.4
)
 
(6.4
)
 
(6.3
)
Decrease in other long term assets
 
12.7

 
0.3

 
3.6

Increase (decrease) in other long term liabilities
 
8.3

 
(12.2
)
 
(1.3
)
Impairment losses on goodwill and long-lived assets
 
62.3

 
—

 
—

Other
 
5.7

 
4.3

 
4.0

Net cash provided by operating activities
 
$
216.4

 
$
186.2

 
$
273.3

 
 
 
 
 
 
 
Non-cash investing activities:
 
 
 
 
 
 
   Purchased intangible assets
 
$
—

 
$
—

 
$
0.2

   Purchased marketable securities and investments
 
$
0.6

 
$
2.2

 
$
—
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.6.0.2
14. Segment Reporting (Tables)
 12 Months Ended
Dec. 31, 2016
Segment Reporting [Abstract]  
Information regarding industry segments
Information regarding industry segments at December 31, 2016, 2015, and 2014 and for the years then ended is as follows (in millions):

 
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
Segment net sales 
2016
 
$
730.7

 
$
1,323.3

 
$
14.2

 
2015
 
695.0

 
1,310.4

 
14.0

 
2014
 
728.3

 
1,432.3

 
14.4

 
 
 
 
 
 
 
 
Allocated interest expense
2016
 
$
6.4

 
$
15.5

 
$
—

 
2015
 
6.1

 
15.4

 
0.1

 
2014
 
5.5

 
15.9

 
0.1

 
 
 
 
 
 
 
 
Depreciation and amortization
2016
 
$
31.7

 
$
80.5

 
$
—

 
2015
 
30.7

 
77.8

 
0.1

 
2014
 
33.2

 
95.8

 
—

 
 
 
 
 
 
 
 
Segment (loss) profit
2016
 
$
(19.2
)
 
$
57.0

 
$
0.9

 
2015
 
(0.7
)
 
152.4

 
0.7

 
2014
 
(14.7
)
 
167.1

 
1.2

 
 
 
 
 
 
 
 
Segment assets
2016
 
$
381.4

 
$
918.0

 
$
4.9

 
2015
 
390.5

 
878.3

 
4.4

 
 
 
 
 
 
 
 
Capital expenditures
2016
 
$
14.3

 
$
67.1

 
$
—

 
2015
 
8.2

 
51.3

 
0.1
Reconciliation of segment profit to consolidated income before taxes he following reconciles total segment profit to consolidated income before taxes (in millions):
 
 
 
Year Ended December 31,
 
2016
 
2015
 
2014
Total segment profit
$
38.7

 
$
152.4

 
$
153.6

Foreign exchange losses
(4.5
)
 
(10.2
)
 
(9.3
)
Net corporate operating, interest and other expense, net not allocated to segments
(7.5
)
 
(7.5
)
 
(25.7
)
Other income (expense), net
14.9

 
11.1

 
13.0

Consolidated income before taxes
$
41.6

 
$
145.8

 
$
131.6
Reconciliation of Assets from Segment to Consolidated The following reconciles total segment assets to consolidated total assets (in millions):

 
 
December 31,
 
 
2016
 
2015
Total segment assets
 
$
1,304.3

 
$
1,273.2

Cash and other current assets
 
980.3

 
926.9

Property, plant and equipment, net, excluding
 

 

  segment specific gross machinery and equipment
 
81.6

 
46.1

Goodwill, net
 
477.1

 
495.9

Other long-term assets
 
1,007.2

 
967.6

Total assets
 
$
3,850.5

 
$
3,709.7
Net sales and assets to external customers by geographic area The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):

 
 
Year Ended December 31,
 
 
2016
 
2015
 
2014
Europe
 
$
742.2

 
$
763.7

 
$
901.7

Pacific Rim
 
427.1

 
392.2

 
417.5

United States
 
770.6

 
735.0

 
704.9

Other (primarily Canada and Latin America)
 
128.3

 
128.5

 
150.9

Total net sales
 
$
2,068.2

 
$
2,019.4

 
$
2,175.0


The following presents Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):

 
 
December 31,
 
 
2016
 
2015
Europe
 
$
221.1

 
$
204.4

Pacific Rim
 
16.1

 
15.1

United States  
 
1,084.7

 
962.6

Other (primarily Canada and Latin America)
 
12.3

 
9.1

Total Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes
 
$
1,334.2

 
$
1,191.2
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.6.0.2
15. Restructuring Costs (Tables)
 12 Months Ended
Dec. 31, 2016
Restructuring Costs [Abstract]  
Restructuring and Related Costs [Table Text Block] The following table summarizes the activity of our restructuring reserves for severance (in millions):

 
 
Life Science
 
Clinical Diagnostics
 
Total
Balance at December 31, 2015
 
$
—

 
$
—

 
$
—

Charged to expense
 
4.1

 
7.6

 
11.7

Adjustment to expense
 
0.3

 
0.5

 
0.8

Cash payments
 
(1.0
)
 
(2.0
)
 
(3.0
)
Foreign currency translation gains
 
(0.2
)
 
(0.3
)
 
(0.5
)
Balance at December 31, 2016
 
$
3.2

 
$
5.8

 
$
9.0
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.6.0.2
16. Quarterly Financial Data (Tables)
 12 Months Ended
Dec. 31, 2016
Quarterly Financial Data [Abstract]  
Schedule of Quarterly Financial Data [Table Text Block]
 
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2016
 
 
 
 
 
 
 
 
Net sales
 
$
471.2

 
$
516.8

 
$
508.7

 
$
571.5

Gross profit
 
264.0

 
280.2

 
279.5

 
314.4

Net income (loss)
 
12.3

 
18.0

 
18.4

 
(20.6
)
Basic earnings (loss) per share
 
$
0.42

 
$
0.61

 
$
0.63

 
$
(0.70
)
Diluted earnings (loss) per share
 
$
0.42

 
$
0.61

 
$
0.62

 
$
(0.70
)
 
 
 
 
 
 
 
 
 
2015
 
 
 
 
 
 
 
 
Net sales
 
$
472.8

 
$
506.1

 
$
470.0

 
$
570.6

Gross profit
 
270.1

 
279.6

 
263.5

 
308.5

Net income
 
17.8

 
28.4

 
17.4

 
49.5

Basic earnings per share
 
$
0.61

 
$
0.98

 
$
0.59

 
$
1.69

Diluted earnings per share
 
$
0.61

 
$
0.97

 
$
0.59

 
$
1.68
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.6.0.2
1. Significant Accounting Policies Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Property, Plant and Equipment [Line Items]    
Other assets $ 47,852 $ 64,618
Long-term Debt and Capital Lease Obligations $ 434,186 433,883
Minimum [Member] | Software [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 3 years  
Minimum [Member] | Building and Building Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 15 years  
Minimum [Member] | Reagent Rental Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 1 year  
Minimum [Member] | Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 3 years  
Maximum [Member] | Software [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 12 years  
Maximum [Member] | Building and Building Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 30 years  
Maximum [Member] | Reagent Rental Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 5 years  
Maximum [Member] | Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 12 years  
Adjustments for New Accounting Pronouncement [Member]    
Property, Plant and Equipment [Line Items]    
Other assets   1,800
Long-term Debt and Capital Lease Obligations   $ 1,800
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.6.0.2
1. Significant Accounting Policies Warranty rollforward (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Movement in Standard Product Warranty Accrual [Roll Forward]    
Warranty accrual, beginning of period $ 17.4 $ 17.8
Provision for warranty 33.4 30.6
Actual warranty costs (33.2) (31.0)
Warranty accrual, end of period $ 17.6 $ 17.4
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.6.0.2
1. Significant Accounting Policies Earnings per share (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Accounting Policies [Abstract]      
Basic weighted average shares outstanding 29,440 29,186 28,876
Effect of potentially dilutive stock options and restricted stock awards 206 223 257
Diluted weighted average common shares 29,646 29,409 29,133
Anti-dilutive shares excluded from the computation of diluted EPS 113 109 122
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.6.0.2
1. Significant Accounting Policies Details (Details) - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Other assets $ 47,852 $ 64,618
Restricted investments 4,560 4,210
Adjustments for New Accounting Pronouncement [Member]    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Other assets   1,800
Restricted investments $ 2,000 $ 1,400
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.6.0.2
2. Acquisitions (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2016
Dec. 31, 2016
Dec. 31, 2015
Jan. 06, 2016
Dec. 31, 2014
Business Acquisition [Line Items]          
Goodwill   $ 477,115 $ 495,948   $ 500,400
Goodwill, Acquired During Period   100 $ 0    
Analytical Flow Cytometer Platform [Member]          
Business Acquisition [Line Items]          
Business Combination, Consideration Transferred $ 32,800        
Payments to Acquire Businesses, Net of Cash Acquired 9,500        
Business Combination, Contingent Consideration, Liability   $ 25,400   $ 23,300  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles       $ 32,700  
Goodwill, Acquired During Period $ 100        
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.6.0.2
3. Fair Value Measurements (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)
$ in Millions
Dec. 31, 2016
Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value $ 4.6 $ 4.2
Available-for-sale investments [1] 1,115.6 957.6
Forward foreign exchange contracts, Asset [2] 0.6 0.9
Financial Assets Carried at Fair Value 1,173.7 1,034.3
Forward foreign exchange contracts, Liability [3] 1.3 1.1
Business Combination, Contingent Consideration, Liability [4] 38.5 19.1
Liabilities, Fair Value Disclosure 39.8 20.2
Interest-bearing Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 3.6  
Corporate Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 179.4 156.9
US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 82.5 74.8
Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 4.4 4.6
Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 15.4 6.4
Marketable Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 767.8 660.1
Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 62.5 54.8
Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   0.6
Foreign Time Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 11.8 11.9
US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 1.1 [5] 14.6
Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 5.9 11.3
Commercial Paper [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 14.1 33.2
Cash Equivalents [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 52.9 71.6
Domestic Time Deposit [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 20.0  
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value 4.6 4.2
Available-for-sale investments [1] 767.8 660.1
Forward foreign exchange contracts, Asset [2] 0.0 0.0
Financial Assets Carried at Fair Value 790.1 687.5
Forward foreign exchange contracts, Liability [3] 0.0 0.0
Business Combination, Contingent Consideration, Liability [4] 0.0 0.0
Liabilities, Fair Value Disclosure 0.0 0.0
Fair Value, Inputs, Level 1 [Member] | Interest-bearing Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 0.0  
Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 1 [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 1 [Member] | Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 1 [Member] | Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 1 [Member] | Marketable Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 767.8 660.1
Fair Value, Inputs, Level 1 [Member] | Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 1 [Member] | Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   0.0
Fair Value, Inputs, Level 1 [Member] | Foreign Time Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 11.8 11.9
Fair Value, Inputs, Level 1 [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0.0 [5] 0.0
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 5.9 11.3
Fair Value, Inputs, Level 1 [Member] | Commercial Paper [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Inputs, Level 1 [Member] | Cash Equivalents [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 17.7 23.2
Fair Value, Inputs, Level 1 [Member] | Domestic Time Deposit [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0.0  
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value 0.0 0.0
Available-for-sale investments [1] 347.8 297.5
Forward foreign exchange contracts, Asset [2] 0.6 0.9
Financial Assets Carried at Fair Value 383.6 346.8
Forward foreign exchange contracts, Liability [3] 1.3 1.1
Business Combination, Contingent Consideration, Liability [4] 0.0 0.0
Liabilities, Fair Value Disclosure 1.3 1.1
Fair Value, Inputs, Level 2 [Member] | Interest-bearing Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 3.6  
Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 179.4 156.9
Fair Value, Inputs, Level 2 [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 82.5 74.8
Fair Value, Inputs, Level 2 [Member] | Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 4.4 4.6
Fair Value, Inputs, Level 2 [Member] | Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 15.4 6.4
Fair Value, Inputs, Level 2 [Member] | Marketable Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 2 [Member] | Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 62.5 54.8
Fair Value, Inputs, Level 2 [Member] | Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   0.6
Fair Value, Inputs, Level 2 [Member] | Foreign Time Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Inputs, Level 2 [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 1.1 [5] 14.6
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 14.1 33.2
Fair Value, Inputs, Level 2 [Member] | Cash Equivalents [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 35.2 48.4
Fair Value, Inputs, Level 2 [Member] | Domestic Time Deposit [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 20.0  
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value 0.0 0.0
Available-for-sale investments [1] 0.0 0.0
Forward foreign exchange contracts, Asset [2] 0.0 0.0
Financial Assets Carried at Fair Value 0.0 0.0
Forward foreign exchange contracts, Liability [3] 0.0 0.0
Business Combination, Contingent Consideration, Liability [4] 38.5 19.1
Liabilities, Fair Value Disclosure 38.5 19.1
Fair Value, Inputs, Level 3 [Member] | Interest-bearing Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 0.0  
Fair Value, Inputs, Level 3 [Member] | Corporate Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | Marketable Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   0.0
Fair Value, Inputs, Level 3 [Member] | Foreign Time Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0.0 [5] 0.0
Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | Commercial Paper [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | Cash Equivalents [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | Domestic Time Deposit [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0.0  
Other Current Liabilities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability 14.5 13.5
Short-term Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 383.2 328.7
Short-term Investments [Member] | Interest-bearing Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 3.6  
Short-term Investments [Member] | Corporate Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 179.4 156.9
Short-term Investments [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 82.5 74.8
Short-term Investments [Member] | Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 4.4 4.6
Short-term Investments [Member] | Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 15.4 6.4
Short-term Investments [Member] | Marketable Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 35.7 31.4
Short-term Investments [Member] | Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 62.2 54.6
Other Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 732.4 628.9
Other Noncurrent Liabilities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability $ 24.0 $ 5.6
[1]
Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31,
2016
 
December 31, 2015
 
 
 
 
Short-term investments
$
383.2

 
$
328.7

Other investments
732.4

 
628.9

Total
$
1,115.6

 
$
957.6
[2] Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.
[3] Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.
[4] Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2016
 
December 31, 2015
 
 
 
 
Other current liabilities
$
14.5

 
$
13.5

Other long-term liabilities
24.0

 
5.6

   Total
$
38.5

 
$
19.1
[5] Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.6.0.2
3. Fair Value Measurements Foreign Exchange Forward Contracts (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2016
USD ($)
Forward foreign exchange contract to purchase foreign currency [Member]  
Derivatives, Fair Value [Line Items]  
Derivative, Notional Amount $ 328.3
Loss on foreign currency derivative instruments not designated as hedging instruments 0.6
Forward foreign exchange contract to sell foreign currency [Member]  
Derivatives, Fair Value [Line Items]  
Derivative, Notional Amount 16.9
Loss on foreign currency derivative instruments not designated as hedging instruments $ 0.1
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.6.0.2
3. Fair Value Measurements Short-term Investments (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)
$ in Millions
Dec. 31, 2016
Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost $ 435.7 $ 382.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 681.7 577.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (1.8) (1.6)
Estimated Fair Value [1] 1,115.6 957.6
Corporate Debt Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 179.4 156.9
Interest-bearing Deposits [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value 3.6  
Municipal Obligations [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 15.4 6.4
Asset-backed Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 62.5 54.8
Marketable Equity Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 767.8 660.1
US Government Sponsored Agencies [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 82.5 74.8
Foreign Government Obligations [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 4.4 4.6
Short-term Investments [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value 383.2 328.7
Short-term Investments [Member] | Corporate Debt Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 179.7 157.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.2 0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (0.5) (0.4)
Estimated Fair Value 179.4 156.9
Short-term Investments [Member] | Interest-bearing Deposits [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 3.6  
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0  
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0  
Estimated Fair Value 3.6  
Short-term Investments [Member] | Municipal Obligations [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 15.5 6.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (0.1) 0.0
Estimated Fair Value 15.4 6.4
Short-term Investments [Member] | Asset-backed Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 62.2 54.8
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.1 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (0.1) (0.2)
Estimated Fair Value 62.2 54.6
Short-term Investments [Member] | Marketable Equity Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 32.4 29.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 3.7 2.7
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (0.4) (0.7)
Estimated Fair Value 35.7 31.4
Short-term Investments [Member] | Available-for-sale Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 380.9 327.3
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 4.1 2.9
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (1.8) (1.5)
Estimated Fair Value 383.2 328.7
Short-term Investments [Member] | US Government Sponsored Agencies [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 83.1 74.9
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.1 0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (0.7) (0.2)
Estimated Fair Value 82.5 74.8
Short-term Investments [Member] | Foreign Government Obligations [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 4.4 4.6
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Estimated Fair Value 4.4 4.6
Other Long-term Investments [Member] | Asset-backed Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 0.3 0.3
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 (0.1)
Estimated Fair Value 0.3 0.2
Other Long-term Investments [Member] | Marketable Equity Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 54.5 54.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 677.6 574.2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Estimated Fair Value 732.1 628.7
Other Long-term Investments [Member] | Available-for-sale Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 54.8 54.8
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 677.6 574.2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 (0.1)
Estimated Fair Value $ 732.4 $ 628.9
[1]
Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31,
2016
 
December 31, 2015
 
 
 
 
Short-term investments
$
383.2

 
$
328.7

Other investments
732.4

 
628.9

Total
$
1,115.6

 
$
957.6
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.6.0.2
3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details)
$ in Millions
Dec. 31, 2016
USD ($)
Fair Value Disclosures [Abstract]  
Mature in less than one year $ 156.1
Mature in one to five years 141.0
Mature in more than five years 51.7
Total Amortized Cost 348.8
Mature in less than one year 156.1
Mature in one to five years 140.7
Mature in more than five years 51.0
Estimated Fair Value $ 347.8
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.6.0.2
3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Price Change Debt Security 5.00%  
Tolerable variance Level 2 debt security pricing 1.00%  
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $ 11.8 $ 10.4
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value 160.5 204.0
Gross unrealized losses for investments in a loss position 12 months or more 0.3 0.4
Gross unrealized losses for investments in a loss position less than 12 months $ 1.5 $ 1.2
Cost Method Investment, Percentage Owned 35.00%  
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.6.0.2
3. Fair Value Investments (Details) - USD ($)
$ in Millions
Dec. 31, 2016
Dec. 31, 2015
Carrying (Reported) Amount, Fair Value Disclosure [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Other Investments $ 92.8 $ 86.5
Total long-term debt, excluding leases and current maturities 422.5 421.9
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Other Investments 984.2 843.2
Total long-term debt, excluding leases and current maturities $ 454.2 $ 454.3
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.6.0.2
3. Fair Value Measurements Contingent Consideration (Details) - USD ($)
$ in Millions
 12 Months Ended 51 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2016
Jan. 06, 2016
Apr. 10, 2014
Sep. 30, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value $ 28.5     $ 28.5      
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability (0.4) $ (5.6) $ (1.4)        
Fair Value, Measurements, Recurring [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Business Combination, Contingent Consideration, Liability [1] 38.5 19.1   38.5      
CellSorter [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value   9.1          
Business Combination, Contingent Consideration, Liability 3.1     3.1     $ 44.6
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3.5     28.9      
Net (decrease) increase in estimated fair value of contingent consideration included in selling, general and administrative expense (2.5)     (12.6)      
Analytical Flow Cytometer Platform [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Business Combination, Contingent Consideration, Liability 25.4     25.4 $ 23.3    
Net (decrease) increase in estimated fair value of contingent consideration included in selling, general and administrative expense 2.1            
GnuBIO [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Business Combination, Contingent Consideration, Liability $ 10.0 $ 10.0   $ 10.0   $ 10.7  
Discount rate [Member] | Analytical Flow Cytometer Platform [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Fair Value Inputs, Discount Rate 10.00%            
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Business Acquisition, Contingent Consideration, Potential Percentage Payout 39.00%     39.00%      
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Business Acquisition, Contingent Consideration, Potential Percentage Payout 20.00%     20.00%      
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low $ 0.0     $ 0.0      
Cost of debt [Member] | Analytical Flow Cytometer Platform [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Fair Value Inputs, Discount Rate 4.70%            
[1] Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2016
 
December 31, 2015
 
 
 
 
Other current liabilities
$
14.5

 
$
13.5

Other long-term liabilities
24.0

 
5.6

   Total
$
38.5

 
$
19.1
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.6.0.2
4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2016
Dec. 31, 2016
Dec. 31, 2015
Goodwill [Roll Forward]      
Goodwill period start $ 524,100 $ 524,100 $ 528,600
Accumulated impairment loss period start (28,200) (28,200) (28,200)
Goodwill, net period start 495,948 495,948 500,400
Goodwill, Acquired During Period   100 0
Goodwill, Impairment Loss   13,500 0
Currency fluctuations   (5,400) (4,500)
Goodwill period end   518,800 524,100
Accumulated impairment loss period end   (41,700) (28,200)
Goodwill, net period end   477,115 495,948
Life Science [Member]      
Goodwill [Roll Forward]      
Goodwill period start 207,200 207,200 207,700
Accumulated impairment loss period start (27,200) (27,200) (27,200)
Goodwill, net period start 180,000 180,000 180,500
Goodwill, Acquired During Period   100 0
Goodwill, Impairment Loss   0 0
Currency fluctuations   (200) (500)
Goodwill period end   207,100 207,200
Accumulated impairment loss period end   (27,200) (27,200)
Goodwill, net period end   179,900 180,000
Clinical Diagnostics [Member]      
Goodwill [Roll Forward]      
Goodwill period start 316,900 316,900 320,900
Accumulated impairment loss period start (1,000) (1,000) (1,000)
Goodwill, net period start 315,900 315,900 319,900
Goodwill, Acquired During Period   0 0
Goodwill, Impairment Loss   13,500 0
Currency fluctuations   (5,200) (4,000)
Goodwill period end   311,700 316,900
Accumulated impairment loss period end   (14,500) (1,000)
Goodwill, net period end   $ 297,200 $ 315,900
Analytical Flow Cytometer Platform [Member]      
Goodwill [Roll Forward]      
Goodwill, Acquired During Period $ 100    
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.6.0.2
4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2016
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Jan. 06, 2016
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Gross   $ 443,200 $ 417,500    
Future Amortization Expense, Year One   27,200      
Future Amortization Expense, Year Two   24,200      
Future Amortization Expense, Year Three   21,400      
Future Amortization Expense, Year Four   19,400      
Future Amortization Expense, Year Five   18,400      
Finite-Lived Intangible Assets, Amortization Expense, after Year Five   51,000      
Finite-Lived Intangible Assets, Net [Abstract]          
Accumulated Amortization   (281,600) (249,900)    
Net Carrying Amount   161,600 167,600    
Amortization [Abstract]          
Amortization expense   35,200 36,500 $ 47,800  
Indefinite-Lived Intangible Assets (Excluding Goodwill)   0 46,400    
Impairment losses on goodwill and long-lived assets   62,305 0 $ 0  
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)   46,400      
Intangible Assets, Gross (Excluding Goodwill)   443,200 463,900    
Intangible Assets, Net (Excluding Goodwill)   161,609 214,026    
Customer Relationships [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Gross   84,400 84,700    
Finite-Lived Intangible Assets, Net [Abstract]          
Accumulated Amortization   (52,800) (46,800)    
Net Carrying Amount   31,600 37,900    
Know how [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Gross   182,600 184,000    
Finite-Lived Intangible Assets, Net [Abstract]          
Accumulated Amortization   (136,900) (121,600)    
Net Carrying Amount   45,700 62,400    
Developed Technology Rights [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Gross   125,900 101,300    
Finite-Lived Intangible Assets, Net [Abstract]          
Accumulated Amortization   (56,300) (48,900)    
Net Carrying Amount   69,600 52,400    
Licensing Agreements [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Gross   39,000 39,200    
Finite-Lived Intangible Assets, Net [Abstract]          
Accumulated Amortization   (30,600) (28,500)    
Net Carrying Amount   8,400 10,700    
Trade Names [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Gross   3,500 3,500    
Finite-Lived Intangible Assets, Net [Abstract]          
Accumulated Amortization   (2,500) (2,400)    
Net Carrying Amount   1,000 1,100    
Noncompete Agreements [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Gross   7,800 4,800    
Finite-Lived Intangible Assets, Net [Abstract]          
Accumulated Amortization   (2,500) (1,700)    
Net Carrying Amount   $ 5,300 $ 3,100    
Minimum [Member] | Customer Relationships [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   1 year 2 years    
Minimum [Member] | Know how [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   1 year 1 year    
Minimum [Member] | Developed Technology Rights [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   3 years 4 years    
Minimum [Member] | Licensing Agreements [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   1 year 3 years    
Minimum [Member] | Trade Names [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   4 years 5 years    
Minimum [Member] | Noncompete Agreements [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   2 years 3 years    
Minimum [Member] | Other Intangible Assets [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   0 years 0 years    
Maximum [Member] | Customer Relationships [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   8 years 10 years    
Maximum [Member] | Know how [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   9 years 10 years    
Maximum [Member] | Developed Technology Rights [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   12 years 12 years    
Maximum [Member] | Licensing Agreements [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   9 years 10 years    
Maximum [Member] | Trade Names [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   8 years 9 years    
Maximum [Member] | Noncompete Agreements [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   9 years 7 years    
Maximum [Member] | Other Intangible Assets [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   0 years 0 years    
Analytical Flow Cytometer Platform [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles         $ 32,700
Analytical Flow Cytometer Platform [Member] | Developed Technology Rights [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-lived Intangible Assets Acquired $ 29,700        
Analytical Flow Cytometer Platform [Member] | Noncompete Agreements [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-lived Intangible Assets Acquired $ 3,000        
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.6.0.2
5. Notes Payable and Long-Term Debt (Details) - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Jun. 30, 2014
Dec. 31, 2010
Debt Instrument [Line Items]        
Debt and Capital Lease Obligations $ 434,500 $ 434,200    
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year 300 300    
Long-term Debt and Capital Lease Obligations 434,186 433,883    
Maturities of Long-term Debt [Abstract]        
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months 300      
Long-term Debt, Maturities, Repayments of Principal in Year Two 300      
Long-term Debt, Maturities, Repayments of Principal in Year Three 200      
Long-term Debt, Maturities, Repayments of Principal in Year Four 425,300      
Long-term Debt, Maturities, Repayments of Principal in Year Five 300      
Long-term Debt, Maturities, Repayments of Principal after Year Five 10,600      
Line of Credit Facility, Remaining Borrowing Capacity 205,700      
Letters of Credit Outstanding, Amount 5,400      
Performance Guarantee [Member]        
Maturities of Long-term Debt [Abstract]        
Letters of Credit Outstanding, Amount 5,400      
Unsecured Debt [Member] | Senior Notes 4.875% due 2020 [Member]        
Debt Instrument [Line Items]        
Unsecured Debt 425,000 425,000    
Long-term debt 422,500 421,900   $ 422,600
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net 2,500 3,100    
Debt Instrument, Interest Rate, Effective Percentage       4.946%
Face amount of debt sold       $ 425,000
Debt Instrument, Interest Rate, Stated Percentage       4.875%
Capital Lease Obligations [Member] | Capital Leases and Other Debt [Member]        
Debt Instrument [Line Items]        
Long-term Debt and Capital Lease Obligations, Including Current Maturities 12,000 $ 12,300    
Line of Credit [Member]        
Maturities of Long-term Debt [Abstract]        
Line of Credit Facility, Maximum Borrowing Capacity     $ 200,000  
Line of Credit Facility, Amount Outstanding $ 0      
Line of Credit Facility, Interest Rate at Period End 2.25%      
Standby Letters of Credit [Member]        
Maturities of Long-term Debt [Abstract]        
Letters of Credit Outstanding, Amount $ 800      
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.6.0.2
6. Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Income Taxes [Line Items]      
Prepaid Taxes $ 12,700    
U.S. (38,500) $ 48,400 $ 30,600
International 80,100 97,400 101,000
Income before income taxes 41,560 145,847 131,557
U.S. Federal 16,100 8,700 9,600
State 3,100 1,700 3,800
International 30,300 34,100 35,600
Current Income Tax Expense (Benefit) 49,500 44,500 49,000
U.S. Federal (42,400) (200) 1,500
State (2,800) 1,200 (200)
International (6,000) (7,100) (7,300)
Deferred tax benefit (51,200) (6,100) (6,000)
Non-current tax expense (benefit) 15,100 (5,600) (300)
Provision for income taxes $ 13,435 $ 32,754 $ 42,712
U.S. statutory tax rate 35.00% 35.00% 35.00%
Impact of foreign operations (15.00%) (4.00%) (4.00%)
Foreign dividends, net (40.00%) (4.00%) 0.00%
Research tax credits (9.00%) (2.00%) (3.00%)
Nontaxable subsidies (4.00%) (1.00%) (2.00%)
Tax settlements and changes to unrecognized tax benefits 42.00% (4.00%) (1.00%)
Goodwill impairment 11.00% 0.00% 0.00%
Domestic manufacturing deduction (4.00%) (2.00%) 0.00%
Stock-based compensation 3.00% 1.00% 1.00%
Nondeductible executive compensation 3.00% 1.00% 1.00%
Fines and penalties 2.00% 0.00% 3.00%
Prior period adjustments 4.00% 1.00% 2.00%
Other 2.00% 1.00% 0.00%
Provision for income taxes 32.00% 22.00% 32.00%
Bad debt, inventory and warranty accruals $ 28,400 $ 26,300  
Other post-employment benefits, vacation and other reserves 26,300 28,100  
Tax credit and net operating loss carryforwards 96,400 80,200  
Other 35,700 23,200  
Total gross deferred tax assets 186,800 157,800  
Valuation allowance (66,400) (58,300)  
Total deferred tax assets 120,400 99,500  
Property and equipment 22,500 30,200  
Investments and intangible assets 287,800 271,800  
Total deferred tax liabilities 310,300 302,000  
Net deferred tax liabilities (189,900) (202,500)  
Unrecognized tax benefits period start 8,900 14,200 $ 16,200
Additions to tax positions related to prior years 10,400 700 1,700
Reductions to tax positions related to prior years 0 (200) (1,500)
Additions to tax positions related to the current year 1,400 1,500 1,600
Settlements (2,400) (500) (400)
Lapse of statute of limitations (2,300) (6,300) (2,600)
Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation 100    
Currency translation   (500) (800)
Unrecognized tax benefits period end 16,100 8,900 14,200
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued 11,500 $ 3,000 $ 3,800
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit 3,500    
Deferred Tax Liabilities, Undistributed Foreign Earnings 447,000    
Deferred Tax Liability Not Recognized, Cumulative Amount of Temporary Difference 47,000    
Foreign Tax Authority [Member]      
Income Taxes [Line Items]      
Operating Loss Carryforward, Valuation Allowance 29,600    
Operating Loss Carryforward With No Expiration Date 140,800    
Operating Loss Carryforwards $ 141,300    
Domestic Tax Authority [Member]      
Income Taxes [Line Items]      
Other 2.00% 0.00% 0.00%
Operating Loss Carryforwards $ 1,900    
State and Local Jurisdiction [Member]      
Income Taxes [Line Items]      
Operating Loss Carryforwards 53,000    
Including accrued interest and penalties [Member]      
Income Taxes [Line Items]      
Unrecognized tax benefits period end 27,600    
Foreign Tax Credit Carryforward [Member] | Domestic Tax Authority [Member]      
Income Taxes [Line Items]      
Tax Credit Carryforward, Amount 27,600    
Research Tax Credit Carryforward [Member] | Domestic Tax Authority [Member]      
Income Taxes [Line Items]      
Tax Credit Carryforward, Amount 3,600    
Research Tax Credit Carryforward [Member] | State and Local Jurisdiction [Member]      
Income Taxes [Line Items]      
Deferred Tax Assets, Tax Credit Carryforwards, Research 25,900    
Limitations On Use | Domestic Tax Authority [Member]      
Income Taxes [Line Items]      
Tax Credit Carryforward, Amount 400    
QuantaLife [Member] | Research Tax Credit Carryforward [Member] | State and Local Jurisdiction [Member]      
Income Taxes [Line Items]      
Deferred Tax Assets, Tax Credit Carryforwards, Research 2,000    
Net of prepaid taxes [Member]      
Income Taxes [Line Items]      
Unrecognized tax benefits period end $ 14,900    
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.6.0.2
7. Stockholders' Equity (Details) - shares
 3 Months Ended 12 Months Ended
Jun. 30, 2012
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Common Class A [Member]          
Class of Stock [Line Items]          
Shares, Issued   24,454,000 24,230,000 23,972,000 23,681,000
Stock Issued During Period, Shares, Conversion of Convertible Securities   13,000 18,000 5,000  
Stock Issued During Period, Shares, New Issues   211,000 240,000 286,000  
Common Stock, Voting Rights   .10      
Election Percentage for Board of Directors   25.00%      
Common Class B [Member]          
Class of Stock [Line Items]          
Shares, Issued   5,124,000 5,131,000 5,099,000 5,097,000
Stock Issued During Period, Shares, Conversion of Convertible Securities   (13,000) (18,000) (5,000)  
Stock Issued During Period, Shares, New Issues   6,000 50,000 7,000  
Common Stock, Voting Rights   1      
Election Percentage for Board of Directors   75.00%      
Treasury Class-A [Member]          
Class of Stock [Line Items]          
Treasury Stock, Shares, Acquired 122        
Treasury Class B [Member]          
Class of Stock [Line Items]          
Treasury Stock, Shares, Acquired 917        
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.6.0.2
7. Stockholders' Equity Treasury Shares (Details) - USD ($)
$ in Millions
Dec. 31, 2016
Dec. 31, 2015
Equity, Class of Treasury Stock [Line Items]    
Stock Repurchase Program, Authorized Amount $ 18.0  
Stock Repurchase Program, Remaining Authorized Repurchase Amount $ 3.3  
Treasury Class-A [Member]    
Equity, Class of Treasury Stock [Line Items]    
Treasury Stock, Shares 122 122
Treasury Class B [Member]    
Equity, Class of Treasury Stock [Line Items]    
Treasury Stock, Shares 917 917
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.6.0.2
8. Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Accumulated other comprehensive income $ 417,766 $ 382,138  
Other comprehensive income, net of tax 35,628 163,193 $ (121,772)
Foreign currency translation adjustments [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Accumulated other comprehensive income 1,300 33,700 71,200
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax (32,400) (37,500)  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax 0 0  
Other Comprehensive Income (Loss), Tax 0 0  
Other comprehensive income, net of tax (32,400) (37,500)  
Other Postretirement Benefit Plan [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Accumulated other comprehensive income (18,600) (20,700) (16,300)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 500 (6,800)  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax 2,500 1,100  
Other Comprehensive Income (Loss), Tax (900) 1,300  
Other comprehensive income, net of tax 2,100 (4,400)  
Net Unrealized Investment Gain (Loss) [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Accumulated other comprehensive income 435,000 369,100 164,000
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 105,100 325,400  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax (800) (900)  
Other Comprehensive Income (Loss), Tax (38,400) (119,400)  
Other comprehensive income, net of tax 65,900 205,100  
Parent [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Accumulated other comprehensive income 417,700 382,100 $ 218,900
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 73,200 281,100  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax 1,700 200  
Other Comprehensive Income (Loss), Tax (39,300) (118,100)  
Other comprehensive income, net of tax $ 35,600 $ 163,200  
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.6.0.2
8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Cost of goods sold $ 930,085 $ 897,771 $ 996,527
Selling, general and administrative expense (816,724) (761,990) (808,200)
Other Nonoperating Income (Expense) 14,850 11,080 $ 13,009
Other Postretirement Benefit Plan [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Selling, general and administrative expense 2,500 1,100  
Net Unrealized Investment Gain (Loss) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Other Nonoperating Income (Expense) $ 800 $ 900  
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.6.0.2
9. Share-based Compensation (Details) - USD ($)
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value $ 2,100,000 $ 2,200,000 $ 2,100,000  
Share-based Compensation Expense $ 19,700,000 $ 17,000,000.0 $ 14,900,000  
2011 Employee Stock Purchase Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of Shares Authorized 600,000      
Stock Option and Award Plans [Member] | Incentive Award Plan (2007) [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of Shares Authorized 2,250,360      
Number of Shares Available for Grant 587,509      
Stock Options [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Options Granted Term P10Y0M0D      
Weighted Average Remaining Contractual Term (in years) - Outstanding 5 years 1 month 24 days      
Aggregate Intrinsic Value (in millions) - Outstanding $ 34.1      
Options - Weighted-Average Exercise Price $ 106.52 $ 100.36 $ 84.50 $ 78.72
Options Granted - Weighted Average Exercise Price 159.37 139.56 119.71  
Options Exercised - Weighted Average Exercise Price 80.70 61.29 63.66  
Options Forfeitured/expired - Weighted Average Exercise Price $ 127.65 $ 62.47 $ 100.29  
Options - Shares Vested and Expected to Vest 437,350      
Options Vested and Expected to Vest - Weighted Average Exercise Price $ 105.39      
Options Vested and Expected to Vest - Weighted Average Remaining Contractual Term (in years) 5 years 14 days      
Options Vested and Expected to Vest - Aggregate Intrinsic Value (in millions) $ 33.6      
Weighted Average Exercise Price - Options Exercisable $ 93.78      
Weighted Average Remaining Contractual Term (in years) - Exercisable 3 years 9 months 18 days      
Options Exercisable Aggregate Intrinsic Value (in millions) $ 27.8      
Options, Exercises in Period, Total Intrinsic Value 1,000,000 $ 13,000,000 $ 5,000,000  
Cash Received from Exercise of Stock Options 1,200,000 2,900,000 5,800,000  
Tax Benefit Realized from Exercise of Stock Options 6,000,000.0 $ 9,300,000 $ 5,300,000  
Total unrecognized compensation cost from stock options $ 4,900,000      
Options Number Exercisable 314,330      
Options Vesting Period 5 years      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 20.00%      
Weighted average fair value of options granted, period for recognition 3 years      
Expected Volatility 21.00% 23.00% 25.00%  
Risk Free Interest Rate 1.35% 1.90% 2.35%  
Expected life (in years) 7 years 4 months 24 days 7 years 8 months 12 days 8 years 8 months 12 days  
Expected dividend $ 0 $ 0 $ 0  
Weighted average fair value of options granted $ 42.40 $ 42.74 $ 43.96  
Expected dividend yield 0.00%      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]        
Outstanding beginning of period 426,705 581,806 629,643  
Options - Shares Granted 45,000 40,500 54,000  
Options - Shares Exercised (15,285) (195,221) (91,387)  
Options - Shares Forfeitures/expired (6,850) (380) (10,450)  
Outstanding end of period 449,570 426,705 581,806  
Employee Stock [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of Shares Available for Grant 96,121      
Cash Received from Exercise of Stock Options $ 11,500,000 $ 10,800,000 $ 10,200,000  
Stock Issued During Period, Shares, Employee Stock Purchase Plans 93,605 96,634 102,222  
Employee Contribution Rate - Maximum 10.00%      
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount $ 25,000      
Employee Purchase Price Discount from Market Price 85.00%      
Expected Volatility 20.00% 18.00% 15.00%  
Risk Free Interest Rate 0.26% 0.02% 0.04%  
Expected life (in years) 7 days 7 days 7 days  
Expected dividend $ 0 $ 0 $ 0  
Expected dividend yield 0.00%      
Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased $ 27.36 $ 25.08 $ 21.88  
Stock Award Plans [Member] | Incentive Award Plan (2007) [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Options Vesting Period 5 years      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 20.00%      
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.6.0.2
9. Share-based Compensation Restricted Stock (Details) - Restricted Stock Units (RSUs) [Member] - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value $ 14.0 $ 12.2 $ 10.6  
Total unrecognized compensation cost from restricted stock $ 46.8      
Nonvested shares - Weighted Average Grant Date Fair Value $ 141.09 $ 125.30 $ 112.60 $ 105.44
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]        
Outstanding beginning of period 412,422 377,365 375,430  
Restricted Stock Units Granted 193,025 177,110 145,695  
Restricted Stock Units - Vested (117,203) (113,347) (107,557)  
Restricted Stock Units - Forfeited (39,422) (28,706) (36,203)  
Outstanding end of period 448,822 412,422 377,365  
Weighted Average Grant Date Fair Value - Granted $ 159.32 $ 139.56 $ 119.56  
Restricted Stock Units Vested - Weighted-Average Grant-Date Fair Value 119.33 107.62 98.52  
Resticted Stock Units Cancelled/forfeited - Weighted-Average Grant-Date Fair Value $ 129.80 $ 116.19 $ 108.17  
Weighted Average Remaining Contractual Term (in years) 2 years 1 month 28 days      
Resticted Stock Units Outstanding Aggregate Intrinsic Value (in millions) $ 81.8      
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition 4 years      
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.6.0.2
10. Other Income and Expenses (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Interest and investment income $ (14,700) $ (10,100) $ (13,500)
Net realized (gains) losses on investments (800) (1,600) 0
Other-than-temporary impairment losses on investments 600 600 400
Nonoperating Income (Expense) 0 0 100
Other (income) expense, net $ 14,850 $ 11,080 $ 13,009
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.6.0.2
11. Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Other Significant Noncash Transactions [Line Items]                      
Net Income (Loss) Attributable to Parent $ (20,600) $ 18,400 $ 18,000 $ 12,300 $ 49,500 $ 17,400 $ 28,400 $ 17,800 $ 28,125 $ 113,093 $ 88,845
Depreciation and amortization                 142,900 131,800 149,900
Share-based compensation                 19,700 17,000 14,900
(Gain) loss on disposition of securities                 (200) (1,000) 300
Loss on disposition of fixed assets                 600 300 400
Excess tax benefits from share-based compensation                 (1,506) (3,610) (1,349)
Changes in fair value of contingent consideration                 (400) (5,600) (1,400)
Decrease (increase) in accounts receivable, net                 12,500 (39,000) 11,100
(Increase) decrease in inventories, net                 (57,100) (54,200) 5,800
(Increase) decrease in Other Current Assets                 (6,600) 100 (5,700)
Increase (decrease) in accounts payable and other current liabilities                 30,100 28,600 (9,900)
Increase in Income Taxes Payable                 10,700 12,700 20,400
Decrease in deferred income taxes                 (51,400) (6,400) (6,300)
Other                 5,700 4,300 4,000
Decrease in other long term assets                 12,700 300 3,600
Increase (Decrease) in Other Long Term Liabilities                 8,300 (12,200) (1,300)
Impairment losses on goodwill and long-lived assets                 62,305 0 0
Net cash provided by operating activities                 216,433 186,210 273,312
Noncash purchased intangible assets                 0 0 200
Noncash Purchased Marketable Securities and Investments                 $ 600 $ 2,200 $ 0
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.6.0.2
12. Commitments & Contingent Liabilities (Details) - USD ($)
$ in Millions
 12 Months Ended 51 Months Ended
Dec. 31, 2016
Dec. 31, 2016
Jan. 06, 2016
Dec. 31, 2015
Apr. 10, 2014
Sep. 30, 2012
Purchase Commitment, Excluding Long-term Commitment [Line Items]            
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value $ 28.5 $ 28.5        
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]            
Operating leases, due next twelve months 42.1 42.1        
Operating leases, due in two years 32.1 32.1        
Operating leases, due in three years 24.7 24.7        
Operating leases, due in four years 20.4 20.4        
Operating leases, due thereafter 38.8 38.8        
Post-Employment Benefits Liability 68.0 68.0   $ 68.6    
Recorded Unconditional Purchase Obligation 142.9 142.9        
Recorded Unconditional Purchase Obligation Due in Next Twelve Months 34.3 34.3        
Recorded Unconditional Purchase Obligation Due in Second Year 7.3 7.3        
Recorded Unconditional Purchase Obligation Due in Third Year 3.1 3.1        
Recorded Unconditional Purchase Obligation Due in Fourth Year 2.5 2.5        
Recorded Unconditional Purchase Obligation Due in Fifth Year 1.6 1.6        
Recorded Unconditional Purchase Obligation Due after Fifth Year 94.1 94.1        
Unrecorded Unconditional Purchase Obligation 35.0 35.0        
Unrecorded Unconditional Purchase Obligation, Due in Twelve Months 17.5 17.5        
Unrecorded Unconditional Purchase Obligation, Due within Two Years 5.0 5.0        
Unrecorded Unconditional Purchase Obligation, Due within Three Years 3.5 3.5        
Unrecorded Unconditional Purchase Obligation, Due within Four Years 3.5 3.5        
Unrecorded Unconditional Purchase Obligation, Due within Five Years 5.5 5.5        
Unrecorded Unconditional Purchase Obligation, Due after Five Years 0.0 0.0        
Letters of Credit Outstanding Amount $ 5.4 $ 5.4        
Employees Covered By Collective Bargaining Agreements U.S., Percentage 7.00% 7.00%        
Analytical Flow Cytometer Platform [Member]            
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]            
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings $ (2.1)          
Business Combination, Contingent Consideration, Liability 25.4 $ 25.4 $ 23.3      
GnuBIO [Member]            
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]            
Business Combination, Contingent Consideration, Liability 10.0 10.0   10.0 $ 10.7  
CellSorter [Member]            
Purchase Commitment, Excluding Long-term Commitment [Line Items]            
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value       9.1    
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]            
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3.5 28.9        
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 2.5 12.6        
Business Combination, Contingent Consideration, Liability $ 3.1 $ 3.1       $ 44.6
UNITED STATES            
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]            
Entity Number of Employees 3,300 3,300        
Fair Value, Measurements, Recurring [Member]            
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]            
Business Combination, Contingent Consideration, Liability [1] $ 38.5 $ 38.5   $ 19.1    
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]            
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]            
Business Acquisition, Contingent Consideration, Potential Percentage Payout 39.00% 39.00%        
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]            
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]            
Business Acquisition, Contingent Consideration, Potential Percentage Payout 20.00% 20.00%        
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]            
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low $ 0.0 $ 0.0        
[1] Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2016
 
December 31, 2015
 
 
 
 
Other current liabilities
$
14.5

 
$
13.5

Other long-term liabilities
24.0

 
5.6

   Total
$
38.5

 
$
19.1
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.6.0.2
12. Commitments & Contingent Liabilities Period Expense (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]      
Letters of Credit Outstanding, Amount $ 5.4    
Operating Leases, Rent Expense, Net 44.4 $ 45.0 $ 46.9
Contribution expense $ 15.1 $ 14.7 $ 13.7
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.6.0.2
13. Legal Proceedings Legal Proceedings (Details)
 12 Months Ended
Dec. 31, 2016
USD ($)
Legal Proceedings [Abstract]  
Loss Contingency, Damages Awarded, Value $ 10,920,000
Litigation Settlement Interest $ 141,608
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.6.0.2
14. Segment Reporting (Details)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Segment Reporting Information [Line Items]                      
Number Of Products And Services                 8,000    
Net sales $ 571,500 $ 508,700 $ 516,800 $ 471,200 $ 570,600 $ 470,000 $ 506,100 $ 472,800 $ 2,068,172 $ 2,019,441 $ 2,175,044
Interest expense                 21,942 21,692 22,131
Depreciation and amortization                 142,900 131,800 149,900
Segment profit                 53,194 166,708 149,984
Total assets 3,850,504       3,709,718       3,850,504 3,709,718  
Payments to Acquire Property, Plant, and Equipment                 141,436 112,000 120,999
Life Science [Member]                      
Segment Reporting Information [Line Items]                      
Net sales                 730,700 695,000 728,300
Interest expense                 6,400 6,100 5,500
Depreciation and amortization                 31,700 30,700 33,200
Segment profit                 (19,200) (700) (14,700)
Total assets 381,400       390,500       381,400 390,500  
Payments to Acquire Property, Plant, and Equipment                 14,300 8,200  
Clinical Diagnostics [Member]                      
Segment Reporting Information [Line Items]                      
Net sales                 1,323,300 1,310,400 1,432,300
Interest expense                 15,500 15,400 15,900
Depreciation and amortization                 80,500 77,800 95,800
Segment profit                 57,000 152,400 167,100
Total assets 918,000       878,300       918,000 878,300  
Payments to Acquire Property, Plant, and Equipment                 67,100 51,300  
All Other Segments [Member]                      
Segment Reporting Information [Line Items]                      
Net sales                 14,200 14,000 14,400
Interest expense                 0 100 100
Depreciation and amortization                 0 100 0
Segment profit                 900 700 $ 1,200
Total assets $ 4,900       $ 4,400       4,900 4,400  
Payments to Acquire Property, Plant, and Equipment                 $ 0 $ 100  
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.6.0.2
14. Segment Information Segment Profit Reconciliation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Income before income taxes $ 41,560 $ 145,847 $ 131,557
Operating Segments [Member]      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Income before income taxes 38,700 152,400 153,600
Corporate, Non-Segment [Member]      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Income before income taxes (7,500) (7,500) (25,700)
NonAllocated Expense Loss Contingency [Member] | Corporate, Non-Segment [Member]      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Income before income taxes     (20,100)
Foreign Currency Gain (Loss) [Member] | Segment Reconciling Items [Member]      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Income before income taxes (4,500) (10,200) (9,300)
Other Nonoperating Income (Expense) [Member] | Segment Reconciling Items [Member]      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Income before income taxes $ 14,900 $ 11,100 $ 13,000
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.6.0.2
14. Segment Information Segment Asset Reconciliation (Details) - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets $ 3,850,504 $ 3,709,718
Operating Segments [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets 1,304,300 1,273,200
Other Current Assets [Member] | Segment Reconciling Items [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets 980,300 926,900
Property, Plant and Equipment excluding segment specific [Member] | Segment Reconciling Items [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets 81,600 46,100
Goodwill [Member] | Segment Reconciling Items [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets 477,100 495,900
Other Noncurrent Assets [Member] | Segment Reconciling Items [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets $ 1,007,200 $ 967,600
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.6.0.2
14. Segment Information Segment Information by Geographical Location (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Segment Reporting Information [Line Items]                      
Net sales $ 571,500 $ 508,700 $ 516,800 $ 471,200 $ 570,600 $ 470,000 $ 506,100 $ 472,800 $ 2,068,172 $ 2,019,441 $ 2,175,044
Other assets and property, plant and equipment, net 1,334,200       1,191,200       1,334,200 1,191,200  
Europe [Member]                      
Segment Reporting Information [Line Items]                      
Net sales                 742,200 763,700 901,700
Other assets and property, plant and equipment, net 221,100       204,400       221,100 204,400  
Pacific Rim [Member]                      
Segment Reporting Information [Line Items]                      
Net sales                 427,100 392,200 417,500
Other assets and property, plant and equipment, net 16,100       15,100       16,100 15,100  
UNITED STATES                      
Segment Reporting Information [Line Items]                      
Net sales                 770,600 735,000 704,900
Other assets and property, plant and equipment, net 1,084,700       962,600       1,084,700 962,600  
Other (primarily Canada and Latin America) [Member]                      
Segment Reporting Information [Line Items]                      
Net sales                 128,300 128,500 $ 150,900
Other assets and property, plant and equipment, net $ 12,300       $ 9,100       $ 12,300 $ 9,100  
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.6.0.2
15. Restructuring Costs (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]    
Restructuring Reserve $ 9.0 $ 0.0
Restructuring Charges 12.5  
Restructuring Reserve, Accrual Adjustment 0.8  
Payments for Restructuring 3.0  
Restructuring Reserve, Foreign Currency Translation Gain (Loss) 0.5  
Restructuring Reserve, Current 6.4  
Restructuring Reserve, Noncurrent 2.6  
Cost of Goods, Total [Member]    
Restructuring Cost and Reserve [Line Items]    
Restructuring Charges 2.1  
Selling, General and Administrative Expenses [Member]    
Restructuring Cost and Reserve [Line Items]    
Restructuring Charges 10.4  
Employee Severance [Member]    
Restructuring Cost and Reserve [Line Items]    
Restructuring Charges 11.7  
Life Science [Member]    
Restructuring Cost and Reserve [Line Items]    
Restructuring Reserve 3.2 0.0
Restructuring Charges 4.1  
Restructuring Reserve, Accrual Adjustment 0.3  
Payments for Restructuring 1.0  
Restructuring Reserve, Foreign Currency Translation Gain (Loss) 0.2  
Clinical Diagnostics [Member]    
Restructuring Cost and Reserve [Line Items]    
Restructuring Reserve 5.8 $ 0.0
Restructuring Charges 7.6  
Restructuring Reserve, Accrual Adjustment 0.5  
Payments for Restructuring 2.0  
Restructuring Reserve, Foreign Currency Translation Gain (Loss) $ 0.3  
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.6.0.2
16. Quarterly Financial Data (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Quarterly Financial Data [Abstract]                      
Net sales $ 571,500 $ 508,700 $ 516,800 $ 471,200 $ 570,600 $ 470,000 $ 506,100 $ 472,800 $ 2,068,172 $ 2,019,441 $ 2,175,044
Gross profit 314,400 279,500 280,200 264,000 308,500 263,500 279,600 270,100 1,138,087 1,121,670 1,178,517
Net Income (Loss) Attributable to Parent $ (20,600) $ 18,400 $ 18,000 $ 12,300 $ 49,500 $ 17,400 $ 28,400 $ 17,800 $ 28,125 $ 113,093 $ 88,845
Basic earnings per share $ (0.70) $ 0.63 $ 0.61 $ 0.42 $ 1.69 $ 0.59 $ 0.98 $ 0.61 $ 0.96 $ 3.87 $ 3.08
Diluted earnings per share $ (0.70) $ 0.62 $ 0.61 $ 0.42 $ 1.68 $ 0.59 $ 0.97 $ 0.61 $ 0.95 $ 3.85 $ 3.05
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.6.0.2
Schedule II - Valuation and Qualifying Accoutns (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Valuation Allowance of Deferred Tax Assets [Member]      
Valuation and Qualifying Accounts Disclosure [Line Items]      
Valuation Allowances and Reserves, Period Increase (Decrease) $ 8,126 $ (338) $ (5,396)
Movement in Valuation Allowances and Reserves [Roll Forward]      
Valuation Allowances and Reserves, Balance Period Start 58,277 58,615 64,011
Deductions 0 0 0
Valuation Allowances and Reserves, Balance Period End 66,403 58,277 58,615
Allowance for Doubtful Accounts [Member]      
Valuation and Qualifying Accounts Disclosure [Line Items]      
Valuation Allowances and Reserves, Additions for Charges to Cost and Expense 3,785 8,783 7,164
Movement in Valuation Allowances and Reserves [Roll Forward]      
Valuation Allowances and Reserves, Balance Period Start 24,418 27,973 32,471
Deductions (4,836) (12,338) (11,662)
Valuation Allowances and Reserves, Balance Period End $ 23,367 $ 24,418 $ 27,973
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.6.0.2
17. Subsequent Event (Details) - Subsequent Event [Member]
$ in Millions
Feb. 15, 2017
USD ($)
Subsequent Event [Line Items]  
Business Combination, Consideration Transferred $ 87.0
Payments to Acquire Businesses, Net of Cash Acquired $ 82.9
EXCEL 90 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

##H]L*$E/WNR'] *DE[2LHJE)89PA/A'4S60"XB M0\G\3 Q5@"0XG.W**8I3 F MV%F%ED135#J@[&$44XBW![U=?>6)@P1Q,SJ1VCV]J9?BVS4?8*5U$1R(-]Q, MU_D^K &^_.X*)9/C2Q85[MSQ@=E+W"DOXATZ]ES:F("!3#P#29<@3Y.V7XE1 M,8#S:KA)X,CBZ]2=XHYU*]H>__7GQC:X7^; M(BUGZ=0%/Y.F6K\K:_II7,_MO?.^[0:4%V1F$C.HI@K$%$33?)6$*]^PN\'J M5S:TMI-TPM&SP4D2/1C$-YPR1HE%B+2819(7KQO]5I*5.)'1LT2LV)\'NSH< MEETXG @N41@5*01E5_3EZBHQN?/-PP;TNUT\;LR*IDURB_@N,2]3DLI/4IDK M1)B6BLV6@@?$"P/ZWS>O3,]'DR',0?.J4!BPGC% M;\C^['KL5UK%!;I+3EY$]QV9$HI$@K$030BG8%'F/ 8B>#IX/(]"LCJI 5V3 M$O@G$F?_]FYWE#%0U(>79S';IG$F2%I:JL?%!>.'F*=0,G+@=[4H!X5B:[K+ M.%IA?9IGS.X[U1A!&RE@D2@,QG]F\TPW6/9?=X F+SY 2,"A686&43>K<"X: M8G&_8JJ_5+/GVDZAF:IC2DSA_X*3L II=CWL!M:S;,S.44\?M&IFS-3TZVMU2LTAR_%T80IME\ ML>%0MB^22(9>3!(-X%?.KL$IG:!U#G3-$S8WF\7V3SD/AQ])D#PVU7LDUGE5 M\*.528<54UZT5FE>U"V/F(P*U7$5HV7$C(9=FR(\;@F36?,:VF-Y4K/Y:/(2 M':SH-8VFG]H=])L?Z6UG^:3M+(?G,)6R2GSN<.W%);S/L>O IA-(D"2&HW^C.(-NDZ=JD/_H'A4/J!K12DY)QDC_B^Y!_&W-M\? GM M9%S-'32=Z97G@M77SZ$L[ZHOD=;,<[#':/ K;[<68>Q7:3GM^F\X4XGA>UG$!R%&\ FO[5.:A$Q5C>*-^]D!"/EY+,*4I M:1FZ7SZ3ME">#1MTP=?D:<3>^15&TJQ]HF<$*VHUK[Q.?!S-2)EV\_GQQJ7Z MZ"@(6HPB)OHX2/L6NIBWGKD^.3[")'D5A="@3/SY\1]>FYY!ZO6!]WQW!5TU M'&"5BMF7NECH[61K7Z2@L#,2JWWI!0.<14Z2')M\G M@5)I7-5:S$V1E80BHL3S@:OEGM-]U/7)L)10QU@Y@U0''B]OR]O 5]OJV5"$ M=K48DD:,<@TO&UEONBG9S]>P]"J^[VI 0'SV+BE9[W 2G2W\$+JH[GTFEF01 MEH'X%4.JY":W^=0H'F"Q(?\'O+DI;45!&Q1%:?1\52+&%\E.U<(!K3FV3)J' MSK.U.^JBQ1Q%F2/S;[?AOVVDH1 BR=(, ]R#XXTB B.^MU8F6DN.GY>*$[_2 M]=1T-%J=3@T/[^]VTJ/M[+F,3N>JDK5>8C*,)SZ^".[36>(["[,KB [3("QOND'F0?,ZUP#QX%=HRE6ULE%!-NQ2POQ%$71Y? M3>#AXD,ME,)'/MG4M#(M(6F!$KJZ<3X0(?952YO0-6/R',26A=3T%U&)GKPT M!MJ+#)2.#1TV+JSF\J79H%4R7Z@DAI.&6_!;+ U_W"R>=YX)&+- 4JLGHR*T M>"^L5N[=HK0+!BQ0:&4[2N- JM;[" M]=#0,CY'("+ICOZ>8Q5W8%T?I M1K&;P[2;=.7N3M(%R4)Y(6GK_3@R774#RE\\-XY.E]NT#/I,7AQ9JNR'+(F4 M?9"K5>MOQ-K(AK!.YS=%!]:T-]@63,*1@!W ?EC;?4W;+8:%P+0=6A-H$"^P M)K08\Z2,U9[>0)!?%KO.6&_8<.]42X^_0;?(E?@^*1&$\0AA&\1VI&D$2DE[ MS+0KC9&/11VIFF[C6:@ 1]#T !O)G1;''&J&'AEJUH3<% BBR3G@B%IR]F?* M-5"2S;G<>V12NH!AY))_OO$]S>]:_]BDN?-TPP0+4[&'>ZL5L46SA[R\9%U[F6-2+FW$.: M=3AP1V_E\NB.#B@.YW;K)?0*KV\@1E15@\1%H&69- M@[J]O,"3,Y\[UX=+IJ>,E,4"@GN[TFO^(F%HAYH,A#C:"-G&45-5*WL+R;+K MZCK,2%-#M11:07D28*8DCIMOP9Q8S]_L?UG_X_0]E^H??X[_U'P98MLU)067U:X7*8SRV2K5E M]+?S^Y+BT/[//L]';WR%\K_=)5_7T>M%/OU<>Q>'3(8]IAJ1&KT!>?KQ N28=J4RWOZC'EO\"Z"2W]-E6N(YYF> MHD/^XTCT-RK,P&HRA8VAK9*2NN84MPVR!)>DF+EM4D8XFX,(\C'NLB\OG M1?,EQO3 @082UV "&(B+2O9=J8P\C5>T9B[KI62IDM7C?!8S']+,GD])(R?A MW[$DRE.06,%Y\-LP^7Q$"LYY1OP++XG&HG]^"8_5 $FR#ZXG12"@M;%T0>8^ MYX-=E71=)HNY5:SLUIBJ/!A*J:.TCZ0N^(&M5,!(KC&!W^V48NZUYI%CJ)IF M'GT0+FVOO[2;-:1ZE1,7*+CV<-JF]VDU#H:#[JG#WCJVI\,^..N.W;>$G4T5 M&"VH=3CWQ,1C2<9X,!AVA^X5JBSI,IZ%([.!S!H4"P>-CV='9$I_?4I9)!M, MCOIFZ6X@$0PH'[C'!U2+9\V)L\BVN088M3)S,4P_^!3[I>:Q:YZ% B%1*U2H M8#93G2]P_ 7Z7\#-);F1RYHA.?;;^L2-"TLZ3,,Z_;M M2T']*ZW?:Z,X?<;,D+;V[!/:Z\E,1D0M3X5!J.S;C$OTW,R.4P MS1%NFVI-0C3RT2BYH0&?.NEJ7S\:PU^.6Y6Q4!AMVH9:NK3YK'WAB_ M8KMDLF>[.(+SJT_17\ZO?[Z,WE^"]/;I\OWEA[M;&5>X*DT&$5]BZ9J*7_5?17_>Y))[BLM!L?"E&1($^$+[-JVD M<0B;&KR2H M[[]3G:VI:_6./GC6RU/1[5.EX^"JZ#>I%;>W44E=#EIOPV.G5 M9)PE1\;3V@)?,*5XK>/05SN;J6*F\8M.*6N./FH$7GMJ:,]+*9NL.Z0+%MU1 M.%S-CWSA!^XYVBL&E]MXLL,8V@8E;)D4]/HJQG0V![0O_<&/F))RU.W7/]!4 M7F3!GB6DQ)=1OP]2H#ZI/^G#-W"[4$+>\ 5]9M#K]L(_R'SS@$UQO&S\^VNNL-[6OH"\CD#.2@\*\7+,[I $3O MX _=.O-^#GSQ010%/X-1\/OK(O],J8'Q)#'C3Z0&"6VF>WAHE@-_?[_)4DFL MTM!-?VQGAW^\]XEPZI["D\E) XGQIT3ZQYBHEM3/VDI.[%+0'[S].URJW/AP M9#ON=_HPUHE+$+DE+>/A],B]UC-+@[]S__,J%VKF.@?1R5F/SN+P=$C98LV9 M[/1/AD"SC="1-F:PS^!G1V$_H)15_[YHTR\.DZ/:3@U/8=GIO^K<=[/=^D"H M(?AQ!EOS;^;EX_^)O)Q2$%?^W),=5$FW]0*H,UKZ\"7\W#)4^J.!H_>1 AIZ M&K;Q] %.=G1JN,U)'YINY>F#6NOXV6_$T\<3LT[\UPL6Z&1D6!']L3=/GP2_ M;V?-$[-6DUV,>3+IF6O8O4:?[F+,8SL?^F,OQLR-#\Y.#%L_&Y]\"UL^"WY_ M(5N>G)XP&QI-S#R0*?>&(R#(?SU3[E?^>A%+[I_!&_3?KV7)E,C\C'Z ##= MAE3G4K6D_:WY$?8)F(<#M^M,5CMDE<9=C20E./>V-IN!O8[,S=Y+[WQEHRQ([PNU$!))4<: M$M?$Y#6:HLFPE(0#Y7.Y3@+W61=4?%Q#-TI"7Y!3X(!(/NBE0'./:O1F3&P< M)^08F]SQ>Y_A46RVYH7[Y^B@/S"30%_[-O/ST%ADV]1YS:N]E+HY?BF?J)8' M.SILD,8)O//&NX+F:5&NJUZ%;]J[[7OR*UV>#AU:-8(K-/G?YF&H>Q;0->IB M.89GW^.+@][WSF@)ZB$ M35;)5J--5XC%]=/H:&M>O5T^M\!%]F_P=.W8Z-_:M2/KY3CS6F#BSHR,'8*@ M F? GGE5IIK8D(LRV4[Y.X\;J[=< M^0Y@;\+" M/P.RA6PC]" XSF8YCN\Q5$/I7>SC%,?0Z,-@Y].O)_[G+2?V-HA0Y04N;05; ME:M*X^F(4I"PM#H",ET)HI14E3;[H6!0"]KVI&VFW>@3L>J_.'G@3A,+1S]; MG\(5I8Y\BQS]+M^#^O ZW'V#W5:NDE?D>J3;@:P"_5[TO2OP12:"$>@!WXOH M-OI-K_]WV>;UU0WCHG;P<&4^Y@Y$MDZK2USNH-\SKNT6P+VY[XU[QD?6,J33 MK2)#A/"*KPMY@OKFX@@2.*# 3Q80-.N>23KMV/_VJTIF1<46*Y=3OV?SRNU( M(Q=1/6SE'PU^)[7Q54U!.QO6*M&(*7IVWD_A"@6CTV__*UZN?OP(.O0J157@ MZL\*WZJ^5T)C"#B\V12V+7*XQVRDW'#:18X2BXTAD]!6MAGQY_G)8)"/4!>Z M/[T_VCLHE;T2#7\UII6I+:A!.O8K%-7+-V/K=RX1*KT M$H>259=C'Y+27BMU;9ZI'F814U@LPEFMU-A!P"Y+$AZ4'68%U^1J$C/COF7< M/G%^B1]?86KAM2NHU.6:=EPI.R:UZ"44$+FJ)\2@5A@'=K/MU(B@ +./&:R/C;WZ$$W81^SX;#.33P8P M*GQ.'J:_]W 7G*()0]X[@??V\?Y:KZ_U_FZU_9.]$MV/T-$(.AJ.T7U^BJ9T MQ H<(@#@2,R>U\ZD%6S.UO;':!B;G)R8948;:;MCH=?@&\+/R+=0;VCD+&DC M&CJ:]/OT4X;N[:]UB]Y_DFK')T2O[!66Q3\0?U(S\4T:]G>RA?8"U\QACRJ8 MCM$6N ?]G8Q@&$)_^-X^GJHV+,56^AC@*1TP_2&A#S$1\'!P CN.L W81#S. M;&[_9OH;GUB?X(0:VX?^Y-#B$M!BMKF$\ :PN4I1VYUBC5U"T^GLC6<7F1L^5M('17$ES$G +1.1[Z@V@)ZL$C MYRC 8($#1BG!#SQ$+VIL(34&;+/0SJ1'-OE!#XWU[UI6@+&Z+QYKC\ /.-)? MT7#+N-F3 !1:H;:%RUDI8?\A40DIQ::\VCR> A&%M;)\4@<7PD9E1SOV*Q3! M\V4ZI6"0U(:ZN$<$"@"BS2+//]-T4:3!J'$MKTFH;H 14Y;3%'!%&4FSG( M%JG+'$ NM6E<2L'-QF89QXJPZOO$"=4D5TJ='T.2K#_^/+X=8?_A]2%M>VN4]9W'58\_;_]HJXWU#O%E8BI0+0OK2; MFI&TDA+:OC7X7106BX[_DB\VRR0HJ[A-R9;5=]%?)D<&OB1\YW<8.['B.,=U M3@QD>^6]REZ0!8LHQF'1R7*QRM=:I!P-FI^2S9H2Z;-NOHA1Q];XLAD%8M 7 MZNC1VWB5IV:%R#C %K?"Y?1FI^OY;P/? F'*4O)OROJ&B^599!ME7E M->[8-T%S=NFXOG XGR#LTT>KJO/0908]$9/W2-LO6PL>_)CA66(U)-+-UV%G!#:J;4IBOJ_MEM"R:;"/A5=9LJ M*ERC?O8^IKLBM8*3RQK#.E??_?0/XR-X7R'39@=T?]0'B; _0E7%/T>2'35J M'AVC$CK&QYV&,#HE,971R-N81O,]XNKZ,I^R#EM;,VPW](5\7(WXG;#2:6'S M2&@%'Y)^* ]*U\K:+E+'F":9OVV-0[$"YC?&H?S_53A_XRJ:H-J1#J1),*:TDPHK?0N3];L'^U$[Q*$3H#:&/N:B2[V5IU/A^H5$ M709([UF^.@HGW"*D5X-X1^1^TG#L<\D#ZRKLXL")"*KO!4_46@CRF+3&&>_= M1L.@W]WAX.>?'Z*H733Z68IX;>FL(_,A2D[P UJ@/YL_UC&QXM _1>__L(_!@:,S_!\_&<,G9_#[N(=& M-YL()[)1#TT1$/K3EVOVEN$^HZ[T9]NK%ZIPS!>;Z5H19&)4/QSK#S3^B^?J M<,13'-%?E?TPQ\+L"*Y['SYBD1.E3-XAWA_>G6_&DNB%?1P>"L^@K)>"343Y(#"R*D]/7*QW15_K!( M,6%8__B4Q (XE0=P. ?B1ARB1^=/6?Y$M;GZQ\A>$)0.+ "/V1%<\[#];[;M M^?"X/XCZ Z3Z0U VA^A%.H,FKF$"6(V26AV> 5$<#GOD/\*8MSN4CC,0*^VP/IN,%M^Q\BC,%QO\>40?YE"ADCRCB!#364 M 4_U3Y&-'_8'/)<).JJWDL:(2*.'09"'HU.BIS&^Y$ACB,T";=#&\.ZC&<(0 MQQB)AXEC1,31;R>.X?%)A![-0V;L0Q=!MILX^B?4Q^B,!MF?G.Q)'"/KOZ8_ M]B*+R9#N"MPQ-N*,:!@A).#1IKXA7TY ] M9#\L01M7\BHBZT1 Z#9,)^=B<7>QY+5D#9,PH;'GZ6(^4X2DCY9Q=A1**^OJ MQHE[Q%8"O..$_ G92!ID )O'&8]9-SPM"H,V,1[;=L["X-@;NXN;Z./YW\])YT' M5*+KFP_OCN\N/[V/WER^OI/4K#/-0.*2"7/&0XISE3 WSN!)@,=L!BK2@DK- MF*_HY0>0?( ?)HE-]5E*+!M&L?7&%B<=U#2]SXM" @TQ J2,V1[8Z%(*BU)S MF!N&L=G@&9;3X %!CK+%ZUO&KZEBX37D$O=Q]ID!P:#_YP476#)('>8\WK.& MET*>J7" MYO#?,!H-46?"_P<\@09CT6&/9#_Y41GF@;R,/_'N:UP\O/[<PD/LQVAZQ!A$^E7="O*TPYG0F_2PP@<1A;LZ\Z3V6FE MI1C@I"04+/8<26$CL4P%G='PGB6%_YKNV5FRE-)-C(J>@WC5:P;,#_28\[J;J:K@*XBTA=YQ"A8%U(/:,3-!<:XE0X1)^ MQO5I>561J;B[DRR&?-UNLG)SSY9-UCR1JI-91JE2M7:RUW2Y_I[B 31Z3N<6 M#-A;_BEP4V:75\+ 7\&W<,5WF&HIDPP>643Z!;B43@1R_@,5BO=IXM6EPD%V MJ&/[A#1:8TA&3B1(XE0JQ2Q2GY=6_?YNEML")8M$]@(E&,(@H!%<2QVQ)/L*IE11:LHL3$0A^&B6(DX 4[(0!W2@'RG 1?99 MQ%+1/>1#WRD:!S=3DH9KK2];7GGD&1)A?UBJ0I09W+$V2@?(1>BOVEPW>JTW MKJ7A6J^X=BHMYXLO)OL/9:;(7"I"K:/JR_<:Z;R4HE-Y\9G@;L+NV11>R.9K MF.#4(7L#"(^D?+56\/O]IM!"'GFAT1^/6B+JH&=DWYKTX"2E=C&"Q Z524A< M\'(-RSNN"$##2.D68_^L;O591!$V(D)Q:X0E1O ("Q_59MAEZ#NFI30U90OKL:$'3>J9E4GC\\X[ M&I-+CDP3]!P%@TC@4LYL2M9*@**=?V%JEDN4LP6S\Y%C$V](=7G*) M"K:B8R1$<6!YY%U01YY9^7Q.,=B)-/!\&G(!\= MLV@5/@W*7:T-H^D=4V"BEXYJ.7') DN!J'?QUZ26L-9_MY\B9MO:FHX?^_UP M&O>+%?MI@!B,>1 8!Z M/P !_E3">"CKUT%$YM"K8$2G:+X_.X&OT6S6TQ4,Q@3O]RGS3G\T9HPX67%9 M_,4S?9O,Z#XA !BZ2$[)M(@V M88*\D6$.371#&'TX_2&2VQ!=.T,,;FGH(QIAZO81J2-H4WZCL0#XS.$]7&7S M='W4,J+#T4"]4@,R)HYE1(=L#^]S( 1^%X[K<,*^H1-2P0Y/2,4)NI:>H\-Q MG[U)$WZ47_R09\?3ALGX ??'&)3DO(0";'_?X1^'49!!BDH M-)LRB;5.<<$1L#J2-1.]8#&PHM"&"B^Y-P)OQ\L.0$-KPW'TO?GO2C+)SQW" MS]0+..RSTT[_4[BEN3%0B3L<]?0)-;@+9-IOE"$],,!]^CN1+^QRGA7VP-KIMJJV;7N\>DX=RP M(3@,97:XPV#G79$+4%IB!)2KR=RA^FUIV:8CZGIR'6BT+K E?,JF@*$BN*UD M6$EDE %/4H)PJ0]JU9ZDP(>.]^] AN4LG1J36_N@1W[064!\GJI(DV53O??P MPL,NYRDK_MH]$X"DX_ ?EIFV7E<40%D%Y)_91;=@JSVSZ18P.\H=F7/X40B MAR=[2H3G)!:39U[O1)\V99G&+.S_W/T3RQ6W\%@,VE/285F_SNP,UK4IA8@4 M-4Y:>25L#F*2NA5Z=]]+S U7XS#.<;)?@,2\X,I12"KNSPZ:61%T MI5%2?O;PU69--A7-++7..Y;Q-$/LF(IA>=[* M5G]63%TN)<^]N^'=VY)?5X " O']:D$&"LV7]K@[#3=Z=MA4Q*CH%4J9L=2Q M:IQJ+9US^5ZGD5$HO(V.\<&&TI2K*]!8*\/FL0FEUMD>*_%2["-QM(8E?A6] MCF>B@IE2F51*!2WW&+.&)KYX47(F(111!H@)8 8/DUD?PRHOR@Q"3&5P\F$)+W5#W4AZ 26N/X\>Q)&U)Q%#SG*\TE)A)VQ2_H5 _YC-+S)%4RGR89%^ M)@PWB&5\^G*6>8NKT29[)Z(U(U?6V2^M_F[ *?8>,(]Q5&:NC.C M< <&U+T&T-VQ=;0O@<*TS]Z$Z3H.^B9C9NPC^#BODC=,JNTI;(YNQXVKLN@M MXF(03PNQ#'IFP97N<&L3QZN!4D]%-!L.7SYK(VTHNZE3Y.#$NH:R2A-%7>=H M:&-HFB CJ/>C!F%FC4M2-J[)7K.M;-EX:+N] ,*$469IO'O[:[DQ US(GS%1 M7(PPIM_@K/V*,V:3LVKX)L%K&@^:FG@]?TGV.SEQ __7[))GC MP>HXX3+4LF1_.>3Z2U*4L?/9-O+VK%F,:Z(Y1LN'"?F8S:IEP)LRC:F)]0:K M'5.-2I$-40AGJ 5QL3ESL0[7E%9WD>.)\6;]F+/AFBO&(BB+K5NP-^P12K[& M2ZVCJJJ%VY]:(W>RB@Q$@@-.?F#;AKHC/%P)5F.H0]-X6*=!=9Q\[1[NU1YV MGI,FY=:>-]8D.U8/I,8D4,7Z.UEUX'A6B993;CWWFA GL#*J$)==\H^2?9T^XQCY.JEA9BC? M9N;89+K%I$WE3O;PF0F4T2!]>AI>"1:NI0$^A-4HQ'B&)STQT8A[56N'S5_ M[F&\,Z;]DT8HO=E&SS-&[6JZ%7>*V@9'.?:?U3R'---23]X%OC?69Z73A$GL MJ)W&P/1U?(\Y,UH2'[-7WZC*[7O6&N+#YN/6]TC9Z/\8I!L^)6AMG]%&_0G6 M2)EIUA:44X*ULL!/?YUQUAU$(J.;XI,_(_N^7TE0)0F?]AL'&1K$5T#($81+ M8@/HY+DU]N?#01!BP]FVKN,51Y>P589^M3+CX8!16@S4/QR0P\$%]) S54(O M)%&6M(WND=W[$*82=NX?MR$J+KEV2H<)$F7<8Y[*A-!9;&^E:=K(H8XD!*)BM>XN ;7;R+F4OZ5ELD%Q40?O MSC=KVD,3&F4D #(?5A1*>3WU1D*A^C(D^^"VK]SR3Q5A4\*+R4*.3F;0*!<8 ML,\)J5()BI><250\I"0S#+W,6862+WA1DBC4MED"(R7_%/1/1Z;&,T \Q31Q))5Y)"(# M)7CEQ7>AN#ET*+#UVMIZ4E52_=VRC32L0H7W\S(F#$KHV*9>D!R\*T1E.-P^ M1'=QWO*OG-ZELK:C41#1QE1$P11!,H56&Z[4517!GU!9];1L.J!@,9P+ #IS M91Q6)$5*R,9L4X@>_TX3''7"S;Y/:$N-32#TMTF9$@2#J>$HA,2Q@.Z4)@8 MIL5TLRSIC9*4'98QW!Y+Z)UXL3Q396&[ILG9W.RA!"A":Z.M_4GS5E0WS.U7 M%>QQTF6WIP#Z?A==4HK!ZF--SX!*S\A 5Z$]ICNW'8+2V I%95H$RQ9H"H[V M[N;B3S_=7+^Y_'0+;?SYYZN[O]9-IXQ\)UNX@=TQ_M$".2ZPW%]T3D7V8-=I M@-&A?,J86_[C=>,CKX^ZT24B5 D4:1NT;[H"RLA7"4;+.;.J/$!FP)VC MYHF,+P4F3%XVN\Y[-';B&YMI&UVN6.;/N)AYZ *'J;NQ+ M8>_ZMG_AM;[ WK_*8XU]N%901&C=1L+-KBZR7A33+KDH.<% M=5B*'0P[D]-^-.[TSD[@!1C.N>QB20+=.#I$[>)*XU,H6-P,;W ZB4YL!U6! M@;HX.QE0%V=-7?0Q&O1T:R>C7C3N;>L%M-!19S"$QSI]T&N:>AEBP/367OK] M:+*MDPEV,AJ/L),!AD=+.A%9Y;MF]D$Z"MM^2,1DI(G),;!9X6@QI"Z(R?=D M84?9\5Z' UO*"7MY3M:2H--WX.RE9+!S:9RV! 5$YTN.FD2^AY5.22ZH09X/ MJY\<\9U05M'#=K*;0@\6IK2?HM4H"%V($%O+'BMV%7CH^J#7.T&H)3)<$)K/ MR4+X$?:J8R'A7!V.!,P$CGI_,+!9;Q 0+@4+1AMZ+/"HFK#$H;8S*5OF8^L'9ND M\-9@7$00GB"8 1<;$HP:Q6ILR\8?5(6STVX05<^( 9":0)][3&!AOB2"QJV^ MN-];T2%F6S_JD,<=QH98AG91,S9M:HB.;5/TNBW"9O1UN7A5@DJ8_/=W*\%2 M?$>3O+CX^?W/U^=WEYJKY^+F_<=/ES]=?KB]^LNE@J?/]QN!S;='A+TC1]^6 M#)@7'C+4*&FW(Y@-(J9B27Q;S9%I+5P6N:@/YEN!*L$KN)$F\;)JG9)>--M5 M+9A!&GLN.0H"+ M1&N(JR/@<'C"5D!.#3&D8GF8T*(O"29*\Q(:N=$AN>>\7,U?-C:>26+Z*V/- M$]26?Q(O6XH91\-J_Y1PUGO,3P)S RBIF]J(FL- Z3ZL'"*$VI,4N34?#CEG MQH"S_,,'$RXVS'GS?]V:LW$7[:]]&M4)#NHW6V]$\HA5%TW<6]9;=@6#%VC% MAV=$8-^\X#PO7)\)NL4)Y[]CK2G6@5+,@RPG:52P, 8%5?=/!/KNR[NI==.! M<_'BR'[=:27[1P5Q2A'H3QGPJ,=TI;)0M3H!125K(C@6@N*F742=#![=F^V* M_65G1N&..NLIZ:F4:1,G7Z>::^U58\")6!:WP08O DSB1=.03=XVZ3[,Q6%A M_]N8<)3"' F;-I!PFL,^\8"7U#U$WMU. IRSH$H"F#WXE/Y7?GK(4W/A)DSS MU;O\K,M2O$#S+PS>OF9A:GENBZ1@3$^R\NXE]7]@$F&0\VSC4GJS%I6%8_WI M_-/E\6O*W8>2 8@%YW=7-Q]^(--5=/,1_Z"T%IKC+_IX??[A%@@"$19.M^;N M7M?G@H)U:4$>)*:9P041"2MZ&D[M@T:;LXNCK$FR*NGG1F0UP;YB*8QN5@X[ MY@7]TH?>/^4J-*_, "A<%NLA)&*U">VG;A"O5*$8AMUA)WA3P.?XZY'#)[3J M'O3T"3_-?,.]7=7Y'HHX4UXK[=@I\(#1/(]&&&8WX?=H8= 9N+Y.*GV585]! M"YV:+E#_!-@O87U%+UH!BYB*QYA-? ;\NWY>,>N4DC&BLH7C_(5@G1@WB5', M-*Y@Y^BCBI['"^AK?O=..NQ/::,_:<1'\#J\E5LBD*G%.P<#'G0&XUYG..DI M__=OBA0N,&]C*@@G6=%+>1.\S0V?9S"_ZIMYBSX)?-VG0?;X&).EWY,GV@]E3)&'U&.F*0-YP1I^,CMQX]'OJ P><7@+F \N^?G M2/"4,Q^]-(G8LOHN@4E:A"=5;%V#<:?70[!7QIZ*=4XL%2?B\455VT:3Z4;" MFW0X8L6MEII,R^C46^617CD'Y5HS4S?1;$"A\[2HE<+@[6ZLD4&."U=$7J:D M3%L65]7RDJXSKQZ_ BJXR&>P-PEC!4>#H9?=- 2+?;[D=N +@RHLP^[A$@QZ M/^J2R#3\@L .TR/]'X5F;3.C.3B>4/B 60^$A MOB/]XD/2ON23H<#:8 YJSFJ[M=Q@Y MT:S7&!I-B98/R$9WV\6L2Q%UKRH6FM:;SH7\\9)1Z0L#OVFX6CM,;.&Z*+JQ MX?(7OA;*PVUC$"PB=Z[5J3$+8DG9H#H^KK>:^=!)XQ29]P*M8/\J+6\U++.. MW F+9>]<;0+.G 7@F@/0:2L@H@!:4T4'(9HQ9;B$RX;#AM3=>YWY0"Z>E149 M8T&>/_F2*)ZO"4/+:J5Z!;N)=F+U6)N>8Q_IX9.6.40%)3LI,;LNBDK(7_FF M\M ,'9(+CO WH;6"RVNAT%\V%K;GXB_$*@(:ITH.()>]4B?,+U)@_=@E:[U4 MMQQG9:T_X+.Y7ICB+Y27$-5I2>YZ_O" "8K7>%CAU(#:/)4: ('.#7>L P-T M:MZVR>"L,QFAE>3DM'LRB-Z)6#,>$6_!BH) 9GTW9N"M9_W.\)1-5Y-A=S)! M I@GZ'O_@2-JX)E^KS,:]]BDV.MU!V?A*.HNN?%IOW/:FW!.V7'/C6/4 V&2 MQC$\ZXXG=AS]LW$'V"@/I(]]- QD>,JCP+2S)]L'@>GM)IV3WE@&/9SX48QU M-<9GW>%), H8Q"E;%$Y[W9->TR FG5-=# 34C;>/8Q*-1F>=\0GUUYMTQX-H MW&73(>:X^(MX2Q"-H" XX'5?*(5.0UO#D\YPS&V-N\,S:*LW8C.D6TTDZ*9W MA_U19SC$=\^&W1/,MWQ*QN$33L$A-,='FA,V6O4P]3G?I$2A1^V$ ;)AA1DI MBR::KO-AD^!D08UI9005T=V]6-4ZW3>SP,'3E("U&J46L-MAR&S'K9S6#YD% M"AIAI2"4#$U<8;O&=3#H!F,9F.P\-)CP^W X!/S@>F5J!_[6]3GH5Y*TVC ^ M6I0MV6G)J,FLS>9"<<96CJ?$+OP+G9_M=8&8,H[[9TWYE*7ZDN.+COR^L,U\7T$\C7\ASEC/J7EY^-YD7C# M( -=^UU**=/OGO7P4?[+M;>@U.K^ L:$2^A'P$Q%[B&'4VK+ /_+]D6N+B^E MZ1GU)%W/B)P8W;-)]!<_.2"/ !L-E(.. \30N25(O6\[T X8DBW4P7 K\1'8 MW798I,2NA910;%G+ZJA(A7,(%4JABIR?3/T:_2)0*T)HA6:$.XOYIHUP]2GY M;O$5>]G^HEJIDJ;BQ[TW!C$J?J6P\2)-*&++Q9+J9FCXG,55L=Q9G?LJ.K'CA8)K_3(J\2W 8T9A89OT9S:7VX\"* MZ@5@U61SO0J,'JF%7\4D2V8]I4?B58->[RS2>HMT_!JL38*+"Z@[;E'Q1'L, M)8#2EM"[9TD=O1:R^M-FPX@8/ S=;!'=6Q1.)\.W+&]=9"=)\?@-;K@IQN6> M^P](]L.3<6394&0 MGG0&/0$)]$Z[_1W"-/8/@N>$NQET)UZD[\,7_;Z1Z5W__6%G.#J1/D!0#@8P M. 797*IA8(S0#I4"I/G^H#,:4#P7IBDT S@;=GJ#L8KS S. $S])6)OA,%B! M,VJ.Q?@S%(5WBO&GG5,> %;+/$/_-6DX?:EZN4,H;':%J(S8)K6P7#8*Y9]^ M34(,TC!^BZ131=M/C*BWK^!C#$7-DWV!'"223^%.V-XRT$AEH.VVZCHW6V^U M] J';;"_[24S_0>$)!1Z^J?XWS8A"=3Y"7S=Z_8&_&.T34B"I\?FO]],3JHN M,ZFE0SQ>F.[]E#!,W5,^9X2N#DJ%Q@$NP\DI1A[ $J7=?[V4%)"M/N2Y7]-Y MM![B_=7!9E;<5 ..=3WNB M-/?D=%W"E)3 M'J,+^M@'K=4+#57:PBN9_XVB][#,R0(NG@33)^2-"\>@)EZ^*OOL.2QA\W+S MO"5)5[]OYMU3H-Z+QR_A?D'QI-HYJE%-'PCZ%LNSDL,D7K"!ZBWLORW&5P,] M[7QC"XF[YSMASYZVMV>+QC'?_OSQX_7E^\L/=^?7T<7Y[4_1V^N;7X#TW]Y\ M>D_8IZ;6KG')BD0527?5#-SS,'Q(#.%3=CR4=(<< M<8_E,L\-5)EU0QI]\LVC?I,8Q(ZD$?'PO?X(38:8BOH4?L>D<:U./G)WD8^+ MZ/;P'9[&(T.)F/#$9P:9NI M6EO]99+!X7#("9K[A($U@/50HD'0 M4R7OO"ZMQ,3[(&:C,CRB,M4>"'"F$] MHHC)Z=3!1$&K9\L^E80E\"Y55#R*Z+P?7KD774BY\>Q1 7!*CCR6!-94S1G+ M)YZVO2O84['GRQH>3FC(;,W(7AQP"C\>\V(<3_3&T2^]FC&@RA@"Y_(W0 M">5+I&3MC=.MOFKG=DIX]8%2+46)-7'?H+X?U0+@8H4RC GF[6A.FXP[@;6X M1Y+.<;_3C%+UA!)T8J[+ 4G=&/1%J.4VJN;"A#LS^A@?6OZ7U M[-%XXT]U>*$SU)84 !J8M%5CW8,N136G\M)_QA=FV8]R0L MA=^:$J?;IR#!_DULNWYP#C?OWU_=X?5S2W+6Q5M],GU=,TP]T]\TZD$P2*G28['3[$K8Q26V!N-JP"#T<1X._:5FV4@HH)Q M,2D$QV/>A'CJLL_B5;%9Y\L<=B,L*E-N[A=R_AA7<4ZH+=5"- *.GY%Z32UY MT5JFWU8Q8V3]:KYDQK#V,=7,&(P,0,,7S1C8C(T_RCI)4<3[Y#F'']CFJ5%L M3.KBCT6.7C*\)G' GY)UR@ ^ALHYS!">97RPE <1=\0%5RB8N)8:A-1& Y.] M4 B=TYS7*%)6MHB<&\1L=U;L]C-DF4FP:L!>-W@9DN' MF55 "[)Q\:GZ\,^6"C$:\T*K.3FMGO/)::NQL"-Y,DM&*]O(OG/)@P1'L,CE MCG*PN" #T8V["H]K5V$3O"H,$>Q&[]&8*)A_*>5F%_L>+10H&[N4>9@;18V9 M*1'GNM@@6*QPI0P)1Z3%LGQDI5Y;B&VCM%JR^$%1R9^T1%69.PN+;I".C(8D M%;K8>H/$L^!4?RZUO!MB_"TCQ#@AQOG26*7&7G6TSLYY8Z*$VTW 4MW*AA23 MP\Q"UKU5-I,ZG+QA)6Z8I'T:!. TB2>6A(U!0"[#]SC9.\&[;$HFB1,7 M%\D#L;3[E!?79S,0ZQ2\Q_!VR8AD,B-PJ#<#:Z2,E8:2FQZG.!$VWKBL&)0S MZUFS$]N5B1=E[F:U(TP4MTGHQ59/\#R%,I;-4L8W$DY>4!3!_2<*#,$;A8U0 M^014NW(7RNVQS-^^CVV!=VW7YW!D4!<==WV>5#^EVW,8L'1W>08&0:TWU:]D M5>9B4_KMV<@TM2>9#X?D:TD+OB*?ZOY_<_Q6T MM_<"OY3^J%Y[G?["+?+T-VZ@O]JG?6YAO(7^>H;XKGT10DY7\<,[K5)' @6A M#JAB:(%A#)N" 6P*Y^^H7(%R6+I,RE"HP&NP5N;P!U<'3SP)VYZ@QGT-99_( M#',OIVM?$=,7UZN45"8PHF1]I210B:F%YVT<6,,D=2;PH!HT08WBYIJ-=JCD M&VL987M"$:/J701FEC<,=O/!%1(EP8$Q_4D5I!VW6VR\I$N)-BC_2)AG&],@ M/D6/Z<,CNH7(9LEE9^+%,Z>_PEKUT?09-" \22@[K/$Q-CE1Z8<%^2 (WVP: MYV*%C,5O&1Y*>4[J($WA7L9[K,Y%E\47/:48.U)+VOZ(49AT@>%^49'8)6IJ MZSRC&JNHYL-RTG"'9]_CBQA>Y.1]C45QJ99/#*($#INOMVP;EAR(JWSM,N%1 M\6_N!XX:)=#&7%*2#DQ0'Y^GPI M&4R@M9A*)F?,]LUI"GTU(RE#8_!]0$1 [A6:Y,%OW6A+L1@&;3W/X:P/!O84 MMI^@*U*?1K_I>7B7;5Y?W7305K9C3DI AB9PFC0+FN(!F?E,_>W&K?+T;]S" MB+HI9LH%S+F@/2.2UR\MK1,C"M(M:CUU5?8(J,9CY.E=8^1)--RU=3(KJA9< MV:R^+1W<>A.J8J>[-OBF7;.94,VZXS!&(R-[;>=VZ,\""9?389;/H*%6N)F& MU\HHN< )YGH[&)P:94%R5>)^U#;#5FW@NKZD#KOT^7)RS0OWSP2/\9. Q=YZ M2JQ@NCUOE<>B^*7DY+DIUQI+[@O";!'WHZL)([$UF3:T? U2?H&)7#5KYX5+ M'@=*#!G6&O5S,_#E&. <$3-P[K MWF,NQ^I#M0>V&$7YV?><:+%N%MTK1Q$-ZO+=^77T\=/-Q>7EFZL/[VZCF\SA MX@9#-O?PW7@AA_I3^B4%>H]>4X"DQ/DZ() #]1@SVZT0;KJ@TV.2!8#,6Z1? M.#@,M?A-NE;N?;LA\ =F.@(V3M*?J^+1$2P@A:OA_\ WT*SBZET@YD-1)6(E MFP6Y(#%7()E K(YP3P)*7OF)YF"[RHMBLUD!ZG(\8C@2F M(?GN[<7'\^^.?G2=XG JMK@90G/@;L# -#I7 JG!5W_T"I6%VY04PY#F:GB; MF2Q[JD9O,O2IPFE*LB+%U2*3"^I$R8P.8T)UU@M,;#%WFD[R&"_FU:W 9RG* ME"+:%"0H4J_DZ?71^[-X&3]0Q3K,Y>%"A@C_<>@+5<"Y T),GAVUSX'RC[IX M>,Y71;HP1^?)!^:@Q@G+MK&T5+IC,4N62*H%Z2?B$8)+<0FJA:]JXBB.CPDF MDXM+N2!= \@P'Q.:+8QG\X!&L(F.1P?#QTHQRFO[/OL5T@41G)2]I_'QR:'% M;DB2Z#OKGVAOF-34N<@6"27^R#GHF%;K-EFMF?..+*_QVR>KD[E 9;\"1.+I M,7;JF9;*U& M*(TG,Q/23=Z\!ZWGQS)J(&WD2,C M00IZ76_?3L(L[2)=.;0=N;"DIHC9'%NN>D$2:5#I\] MCA8@=^RZ##,2LUVKW"26B)5.\"U#(W)-;:,'YQEJ.Q*TBC=P!O 43E[,MDK$ MN\P<\^@XY@SS$/8EVFN9M' 6-,LLJ!C",4D ED3H-61H2(+)S%6,@6FGL3^. MTYACB6'U?[6<\J7K,P2CR6S1[2!<*HD^Y"!P'O?'Q[T>5CYD/B!2"QOP+*>) M62>57.UYF,18PCLUX8*O3W8^U>BA0?]'OE"$IPZ-[TT_.]7M"OU+-&.*HK>E M(5\79$U_S!G1?8FC833N+WGQ&4GOFMPIP]/H(Z84@^5\N\G8-OE+_)PE(FB] M2-;SE&UEOKA/\IV!-<%]$4/A'I MCH5*QF(%\B0S+!2F1)1R5>9$R@@D(PX&(@D(&4 )K\4:C5RM!\(K,H/+,O?5 MM:B E::(1=E,0GF?M^D%QP&(CA\T]GW5BC?-#61DIT8>E5#/^F( ML2*VR(!B,J%&UXY3=L2)"N>^"_N #*#?'YZ>'/_EXD-T^ 8U\(O'[I$?KO+% MG60-MU3^D-!*N7-1?C MWT%^XJ@W].7(B>'S8W>IVE^'C@6:"&;'9#N1$I-D=B0A%,4> OJC-#1#^&M' MLK]A"9MDC2=0@#06NV%/6Z,2P3GO2/D0"<4??'U.Y%+F;7))JX?;L26-29@M M4Q8;#)8$+V$\RBGB6[),LNFX[6Y89[J)G)5D,! *^6;B<)4WT'6C6>4X2C%! M.S0Y #!1)3YK^H&%_T1MZ4HE=\T\4<7&I.2F5A2NZ6)XP86B3WB_R) M;A3,N*, 'W_QZ,[=QL4]:(+E\P8JTM^IH]Q]XLXI2 R MO&&/U56#LC_,'/$QA2X>ZT5N2 5<SVMPOTFFT@FMH"IP>,T(Z M7C"'&^U!SOE3S,1 446^C%C3Y,R98@LG)[P*-;@2'39H;<$T43$5SA!L=4ZI MYOAFQ]DOT._YQ*8.K2V#4J23XP*P49A[TY23#[#;V*Y$!:PH@H<.R\,F+1\% MR)2+)#I#PF+?;.,*H%Z9I<20G4'&J"_,'G>:8T3,05*5U%*4Y,3!2.A4_7$# M%^E Y&@RXGR@ M-:%QV^%5G1?8MYV*O>6DPM$'\@9[M2V\_OF8\$!G29:&XZSJJ;R&[9OAU_<> MSH4RP98!AK)7DCW$#WP/.!G6T06A.]1^V#\S[JC1H8Y4EPS2C0)1TB? MV>PVJP4B&F@;'I;.3IV4BF?K=R:]4WP.\5VUA_BZ]7TU63*FG'*94E%034'* MX#A/5!QS%023-G%+_#=?$I#)28?8IP'[2_9Y>-X<(9@\+; N.4E[[^,, MB(Y6UAW:0]49Y /-]LA4XAX+W!A/B:"^W6@.AT>P=4].!.'LH!1QK\ G:_@$ MN3A%G4N*(W/4V^DG>)B3&2EZ!9Y'BGE8H"+-*8KI,Z['(K@32D%MZAVZ M1?;X="=H^5GAO5184ZV:6&F^VM:'G&06O,VYM#P1)*NA/C1'U.XXP$_C7+RG2CF@*:ZIQ%19[@'Y3P MB^M'=[!>)GM)7>C&JLL= X+24#84P!: 03\5B=!YL9@]H2^2A$J,=: ,\F17 MSY\RSA)03BE/$64&)XT.CC2F1Y,SMX#33!D,TO@A W:=3DOW1#?(6,_N PFK MH@F6KZ)K[.)6NB!A31M\XQM4J'-#"Q+V@*SU =0&EX@8LWRJ#QG3 ')=]YD$I=IG'%)%:9RQ,F(L%6Y]F# ( MH!OU:^\8@9;R39=2[98)'+H"[MB07PII--N IDA@R,8V]38J$XF0P'<>%OD] MT0?.S3Y3*.0[V"59>C73 D,PE(6Y\Z'M2K? 2Q^DCOP*3F"\WF@\'2SCAC>2 M0@O(( NW<_Y LU6:4P+PDRHDC0/5W*:,X*F8;%&LPW?+Z6.>8X"#M5>N'F/8 MB&FRX=4D+V,*#'OZF&&GSY*,BIZ=H[%_+=YDVPR]]H#!39DS":?9;%.RB.@. MBH\O$RFZ@;2_934I4(UE"12@!*K0\62&S>J'],AGU49)TY($ _\0(<=9UY7/ M/8)8M7Z<W\K'I% B0 L^S"*,ZTH(_. 7"W?I MN4QAG)F3-[FL1:4IJI,UWY"WI;8_::87COAO$TILU;2?&GIUX^XXAYE?.US5 M+'&&FG,/F[TR!"P[Z>\"O7LX]I! >=YP6L9+7-XL2ZAD^)-[Q%Y@/!3V@K"7 MF-Q^_GJ;P7:63@!"XRSP/@/QU;R7! \D&R':521Q#-O>#!]UXR+K.+*Q&=5+ MN>=AWQHX_[EO\J,V>5@F"=<:[A_Y59#(0#::/ELT.6\8UF@[YG%L M1"9D+IM%*N\Y3:+AM88 =1?(F^GN$P"D(5DLY932\^E3?5?[(PFB/>L *U.2 M])K? 2F)DCXXVT->B).>NF9P:&<"URW=XDN-7I/% M:DD:#=P6Y ,A%P.)S0D!\)SF3G4+B"U0Q4&2GQ^HS+J=QYO=:=,O#FVS(GY\]Y0-VQTXE+*G!B,7" MS0WL!=#_K[UW[VU;R?)%OPK12)^C'- :D7KO!B[@V,X>]\G#;3N]T=BX?\@6 MG6A:ECRBE+0O[H<_M5Y5JUA%BI*=/;BX\T=B6R+K7>N]?HN)]K.Z!?%X1C1P MI2YUDTD*;IX 0)JQ491-(W*&QTFC#"&@17*1 !V!K@'7&QOW>UC<+4O[& 4. MR&_=G 8[FD*>B?DF@_Q?!&C#D8]S2/;/TD$?DO4SR+D^K3W9TA'GX$/>BF%S>,$QP ;=OO0XVY*:!" MR).R/ES:C>D--][)IEU"T1N.L1@;5,;"MCM4$2\;YCC\,34O\#S9"& H '#X MQC_Q,NA)AHLRQ;*U;Y*!--N?PCPFXPFB'0R2L]C%YT:R >X:=E69^<3T/,P0 M"R0CQ 1[UAWUEVW252?QVCWI^#OIU"99@:!*OBJXM,\<(%0N7/"Y7"77U:.S MA##58MPM:= KA>!Q%K@H7M8)Q0[7TN0?.2'$$,GE)>EP4V\9R09N-B+8(%C5V;Y%A'*/ M7;K<0RS%!W!#H[:[Y9*IO=VBAP3AIJ'&H=N;VUB[R"MZ1'6R-,=ZG8A.%6+? M\!O3">#*3'. WL#$B0T8>""U?.MS;5RME),[44'FKL6YT\ST :9TE R GPCW MI_4?C($Z#J9#6]'0)>X+_(U1Z,? %0PA'?'$[83[4 T!.4L_'?>F7(C3;86% M=7;L%5&6)?3(7'RSQQO,W/A:K+]N9D_F\H(0 92B1@O7XBE:N4J'MD@ZE$JX M/?+>7>Q@.T ,&! $S7A$M5ZG/6"H5S-:]>O%8S+(80W[4WAN@&FI "Q<<.&8 MTG!8@+(98_;PN#=PM2/=Q,X,_9_/<,\^P"V$*ND0 &:0?< M>KY)\K0WFA" 3]K#NKCP6S:&#FNVH\UADWOK0'G<.:8#H ]D%'0I;=I76[>\ MNI_8>,N+:/P*7UK1'6_$' MK261E_X -SI+LZD1GP*[Y9!1Q'=@X"!H:O1(@]Y8OJT^'GNTWF[J/TTQS!2< M<*H@XMJA'EU?W-Q>?SF[_7)]^>G7Y.SSS>T-UAX2D9^%_9K$?@M+^";3& )5 M!&(W5HF(P4AH97S@B!XQLIL&U%&TB<^"*">&&NL5\6H/4L$LQ,/OQ"/\?H_2,ODY/P-ETVC MGLJ]X.@DS1$4NEA:_$7B[*N2M3W!KSE8PZ)+(:@N$95/ZR&QW\Z^S39?:1U% M! ?0!^ ^&=!>!VNH'R%DOR%6Z$6F:\&B&"FPD],/ L5L+ M/X* "--A#<:G3 M0Z&F85ZHN.#M)-$$X/DN.3H*H_\]*7]E]/A[%9V/&OD6[$^2<2''C*NV,:4+ MJ>F\ "0(">BB".\ER8&<'\3F##DSVD:P^6J:1[&2;3?6Z;2CDP#F5/8LV@% )!GE=/BNSB6^/BM-U]G*]%6W7DG7R/Y%#W]8O$HX)ZZ%3:O M@S\2JS4#VH#9GXOK*YMFGP9VFCO$&]M1[*HK?3!%0!&))_9)3;5\D"8\BU7E M+MWC$2Z]XGGV1C7$+7EFCP8:"+%:J.2\F:K$83"-6*!GF2?FI_IS!%*A8BX? M_%;JTF"+%5KORY)3)0T=\P&>J*F13CM?861? 5%3^H\W: L.BUZF#X?E@'D MMC3 #-D@#RK\QUG8 [VG%'*QIQ)@JRT+^/2H"U$07(KTO?7XGL^VL^JS=<\U M<.KZ5YJ "&%,7TZO;R^N/_PC>7_YZ?33V>7IA^3\]/8TZ7SY=/KE_/+VXOQM ML^CHO'5E()EH)RM9B#BXT8;O,>L3MX.F!;@(0> M^?/VVV+C_GI/BKS\B9U_4D+R8)P1;M*8S.SNPDPURPKC, MZ ?HC!VL.??6<%-#*,WJ'M1 KAK !?XW2"/X93$&"[HVDXT?AK M8^^U"3I!?M&46A0'4(K0#6++C6$TT.-ZM?U6UMU-JOZM04@0PQWD)\']KY;Q M9HREN8MOFO-,Z-$@X@ L3CO3X.5EGMY^O+BYL44..[ MR3_NCL&Y';;*W M-CKYUK%GJW8"+#9II?_KT)7J$!)6,7\+B\8L\M:T9TL.M%VTX23-Q^BZ2+-\ MY&D*HU$ZZ/5ES,E&@Q1J,9@GAVE_.@J?A7;^%S[,1:S0 MDT?UTJV+F<'-RII5_!ZN.1&DR/(F\UUA(Y#G:YLM=GKS!6=WDHT9X'1HX9TD MG5*J[-Z*LR"M.,T\_LM0HI'S8&;J!E\SSK!RQ;@+2"8E1).;%;CXCBZBN)6A M^ER3C2'R;)/( J/X\N[FXF]?(%+KXN_PO\Z\EC05RAJ^Y\07"=NVJ3YSKQ@< M5R![2*Z-%G:.:W0K(2PN+:]COWU+X6^^?C#1"+5BU[&:'< 4F9Z17SEXU&Y% M<9UM;8DT%(3?3#3,I@0?.' >J6RWJ-3[CL47V9#E:!2B8VP!UA*&MG%'3%DE M+1\8L@T1,Q?_CDTK6K@G\"7;ILIO ?(*#AJ$?$8;LPVW2XL58E%Y@U$I]4RBD+JI0QI8"6$>E>H,O\ NPJ ?2_FBQD&>W1T JY@@?!! M-(>(0^FYVY1#Z>7C'T7UDYWDY6+'_*$9CL3@,_R=9S3E "&I,FE#2M"-[0ZU MS9,M,$"17ZU9/5AB.*4VMAL=O\[2:M84DD[F7N05H<\O'8IFJ>UM$MLEL>8V MHLO"Q9'_G@*TMYXM@F$YQ&$<&S,V=L^+ ,-9 2>$X!ZL"2DTEB*J*1A*;BK$ M@=E1!9?+N@_QEPLSL>^ M;@-50QGCU%U+B^5PZ'%#=K?B'I"%?G3?@W$D8-* MD'YQ@6Z>:1B_>G2[ZIA.I;S6B3D2)Z#0Z@&U@A/SF[BI-)%$>M 3XO //X9. M8:2FR>-NA4:WI2IHD;(7"S(>,2W8?4&GV06X8GC(&@43J1U!%]_6R8 #O7U6 MC71U[LS]$J#!'R@_4SF8_+IPEBE1Z#6SH(+@TVT;]Q98'F$;?(A>('E=;^GP M=IJ3*R$?7/( LFI1:'Z&+.QEI5";".\Z26?/22#( R8'IDV%)6@G\I^[-7S+Q6]1 M -"^OO4=G$DNV1)1'KJ.&_((""\Q'F^(;A.%^ MEV(:Y.)?8P*-,T4;@8;R4+Q>55_WK,I),B%+0C\@!@_ MN[1KR7DT"\)K'&B M9).PW*+&(T(9#(==J4J& M:&@)$0>;)Y/QX$/[]:W,S5U)DI$R7K2V$5%P74 MB(4R4X9SYC_:2R!^4^L'W8XRQ>JX?#RALL=,]%C"WOGA["QO_K"/"UG]^+% M$8\J0"4CV"]=E?]@R(,(]+.+G50)'8$++"A/LE4(,1HFG0\&LEZ]"]^@B"7< MZ.@HQ+FZ07P,MTZ[DC-F@1:C640A_5O'HJ2RL0$1JF@Z4!'T*;,#6?9$+H#*&X 5!:MJ=(E MZ@3S!66L?=VL=T_0"VW9"6W9W- #1>*\W0X;=H M-R*,C>ZFNY(,V2!^4G*F"+U@DP,GP% $_ YJ[\#B.IF:IR0Y68#F UE_LV6W M:FB7$G5S>WB;^\ R&'(].=$ $EP<#J[K+,2(I[M* !X<*]85LHK]H\VKCE@! MYW%S%!AQ971; JN#M*X["OYT 6DN)1**"D(&%"8\L-M\Y84US6!!U!&9>43' M';W(QDF A[U *CU(4%)1(^+UQ*>9]U)$@"$H7U9@90DD9UF/:]MA]9%+SAQX MKG[A8IJN;$S3A<0T'?1P] MW=WM%DM",:Y\)_9!RM.0G!(J/6:&"%R2F2=GW"7 CB#ZW+7ADE%0K"K7#UN MV=*0F63JPB@;_E9N#HB0(",RYR(S%(=*[@!,=?]:4OBWO.S*##HQ" .DS9V M$NL%V5A!'':5+.\7&[/R%$?ABM0H%B74F \V\"BVH0$=A# 'E!.\](0%9<+L M&%5MAAF>4)[@!*7).S*W?!=T?55/O0 ?#E1"=-R.;-+).V\C<9\03(E#5IP, MPJ>EX,+RV3 Y2?H]-I.+JQ#T$>Z *\=AVK6KY*V;Y>HON(@+5FD@EOZW*!&N M.RZVADQ9'>(L@6HC0W8]<"KU_F-&DC8ON[35-RUE0:B@Q '7?>[2A"Q#+>W, M2KL7&*QF]\W7!D#[WYOD-0 MKN4S)3M6]+)M0;X[J&ZSM'"QU=#_/^I>**ZO)K 5&%97!G3+45N2< 4 %I0^ MKPX.Z-J44G]70)41/T%?0O.[R>>@*:X/PWM"TH^JT.TR*;A 8.$)7,J,K%5K MW&8LO@ H &BQ!W6.T"B<04YMJAC:F'K94+9@L+X]0]GZ*S;^RJ)Z^3LSR)4_ M,6SUR7<04)$8_)P/=EUSJ:W2QBOWK# IW+.$0#7;2 UT7TVN;BJ7*?#E7,TS M9#1X>L @,E,AH:I !:ID6&WF<3TO**%=-.\6 S&L]"'R&.7I>B,F1)32'S9M M9>K6+O[NHK1@,P4A ]&Z24T_D>J^,IZQX-EQC1GW'F*'R+>5_8!8 M0CCR>^=IIV+%Z^HUQ_=F6[5%M_LW?%'Z*30SMUAQMXOM!E_7"&. 6+)214 " MNOH6L0ZBLP-4:8QHL707P9EB3CR[,WN7[ >C?Y+WB^(/U])#Y 5[Z*(K6WW: M.B[MSNBC&.XK F:JHT/6+:)1:LTP\9FZA<(!2U(09EMF=X%P_0%QI@%_V*!6IA),J>I")^N-/3$;UM?%W*+3 M"X+SQ.04 Q+YBJ*Y'NT4E%%?N=RH MHU>K7ZL3WRQ%O/TIHBZ=]SJ._GY&0':"[2'4#68%D"IHBT#M!DP.1H_[^A5= MLWK6;/9DW^$OY'X;_<73)%$Q\B1$ >0FM%K%M\MRQMHB'(N!2. M!!3E"3:&,/4C6LE#H9REE?5;(6(7FI3XKE8JF.JPECI/K"NB; B\3*#-\#C(G$1, MZR(IQ6"(A5?0ZL3P?<[9X+ M2@=N$7(S$C_KU\;-)D18L+Q7FK)H/M$H%2-_ M/"=D5K!.EQV&$16KV;TX@3;H_3-KR:AD7AR[KEGLS;":20$Y)1NI\R+X9E@3 MC[P*L%>V,TQ6V;\7 6_F64J9#U2'O60NUDQA=@3W@Y[*WR32)]HK6P A%Q6A MD047CNW0_!02D1C)(29 ^C>:MQ]G6%P"/96V8"H%]&B6 3/J4N4;?.=]"9+ M, J =33+K36 DF-WY[SD,X(>]&:F%C$-R;YY@EDF.0?QT"QG%-'I +?808S5 MQ-RAU&[2V^K*:16#." J)4+G"S$8'=D*WF@:[6/F&!B/.@3G!I>.P MJO&CX%H=1H;R\L+JPAWI6 ,GIZ)R+*JNN6ICE48"?*"YT#_0)F5F!)#!F"EH MWXUU(JY3;\INK@227=\IG3HQM"<8DTF_5^MI1*Z$=_;0O$XWL2'^\W$V=]<% MKYVE@U)UGG$/$TA:(VL_'A^+4 AQLHL'AE2+WAF(46;=C*HTIC:VA^)N';"A-WQ$ M\2*Y?>X/"*7DTL)5NZCAF1'2B]G6XNXGP]Z?:;$64@#EKB#AC*U[@O/O >8Z M';=[)K,I59C&X^T*3*=22D+D$.S?HH4BU"5'[6X79DEP43DOC3L0+PY+OX@( M8/%1YP4(B=C$7>E!*(AG%V,7!#2;:9XL1A7XQ-ED<8.ME/2 *L$S)20NE]92 M1A8+)F(0N[8,'K%!GFCEE:E0T-N,N(*S:^A! T& ::[OR9UI2PHSXFID.U,R M)#$=\G<:J)(3>64=-X6ASRL$P2)\!6ZWI(O+.= _\" (_-U,4.U4ZX:;X'Y: MV[$VM0MV@_5KIZ3G*I2^C;6BPOU]P(5EQPUWV54I4(*_)KM+F8%\+"$Z2K#W M@%XZ1^/IZIDILCF+R\@!ZS"FQ>Q?*>N(L_F# ,".F/ZWM57RV MQBWM&5$<%T.B@01C3$V0 >H?XD#1('\;X"Z!:&9/IJ762EM&M.X%B5Z6+-@W M*.3"NY4/13&'$#]S5*P&7ZJ#&0M!0FN8LWQ0I/6! MU-.,"&E"U&?/XF,&7L5X\21&3#*H!U=SH!L6F1TR\L:$0 0Y@5?>)MAQ]OOF MD3YD&G(\K*(.B$Z!J&.0FD^9^BHXE%H><3_5$VRQH#C69M_W-N.(XAEU;+8? MQ>)%62/M8'0 \E(3"1 #!\Y M+DH66T%^,>D/J989Q@G=OS-=IP/"!VJ>?M?RZ0M));V"A&%X=?\3]76'P4XN6&Q>1M5K(F77:HSD&AO9UN[N0V)L@ 9 M47(J!]MYMIXJCJFI9(:R05(I5S@O)=GIR>&\J[AN_)+L';M20$1X'M0[,5#_ M+!*+((%.8LSYJNF";!=UJ;N1M34LX5XJ MD;$#A=?UAV"C ^#"B2PQW<*CMERC4;DIY3] M GF,])1]E3\1@->:^.-*S*>-#W )ELJ]%["C3T8$TSEHFS4A[? T#DDG0Q.8 M:NL&#CJ>A2]/G-.YM?Q0FI#5UBH4=Y M]_3FBWT5NC_I#=+D3S?H Z5[X^$J'@&9LFWYR?PLA!Z=VT:) C+L4;%%N0LW/J\JE@K!ZV$90 MPS#TCI&-0$J%]6$+(0@A9(B-;12J>P7P(QE[X5=LDG%(@0J$#)7(+7'WWK/- M)!@LOK(6,+1]V9:2(C2+#E7R <0F4K=B\9ML+J>]E':4YIT_G2V-;N#NV'GQ ML'#NL%GR3LK?Z/N568\JBAV55VS,!6F'"ZR+NR7-C2Q-;FLX%8=+?TKN[\9Y MRRD?T8+R+71F-H9;@((#?FGBQBKZ1$5W4)@.IY](: CC;+G8 Y(9D;V$S%3S.YJ_*4 AUF+YZ!*Q$4IZV"ZS4"F@K-E7-S'O[C=EQUR:W(]T)"P]AD+=5PE6]WR88M$/P= M@ -;F@Q)"89TX+).@_8/SC6D2A9<]#VL/W!3HJ!QP6D_+&LBV M$@W5(8==61DQRRTSB2YAGZ^.H].'U2-[Y*&T*1'[2=LXC5)$&[T.::_8DM^I M119XHC@>G]S"U5@]>WG%?+$77$_+]X? /)FR-E):+1K9H&LS:D?=9?R>7S1* MCBR](Y\U$0^H/XDI"EX*(N(,(8C>;U5BJMHU*33Z5 M\4RE]4I)Z]ZR&Z+FC*ER%&-K%MU'K-\BH;7EG E^J8;2CDZ@B/R?5"(R))XY MB@K?.]G#TDJ VONV_D'C\0UGA//,.7)I1/95HK^5D*N?Z7PW*3:BJWBZ$*@* MF*"BY@@Z@5:XP@++6#+NH@AJI?3HP%X\6+6LU6NX*;;>1>0HWS^&/C1<7"=A M0"3CS&;X.)%NDZ"TH]:$X )[?GYZIE$+:P 0'92.[X,E@D#8\BK3&+(]>9YJ(E M5Z0)SA+K7'(.,#\2H^EF4C2\^LH/"H^#S4@3L5\YTSIAMW .01DY C(XI$JE@;!32I2 MH1JGY$%?$#NUMSC5Q=5UCS__WN@&FS4,9ZV^T]A>6 Y^M?-CD8BENA!1I.^) MU)YY=C,W78+G%U[Z]?3T"GCXM\6=\KB_<&7A &\*MJ\RS T&690H'5#6B41P M60N9=3K+<.2*BD^2>%T8K2$._5@-HV]8:PND013XZ*T[@8YQ@740P[1%-V'R M'[O-HIPO[FW8+VJJ(:\,]--9B$6RE]]VO9/G%8)F +^RM?&1W MO=6O;&BPDP[4&-/ 27%!_<\VO"AMK;,M GIRYF\W>2W)BE-;(=0)2;&[#WIU M7(E6HL6P1$[C4J9?O:*'JZM(Y$YW7W?E=B^-&Y*BJ8$YP/_)1CY,P[_6]6CP MDRM&#_/HW! +'2J 0H&R@CQ:W<84YO>3R1]#^^>=EK:A'<,?+8&(%RQV=86S41E,LON.(.T#8N: M;55V(^8+DJA*^2!:<)A\W,8(",B_NMAX&S,SQ6A6:5R6A+M[9HK]L(_ A MRGR$<^]ZB_JR8SQ]5?Z-RP,I,+*(#Z'*NF]$D_B(8&&,_G?$/>D?2Q8_(GK; MGLO1FX+DIS-\S<&Y$"!U[2QF2JC,Z?IZ]*9R/>@<$CB>%4A4_#?[?QQTH!\T MN*@Z\BV3XQ>_8UGY#:$>8!0?N/^W5(:;4B#AP./%HWEL./]1#.AHLR6Y3"#C MK?W;N4]!Q@!1W[P\GY%M&F8"1PL\^5Y N51!YUP4^"X(19*X(L%.FU%YRV? M+[F7X%*=6V#^/112?!%/T#.99[K>LK_L HT.OD"_%56S"@XC-*LP[-;\95/] MK8H/HCLUS52+@[,I_"?\6^1K2]+=@J33@(GA43\HZ7.XHW M_9FM=CN*>OA<".Q#DR4+86/S&1> M2M&+3-H"$LX/7JO%>A-:'B%M$]1Q$:-YQ+B0BRW:L0E!URYA,8^OH;Z6X\#F M$\<;CIM^ A[TZE>ZZ2Z/Z^ZR?P\7# -)]P[6GD,3VER[U&PZPI+ T^8"<1B] M6!A=U5.TRCI/@#NP;K\*AYY&/K8*6) M F3/@MUEJ&IA]*/U9F'NT.FOR@K; M/] (:S&2]U&1W%"1#PB(8Y!1 <*A@; ML[(VX9F6R(,@[!)0/1=^AS>\2O!SBUCOC$O%ZMN,"NW8ZCAX?3%J1;F:4S"= M"&39_'0-'86>AJA=WI%*N4X5CRS#%B\)@-XA9LWXXV=D< M,2C'\X!8G\]B\I$4 2_AV7_P2EZU9S M6@_B75Y7D0LL4C'Y4I=+X4X:W6^!V4":VE@6T/%8XMK1 M99*!LQY'J(ZR%$ MXRV=2(??=5=X2J5R54M](XF08U3\JJOECO+$0GW2AS_55625"TGUYT%R LKZ MMAZ#$],HJ@"N=',VQ6P.L(TZ_45U4Y*?+[+T(K[O:X!#J30O*4GOL!*=AK;S M751W+H6O6/I =R\84@7E2R.FP E^6N[0_V'>W)5*F/&BF#&!W"&I4GP1[U00 M+J_-L641'SK-5N^H#>^V)TI=F3_H8HV=)&HN* *%#9N]X@(E#D;B.: MZI:30P\5)U[H>HI=C5JG4^3A]FXGN V6.*Y@D/$/D =>:'#UEUT@4%3QHSVP@/%:X.7C<"@;:*]SC)!\X5(8C!IPP6/L33\=;=\WGLGS)@Y M)+5Z,RI"B_/"2J6!!J6=8\ \A9:WHU0.) 5DPS'V9&ZCV.14,,H);!N"[LCO MR69Q'/C6,FJ^[5G8J.3 MY58M&WUFO7FK3V7FDR14]HU<+5I_--:&-X1T.K*9MWYJ @SC FE!CS&.@WI;>0"._+/?=L5X_PG>\VB08LW*W32[9 M]TD5RYS)&]I LL--0Z 4MT=$N](8^EC$DG?/? I@!+$'N.:HK=&#%&HN M);]TZL0&@FC6J[EMR=J?@? B*,$_B[+UR!CDC\+(&:DM^IZ Y964'%X\+G:/ M%C:&3&Y8H %"%])H5UR4E*6*F)FB8M5PWJ\9>6$A=D9B@ (>##L=[1;$%H@Z M7:QV-DO*MHRF)K]EK679.V4?(GV@XHYNI/+@CO9.',Q-%>RJT/K(8015U MAUJ%H$RS=_-4@>S^">-H*:"AY($V7$BYIN]X@-)0&=K@'BC[,NZ^+.:F+DA1\553-XH-')&)>&: M0)]>Q!LL^0=5F/!N:XM9R%*XLB,IM/0FZTY4"6 =HM=59;@'M2=\@*Y%9EP" M]X $RR:RTJ$]$WP 6S^I:N^R1\XS>SJQE]#_J ?SB+7K$VL1*HIM+-EB@B=' MBGP18,'C C:%TN"Q9#M#(U0@#-SL_'@ Y-B%1&K)<'1$CTAC<#@PDDM\#'<% MF#84JSZ$C P(E/1!H)XM:4*Y67'Y:NQ9*\5:P036J=<(T^$WW39*SBB59@0 M%."/>K'R3Y&#=3YV*D9T^:8J#MA"=9[UUBRZ?6^/23'O&>I]:T%RSH#_2DB/ MN6M5A_KM^FEQGXQZILE65T%T6G:IK PE X]V^21.=!B8.T\T.'_5]"UMC(X! MA\0G[.#D!D/6O,'#;*Z(2IIY0AFY^<)3NV=@"V48!V0O(,FZRHQ/@G*A+X[& M&A-XFL4=""MI(&4PX(@-DB'\$'[)Q@5;&@*5,-"_( AA;(*4=$BVP#,0#0W; MJJX*784#)!>"B._$RL;%A&-QR4#&F"^IP"4_NR)71) ->5F5VB_,:^EOKK]T MZU4U:66)S;@X3UR8'6DLB&Z?**SP9[XT=E"J\M8!KO )RBY8(LYT!$%OX#]# M4/8SO>YETKFV=U5./M7'YI<^%=NWL?D_55LGR/>:96&P8IO=J1+?&T+NB21A M=XS!R7'E9#_2'!XK7&'Y!$1IXBP/Y_P7\>\WIBV28-3BI62-.&J%BZ$L'>6S MQ,;>53YG$CX/FQ%**1,7R>].=XPGS1>SKZLU%I\QPN;WXKF4HAPSY&U8#BCA MPJ?S@K+7&"0?+Z9<&8+_P3PO1:\M* SDJBZY[,8SII47&T9G_,J0 "7+D221 ME6X&AK;O5ISO2)S(EL1R%]8#$(^?;Q>O9C:'DWU!\$T%J7VV*53=%T;3<15A M++0' :A[SA6-:ZH@X'>>.48I0@&0N)P.1G7S1WA,'B>9&+C>AW/D'E5O]!87 M(:Q$K.J?7S&>E45!$H]9@"+SW_ [-? [>CE_$R2&4T9B^&1!+S F+\ TN/UO MI(S_1LIH1LKH [*V1;Y0YH7Z&ZZ>OX3D7G.M/N@[]C<=+G*IBEC\#J:(Y!*\ MWP$2A&O4:TU&A/SBNI TU'<4&O%EI3R4.!8$5S1D;\DE<7['.31!4, =H3.) MI@9V=J+UF"*&O/98ROZ 4.Y](](:$ERR*$.EI%RL!$G'6"CB_ADD4=!!C%ZX MI6)D:&7Z2A9K)1UY]$R[XAU,8*PFIM6:+/PHG9_=$[$#AX_F81 7-1'AO1]0A\!PZX"#%YL7DB=:A9(LX(; M AFT5=9H]>>0!HYHNRACL:FNDV/_IWOWYA=#Q+V47RC,YPD0+?8W[W?[D!/\ MQ\\S-WOC\Y=\T@UJ_AY_B_==J3A@>N,]\R+,=-V;V1W$.\AU0RP!#GYT:QC4 M='CYW7NN35#U!2.!#RXU?K!(,;CM.&!(33.2&8Y1IOBWRW:,!D>_M,\%B&+[X%+W*Y;''Z0<.YX%4XL1Q,@-LEBN?'O M=OF+88)D\T?H/,-MDC];%$DTV0ZZ8_-1DWAS7FP6W^6\N1R70TDX G&4N\?' MV<;B/4I=T4CAT* R:X7TA4? V6?(/(K:AZ6.$B9E=6;,W(<4RJ#W7R ,A, 0 M:7^-"#CJ3JLE@\W'/2"W1W1KLQM:=-TW5*(?[7L4T ZK6]3$E:IJ@YK8D9%< MF#@:R%^I:57;91[MIS[C/)IL]VUA2()9N^<&98&H4L8_C?/QH:\2P! @\[L.<,S4&O MC@L^H]4+D!6,;C1.^D.C1-F'<_.T0JYP<5:_&&(S"AJ'S_84'^_';)UZ7YLHW P&WN_O-NM_(L@V6%;)?EEPP0+< M3/MP7RT'_/YQMUJ0'2W633;4LX,_/CH(NC Z;#P:1XX8?8I'_P3 >T%_"5=R MI)<"_Z#MWQ-&1XWW![KC+,W,6$?)^PJICU'X^[?VM9Y:&OB=^G^H4J$XU7F3 MC*<]O(O]21]5>'4GTVS<-V!OL5-\( MA_1?=>[[R6XX$&S(_)B:K?F#:?GP_XNT'.U"E3];DH/JT:UE "&AQ0\/H>>: MH.(?$8J>P0F(]-2OH^DY3'8P4=1FG)FF:VEZ'K0.G[T231^.U#K17P#?[0BS-1X/ATKLCX= MCH\ARU/O]P/)\F@R)C(T&*EY %'N]0?F0/Y\HIQ5_CJ()&=@7L'_7DJ2T;H\ MQ1]&ALN!((54"E&XE;'AK!83JPU(DKEP^^YDM<.MI\#93-#]O34J:R%_N(GB M[C+[SED'&K,'P1,X^KFY;2/SK1S%-U;@>,,G'(YOBZ/"93 QZ,DK<5/OX3@ MH0H.8LM!*&-'RW%X]>"CJYXB*%9"1#"R7#7ZE M)!\8_6AHQ4Q?EU(8XHLE&V0!^Q>QP M]0&#HUQ88Z:R(\:O5Q/W?8/:TQBM#'#_.CTTT;YAI6JO@M./Z'GU"HZYKHXM M=8!3O27]IHX;&HTD1]L+/XQ_MY *##7)Y+VQ>:^-DJ>5.ZWD-;)X)$N@99B. M!J8CHR ;+7D"'!-, AW0\]\R=7.A?M[F-+8_A/,_&H_5,@,IK)A$1$#Y# M$2)L:& OS "'#IP[PY\\=$=FPXO[7WEJ#<7/V2[W1A;_#8N-\<,WBNSOJ.'L M>1)8IX?>XR%(B"W.GQ% IW+^X+TV FF=R:3Q?.1P2W,Z?W#0^X#QV,_'9L?! M.F,V$:XS<=6CS]]PK$7_$3;6YOSQI84EP,6D=NQ5UKR\/\EQ)X?FA&9T^D:X MH\C: PKNC,O5[$Q :BY++!>GK*B%JB[JHK.=T':80?MU^CQ0='KO^:PJ**$5F>/!J^_XVR3 %8YPW9',T/N"L'-;9DE&C=+!C*>\AA\QZPWE]K5H" MA@\>:P]-&3#2%S1<,VZ2"[J!(UX=J@B25YWSL$J:[EPU.(A"X?CM9XR@/>R4 M<21UVX%0*)@_&*.8A+)&TPBK9[)"X:/D^^-,:IFZ!;?Y@D22,_O3/0R/;-=& ML_K.N"=&UH/0G&P E,P]]TCEJF@0>-00'K<$9##!XXTVR: :4LV:14N( MQ':I;M%1S(LU@L%=.ZP$0!EO0@JH!GV(0^]L9!S"K1"XXYY60$^':K;K#67= M-,95M9'#SP1([I3B]Z.[K7[]=SMD,M:]]/U0ZS/D/\==G4Z H.WFV7%!@/*U:[#/6 MYL3":R-.?G%3!))/PE<#-G",473LYSW^?(+Q>!QN"ZJE QU4+/*' MV0[($'HP$\C'%*9'47H=TP+^&?]8QD1I,]D$G&3]#)Q8@RG\#Y\,S2=3\_NP M!^Q$Q964B;;.Q2QU\M.5DG&B34:Q-/*S[E5;E.]AN;O?2EP02X6=H?P Z955 MK\Z ICC ORK[H2ZMVA%8]\Q\1$01Z"#M$.T/[7CNX"!]G_V$T<<2/K3:D0V9\ MY"H)!:80&/;08P:M=&#KHF^_20V3@K-L[9\0ATQ51PZ@NA(X>ET\SJA2!M[" M#K*UM\F5A M<(=J'WC1FQ30?".&JDEM)4Z'X8AC!M\53^6]+J$^<9"<3I)H8 M1]L9YJS;]4',_M^K]0_$PLU.X,KD8$K+^G!TWAHJ:#;^',CS^JEP]7&W4GCA M.>F?&.DJRV%'.X;%]T&TGYHF/D@"!+3:GYJ-[V!XKE'&0>L$D-75#/*K!F9H M<(DX.@R.UIGAF(:I;DNI: 2AE5 L.#=M@<^1GQU:UX;LRLD2STJXE0-D&.;$ MDF*1C>#GY>I$JJ! F!1&;F"$+4W8N_'5G]1OT^EYPYV^<=V^X8XCNO1_T<'( M(6L!3P8J_6BNQY,Q-ANJ3H9Y*IL :>ID.CJS^I8C/I(_VR'AE0:2MNK4K!A%V%J2HCIM"7E4(N_ M!5D'QI@6*I$SXI2PY?S* NA_FOGPSZP%[A_YPF$!%1.STDJ?RC,LPW_#+\ M[(>L=&0+\-YB>E[=64&#EL60L/6!_;WF ,2[X@$5,FRPW>DYNOGF\]0R7P%[ M-W>M/V'+-OJ[WU"NR*4WH@D(@5/(-0&BU9/%\\9DWL\H5\2P1K2G \-;Y]. M4G&(RZW7[*F^ ?8RE'O=#"T7Z(P/'0)"4P3S+[1J[XLYACIC5"0(/;!=ASIPTA_488TC-3HQ \(F0+B\;!@" M6L@Q6GU]']R@%2'V[Q"O!I]L=_XJ61=2"P2DY[K>(_>7;1YN!/8-3VP^["Y' M6NL/DS^K_RX9 NK!>F AY59TKXPT&OE/K/*8O0B)KL1L.H.>/"'\_5JD *P M@F 6IKDI*D+(2>A\F&^I5BR55P>ZBYUE\J AQ@R1[G("[YV>#[9."[^N3B3P M&-74KY$ZD%FHP]H@TT>CRC^ S8]A;02MAEK,U3QO(,V)*Y??ZUKD_<1<=Y@B MOXTN@W\5]Y0Z%7GT/4"Y<5*ON7WDL7!^0A!F+?BS![-F*'#"CCY83CKX*[N= M?-C"<"0RO1BATW[22TK; =J<@UI+1\M, M9GM"Y0GPQLG=3)/OLWL'&&2KAT'J34D-F,8RO/N"@V.>0[&6:!,8*\%]@3O$ MZ1)E,@6=8@*5@.9L"N_965.W/+W#/'*P!^!%)04*IN _CO]3A1ZN88I1/8*SY.+/! M;O.:[LP^HWS1 U&:TMEJ'@1/XD24K([1)4 (#!C>[&X'-5TW549+M1355:FG MS4PO7F;A!'73C/0*(_CER:F'& VW>BTF M5 4\3;!B[,J!$P.J/$B'U\)KVK]?<;NS&[O=.+:J\@WZH, E#@V W'ZC^&XG M]^RN%$/P8?9$H!,D9N"O6'!1Q(><]#&R='5RE/.LE1=A)/C\L/N?VP:I=/\^ M5++21>J6#:D>J7&7F#54/BDVY?^4,A?Q#RD)^KS8SA;+>O<$F%(QH1V3G9LR MAK6EEIZ^>T[H_?VW03DVWBW6)]>S^?^TH'V2M8UMMDM>IVY/99+TYSOY4V+4 M9ML*(L? T-)T-,F28=J;CLT+9CBGH&%AQ3#8[Z$AD*!%B+:OLO9Q>/EDE(QU M!U5>A%U,QSEV,8UUD8'):M+8B1%&A[VF7LQ-'Z1YWSR6&H4TVDL?K+J-O1CQ M<=34R0@Z&0P'T$D> "5,NIY9DOC5F8<6S@IUR\?JCFC;UR'FZ&WK$WQ@JWL/ MN&ZO'CG=B[H$[:HIMA++W^GO;[QB; K"(TH Z@T'2AZK<)+WE;1%C\)IB5T> M7#>*2=XKP+A58(>4;_J*L6/K*(2]=@Z3B-!RF>O\FGQYWD#B UKJ,R+L0'P' M:%_,,Z"_GR--=Y9X% 0"GU5?5QY7T*PZ_3%Q ;*M]W/P]X%'(&,+?:RF;LMY MZ1R_3@_E'!*V@AI?[DD@!-F4>%^63="\T6)^;(+U5"@[M0$VE_? ^)&-0#ZM M]US:->_WR>F04^R:^6 TY60NB 9[V9H3 MO"M@?\05[T_Q@!V]X#0O6)\1^-S0O+9GK4Y$>&YD%R[<-7."23P_ZKCW8 M/D#[DI(%GC3U2]32S2C/3:KVF:?'G\6&K$)0UK*7VF&IC71-K(-JMB"U8#M^ M)T/*=0@P!W"<>C:#MHN S4 8X@3_%R[0H:E9VS3=U.KAFG:Y3B,9TLZT=:P6 MN@OEL,^,/G0*5M8(5)?_5 S6@Z((#5%%I()N/ M$+ )Z-9XTC42]*]@H#%K.1RDO5X/0UJGW7%FQSQ/.M,L[4^(F1@N-,*T-ZAA M6,S_S>P6UJ?K9#TCQ/:(R?<,MYSZHP@%^.$D2R>]$;G)AST[CD$O'=(X#%$? MCO0XLNDPS?.,!I)!'Y&!]"=")J8'_OI0X5]Y=W DA& M/^IM+#%N'07>9@ #,WX-8^DPO9A^^(?X/I9N9@ M_MFHI? ?^$NN%^4_3QXVA0).)PR9+KI3LNX4P&1R^LNVM\3X%'?EP6\*\7_@ M)+0/B5>E-HSFM^9%KBXO>L@&/?:4#5"0Z4X#_^LU^CR(.<(NU9'2/<0SP'X# MC$E%156B-/7S!3$H0Z*)=_7D'!95!<#:Y_X+:&M_/$P'?;EZ@X$E)YFA)Z/I MD*FKH6I\IPW9'*?#(='6Z01NOJ4FAI2-TKS'BE//J!1[R!GT;Z[^B+K)NR-' M5#/S198IJFK[S_II?S#F/@RI\@:03PQUY! KL)OM(>J&GF9Y.LC1QFD4LKX: MP+2?]O*A$-1<#6#L)FG6IM_W5F"*S1$AG0(QVDM()^F$!@"![U.0Z9''9)$ M=EOZ&8^9BP8SM2:;ED4%,'6(0U !4Z*PS:L-J;JZM6-.Z_@*@! MDRF:1 MCTC5A,4!O\&8Y#$K )1)]L9&87^RQ8U,+U; ]\ H2&?G]#+/;7P"228GSH4: M1DE7VH( (OHW2#XN2H"BG*T*J,RUCBZ MK^L_'KF]6,UW)>!4<_)#RX#OX+6X99NY0BH(W@/\14-UXE%?,6!G8]@W1N[> MW"^P(K)-L#BWH-XE;_5G%Y4BBP-[3;"=;+<9]WMH)#-Z#0):LF<.!VO8-(02 MIGUTMT$$*8U\C$!RF>'OX*S*P#9WND3MOY@G00$=[FA$$,M#3(=QL&/0#=CT MANC0RU@A JO:D%-="3#!=EFDW(5B;-]J"C&\#7#71F,/,@Z;@>R) M(1CF>B%(P77@$I:<'YX[!CXK*U D *O:ID>IQ>>,/C@8_.'M'TGB;V/=(6(# M'G3<*_C95Y!*%D*#23&GQP +0 !DV#0>BWGUXQ<]]>L M[M2> +X%U1/ \0CT9;L(G-M8NTC,>G0MLC1'P[Q%O%G'@%>F$PCWF.:0DR*! M)BG6^M[Z\2:X SK_3[J&DA%@Y^6 F$N;AJG*!.-;/VT6H!-#A:\5%SN\]V)5 MN%('U0BA1!!7K>E(.G&Q@ZT&'CC(T3DW'I'#:-H#;G(UHQV]7CPF@QPSX*;P M'"5S@"8NMO'2L!<0U,;H\QCW!LZ4ZR9V-EO-YC-*L0"J >7$H;JN81/$3C%# M)1LZ,"RWGD9:3WNC"0[2_(;.-?@M&T.'-=O1YB"'*;'NCDA==G?8;124=AFE M3?NZ>ZK93X)':G?)[3[E><9YH, 4]?YD+$-DE7TQEP8SCZ8C"*0Y:$^ (-@, MGS]H+8ET<M=7?I9&-(UQS+1>\%Z@S%E.0^1Y_B3'Z.*,X8,FGS4Q]!8X"IJ M\ECC!N..L>@-)LE4INP/E<=@2S$!1] M(8M"BT&\VRW(7PV-VS^\8H!UPS/GM&TOUP45D6+>]OZN/L M7P>O?);73"ULZP4+V.^U[N7@!:S;F[#I_6V=JJ Z8.&?BA_>3=VL5^9WKLY> MNZ3[;[JM(K8QTH94=*B]X!]9= BFR.M.<8I4&S L5'9*61C)[]>F+T'4# ;] M6U"FS)4A_!NYIN'N*;G=E"U-YCF%Z_ M;(Y6R[L^>LWAH^L#:#B@H*'N'9*>3=<*M-4O_SI;=1,HE!O[\AVX "%_75=M M:IJ*,Z[@&Z!FG9,JK@J4_KU<8O7+?_CT+R^_MQ8SFF0=MY6%; MK:HE'#."VJ/Y>S\8Q>^#4$#7]%$N">EM7DZX5>"T\;:NG'3RK)'+M MGY*'SMKB^2HB?=U,;Z&RQ=XM^'T8S@*K5=!VP-7N=WU;;L.[:]TZU/<\N:W;:\M@6C9WFO1D?Q%[[PR M'@]1SY^%+W9W^;AI&9_FT=3F?U-'TE@ M]C=\&&UIT=XQ9&5_LX=2%$EVV'_\Z,E/Z]7] 4?\_X=U\@ZW^_W;G!7NG10PLPGDEE!.PNB8LM0@FG8\<]N& M5\$&8N+G16D>QPFY_MC?)@HT(& MHKE:P];YM95:,";7;NH!AE"(6:7ZGL7&N9W]ZS7;AE/4U':LZ,\14D+SJC9* M "X*[%5%D+W-'B4PM1WR4>O1<',JA;V 1*M'$4/(%Z9;DL^F8F#USP:UP.H? MC94#JS[-R&"-]ZN)F;C/85VB5Z#@XC#AQP?'0Q'0"@>&Z&4/G*S#;J\7X!3? MKI=&#H%3]]WH5,@_Q>2DR\$])PPW$<;#1!K=0R%($MI!JFME 9(KEL72Y/9' ML30[]-'6]H-37FS2P[SH!W?[P9X[;P!-W;YF\<)7;#M2OS 429A8:%8 4N] KT.$U>#&&:'Z9HWY M&6VNTA&+VK2FJ496KO8+07*=>7&_@6FCM?5V'([]Z7;G^LCWCIVZ8X MHB_(,CWB+;-,AZY@O+G9 Q"[HQL%*>?WT[L2S9R-:BTYLD52Z^WZ4B/UUM5&O2;SZQ7FKR"0NF MUCT#?E&ND]JBQ4@BYX&KLN^V.*A+[YS&\W_JLCW#4>[=C,@[Q^S/H/6(#MK) MR/MM-C?RVHOWNXXGUC71/E?VP),TB3>]P[Z&8MF[JF+,2:>:P0Q&^W^I0 MA*\==BC&K5?ET+-R@*IQY)J_U\PF'%A=JMYA SML.5M5:. :@T8)==%'" M)OVCSJU$3BOS8&4<]>*2_V"[(2V@X/J_MKZGX94:KA._7]1<3#!_28,QD?U% M[47D[F/:VR/*XTD'$RU58GP_NVLKGZ=9Y' MOJU0BS3YHJJC6SMFYVI3/"YVCV_QPM,[4FX,X:Q0"M_;M@4!!KMHFES8BL/. MGA@:!::#46"#,CLK]4FMR:M<+P.ZOV\$Z%::-W8/6Q!ZP6HHGA\5K!XJE3W" MV_.7T=?+E6@]$O_[L=9+5;D<]1I*S1T2^:#%#:IK@ITHZCZU?M7;.$AX)HT" M_%.!5M'-PRU#1)*[YR2\W74+,>H*%OS,.]UYO8L+E=1M&>TY/![>[> M!"%S7O'SV M243VR#*%'0LZ.&Z\83Y+..ZY_'MZLL+9Z1#=M+JH>'7E8!SQF MEJBK UY]MI.A2SSHJC.(?ARO&AZ^W(N^'74SQ,J+!PU.XX/,XQ_WHQ_':I2' MRQ%]]=C2Y0&YS&,K$"EI'FA]T7"5?47.P],=KW!>?:X?ZZQ-_?.(.E(MA!Y2 MHTA?=0720_83>1FY2#"E:#]Y]-/6I;*C/1]7*SMVX@XHF!V\WEPEN_IXI%!V MO,46;<4K8H<4>D]9[!;]J_#MF#FY[;/UY8D;'6*'%H<.Z=ZAY:&/&T*U+G1 M%.H#&/84A6Y<2#C [^S)OY38!T/M=TL\Q(AA)?S$^O1N'2AIG W[P*4'[V7$ M4]<\;.'X5T+ \+A:<0OQVD*#BH;:W4 (R+NX.&%%#FC9@YSY8F1) />Y0W PFS3 D&NMVGD&G4MA+J5FR]"O M RS C?+6EA$Y7QCM!?8K!KA#69"F^=/=]ML:PS1K(X4MU<. QS-%];P*0'5T MJ^']Y#<( /JT!FENP0$&YQ%YJJ&)^: MB'NGIC,TV=!X0HW.TM/D\PK 4P^?Z]]VAL[,,.) S>JGKP"#P#VQ=D90X;56 M]6Z\.G>(\MADZ@T")K6IMQ_<+FPO15M,A$8C:"-]Y^/PI8F\>68KR7-HH_F+ M!& 7H'U,NP"8B$]$0IL1%1(;,01NC72'K/[51[NAIU(U%461I.S\'T-.ZS]NVKV:8)K/B/*U!^\#FS:>A. M396VV%@66%7:+S)RLY<5+7^5[?IYXV@LFQUN1I33Q=Y5 ;-0$$4_QQBOR2D) M TVD\J6MIU*%.)6JHHN5O;M-"9,U_5[$P[JH5&=#S=#Z8[##C'*SC\R*'/F. M$__/3]:00^L'S5= /X !HWID'X!J#KUQ_?4/A^$5:<=2K4WC::#B_+U4>P7? M>T!\LMX_>A][Y]7/I:;G@;703YH<&8P#GV24X97D@V0^>PY-'"UK_C;V)7,_ M"2L/^V7?]RV::Z"F;GQ= ZXV^=%-<,E=<&/:(N9'-W8BYTL5+K]0AN?A1:S>4E@=R[Q7REP7.KW]4X,Z_VCUL:),K?, M)HVKHYHZ=BTL*Y U*#4W(#MOI<% 20)8#<.)"XQS0LG1+B@03TT28R8*$3*N MA>\?V 2.T?/Z:"\(UDR@)KVJ 75KRE2_89?TV:R'BW\%-DVL2KHAM3-M\/_; M(]FJC'TJ5EA@9KQX,2NNO7=_MV6N U8?=8CE4<\5E,1.WD-);,]+'OC8NOW0 M+YYUIY%N8D_6U=(.E&&^<0.Y<36L3YZ;V)N91Y^;M'PNJ.']LKW)QT[+X6=-PVZL;Q*1>*MMS7O MMTLU"<_AB9*'D?N =P$V$@-03B0E]>-,[,,WVBVK:>&P ?*QB>B[V,[)GFV[1M]3M=$S M\*XNET;]?)#I'-W#ZRAT>=6&$%==XM/1W/5(1<8Q2Z[W7'?>]?D\97\@75?O M5F"&.KC9GPO?U7[EI.;K>JDYZW43FY*"QD;185>- $T-\9G*J^Q >[AD9\R2 M:NVH'2PH^U90?Q# HA9L!L=\ A?Z9&OC!RH9V7L;.\'!#HOG@S?6+CHM%E#KJX^YDW1?QTPH=,9@,V;+TJ+\00Q1;4.U _Q%QX6 M_RKF-=%A9QR,:;:F':!*Q(], 4H=@6EYB]A4 ERZ06/##(-R8A&OE_8M 7R! MUR5^$*-PVK_F0U:?1F=L(ZH\A!DWX">5;;6NPT>M;=2TY$5G<^Y6[:J9YZ.5 MPYM>6%LTU@0#^N,[Z^9YKN?I 2)2WQHB 7DR_!DD1+V!AO**PY<0:$<*G1 M"@6KI4E9WD4P]06[6/_'[/'I+QK<1$,U'PZ@)ZJ,ZP)L:A(;Y#(EW/?-H& N MS E3,HRP22@$DB5KBP*>(RR72T63K(KGACPSU_J26X>\G16DD6TIC2P.]19_ M#V!T?ZSC89'U;T :V('O/$#9^ ->@6-98!I6L%T0%GSAPH)M[%\M+-:U!/Q] M64&1\@7#W-I]=ZDNQ[\)>]DNG^_P-KFV>BQ9\?#&J#+[Z[3%==U?J;'%P^NT M1:K!#>YM&_(26KR$(QCIK"? MBLBG S7;SSET^7MQ?GRU%4#;YPO!J"'ZVCGF[2B]B]I*=)QE? MA_+^D%=#!7:'Z1/)-O6LI#6X.%F_:QK\"B=OL[XOBCF6Y X_L>.-BNYVSO=F M-\YGCS.0S%'O+3AF.Y*9O!52Z/(1K+LF&.:@:Q[[BL\0SBI"KOI0S>U4M)IX M&JV,U3WC%8ZN>4:'IP[K8G>T5MAB/'7/>#IBB_$,:L=375FM$C=)D'Q+/C]( M77NS[:NYF$N MA:TLA&:K$^FM 6$)DB_N<0A"T*IT(%JYJ%W[08I036">6UI_/5M4SJDW'+VL M@WVG"C7[GW*H*BW+T=J/">T;'5XV_7RJ;@'"];+>G6HEZ]R M-NY?<4'VG0?]V9TYZ 5$E3]]0UP>R,LX\GS07&:N?OR3W9@GNS$V4S-JJ+K8 MP2L-8+>K!41C%]VBP>9YO%\AD<"K/YC)).X/89L=1(1?>S>J=@-NR2 M?V\GJ_Q%K<8F)1FX '>Q%+%SVVF M]\L[B."YN'4'>G"^WMUM'W9+VM,F.:]%YR[#')IF.D9R)Y/,FDC\#%*^=D:- M_\\=ZJ7@!O$.5_"E9:R-A/M]<==-LB'J+^,Z_25H.DK._ZTLM__7_P%02P,$ M% @ IZ%<2A#X$7I< @ 7@P T !X;"]S='EL97,N>&UL[9=;:]LP M%,>_BE#&:&'4ERQIN]J&K5 8K*/0/.RM*+9L"W3Q9#E+^NFGBR^)1[LU:T<* MRT-T=([.[_P524B):K6A^+;$6($UH[R.8:E4]<'SZK3$#-4GHL)<1W(A&5*Z M*PNOKB1&66V2&/5"WY][#!$.DX@W[(JI&J2BX2J&L]X%7/ZER' ,[X[>?F^$ MNG@#7#MY-YGX=\<78_^1#1Q#X!B?LQ@&\_?0^W/HB:\_#Y)M=(2?/1'_&'R$ MGC\-_0AY!#Y] #R 'D@\,XE>NVA)E L^K-T4.HF8_M1Q&N)"VMJO@OI?M\%&@ZQF!A-)> M8 B=(XDJI!26_$IW[&#K_"4$6GNQJ;3"0J)-$,[@D& ;760I9(9E7R: G2N) M*,Z-'$F*TK1*5)X)*B68-C*""L&1U=!EM(;&IIC26W/8ON4[['4.W!BS)#X$ M1D5GZEFWYK!JOI6\37/L;6RX%Q=49"74IT9/A]N^V7/X1N*XUSVR55#NPA&"%I2+IMN>'1-4"KU6W MG=;YOIK#_YIA@3F6B&Z+UGO_Q11/3_]>LCVC8\'/J-%<1(>G,! M'^+/&HZO\E<@\E6,56NK'_@Y?YV8X1PU5-V:*-AC#P?YBA ?S?M2B1\1P ML*]Q1AIV;@L._RB2GU!+ P04 " "GH5Q*0;1!SG$% !F,0 #P 'AL M+W=OZ_8 M(O%@6UG9YN/?5W)(.5G"N[TYFQN2*(K]C&WI.>=(G#X9^S WYD$\5V7=G V6 M;;LZ&8V:;*DKU0S-2M?NFWMC*]6ZCW8Q:E96J[Q9:MU6Y2@G_LW70C\U;^W^HU!96SSJ.S4_&XP'KM^(=.P/NGE=$YW8_\-D[N^+ M3%^9K*MTW:ZAK"Y56YBZ61:K9B!J5>FSP::+4'4N/M5MT;Z(2;T^E.L[$/VI M)_G9('#O6]6ZWSP633$O]4#8D\)]82=YX,'Y("_=9U,6N3M[+OY4I:HS+6;] MM2& (0 ,]P8H#J:*0$8 ,OJ)D#,/X7_0"'/O[GAF"&0,(..]05ZJ9DD@$P"9 M[ ]RJ>B@D0!2[@_25"L"F0+(E!@BRTSG)J%Z(::./2.0 M1P#RB!\4-%07*O"BJ^J[+3X6ZNFL^L[3.?L,9JT MQ[R$\=#-*ZVJ%_Z\XJ)IW&SXN_C+F/RI*$M!,:%;F.62#,5GT^I&3-6+\J3> MA#>F7AS>:5MM82+#!,R*D<-^EJZTN%//>NLF(Z<$S%))W0!N3?:P-&6N;?.K M^.0&2OM"\9!- F:='/FAZWIU93\-?FF7VO;3G]5+O364 ^23@%DHQ^XJ+I75 MAW/5.$P/Z.C>16#()@&S3H+Q4+Q>O]?GL(\8GSWH]N.(=!)P^\0)1%6U(T4$S(K)G".F>E%G\#\%.YV M7ZF6)BXALDS(;)F9.T;>.3=/)N*P#WGZ/OT4Y-@I)K)-R&R;P-NPFS?Z6^>? MR$^/_N^.VXU4$S*K!D;C,_C:":*"9(/\DS/X!5]/7 M62DF\D_"[!\7P/VW(N8C8=.'QM/.9DL?QU-,Y)^$V3\0,Z'^29!_$F;_P )" MDE!,N'V V4+O"@@[-)D@_R3,_OFH@O *2C&1?Q)F_WR$>6?[X4XQD7\29O_ M"D)"JV\)\D_"[!^(*6GU32+_2&;_P$+'%8V-)/*/9/8/PKS=2GHE\H_DSG]0 M/4;2_$")-S(QEV, MV[4$_=9",9&-Y'Z*<3O<+I&-)'Q$<*\5$-DKWN1TAI39*D8W2O6Q'V#$? MI4A$:2^B4=^Y.3_-]7U1Z_RS.T/CVC-59E,K_,MZBV2<^.U*]UU97KJV+_6- M4;Z]/\;F_Q[._P502P,$% @ IZ%<2F[%".EF @ ]BP !H !X;"]? M7_*Y'DYM4XZGKJS> M+^>F;*KC,'3?G"O;8[[4Y:[MMYMJOYYYZO5S[H_Y&%3N?>S>VO[UW+,>2CN^N;OQ@7C3SZZ_#_KV_W^ MM,W?V^VO2VZ&3RK^+JCI!? QG7_"2$-5]K#[CV?*\] -OSQ?: ;,\WVP.T/5]M M#]CV?+<]@-OSY?: ;L^WVP.\/5]O 7H+7V\!>LL"U]KH8INOMP"]A:^W +V% MK[< O86OMP"]A:^W +V%K[< O86OMP"]A:^W KV5K[<"O96OMP*]=8&S$G18 MPM=;@=[*UUN!WLK76X'>RM=;@=[*UUN!WLK76X'>RM<[ +T#7^\ ] Y\O0/0 M._#U#D#OL,!9-SKLYNL=@-Z!KW< >@>^W@'H'?AZ!Z!WX.L=@-Z!KW<$>D>^ MWA'H'?EZ1Z!WY.L=@=Z1KW<$>L<%[E6BFY5\O2/0._+UCD#OR-<[ KTC7^\( M](Y\O0WH;7R]#>AM?+T-Z&U\O0WH;7R]#>AM?+T-Z&T+/&N"'C;AZVU ;^/K M;4!OX^MM0&_CZYV WHFO=P)Z)[[>">B=^'HGH'?BZYV WHFO=P)Z)[[>::)W M.=9]WOT8^E-S*+A7$K?"ILD6-Z]_ B+(9V Y(,R]@DMLF:A);MF'* MV^,$&&E0D4"TTMDT3:YS[TEJ?:M>_GGR%!?[H1_CNFA3\C\8BW5+@XVE\S3F MRL:%P:9\&K;,VWIGM\3$:F58[<9$8UJFJ4=Q=7E-&_O0I\7/E^M3ZW5AO>^[ MVJ;.C>QQ;-XU7;XV+ /U\YK8=CZ>Y07%XF:?N\1\;5WD:BS8)R:\OW$ZS_?= M/E((74-?BN8VFZZFQM4/0[ZEC#Z0;6)+E(:^C*T-U/Q.H1NWKWGO;$B_[) ; MLWW/_EM0GBY'>NKI<("YKD4T+C_F(-&V=AII/#<^M3_?#_G5A-W\_],+_%2.;#]][Z\?+(4!R2) < M"B2'!LEA0')4(#G.07)<@.3@*Y0@**)R%%(YBJDA M7$I7<1!J[P "L" 1 " 9D! !D;V-0A7$J97)PC$ 8 )PG 3 " M ;<" !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#% @ IZ%<2HOU!KZV M @ 30H !@ ( !^ @ 'AL+W=OA7$JS%U_AW04 "0? 8 " M >0+ !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ IZ%<2B?EK*#E P DA !@ M ( !'A4 'AL+W=OA7$J0)R(*)04 '<9 8 " 3D9 !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0# M% @ IZ%<2I2F!=Z1 @ )P@ !@ ( !CR( 'AL+W=O MA7$HI[78^L@$ -(# M 8 " 58E !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ IZ%<2O@#AR&W M 0 T@, !D ( !*BD 'AL+W=O&PO=V]R:W-H965TA M7$J_3R>-M@$ -(# 9 " 04M !X;"]W;W)K&UL4$L! A0#% @ IZ%<2I)+L6NW 0 T@, !D M ( !\BX 'AL+W=O&PO=V]R M:W-H965TA7$HA;!8IMP$ -(# M 9 " &UL M4$L! A0#% @ IZ%<2I,DN>RV 0 T@, !D ( !NS0 M 'AL+W=O&PO=V]R:W-H965TA7$JDFA!NMP$ -(# 9 M " 98X !X;"]W;W)K&UL4$L! A0#% @ MIZ%<2@7YA'^V 0 T@, !D ( !A#H 'AL+W=O&PO=V]R:W-H965TA7$KW MV02%M@$ -(# 9 " 2=$ !X;"]W;W)K&UL4$L! A0#% @ IZ%<2DI&PO=V]R:W-H M965TA7$JZS@/ZQP$ #<$ 9 M " ?Q* !X;"]W;W)K&UL4$L! M A0#% @ IZ%<2F"ZO802 @ G 8 !D ( !^DP 'AL M+W=O&PO=V]R:W-H965TA7$J>.HY[MP$ -(# 9 " M 3Y1 !X;"]W;W)K&UL4$L! A0#% @ IZ%< M2J2 K-_I 0 9@4 !D ( !+%, 'AL+W=O&PO=V]R:W-H965TA7$IP,C6RLP$ -(# 9 " 3E7 !X;"]W;W)K M&UL4$L! A0#% @ IZ%<2@44I46S 0 T@, M !D ( !(UD 'AL+W=O&PO=V]R:W-H965TA7$INPY38 MM0$ -(# 9 " 2-= !X;"]W;W)K&UL4$L! A0#% @ IZ%<2CZ6UTBX 0 T@, !D M ( !#U\ 'AL+W=O&PO=V]R:W-H965T MA7$J#V]I6MP$ -(# 9 M " 1=C !X;"]W;W)K&UL4$L! A0# M% @ IZ%<2A8&<#"X 0 T@, !D ( !!64 'AL+W=O M&PO=V]R:W-H965TA7$JU6L$M'@( @& 9 " 2QJ M !X;"]W;W)K&UL4$L! A0#% @ IZ%<2OR MM%-$ @ [08 !D ( !@6P 'AL+W=O&PO=V]R:W-H965TA7$HV:'7SE0( .L( 9 " 31Q !X;"]W;W)K&UL4$L! A0#% @ IZ%<2J6&PO M=V]R:W-H965TA7$KY@W>= P< M !@N 9 " 1:$ !X;"]W;W)K&UL4$L! A0#% @ IZ%<2AC.J@@4 @ +P8 !D ( ! M4(L 'AL+W=O&PO=V]R:W-H965TA7$HC'&IM$@( $ & 9 M " 0^0 !X;"]W;W)K&UL4$L! A0#% M @ IZ%<2KNO2G<%! ^A, !D ( !6)( 'AL+W=O&PO=V]R:W-H965TA7$KO-\8G/P< 4N 9 " 1Z; !X M;"]W;W)K&UL4$L! A0#% @ IZ%<2E3Q% Z/ M P :Q$ !D ( !E*( 'AL+W=O&PO=V]R:W-H965TA M7$I ,>33-@, -<- 9 " 3RN !X;"]W;W)K&UL4$L! A0#% @ IZ%<2HJ&PO=V]R M:W-H965TA7$J?QS!1AP( &T( M 9 " 2*X !X;"]W;W)K&UL M4$L! A0#% @ IZ%<2I[/$]J&!@ W"0 !D ( !X+H M 'AL+W=O&PO=V]R:W-H965TA7$J> XX 4@( %D' 9 M " 4?% !X;"]W;W)K&UL4$L! A0#% @ MIZ%<2HBN@4* ! ?!8 !D ( !T,< 'AL+W=O&PO=V]R:W-H965TA7$JU9>E!)P( /$% 9 " 2C2 !X;"]W M;W)K&UL4$L! A0#% @ IZ%<2KYF62/5 0 M000 !D ( !AM0 'AL+W=O&PO=V]R:W-H965TA7$H' M'5Q.PP( ,,* 9 " ?_; !X;"]W;W)K&UL4$L! A0#% @ IZ%<2D9@EGI[ @ 00D !D M ( !^=X 'AL+W=O # !N$@ &0 @ &KX0 >&PO=V]R:W-H M965TA7$K 1+ M0P, . . 9 M " <+E !X;"]W;W)K&UL4$L! M A0#% @ IZ%<2I.7FAVZ P CQ !D ( !/.D 'AL M+W=OX" M 6"P &0 @ $M[0 >&PO=V]R:W-H965TA7$I;]8I!LP$ ,P# 9 " M 5+P !X;"]W;W)K&UL4$L! A0#% @ IZ%< M2AYO:Z;NR0 Y"H# !0 ( !//( 'AL+W-H87)E9%-T&UL4$L! A0#% @ IZ%<2A#X$7I< @ 7@P T M ( !7+P! 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% M @ IZ%<2F[%".EF @ ]BP !H ( !@<0! 'AL+U]R96QS M+W=O XML 91 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 92 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 94 FilingSummary.xml IDEA: XBRL DOCUMENT 3.6.0.2 html 429 450 1 true 111 0 false 4 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.bio-rad.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.bio-rad.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 1002000 - Statement - Consolidated Statements of Income Sheet http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome Consolidated Statements of Income Statements 4 false false R5.htm 1003000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 5 false false R6.htm 1005000 - Statement - Consolidated Statements of Changes in Stockholders' Equity Sheet http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity Consolidated Statements of Changes in Stockholders' Equity Statements 6 false false R7.htm 1005000 - Statement - Consolidated Statements of Comprehensive Income Sheet http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 7 false false R8.htm 2101100 - Disclosure - 1. Significant Accounting Policies Sheet http://www.bio-rad.com/role/A1SignificantAccountingPolicies 1. Significant Accounting Policies Notes 8 false false R9.htm 2102100 - Disclosure - 2. Acquisitions Sheet http://www.bio-rad.com/role/A2Acquisitions 2. Acquisitions Notes 9 false false R10.htm 2103100 - Disclosure - 3. Fair Value Measurements Sheet http://www.bio-rad.com/role/A3FairValueMeasurements 3. Fair Value Measurements Notes 10 false false R11.htm 2104100 - Disclosure - 4. Intangible Assets, Goodwill and Other Sheet http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther 4. Intangible Assets, Goodwill and Other Notes 11 false false R12.htm 2106100 - Disclosure - 5. Notes Payable and Long-Term Debt Notes http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebt 5. Notes Payable and Long-Term Debt Notes 12 false false R13.htm 2108100 - Disclosure - 6. Income Taxes Sheet http://www.bio-rad.com/role/A6IncomeTaxes 6. Income Taxes Notes 13 false false R14.htm 2109100 - Disclosure - 7. Stockholders' Equity Sheet http://www.bio-rad.com/role/A7StockholdersEquity 7. Stockholders' Equity Notes 14 false false R15.htm 2111100 - Disclosure - 8. Accumulated Other Comprehensive Income Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncome 8. Accumulated Other Comprehensive Income Notes 15 false false R16.htm 2112100 - Disclosure - 9. Share-based Compensation Sheet http://www.bio-rad.com/role/A9ShareBasedCompensation 9. Share-based Compensation Notes 16 false false R17.htm 2114100 - Disclosure - 10. Other Income and Expenses Sheet http://www.bio-rad.com/role/A10OtherIncomeAndExpenses 10. Other Income and Expenses Notes 17 false false R18.htm 2115100 - Disclosure - 11. Supplemental Cash Flow Information Sheet http://www.bio-rad.com/role/A11SupplementalCashFlowInformation 11. Supplemental Cash Flow Information Notes 18 false false R19.htm 2116100 - Disclosure - 12. Commitments & Contingent Liabilities Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilities 12. Commitments & Contingent Liabilities Notes 19 false false R20.htm 2121100 - Disclosure - 13. Legal Proceedings Sheet http://www.bio-rad.com/role/A13LegalProceedings 13. Legal Proceedings Notes 20 false false R21.htm 2124100 - Disclosure - 14. Segment Reporting Sheet http://www.bio-rad.com/role/A14SegmentReporting 14. Segment Reporting Notes 21 false false R22.htm 2125100 - Disclosure - 15. Restructuring Costs (Notes) Notes http://www.bio-rad.com/role/A15RestructuringCostsNotes 15. Restructuring Costs (Notes) Notes 22 false false R23.htm 2127100 - Disclosure - 16. Quarterly Financial Data Sheet http://www.bio-rad.com/role/A16QuarterlyFinancialData 16. Quarterly Financial Data Notes 23 false false R24.htm 2128100 - Disclosure - Schedule II - Valuation and Qualifying Accoutns Sheet http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns Schedule II - Valuation and Qualifying Accoutns Notes 24 false false R25.htm 2129100 - Disclosure - 17. Subsequent Event (Notes) Notes http://www.bio-rad.com/role/A17SubsequentEventNotes 17. Subsequent Event (Notes) Notes 25 false false R26.htm 2201201 - Disclosure - 1. Significant Accounting Policies (Policies) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies 1. Significant Accounting Policies (Policies) Policies http://www.bio-rad.com/role/A1SignificantAccountingPolicies 26 false false R27.htm 2301302 - Disclosure - 1. Significant Accounting Policies (Tables) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables 1. Significant Accounting Policies (Tables) Tables http://www.bio-rad.com/role/A1SignificantAccountingPolicies 27 false false R28.htm 2303301 - Disclosure - 3. Fair Value Measurements (Tables) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsTables 3. Fair Value Measurements (Tables) Tables http://www.bio-rad.com/role/A3FairValueMeasurements 28 false false R29.htm 2304301 - Disclosure - 4. Intangible Assets, Goodwill and Other (Tables) Sheet http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables 4. Intangible Assets, Goodwill and Other (Tables) Tables http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther 29 false false R30.htm 2306301 - Disclosure - 5. Notes Payable and Long-Term Debt (Tables) Notes http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtTables 5. Notes Payable and Long-Term Debt (Tables) Tables http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebt 30 false false R31.htm 2308301 - Disclosure - 6. Income Taxes (Tables) Sheet http://www.bio-rad.com/role/A6IncomeTaxesTables 6. Income Taxes (Tables) Tables http://www.bio-rad.com/role/A6IncomeTaxes 31 false false R32.htm 2309301 - Disclosure - 7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables) Sheet http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables 7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables) Tables 32 false false R33.htm 2311301 - Disclosure - 8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables) Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables 8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables) Tables 33 false false R34.htm 2311302 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables) Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables) Tables 34 false false R35.htm 2312301 - Disclosure - 9. Share-based Compensation (Tables) Sheet http://www.bio-rad.com/role/A9ShareBasedCompensationTables 9. Share-based Compensation (Tables) Tables http://www.bio-rad.com/role/A9ShareBasedCompensation 35 false false R36.htm 2314301 - Disclosure - 10. Other Income and Expenses (Tables) Sheet http://www.bio-rad.com/role/A10OtherIncomeAndExpensesTables 10. Other Income and Expenses (Tables) Tables http://www.bio-rad.com/role/A10OtherIncomeAndExpenses 36 false false R37.htm 2315301 - Disclosure - 11. Supplemental Cash Flow Information (Tables) Sheet http://www.bio-rad.com/role/A11SupplementalCashFlowInformationTables 11. Supplemental Cash Flow Information (Tables) Tables http://www.bio-rad.com/role/A11SupplementalCashFlowInformation 37 false false R38.htm 2324301 - Disclosure - 14. Segment Reporting (Tables) Sheet http://www.bio-rad.com/role/A14SegmentReportingTables 14. Segment Reporting (Tables) Tables http://www.bio-rad.com/role/A14SegmentReporting 38 false false R39.htm 2325301 - Disclosure - 15. Restructuring Costs (Tables) Sheet http://www.bio-rad.com/role/A15RestructuringCostsTables 15. Restructuring Costs (Tables) Tables http://www.bio-rad.com/role/A15RestructuringCostsNotes 39 false false R40.htm 2327301 - Disclosure - 16. Quarterly Financial Data (Tables) Sheet http://www.bio-rad.com/role/A16QuarterlyFinancialDataTables 16. Quarterly Financial Data (Tables) Tables http://www.bio-rad.com/role/A16QuarterlyFinancialData 40 false false R41.htm 2401403 - Disclosure - 1. Significant Accounting Policies Property, Plant and Equipment (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails 1. Significant Accounting Policies Property, Plant and Equipment (Details) Details 41 false false R42.htm 2401404 - Disclosure - 1. Significant Accounting Policies Warranty rollforward (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails 1. Significant Accounting Policies Warranty rollforward (Details) Details 42 false false R43.htm 2401405 - Disclosure - 1. Significant Accounting Policies Earnings per share (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails 1. Significant Accounting Policies Earnings per share (Details) Details 43 false false R44.htm 2401406 - Disclosure - 1. Significant Accounting Policies Details (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails 1. Significant Accounting Policies Details (Details) Details http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables 44 false false R45.htm 2402401 - Disclosure - 2. Acquisitions (Details) Sheet http://www.bio-rad.com/role/A2AcquisitionsDetails 2. Acquisitions (Details) Details http://www.bio-rad.com/role/A2Acquisitions 45 false false R46.htm 2403402 - Disclosure - 3. Fair Value Measurements (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsDetails 3. Fair Value Measurements (Details) Details http://www.bio-rad.com/role/A3FairValueMeasurementsTables 46 false false R47.htm 2403403 - Disclosure - 3. Fair Value Measurements Foreign Exchange Forward Contracts (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails 3. Fair Value Measurements Foreign Exchange Forward Contracts (Details) Details 47 false false R48.htm 2403404 - Disclosure - 3. Fair Value Measurements Short-term Investments (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails 3. Fair Value Measurements Short-term Investments (Details) Details 48 false false R49.htm 2403405 - Disclosure - 3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails 3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details) Details 49 false false R50.htm 2403406 - Disclosure - 3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails 3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) Details 50 false false R51.htm 2403407 - Disclosure - 3. Fair Value Investments (Details) Sheet http://www.bio-rad.com/role/A3FairValueInvestmentsDetails 3. Fair Value Investments (Details) Details 51 false false R52.htm 2403408 - Disclosure - 3. Fair Value Measurements Contingent Consideration (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails 3. Fair Value Measurements Contingent Consideration (Details) Details 52 false false R53.htm 2404402 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details) Sheet http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details) Details 53 false false R54.htm 2404403 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details) Sheet http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details) Details 54 false false R55.htm 2406402 - Disclosure - 5. Notes Payable and Long-Term Debt (Details) Notes http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails 5. Notes Payable and Long-Term Debt (Details) Details http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtTables 55 false false R56.htm 2408402 - Disclosure - 6. Income Taxes (Details) Sheet http://www.bio-rad.com/role/A6IncomeTaxesDetails 6. Income Taxes (Details) Details http://www.bio-rad.com/role/A6IncomeTaxesTables 56 false false R57.htm 2409402 - Disclosure - 7. Stockholders' Equity (Details) Sheet http://www.bio-rad.com/role/A7StockholdersEquityDetails 7. Stockholders' Equity (Details) Details http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables 57 false false R58.htm 2409403 - Disclosure - 7. Stockholders' Equity Treasury Shares (Details) Sheet http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails 7. Stockholders' Equity Treasury Shares (Details) Details 58 false false R59.htm 2411403 - Disclosure - 8. Accumulated Other Comprehensive Income (Details) Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails 8. Accumulated Other Comprehensive Income (Details) Details http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables 59 false false R60.htm 2411404 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) Details http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables 60 false false R61.htm 2412402 - Disclosure - 9. Share-based Compensation (Details) Sheet http://www.bio-rad.com/role/A9ShareBasedCompensationDetails 9. Share-based Compensation (Details) Details http://www.bio-rad.com/role/A9ShareBasedCompensationTables 61 false false R62.htm 2412403 - Disclosure - 9. Share-based Compensation Restricted Stock (Details) Sheet http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails 9. Share-based Compensation Restricted Stock (Details) Details 62 false false R63.htm 2414402 - Disclosure - 10. Other Income and Expenses (Details) Sheet http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails 10. Other Income and Expenses (Details) Details http://www.bio-rad.com/role/A10OtherIncomeAndExpensesTables 63 false false R64.htm 2415402 - Disclosure - 11. Supplemental Cash Flow Information (Details) Sheet http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails 11. Supplemental Cash Flow Information (Details) Details http://www.bio-rad.com/role/A11SupplementalCashFlowInformationTables 64 false false R65.htm 2416401 - Disclosure - 12. Commitments & Contingent Liabilities (Details) Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails 12. Commitments & Contingent Liabilities (Details) Details http://www.bio-rad.com/role/A12CommitmentsContingentLiabilities 65 false false R66.htm 2416402 - Disclosure - 12. Commitments & Contingent Liabilities Period Expense (Details) Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails 12. Commitments & Contingent Liabilities Period Expense (Details) Details 66 false false R67.htm 2421401 - Disclosure - 13. Legal Proceedings Legal Proceedings (Details) Sheet http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails 13. Legal Proceedings Legal Proceedings (Details) Details 67 false false R68.htm 2424402 - Disclosure - 14. Segment Reporting (Details) Sheet http://www.bio-rad.com/role/A14SegmentReportingDetails 14. Segment Reporting (Details) Details http://www.bio-rad.com/role/A14SegmentReportingTables 68 false false R69.htm 2424403 - Disclosure - 14. Segment Information Segment Profit Reconciliation (Details) Sheet http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails 14. Segment Information Segment Profit Reconciliation (Details) Details 69 false false R70.htm 2424404 - Disclosure - 14. Segment Information Segment Asset Reconciliation (Details) Sheet http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails 14. Segment Information Segment Asset Reconciliation (Details) Details 70 false false R71.htm 2424405 - Disclosure - 14. Segment Information Segment Information by Geographical Location (Details) Sheet http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails 14. Segment Information Segment Information by Geographical Location (Details) Details 71 false false R72.htm 2425402 - Disclosure - 15. Restructuring Costs (Details) Sheet http://www.bio-rad.com/role/A15RestructuringCostsDetails 15. Restructuring Costs (Details) Details http://www.bio-rad.com/role/A15RestructuringCostsTables 72 false false R73.htm 2427402 - Disclosure - 16. Quarterly Financial Data (Details) Sheet http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails 16. Quarterly Financial Data (Details) Details http://www.bio-rad.com/role/A16QuarterlyFinancialDataTables 73 false false R74.htm 2428401 - Disclosure - Schedule II - Valuation and Qualifying Accoutns (Details) Sheet http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails Schedule II - Valuation and Qualifying Accoutns (Details) Details http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns 74 false false R75.htm 2429402 - Disclosure - 17. Subsequent Event (Details) Sheet http://www.bio-rad.com/role/A17SubsequentEventDetails 17. Subsequent Event (Details) Details http://www.bio-rad.com/role/A17SubsequentEventNotes 75 false false All Reports Book All Reports a10k123116.htm bio-20161231.xsd bio-20161231_cal.xml bio-20161231_def.xml bio-20161231_lab.xml bio-20161231_pre.xml true true JSON 96 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a10k123116.htm": { "axisCustom": 3, "axisStandard": 29, "contextCount": 429, "dts": { "calculationLink": { "local": [ "bio-20161231_cal.xml" ] }, "definitionLink": { "local": [ "bio-20161231_def.xml" ] }, "inline": { "local": [ "a10k123116.htm" ] }, "labelLink": { "local": [ "bio-20161231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-doc-2016-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-doc-2014-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-doc-2013-01-31.xml" ] }, "presentationLink": { "local": [ "bio-20161231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-ref-2016-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-ref-2014-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-ref-2013-01-31.xml" ] }, "schema": { "local": [ "bio-20161231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-parts-codification-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd", "http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd", "http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd", "http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd", "http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" ] } }, "elementCount": 761, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2016-01-31": 69, "http://www.bio-rad.com/20161231": 1, "http://xbrl.sec.gov/dei/2014-01-31": 15, "total": 85 }, "keyCustom": 16, "keyStandard": 434, "memberCustom": 29, "memberStandard": 79, "nsprefix": "bio", "nsuri": "http://www.bio-rad.com/20161231", "report": { "R1": { "firstAnchor": null, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information", "role": "http://www.bio-rad.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": null }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - 3. Fair Value Measurements", "role": "http://www.bio-rad.com/role/A3FairValueMeasurements", "shortName": "3. Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - 4. Intangible Assets, Goodwill and Other", "role": "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther", "shortName": "4. Intangible Assets, Goodwill and Other", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - 5. Notes Payable and Long-Term Debt", "role": "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebt", "shortName": "5. Notes Payable and Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - 6. Income Taxes", "role": "http://www.bio-rad.com/role/A6IncomeTaxes", "shortName": "6. Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - 7. Stockholders' Equity", "role": "http://www.bio-rad.com/role/A7StockholdersEquity", "shortName": "7. Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bio:AccumulatedOtherComprehensiveIncomeTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - 8. Accumulated Other Comprehensive Income", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncome", "shortName": "8. Accumulated Other Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bio:AccumulatedOtherComprehensiveIncomeTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - 9. Share-based Compensation", "role": "http://www.bio-rad.com/role/A9ShareBasedCompensation", "shortName": "9. Share-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - 10. Other Income and Expenses", "role": "http://www.bio-rad.com/role/A10OtherIncomeAndExpenses", "shortName": "10. Other Income and Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - 11. Supplemental Cash Flow Information", "role": "http://www.bio-rad.com/role/A11SupplementalCashFlowInformation", "shortName": "11. Supplemental Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - 12. Commitments & Contingent Liabilities", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilities", "shortName": "12. Commitments & Contingent Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Consolidated Balance Sheets", "role": "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121100 - Disclosure - 13. Legal Proceedings", "role": "http://www.bio-rad.com/role/A13LegalProceedings", "shortName": "13. Legal Proceedings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124100 - Disclosure - 14. Segment Reporting", "role": "http://www.bio-rad.com/role/A14SegmentReporting", "shortName": "14. Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125100 - Disclosure - 15. Restructuring Costs (Notes)", "role": "http://www.bio-rad.com/role/A15RestructuringCostsNotes", "shortName": "15. Restructuring Costs (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127100 - Disclosure - 16. Quarterly Financial Data", "role": "http://www.bio-rad.com/role/A16QuarterlyFinancialData", "shortName": "16. Quarterly Financial Data", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128100 - Disclosure - Schedule II - Valuation and Qualifying Accoutns", "role": "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "shortName": "Schedule II - Valuation and Qualifying Accoutns", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129100 - Disclosure - 17. Subsequent Event (Notes)", "role": "http://www.bio-rad.com/role/A17SubsequentEventNotes", "shortName": "17. Subsequent Event (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpensePolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - 1. Significant Accounting Policies (Policies)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies", "shortName": "1. Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpensePolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301302 - Disclosure - 1. Significant Accounting Policies (Tables)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables", "shortName": "1. Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - 3. Fair Value Measurements (Tables)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsTables", "shortName": "3. Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - 4. Intangible Assets, Goodwill and Other (Tables)", "role": "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables", "shortName": "4. Intangible Assets, Goodwill and Other (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - Consolidated Balance Sheets (Parentheticals)", "role": "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - 5. Notes Payable and Long-Term Debt (Tables)", "role": "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtTables", "shortName": "5. Notes Payable and Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - 6. Income Taxes (Tables)", "role": "http://www.bio-rad.com/role/A6IncomeTaxesTables", "shortName": "6. Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - 7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables)", "role": "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables", "shortName": "7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - 8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "shortName": "8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables", "shortName": "8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - 9. Share-based Compensation (Tables)", "role": "http://www.bio-rad.com/role/A9ShareBasedCompensationTables", "shortName": "9. Share-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - 10. Other Income and Expenses (Tables)", "role": "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesTables", "shortName": "10. Other Income and Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - 11. Supplemental Cash Flow Information (Tables)", "role": "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationTables", "shortName": "11. Supplemental Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324301 - Disclosure - 14. Segment Reporting (Tables)", "role": "http://www.bio-rad.com/role/A14SegmentReportingTables", "shortName": "14. Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325301 - Disclosure - 15. Restructuring Costs (Tables)", "role": "http://www.bio-rad.com/role/A15RestructuringCostsTables", "shortName": "15. Restructuring Costs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesRevenueNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Consolidated Statements of Income", "role": "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome", "shortName": "Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327301 - Disclosure - 16. Quarterly Financial Data (Tables)", "role": "http://www.bio-rad.com/role/A16QuarterlyFinancialDataTables", "shortName": "16. Quarterly Financial Data (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401403 - Disclosure - 1. Significant Accounting Policies Property, Plant and Equipment (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "shortName": "1. Significant Accounting Policies Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_us-gaap_RangeAxis_us-gaap_MinimumMember", "decimals": null, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2015Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401404 - Disclosure - 1. Significant Accounting Policies Warranty rollforward (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails", "shortName": "1. Significant Accounting Policies Warranty rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2014Q4", "decimals": "-5", "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401405 - Disclosure - 1. Significant Accounting Policies Earnings per share (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails", "shortName": "1. Significant Accounting Policies Earnings per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401406 - Disclosure - 1. Significant Accounting Policies Details (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "shortName": "1. Significant Accounting Policies Details (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_NewAccountingPronouncementMember", "decimals": "-5", "lang": null, "name": "us-gaap:RestrictedInvestmentsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - 2. Acquisitions (Details)", "role": "http://www.bio-rad.com/role/A2AcquisitionsDetails", "shortName": "2. Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q1QTD_us-gaap_BusinessAcquisitionAxis_bio_AnalyticalFlowCytometerPlatformMember", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestrictedInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - 3. Fair Value Measurements (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "shortName": "3. Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestrictedInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember", "decimals": "-5", "first": true, "lang": null, "name": "invest:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - 3. Fair Value Measurements Foreign Exchange Forward Contracts (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails", "shortName": "3. Fair Value Measurements Foreign Exchange Forward Contracts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember", "decimals": "-5", "first": true, "lang": null, "name": "invest:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - 3. Fair Value Measurements Short-term Investments (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails", "shortName": "3. Fair Value Measurements Short-term Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403405 - Disclosure - 3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails", "shortName": "3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "2", "first": true, "lang": null, "name": "bio:PriceChangeDebtSecurity", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403406 - Disclosure - 3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "shortName": "3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "2", "first": true, "lang": null, "name": "bio:PriceChangeDebtSecurity", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403407 - Disclosure - 3. Fair Value Investments (Details)", "role": "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails", "shortName": "3. Fair Value Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403408 - Disclosure - 3. Fair Value Measurements Contingent Consideration (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "shortName": "3. Fair Value Measurements Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD_us-gaap_BusinessAcquisitionAxis_bio_AnalyticalFlowCytometerPlatformMember_us-gaap_ContingentConsiderationByTypeAxis_bio_DiscountrateMember", "decimals": "2", "lang": null, "name": "us-gaap:FairValueInputsDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2015Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details)", "role": "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "shortName": "4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2014Q4", "decimals": "-5", "lang": null, "name": "us-gaap:GoodwillGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details)", "role": "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "shortName": "4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - 5. Notes Payable and Long-Term Debt (Details)", "role": "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails", "shortName": "5. Notes Payable and Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PrepaidTaxes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - 6. Income Taxes (Details)", "role": "http://www.bio-rad.com/role/A6IncomeTaxesDetails", "shortName": "6. Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PrepaidTaxes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - 7. Stockholders' Equity (Details)", "role": "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "shortName": "7. Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - 7. Stockholders' Equity Treasury Shares (Details)", "role": "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "shortName": "7. Stockholders' Equity Treasury Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - 8. Accumulated Other Comprehensive Income (Details)", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "shortName": "8. Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember", "decimals": "-5", "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2013Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Consolidated Statements of Changes in Stockholders' Equity", "role": "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "Consolidated Statements of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2013Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CostOfGoodsSold", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details)", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "shortName": "8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember", "decimals": "-5", "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - 9. Share-based Compensation (Details)", "role": "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "shortName": "9. Share-based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - 9. Share-based Compensation Restricted Stock (Details)", "role": "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails", "shortName": "9. Share-based Compensation Restricted Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - 10. Other Income and Expenses (Details)", "role": "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "shortName": "10. Other Income and Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - 11. Supplemental Cash Flow Information (Details)", "role": "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "shortName": "11. Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416401 - Disclosure - 12. Commitments & Contingent Liabilities (Details)", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "shortName": "12. Commitments & Contingent Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2015Q4", "decimals": "-5", "lang": null, "name": "us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LettersOfCreditOutstandingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416402 - Disclosure - 12. Commitments & Contingent Liabilities Period Expense (Details)", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails", "shortName": "12. Commitments & Contingent Liabilities Period Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesAwardedValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421401 - Disclosure - 13. Legal Proceedings Legal Proceedings (Details)", "role": "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails", "shortName": "13. Legal Proceedings Legal Proceedings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesAwardedValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "0", "first": true, "lang": null, "name": "bio:NumberOfProductsAndServices", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424402 - Disclosure - 14. Segment Reporting (Details)", "role": "http://www.bio-rad.com/role/A14SegmentReportingDetails", "shortName": "14. Segment Reporting (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "0", "first": true, "lang": null, "name": "bio:NumberOfProductsAndServices", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424403 - Disclosure - 14. Segment Information Segment Profit Reconciliation (Details)", "role": "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "shortName": "14. Segment Information Segment Profit Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember", "decimals": "-5", "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Consolidated Statements of Comprehensive Income", "role": "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424404 - Disclosure - 14. Segment Information Segment Asset Reconciliation (Details)", "role": "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "shortName": "14. Segment Information Segment Asset Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember", "decimals": "-5", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SalesRevenueNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424405 - Disclosure - 14. Segment Information Segment Information by Geographical Location (Details)", "role": "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "shortName": "14. Segment Information Segment Information by Geographical Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember", "decimals": "-5", "lang": null, "name": "us-gaap:SalesRevenueNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425402 - Disclosure - 15. Restructuring Costs (Details)", "role": "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "shortName": "15. Restructuring Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SalesRevenueNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427402 - Disclosure - 16. Quarterly Financial Data (Details)", "role": "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "shortName": "16. Quarterly Financial Data (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4QTD", "decimals": "-5", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428401 - Disclosure - Schedule II - Valuation and Qualifying Accoutns (Details)", "role": "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails", "shortName": "Schedule II - Valuation and Qualifying Accoutns (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "D2017Q1_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429402 - Disclosure - 17. Subsequent Event (Details)", "role": "http://www.bio-rad.com/role/A17SubsequentEventDetails", "shortName": "17. Subsequent Event (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "D2017Q1_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - 1. Significant Accounting Policies", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPolicies", "shortName": "1. Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - 2. Acquisitions", "role": "http://www.bio-rad.com/role/A2Acquisitions", "shortName": "2. Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 111, "tag": { "bio_A2011EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2011 Employee Stock Purchase Plan [Member]", "label": "2011 Employee Stock Purchase Plan [Member]", "terseLabel": "2011 Employee Stock Purchase Plan [Member]" } } }, "localname": "A2011EmployeeStockPurchasePlanMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_AccumulatedOtherComprehensiveIncomeTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "accumulated other comprehensive income [Text Block]", "label": "accumulated other comprehensive income [Text Block]", "terseLabel": "accumulated other comprehensive income [Text Block]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeTextBlock", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "bio_Additionalperformanceperiod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Additional performance period", "label": "Additional performance period", "terseLabel": "Additional performance period" } } }, "localname": "Additionalperformanceperiod", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "durationItemType" }, "bio_AnalyticalFlowCytometerPlatformMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Analytical Flow Cytometer Platform", "label": "Analytical Flow Cytometer Platform [Member]", "terseLabel": "Analytical Flow Cytometer Platform [Member]" } } }, "localname": "AnalyticalFlowCytometerPlatformMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bio_BalanceSheetParentheticalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Balance Sheet Parenthetical [Abstract]", "label": "Balance Sheet Parenthetical [Abstract]" } } }, "localname": "BalanceSheetParentheticalAbstract", "nsuri": "http://www.bio-rad.com/20161231", "xbrltype": "stringItemType" }, "bio_BusinessAcquisitionContingentConsiderationPotentialPercentagePayout": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "business acquisition contingent consideration percentage payout", "label": "Business Acquisition, Contingent Consideration, Potential Percentage Payout", "terseLabel": "Business Acquisition, Contingent Consideration, Potential Percentage Payout" } } }, "localname": "BusinessAcquisitionContingentConsiderationPotentialPercentagePayout", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "bio_CapitalLeasesandOtherDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Capital Leases and Other Debt [Member]", "label": "Capital Leases and Other Debt [Member]", "terseLabel": "Capital Leases and Other Debt [Member]" } } }, "localname": "CapitalLeasesandOtherDebtMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "bio_CellsorterMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CellSorter [Member] [Member]", "label": "CellSorter [Member]", "terseLabel": "CellSorter [Member]" } } }, "localname": "CellsorterMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_ClinicalDiagnosticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Clinical Diagnostics [Member]", "label": "Clinical Diagnostics [Member]", "terseLabel": "Clinical Diagnostics [Member]" } } }, "localname": "ClinicalDiagnosticsMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "bio_CostMethodInvestmentPercentageOwned": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cost Method Investments, Percentage Owned", "label": "Cost Method Investment, Percentage Owned", "terseLabel": "Cost Method Investment, Percentage Owned" } } }, "localname": "CostMethodInvestmentPercentageOwned", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_CostofdebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cost of debt [Member]", "label": "Cost of debt [Member]", "terseLabel": "Cost of debt [Member]" } } }, "localname": "CostofdebtMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_CreditAdjustedDiscountRateHigherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Credit Adjusted Discount Rate Higher [Member]", "label": "Credit Adjusted Discount Rate Higher [Member]", "terseLabel": "Credit Adjusted Discount Rate Higher [Member]" } } }, "localname": "CreditAdjustedDiscountRateHigherMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_CreditAdjustedDiscountRatesLowerMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Credit Adjusted Discount Rates Lower [Member]", "label": "Credit Adjusted Discount Rates Lower [Member]", "terseLabel": "Credit Adjusted Discount Rates Lower [Member]" } } }, "localname": "CreditAdjustedDiscountRatesLowerMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_DiscountrateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Discount rate [Member]", "label": "Discount rate [Member]", "terseLabel": "Discount rate [Member]" } } }, "localname": "DiscountrateMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_DocumentAndEntityInformation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Document and Entity Information" } } }, "localname": "DocumentAndEntityInformation", "nsuri": "http://www.bio-rad.com/20161231", "xbrltype": "stringItemType" }, "bio_EffectiveIncomeTaxRateReconciliationFinesandPenaltiesPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Fines and Penalties, Percent", "label": "Effective Income Tax Rate Reconciliation, Fines and Penalties, Percent", "terseLabel": "Fines and penalties" } } }, "localname": "EffectiveIncomeTaxRateReconciliationFinesandPenaltiesPercent", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "bio_ElectionPercentageForBoardOfDirectors": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Election Percentage for Board of Directors", "label": "Election Percentage for Board of Directors", "terseLabel": "Election Percentage for Board of Directors" } } }, "localname": "ElectionPercentageForBoardOfDirectors", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "bio_EmployeeLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee Location [Axis]", "label": "Employee Location [Axis]", "terseLabel": "Employee Location [Axis]" } } }, "localname": "EmployeeLocationAxis", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "bio_EmployeeLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Employee Location [Axis]", "label": "Employee Location [Domain]", "terseLabel": "Employee Location [Domain]" } } }, "localname": "EmployeeLocationDomain", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "bio_EmployeesCoveredByCollectiveBargainingAgreementsUSPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employees covered by collective bargaining agreements, percentage", "label": "Employees Covered By Collective Bargaining Agreements U.S., Percentage", "terseLabel": "Employees Covered By Collective Bargaining Agreements U.S., Percentage" } } }, "localname": "EmployeesCoveredByCollectiveBargainingAgreementsUSPercentage", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "bio_ForeignTaxCreditCarryforwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign Tax Credit Carryforward [Member]", "label": "Foreign Tax Credit Carryforward [Member]", "terseLabel": "Foreign Tax Credit Carryforward [Member]" } } }, "localname": "ForeignTaxCreditCarryforwardMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forward foreign exchange contract to purchase foreign currency [Member]", "label": "Forward foreign exchange contract to purchase foreign currency [Member]", "terseLabel": "Forward foreign exchange contract to purchase foreign currency [Member]" } } }, "localname": "ForwardforeignexchangecontracttopurchaseforeigncurrencyMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "bio_ForwardforeignexchangecontracttosellforeigncurrencyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forward foreign exchange contract to sell foreign currency [Member]", "label": "Forward foreign exchange contract to sell foreign currency [Member]", "terseLabel": "Forward foreign exchange contract to sell foreign currency [Member]" } } }, "localname": "ForwardforeignexchangecontracttosellforeigncurrencyMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "bio_GnuBIOMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "GnuBIO [Member]", "label": "GnuBIO [Member]", "terseLabel": "GnuBIO [Member]" } } }, "localname": "GnuBIOMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_IncentiveAwardPlan2007Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Incentive Award Plan (2007) [Member]", "label": "Incentive Award Plan (2007) [Member]" } } }, "localname": "IncentiveAwardPlan2007Member", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_IncludingaccruedinterestandpenaltiesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Including accrued interest and penalties [Axis]", "label": "Including accrued interest and penalties [Axis]" } } }, "localname": "IncludingaccruedinterestandpenaltiesAxis", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "bio_IncludingaccruedinterestandpenaltiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Including accrued interest and penalties [Domain]", "label": "Including accrued interest and penalties [Domain]", "terseLabel": "Including accrued interest and penalties [Domain]" } } }, "localname": "IncludingaccruedinterestandpenaltiesDomain", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_IncludingaccruedinterestandpenaltiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Including accrued interest and penalties [Member]", "label": "Including accrued interest and penalties [Member]", "terseLabel": "Including accrued interest and penalties [Member]" } } }, "localname": "IncludingaccruedinterestandpenaltiesMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_KnowHowMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Know how [Member]", "label": "Know How [Member]", "terseLabel": "Know how [Member]" } } }, "localname": "KnowHowMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bio_LegalProceedingsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Legal Proceedings [Abstract]" } } }, "localname": "LegalProceedingsAbstract", "nsuri": "http://www.bio-rad.com/20161231", "xbrltype": "stringItemType" }, "bio_LifeScienceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Life Sciences [Member]", "label": "Life Science [Member]", "terseLabel": "Life Science [Member]" } } }, "localname": "LifeScienceMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "bio_LimitationsOnUseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Limitations On Use [Member]", "label": "Limitations On Use [Member]", "terseLabel": "Limitations On Use" } } }, "localname": "LimitationsOnUseMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_NetofprepaidtaxesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net of prepaid taxes [Axis]", "label": "Net of prepaid taxes [Axis]", "terseLabel": "Net of prepaid taxes [Axis]" } } }, "localname": "NetofprepaidtaxesAxis", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "bio_NetofprepaidtaxesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Net of prepaid taxes [Axis]", "label": "Net of prepaid taxes [Domain]", "terseLabel": "Net of prepaid taxes [Domain]" } } }, "localname": "NetofprepaidtaxesDomain", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_NetofprepaidtaxesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net of prepaid taxes [Member]", "label": "Net of prepaid taxes [Member]", "terseLabel": "Net of prepaid taxes [Member]" } } }, "localname": "NetofprepaidtaxesMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_NonAllocatedExpenseLossContingencyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "NonAllocated Expense Loss Contingency [Member]", "label": "NonAllocated Expense Loss Contingency [Member]", "terseLabel": "NonAllocated Expense Loss Contingency [Member]" } } }, "localname": "NonAllocatedExpenseLossContingencyMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "bio_NonCurrentIncomeTaxExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Non Current Income Tax Expense", "label": "Non Current Income Tax Expense", "terseLabel": "Non-current tax expense (benefit)" } } }, "localname": "NonCurrentIncomeTaxExpense", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_NumberOfProductsAndServices": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Products And Services", "label": "Number Of Products And Services", "terseLabel": "Number Of Products And Services" } } }, "localname": "NumberOfProductsAndServices", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "integerItemType" }, "bio_OperatingLossCarryforwardWithNoExpirationDate": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Loss Carryforward With No Expiration Date", "label": "Operating Loss Carryforward With No Expiration Date", "terseLabel": "Operating Loss Carryforward With No Expiration Date" } } }, "localname": "OperatingLossCarryforwardWithNoExpirationDate", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_Paymentsofcontingentconsideration": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments of contingent consideration", "label": "Payments of contingent consideration", "negatedTerseLabel": "Payments of contingent consideration" } } }, "localname": "Paymentsofcontingentconsideration", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bio_PriceChangeDebtSecurity": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price Change Debt Security", "label": "Price Change Debt Security", "terseLabel": "Price Change Debt Security" } } }, "localname": "PriceChangeDebtSecurity", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_Proceedsfromderivativeinstrumentsoperatingactivities": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from derivative instruments, operating activities", "label": "Proceeds from derivative instruments, operating activities", "terseLabel": "(Payments for) proceeds from forward foreign exchange contracts, net" } } }, "localname": "Proceedsfromderivativeinstrumentsoperatingactivities", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bio_PropertyPlantandEquipmentexcludingsegmentspecificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Property, Plant and Equipment excluding segment specific [Member] -- excludes segment specific gross machinery and equipment", "label": "Property, Plant and Equipment excluding segment specific [Member]", "terseLabel": "Property, Plant and Equipment excluding segment specific [Member]" } } }, "localname": "PropertyPlantandEquipmentexcludingsegmentspecificMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "domainItemType" }, "bio_QuantalifeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "QuantaLife [Member]", "label": "QuantaLife [Member]", "terseLabel": "QuantaLife [Member]" } } }, "localname": "QuantalifeMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_RangeOfExercisePricesGroupFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Range of Exercise Prices, Group Four [Member]", "label": "Range of Exercise Prices, Group Four [Member]" } } }, "localname": "RangeOfExercisePricesGroupFourMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_RangeOfExercisePricesGroupOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Range of Exercise Prices, Group One [Member]", "label": "Range of Exercise Prices, Group One [Member]" } } }, "localname": "RangeOfExercisePricesGroupOneMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_RangeOfExercisePricesGroupThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Range of Exercise Prices, Group Three [Member]", "label": "Range of Exercise Prices, Group Three [Member]" } } }, "localname": "RangeOfExercisePricesGroupThreeMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_RangeOfExercisePricesGroupTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Range of Exercise Prices, Group Two [Member]", "label": "Range of Exercise Prices, Group Two [Member]" } } }, "localname": "RangeOfExercisePricesGroupTwoMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_ReagentRentalEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reagent Rental Equipment [Member]", "label": "Reagent Rental Equipment [Member]", "terseLabel": "Reagent Rental Equipment [Member]" } } }, "localname": "ReagentRentalEquipmentMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "bio_SalesmilestoneminimumamountMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales milestone minimum amount [Member]", "label": "Sales milestone minimum amount [Member]", "terseLabel": "Sales milestone minimum amount [Member]" } } }, "localname": "SalesmilestoneminimumamountMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_SalesmilestonepercentageofannualinvoicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales milestone percentage of annual invoices [Member]", "label": "Sales milestone percentage of annual invoices [Member]", "terseLabel": "Sales milestone percentage of annual invoices [Member]" } } }, "localname": "SalesmilestonepercentageofannualinvoicesMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_SalesmilestonepercentageofannualinvoiceslowMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales milestone percentage of annual invoices low [Member]", "label": "Sales milestone percentage of annual invoices low [Member]", "terseLabel": "Sales milestone percentage of annual invoices low [Member]" } } }, "localname": "SalesmilestonepercentageofannualinvoiceslowMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_SeniorNotes4.875due2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 4.875% [Member]", "label": "Senior Notes 4.875% due 2020 [Member]", "terseLabel": "Senior Notes 4.875% due 2020 [Member]" } } }, "localname": "SeniorNotes4.875due2020Member", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "bio_SettlementwiththeSECandDOJrelatingtotheFCPAincludinginterest": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Settlement with the SEC and DOJ relating to the FCPA, including interest", "label": "Settlement with the SEC and DOJ relating to the FCPA, including interest", "negatedTerseLabel": "Settlement with the SEC and DOJ relating to the FCPA, including interest" } } }, "localname": "SettlementwiththeSECandDOJrelatingtotheFCPAincludinginterest", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeContributionAmount", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "bio_ShorttermRestrictedInvestmentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Short-term Restricted Investments [Policy Text Block]", "label": "Short-term Restricted Investments [Policy Text Block]", "terseLabel": "Short-term Restricted Investments [Policy Text Block]" } } }, "localname": "ShorttermRestrictedInvestmentsPolicyTextBlock", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bio_StockAwardPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Award Plans [Member]", "label": "Stock Award Plans [Member]", "terseLabel": "Stock Award Plans [Member]" } } }, "localname": "StockAwardPlansMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_StockOptionAndAwardPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Option and Award Plans [Member]", "label": "Stock Option and Award Plans [Member]", "terseLabel": "Stock Option and Award Plans [Member]" } } }, "localname": "StockOptionAndAwardPlansMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_TolerablevarianceLevel2debtsecuritypricing": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tolerable variance Level 2 debt security pricing", "label": "Tolerable variance Level 2 debt security pricing", "terseLabel": "Tolerable variance Level 2 debt security pricing" } } }, "localname": "TolerablevarianceLevel2debtsecuritypricing", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_TreasuryClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Treasury Class A [Member]", "label": "Treasury Class-A [Member]", "terseLabel": "Treasury Class-A [Member]" } } }, "localname": "TreasuryClassAMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "domainItemType" }, "bio_TreasuryClassBMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Treasury Class B [Member]", "label": "Treasury Class B [Member]", "terseLabel": "Treasury Class B [Member]" } } }, "localname": "TreasuryClassBMember", "nsuri": "http://www.bio-rad.com/20161231", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word \"Other\".", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r611" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityFilerCategory": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityNumberOfEmployees": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of persons employed by the Entity", "label": "Entity Number of Employees", "terseLabel": "Entity Number of Employees" } } }, "localname": "EntityNumberOfEmployees", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "decimalItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r611" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "invest_DerivativeNotionalAmount": { "auth_ref": [ "r612" ], "lang": { "en-US": { "role": { "documentation": "Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r81" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r69", "r75" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, less allowance for doubtful accounts" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r11", "r50", "r52", "r86" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r108", "r113", "r350", "r476" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Other Postretirement Benefit Plan [Member]" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r80", "r286" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r107", "r113", "r476" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from the appreciation (depreciation) in value of securities attributable to the parent.", "label": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]", "terseLabel": "Net Unrealized Investment Gain (Loss) [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r110", "r112", "r113" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r109", "r113", "r476" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r105", "r113", "r476" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation adjustments [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r70" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortizationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Amortization [Abstract]" } } }, "localname": "AdjustmentForAmortizationAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r351", "r353", "r391", "r392" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words \"stock-based compensation\".", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation": { "auth_ref": [ "r324", "r331", "r395" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit.", "label": "Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation", "terseLabel": "Tax benefit-exercise stock options" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r191", "r192", "r193", "r194", "r195", "r196" ], "lang": { "en-US": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "terseLabel": "All Other Segments [Member]" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r353", "r383", "r390" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Share-based Compensation Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Allowance established for amounts due that are unlikely to be received.", "label": "Allowance for Doubtful Accounts [Member]" } } }, "localname": "AllowanceForDoubtfulAccountsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r96", "r218" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.", "label": "Allowance for Doubtful Accounts Receivable, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmericasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Continents of North and South America.", "label": "Americas [Member]", "terseLabel": "Other (primarily Canada and Latin America) [Member]" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r145", "r271", "r277" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r1", "r9", "r16", "r179" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive shares excluded from the computation of diluted EPS" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region of Asia Pacific.", "label": "Asia Pacific [Member]", "terseLabel": "Pacific Rim [Member]" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset-backed Securities [Member]" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r145", "r284" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment losses on goodwill and long-lived assets" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r547", "r585" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r44", "r46", "r103" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r502" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Financial Assets Carried at Fair Value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r85", "r233" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Debt Securities, Amortized Cost Basis", "totalLabel": "Total Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [ "r226", "r229", "r242" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "terseLabel": "Available-for-sale investments", "verboseLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses": { "auth_ref": [ "r245" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized loss on securities classified as available-for-sale that have been in a loss position for twelve months or longer.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss", "terseLabel": "Gross unrealized losses for investments in a loss position 12 months or more" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses": { "auth_ref": [ "r245", "r247" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized loss on investments in available-for-sale securities that have been in a loss position for less than twelve months.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss", "terseLabel": "Gross unrealized losses for investments in a loss position less than 12 months" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue": { "auth_ref": [ "r244", "r247" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for less than twelve months.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value", "terseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue": { "auth_ref": [ "r244", "r247" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for twelve months or longer.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value", "terseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "auth_ref": [ "r85", "r240" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after adjustments of available-for-sale debt securities at cost, maturing in the sixth fiscal year through the tenth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Amortized Cost Basis", "terseLabel": "Mature in more than five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "auth_ref": [ "r236", "r240", "r572" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of available-for-sale debt securities maturing in the sixth fiscal year through the tenth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Fair Value", "terseLabel": "Mature in more than five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "auth_ref": [ "r85", "r239" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after adjustments of available-for-sale debt securities at cost, maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis", "terseLabel": "Mature in one to five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r236", "r239", "r571" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of available-for-sale debt securities maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value", "terseLabel": "Mature in one to five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r85", "r238" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after adjustments of available-for-sale debt securities at cost, maturing in the next fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis", "terseLabel": "Mature in less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r236", "r238", "r570" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value", "terseLabel": "Mature in less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r226", "r229", "r233", "r568" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of debt securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities, Debt Securities", "totalLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [ "r237", "r241", "r246", "r247", "r251", "r569", "r573" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Schedule of available-for-sale investments" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AvailableforsaleSecuritiesMember": { "auth_ref": [ "r226", "r227", "r228", "r231", "r232" ], "lang": { "en-US": { "role": { "documentation": "Investments in available-for-sale securities.", "label": "Available-for-sale Securities [Member]", "terseLabel": "Available-for-sale Securities [Member]" } } }, "localname": "AvailableforsaleSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r354", "r386" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r485", "r488" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r567" ], "lang": { "en-US": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Foreign Time Deposits [Member]" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building and Building Improvements [Member]" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r48", "r285" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Buildings and leasehold improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r441", "r442" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r460", "r461", "r463" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Business Combination, Consideration Transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r469" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "verboseLabel": "Changes in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r465" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": { "auth_ref": [ "r465" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r459", "r462", "r464" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Business Combination, Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r440", "r441", "r442", "r443", "r444", "r445", "r448", "r449", "r450", "r451", "r452", "r466", "r467", "r468", "r470" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combination Disclosure [Text Block]" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r446", "r447" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalLeaseObligationsMember": { "auth_ref": [ "r543" ], "lang": { "en-US": { "role": { "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.", "label": "Capital Lease Obligations [Member]" } } }, "localname": "CapitalLeaseObligationsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r519", "r520" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying (Reported) Amount, Fair Value Disclosure [Member]" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r5", "r40", "r76", "r147" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents at end of year", "periodStartLabel": "Cash and cash equivalents at beginning of year", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [ "r4", "r5" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [ "r137", "r532" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r4", "r5", "r54", "r149", "r155", "r215" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r5", "r54" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash Equivalents [Member]" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r151", "r152", "r153" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "Cash Flow, Supplemental Disclosures [Text Block]" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r574" ], "lang": { "en-US": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Domestic Time Deposit [Member]" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables", "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r333", "r334", "r335", "r336" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r316" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r91", "r303", "r561", "r592" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingent liabilities" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r91", "r300", "r305", "r314", "r528" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A [Member]", "verboseLabel": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Common Class B [Member]", "verboseLabel": "Common Class B [Member]" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r68" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r68" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r68" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r68", "r324" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r68" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r325" ], "lang": { "en-US": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock, Voting Rights", "terseLabel": "Common Stock, Voting Rights" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r8", "r28", "r29", "r116" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income attributable to Bio-Rad" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r457" ], "lang": { "en-US": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Software [Member]" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r522", "r523", "r527", "r576", "r577", "r603" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration Risk, Credit Risk, Policy [Policy Text Block]" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationItemsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r155", "r474", "r477", "r478" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": { "auth_ref": [ "r155", "r157", "r474", "r477", "r478", "r479" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.", "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]", "terseLabel": "Noncontrolling Interests" } } }, "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate, Non-Segment [Member]" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsSold": { "auth_ref": [ "r122" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs related to goods produced and sold during the reporting period.", "label": "Cost of Goods Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsTotalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consolidated cost of goods (such as cost of goods sold, or purchases) for the period after providing for returns, allowances and discounts, when it serves as a benchmark in a concentration of risk calculation.", "label": "Cost of Goods, Total [Member]", "terseLabel": "Cost of Goods, Total [Member]" } } }, "localname": "CostOfGoodsTotalMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r12", "r160", "r430", "r436" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "U.S. Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r165", "r433" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "International" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r12", "r160", "r430", "r436" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Current Income Tax Expense (Benefit)" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r12", "r160", "r430", "r436" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r455" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndCapitalLeaseObligations": { "auth_ref": [ "r558", "r595" ], "calculation": { "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.", "label": "Debt and Capital Lease Obligations", "totalLabel": "Debt and Capital Lease Obligations" } } }, "localname": "DebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r59", "r61", "r62", "r548", "r550", "r579" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r537", "r539" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount of debt sold" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r88", "r537" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r88" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r89" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r89", "r162", "r325", "r328", "r329", "r330", "r536", "r537", "r539", "r575" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r538" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualEmployerContribution": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of payment into the fund established for purposes of making future disbursements to the individual in accordance with the terms and understanding of the deferred compensation arrangement.", "label": "Deferred Compensation Arrangement with Individual, Employer Contribution", "terseLabel": "Contribution expense" } } }, "localname": "DeferredCompensationArrangementWithIndividualEmployerContribution", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r14", "r160", "r432", "r436" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "verboseLabel": "U.S. Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r14", "r160", "r432", "r436" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "verboseLabel": "International" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r14", "r145", "r160", "r432", "r436" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Deferred tax benefit" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r15", "r64", "r65", "r420", "r549", "r578" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "verboseLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r51", "r338", "r339", "r340", "r341", "r342", "r343" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r14", "r160", "r432", "r436" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "verboseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r13", "r421" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r422" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "verboseLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetNoncurrent": { "auth_ref": [ "r402", "r403", "r404", "r405", "r421" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as noncurrent.", "label": "Deferred Tax Assets, Net of Valuation Allowance, Noncurrent", "terseLabel": "Long-term deferred tax assets" } } }, "localname": "DeferredTaxAssetsNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r398", "r428", "r429" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r3", "r425", "r428", "r429" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit and net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r425", "r428", "r429" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Research" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther": { "auth_ref": [ "r397", "r428", "r429" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other", "terseLabel": "Other post-employment benefits, vacation and other reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": { "auth_ref": [ "r397", "r428", "r429" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies", "terseLabel": "Legal reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves": { "auth_ref": [ "r397", "r428", "r429" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warranty reserves.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves", "terseLabel": "Bad debt, inventory and warranty accruals" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r423" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r404", "r424" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r402", "r404", "r405" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets": { "auth_ref": [ "r398", "r428", "r429" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from long-lived assets other than property, plant, and equipment.", "label": "Deferred Tax Liabilities, Other Finite-Lived Assets", "terseLabel": "Investments and intangible assets" } } }, "localname": "DeferredTaxLiabilitiesOtherFiniteLivedAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r398", "r428", "r429" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "auth_ref": [ "r398", "r428", "r429" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiaries and other recognized entities not within the country of domicile of the entity.", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "verboseLabel": "Deferred Tax Liabilities, Undistributed Foreign Earnings" } } }, "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries": { "auth_ref": [ "r439" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability not recognized because of the exceptions to comprehensive recognition of deferred taxes related to undistributed earnings of foreign subsidiaries.", "label": "Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries", "terseLabel": "Deferred Tax Liability Not Recognized, Cumulative Amount of Temporary Difference" } } }, "localname": "DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r145" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [ "r494" ], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r486", "r487", "r491", "r494" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r166", "r480", "r481", "r482", "r483", "r484", "r489", "r491", "r495", "r497", "r499" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r155", "r167", "r480", "r481", "r483", "r484", "r496" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Forward Foreign Exchange Contracts" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r458" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed Technology Rights [Member]" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r337", "r354", "r386", "r387", "r388", "r394" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.", "label": "Dividends [Axis]", "terseLabel": "Dividends [Axis]" } } }, "localname": "DividendsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock.", "label": "Dividends [Domain]", "terseLabel": "Dividends [Domain]" } } }, "localname": "DividendsDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r119", "r176", "r180", "r182", "r564", "r597" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income per share basic attributable to Bio-Rad", "verboseLabel": "Basic earnings per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic earnings per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r119", "r176", "r564", "r597" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net income per share diluted attributable to Bio-Rad", "verboseLabel": "Diluted earnings per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted earnings per share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r155", "r179", "r180", "r181" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r532" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of foreign exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r164", "r406", "r407" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Provision for income taxes" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r406", "r407", "r435" ], "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "U.S. statutory tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities": { "auth_ref": [ "r406", "r407", "r435" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for qualified production activity.", "label": "Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent", "negatedTerseLabel": "Domestic manufacturing deduction" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r406", "r407", "r435" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Impact of foreign operations" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": { "auth_ref": [ "r406", "r407", "r435" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent", "terseLabel": "Goodwill impairment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r406", "r407", "r435" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent", "terseLabel": "Nondeductible executive compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r406", "r407", "r435" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent", "terseLabel": "Stock-based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r406", "r407", "r435" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent", "terseLabel": "U.S. taxation on foreign income" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r406", "r407", "r435" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent", "terseLabel": "Prior period adjustments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r406", "r407", "r435" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent", "negatedTerseLabel": "Foreign dividends, net" } } }, "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r406", "r407", "r435" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedTerseLabel": "Research tax credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome": { "auth_ref": [ "r406", "r407", "r435" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.", "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent", "negatedTerseLabel": "Nontaxable subsidies" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxExemptIncome", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": { "auth_ref": [ "r406", "r407", "r435" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent", "terseLabel": "Tax settlements and changes to unrecognized tax benefits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r86" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and employee benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions": { "auth_ref": [ "r385" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate proceeds received by the entity during the annual period from exercises of stock or unit options and conversion of similar instruments granted under equity-based payment arrangements.", "label": "Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options", "terseLabel": "Cash Received from Exercise of Stock Options" } } }, "localname": "EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r384" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested share-based compensation awards.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized", "terseLabel": "Total unrecognized compensation cost from stock options", "verboseLabel": "Total unrecognized compensation cost from restricted stock" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r384" ], "lang": { "en-US": { "role": { "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Weighted average fair value of options granted, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions": { "auth_ref": [ "r385" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disclosure of the aggregate tax benefit realized from the exercise of stock options and the conversion of similar instruments during the annual period.", "label": "Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options", "terseLabel": "Tax Benefit Realized from Exercise of Stock Options" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee Severance [Member]" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock [Member]", "verboseLabel": "Employee Stock [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options [Member]", "verboseLabel": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r324" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r55", "r60", "r224", "r556", "r580", "r607" ], "lang": { "en-US": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Marketable Equity Securities [Member]" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r502", "r517" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimate of Fair Value, Fair Value Disclosure [Member]" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Continent of Europe.", "label": "Europe [Member]", "terseLabel": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities": { "auth_ref": [ "r393" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.", "label": "Excess Tax Benefit from Share-based Compensation, Financing Activities", "terseLabel": "Excess tax benefits from share-based compensation" } } }, "localname": "ExcessTaxBenefitFromShareBasedCompensationFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": { "auth_ref": [ "r393" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.", "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities", "negatedTerseLabel": "Excess tax benefits from share-based compensation" } } }, "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r501", "r502", "r503", "r504", "r510", "r511" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r502", "r515", "r517", "r519", "r520", "r525" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r502", "r515", "r517", "r519", "r520", "r525" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Estimated fair value of financial instruments" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r503" ], "lang": { "en-US": { "role": { "documentation": "Information by level within the fair value hierarchy.", "label": "Fair Value, Hierarchy [Axis]", "terseLabel": "Fair Value, Hierarchy [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r509", "r511" ], "lang": { "en-US": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r502", "r512" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r501" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r502", "r515", "r517", "r519", "r520", "r525" ], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r509", "r518", "r521", "r523", "r524", "r526" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsDiscountRate": { "auth_ref": [ "r505" ], "lang": { "en-US": { "role": { "documentation": "Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.", "label": "Fair Value Inputs, Discount Rate", "terseLabel": "Fair Value Inputs, Discount Rate" } } }, "localname": "FairValueInputsDiscountRate", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r24", "r503" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r25", "r27", "r500", "r503" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r26", "r503" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Inputs, Liabilities, Quantitative Information [Line Items]", "terseLabel": "Fair Value Inputs, Liabilities, Quantitative Information [Line Items]" } } }, "localname": "FairValueInputsLiabilitiesQuantitativeInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable": { "auth_ref": [ "r505" ], "lang": { "en-US": { "role": { "documentation": "Schedule of the inputs used in the fair value measurement of liabilities. This disclosure may include, but is not limited to, the fair value of the liability, valuation technique used to measure fair value, the inputs used to measure fair value, the ranges of the inputs, and the weighted averages of the inputs.", "label": "Fair Value Inputs, Liabilities, Quantitative Information [Table]", "terseLabel": "Fair Value Inputs, Liabilities, Quantitative Information [Table]" } } }, "localname": "FairValueInputsLiabilitiesQuantitativeInformationTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock": { "auth_ref": [ "r505" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quantitative information about the inputs used in the fair value measurement of liabilities. This disclosure may include, but is not limited to, the fair value of the liability, valuation technique used to measure fair value, the inputs used to measure fair value, the ranges of the inputs, and the weighted averages of the inputs.", "label": "Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]", "terseLabel": "Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]" } } }, "localname": "FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r506", "r511" ], "lang": { "en-US": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r506", "r511" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [ "r501", "r509" ], "lang": { "en-US": { "role": { "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).", "label": "Fair Value, Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r507" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedTerseLabel": "Net (decrease) increase in estimated fair value of contingent consideration included in selling, general and administrative expense", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r508" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r506" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "verboseLabel": "Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r501", "r509" ], "lang": { "en-US": { "role": { "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.", "label": "Fair Value, Measurements, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r155", "r513", "r516" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r276" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r278" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "Future Amortization Expense, Year One" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r278" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "Future Amortization Expense, Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r278" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "Future Amortization Expense, Year Four" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r278" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "Future Amortization Expense, Year Three" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r278" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "Future Amortization Expense, Year Two" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r272", "r275" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Acquired Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r276" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-Lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r272", "r275" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r276" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "verboseLabel": "Net Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Finite-Lived Intangible Assets, Remaining Amortization Period" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Finite-lived Intangible Assets Acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "terseLabel": "Forward foreign exchange contracts, Asset" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "terseLabel": "Forward foreign exchange contracts, Liability" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyGainLossMember": { "auth_ref": [ "r492" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing foreign currency gain (loss).", "label": "Foreign Currency Gain (Loss) [Member]", "terseLabel": "Foreign Currency Gain (Loss) [Member]" } } }, "localname": "ForeignCurrencyGainLossMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r529", "r530", "r531" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Foreign exchange losses, net" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r155", "r531", "r534" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by a national, local, or municipal government not within the country of domicile of the reporting entity.", "label": "Foreign Government Debt Securities [Member]", "terseLabel": "Foreign Government Obligations [Member]" } } }, "localname": "ForeignGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "auth_ref": [ "r486", "r490" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "terseLabel": "Loss on foreign currency derivative instruments not designated as hedging instruments" } } }, "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r145" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedTerseLabel": "Loss on disposition of fixed assets" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfSecuritiesNet": { "auth_ref": [ "r565", "r599" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net gain (loss) realized from the sale, exchange, redemption, or retirement of securities, not separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.", "label": "Gain (Loss) on Sale of Securities, Net", "negatedLabel": "(Gain) loss on disposition of securities" } } }, "localname": "GainLossOnSaleOfSecuritiesNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r259", "r261", "r262" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, net period end", "periodStartLabel": "Goodwill, net period start", "terseLabel": "Goodwill, net", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r264" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill, Acquired During Period" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r267", "r269", "r273", "r280", "r282" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets Disclosure" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r155", "r267" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r266" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency fluctuations" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r263" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "periodEndLabel": "Goodwill period end", "periodStartLabel": "Goodwill period start" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r263" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "negatedPeriodEndLabel": "Accumulated impairment loss period end", "negatedPeriodStartLabel": "Accumulated impairment loss period start" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r145", "r260", "r265", "r268" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill, Impairment Loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill [Member]", "terseLabel": "Goodwill [Member]" } } }, "localname": "GoodwillMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r121" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Gross profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r281" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r155", "r283", "r288" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r163" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "U.S." } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r163" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "International" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r163" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "Income before income taxes", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r410" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r36", "r411", "r417", "r419", "r434" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r165", "r411", "r424", "r427", "r433" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r20", "r165", "r431" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for income taxes", "verboseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r155", "r400", "r401", "r418", "r419", "r438", "r608" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r150" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "negatedTerseLabel": "Income tax payments" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.", "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities", "terseLabel": "Increase (decrease) in accounts payable and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r144" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Decrease (increase) in accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r144" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Increase in Income Taxes Payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r144" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedTerseLabel": "Decrease in deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r144" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "(Increase) decrease in inventories, net" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "(Increase) decrease in Other Current Assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Decrease in other long term assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net", "negatedTerseLabel": "Increase (Decrease) in Other Long Term Liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r144" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r177", "r180" ], "calculation": { "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Effect of potentially dilutive stock options and restricted stock awards" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r279" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill)" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Intangible Assets, Gross (Excluding Goodwill)" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r270", "r274" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible Assets, Net (Excluding Goodwill)", "verboseLabel": "Purchased intangibles, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestBearingDepositsMember": { "auth_ref": [ "r545", "r552" ], "lang": { "en-US": { "role": { "documentation": "Cash on deposit with financial institutions that earns interest, either at a fixed or market rate.", "label": "Interest-bearing Deposits [Member]", "terseLabel": "Interest-bearing Deposits [Member]" } } }, "localname": "InterestBearingDepositsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r535", "r538", "r566" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r141", "r150" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid for interest during the period.", "label": "Interest Paid", "negatedTerseLabel": "Interest paid" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r97" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r41", "r100", "r254" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventories:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r53", "r101", "r155", "r255", "r256" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r99" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r98" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r125" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "negatedTerseLabel": "Interest and investment income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Summary of amortized cost and estimated fair value of debt securities by contractual maturity date" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Land": { "auth_ref": [ "r47", "r79" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land and improvements" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Legal Matters and Contingencies" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedings" ], "xbrltype": "textBlockItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of Credit Outstanding, Amount", "verboseLabel": "Letters of Credit Outstanding Amount" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r84" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r74", "r553", "r589" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY:" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r87" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r502" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Liabilities, Fair Value Disclosure" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r456" ], "lang": { "en-US": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements [Member]" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r62", "r550", "r579" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Line of Credit Facility, Amount Outstanding" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r82" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Line of Credit Facility, Remaining Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r82" ], "lang": { "en-US": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Line of Credit Facility, Interest Rate at Period End" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r82" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Interest expense (income) directly attributable to an award in settlement of litigation.", "label": "Litigation Settlement Interest", "terseLabel": "Litigation Settlement Interest" } } }, "localname": "LitigationSettlementInterest", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r62", "r550", "r586" ], "calculation": { "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r62" ], "calculation": { "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Long-term Debt and Capital Lease Obligations", "terseLabel": "Long-term Debt and Capital Lease Obligations", "verboseLabel": "Long-term debt, net of current maturities" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligations including current maturities.", "label": "Long-term Debt and Capital Lease Obligations, Including Current Maturities", "terseLabel": "Long-term Debt and Capital Lease Obligations, Including Current Maturities" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligation maturing in the remainder of the fiscal year following the latest fiscal year ended.", "label": "Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year", "terseLabel": "Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Total long-term debt, excluding leases and current maturities" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r168", "r317" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal after Year Five" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r168", "r317" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r168", "r317" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Five" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r168", "r317" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Four" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r168", "r317" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Three" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r168", "r317" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Two" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r89" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Notes Payable and Long-term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r77" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Other investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r89" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r89", "r318" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyDamagesAwardedValue": { "auth_ref": [ "r303", "r304", "r306" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of damages awarded to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Awarded, Value", "terseLabel": "Loss Contingency, Damages Awarded, Value" } } }, "localname": "LossContingencyDamagesAwardedValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r48", "r285" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "terseLabel": "Equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by major type of debt and equity security.", "label": "Major Types of Debt and Equity Securities [Axis]", "terseLabel": "Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis]" } } }, "localname": "MajorTypesOfDebtAndEquitySecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain": { "auth_ref": [ "r223", "r224", "r225", "r569" ], "lang": { "en-US": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions. Equity securities are ownership interests or the right to acquire or dispose of ownership interests in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock.", "label": "Major Types of Debt and Equity Securities [Domain]", "terseLabel": "Major Types of Debt and Equity Securities [Domain]" } } }, "localname": "MajorTypesOfDebtAndEquitySecuritiesDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy": { "auth_ref": [ "r55", "r60", "r155", "r237", "r252", "r555", "r556", "r583" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investments in debt and equity securities that are classified as available-for-sale. This policy also may describe the entity's accounting treatment for transfers between investment categories, how the entity determines whether impairments of available-for-sale securities are other than temporary, and how the fair values of such securities are determined.", "label": "Marketable Securities, Available-for-sale Securities, Policy [Policy Text Block]", "terseLabel": "Available-for-sale Investments" } } }, "localname": "MarketableSecuritiesAvailableForSaleSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r204", "r205" ], "lang": { "en-US": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Segment Reconciling Items [Member]" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaturitiesOfLongTermDebtAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maturities of Long-term Debt [Abstract]" } } }, "localname": "MaturitiesOfLongTermDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r604" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Standard Product Warranty Accrual [Roll Forward]" } } }, "localname": "MovementInStandardProductWarrantyAccrualRollForward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Valuation Allowances and Reserves [Roll Forward]" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]", "terseLabel": "Municipal Obligations [Member]" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r137", "r143" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r137", "r143" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r137", "r142", "r146" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r28", "r29", "r118", "r146", "r180", "r563", "r596" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net Income (Loss) Attributable to Parent", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementMember": { "auth_ref": [ "r0", "r6", "r17", "r21" ], "lang": { "en-US": { "role": { "documentation": "Sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues \"Accounting Standards Updates\" to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Adjustments for New Accounting Pronouncement [Member]", "terseLabel": "Adjustments for New Accounting Pronouncement [Member]" } } }, "localname": "NewAccountingPronouncementMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r6", "r17", "r21", "r33", "r171", "r172", "r173" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "auth_ref": [ "r151", "r152", "r153" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired", "terseLabel": "Noncash purchased intangible assets" } } }, "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1": { "auth_ref": [ "r151", "r152", "r153" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Investments Acquired", "terseLabel": "Noncash Purchased Marketable Securities and Investments" } } }, "localname": "NoncashOrPartNoncashAcquisitionInvestmentsAcquired1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r454" ], "lang": { "en-US": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Noncompete Agreements [Member]" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r212" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Other assets and property, plant and equipment, net" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r126" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTerseLabel": "Nonoperating Income (Expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansPayableCurrent": { "auth_ref": [ "r83" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.", "label": "Notes and Loans Payable, Current", "terseLabel": "Notes payable and current maturities of long-term debt" } } }, "localname": "NotesAndLoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Segment profit", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r540", "r542" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "Operating leases, due next twelve months" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r540", "r542" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "verboseLabel": "Operating leases, due in four years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r540", "r542" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "Operating leases, due in three years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r540", "r542" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "Operating leases, due in two years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r540", "r542" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "verboseLabel": "Operating leases, due thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r541" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating Leases, Rent Expense, Net", "terseLabel": "Operating Leases, Rent Expense, Net" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r425" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsExpirationDate": { "auth_ref": [ "r425" ], "lang": { "en-US": { "role": { "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.", "label": "Operating Loss Carryforwards, Expiration Date", "terseLabel": "Operating Loss Carryforwards, Expiration Dates" } } }, "localname": "OperatingLossCarryforwardsExpirationDate", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "dateItemType" }, "us-gaap_OperatingLossCarryforwardsValuationAllowance": { "auth_ref": [ "r399", "r423", "r426" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.", "label": "Operating Loss Carryforwards, Valuation Allowance", "terseLabel": "Operating Loss Carryforward, Valuation Allowance" } } }, "localname": "OperatingLossCarryforwardsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r187" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r58", "r546", "r584" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "terseLabel": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r102" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r472", "r473", "r475" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of (increase) decrease in accumulated other comprehensive (income) loss related to pension and other postretirement defined benefit plans, attributable to parent entity.", "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent", "negatedTerseLabel": "Other post-employment benefits adjustments, net of tax" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r113", "r117" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r104", "r533" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r114", "r115", "r117", "r324" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r472", "r473", "r475" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r111", "r437" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "negatedTerseLabel": "Other Comprehensive Income (Loss), Tax" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r106", "r110" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax", "terseLabel": "Net unrealized holding gains on available-for-sale investments, net of tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r485", "r498" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets [Member]" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities [Member]" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other Income and Other Expense Disclosure" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [ "r22" ], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other Intangible Assets [Member]" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherInvestments": { "auth_ref": [ "r77", "r593" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments classified as other.", "label": "Other Investments", "terseLabel": "Other Investments" } } }, "localname": "OtherInvestments", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other investments.", "label": "Other Investments [Member]", "terseLabel": "Other Investments [Member]" } } }, "localname": "OtherInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r49", "r50", "r86" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r90" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermInvestmentsMember": { "auth_ref": [ "r581", "r602" ], "lang": { "en-US": { "role": { "documentation": "Long-term investments classified as other.", "label": "Other Long-term Investments [Member]", "terseLabel": "Other Long-term Investments [Member]" } } }, "localname": "OtherLongTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets [Member]" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities [Member]" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r127" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense, net", "terseLabel": "Other Nonoperating Income (Expense)", "totalLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other Nonoperating Income (Expense) [Member]" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherSignificantNoncashTransactionNameDomain": { "auth_ref": [ "r151", "r152", "r153" ], "lang": { "en-US": { "role": { "documentation": "The name of other significant noncash (or part noncash) investing and financing activities required to be supplementally disclosed to enable users of the financial information to fully understand the period cash flows of the Entity in relation to the statements of financial position, income statement, and statement of changes in shareholders' equity. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.", "label": "Other Significant Noncash Transaction, Name [Domain]", "terseLabel": "Other Significant Noncash Transaction, Name [Domain]" } } }, "localname": "OtherSignificantNoncashTransactionNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherSignificantNoncashTransactionsByUniqueDescriptionAxis": { "auth_ref": [ "r151", "r152", "r153" ], "lang": { "en-US": { "role": { "documentation": "Information by other significant noncash transactions.", "label": "Other Significant Noncash Transaction [Axis]", "terseLabel": "Other Significant Noncash Transaction [Axis]" } } }, "localname": "OtherSignificantNoncashTransactionsByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherSignificantNoncashTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Significant Noncash Transactions [Line Items]", "terseLabel": "Other Significant Noncash Transactions [Line Items]" } } }, "localname": "OtherSignificantNoncashTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherSignificantNoncashTransactionsTable": { "auth_ref": [ "r151", "r152", "r153" ], "lang": { "en-US": { "role": { "documentation": "This table may contain information related to other significant noncash investing and financing activities that occurred during the accounting period and are not otherwise listed in the existing taxonomy. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.", "label": "Other Significant Noncash Transactions [Table]", "terseLabel": "Other Significant Noncash Transactions [Table]" } } }, "localname": "OtherSignificantNoncashTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet": { "auth_ref": [ "r249" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of other than temporary impairment (OTTI) losses on equity securities, OTTI related to credit losses on debt securities, and OTTI losses on debt securities when the entity intends to sell the securities or it is more likely than not that the entity will be required to sell the securities before recovery of its amortized cost basis. Additionally, this item includes OTTI losses recognized during the period on investments accounted for under the cost method of accounting.", "label": "Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net", "terseLabel": "Other-than-temporary impairment losses on investments" } } }, "localname": "OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total Bio Rad [Member]", "verboseLabel": "Parent [Member]" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r142", "r290" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "terseLabel": "Payments for Restructuring" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r136" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Debt issuance costs on long-term borrowings" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAssetsInvestingActivities": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate cash payments for a combination of transactions that are classified as investing activities in which assets, which may include securities, other types of investments, or productive assets, are purchased from third-party sellers. This element can be used by entities to aggregate payments for all asset purchases that are classified as investing activities.", "label": "Payments to Acquire Assets, Investing Activities", "negatedTerseLabel": "Payments for acquisitions, net of cash received, and long-term investments" } } }, "localname": "PaymentsToAcquireAssetsInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r23", "r131" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r23", "r132" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Payments for purchases of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r23", "r133" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Payments for purchases of marketable securities and investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r23", "r132" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Capital expenditures", "terseLabel": "Payments to Acquire Property, Plant, and Equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireRestrictedInvestments": { "auth_ref": [ "r23", "r133" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.", "label": "Payments to Acquire Restricted Investments", "negatedTerseLabel": "Payments for purchases of restricted investment" } } }, "localname": "PaymentsToAcquireRestrictedInvestments", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToSuppliersAndEmployees": { "auth_ref": [ "r140" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash payments to suppliers for goods and services provided and to employees for services provided.", "label": "Payments to Suppliers and Employees", "negatedTerseLabel": "Cash paid to suppliers and employees" } } }, "localname": "PaymentsToSuppliersAndEmployees", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceGuaranteeMember": { "auth_ref": [ "r30", "r308" ], "lang": { "en-US": { "role": { "documentation": "An agreement (contract) that requires the guarantor to make payments to a guaranteed party based on another entity's failure to perform under an obligating agreement. This may include the issuance of a performance standby letter of credit which requires the guarantor to make payments if a specified party fails to perform under a nonfinancial contractual obligation.", "label": "Performance Guarantee [Member]", "terseLabel": "Performance Guarantee [Member]" } } }, "localname": "PerformanceGuaranteeMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r354", "r386" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r514", "r515" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent": { "auth_ref": [ "r348", "r349", "r560", "r594" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount as of the balance sheet date of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.", "label": "Postemployment Benefits Liability", "terseLabel": "Post-Employment Benefits Liability" } } }, "localname": "PostemploymentBenefitsLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r67" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r67" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r67" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r67" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r67" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r10", "r42", "r45", "r258" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r10", "r43", "r45", "r257", "r258" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "terseLabel": "Prepaid Taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCustomers": { "auth_ref": [ "r138" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services.", "label": "Proceeds from Customers", "terseLabel": "Cash received from customers" } } }, "localname": "ProceedsFromCustomers", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r18", "r134" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r23", "r129", "r230" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with maturities (principal being due), prepayments and calls (requests of early payments) on securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.", "label": "Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities", "terseLabel": "Proceeds from maturities of marketable securities and investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherOperatingActivities": { "auth_ref": [ "r139" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from operating activities classified as other.", "label": "Proceeds from Other Operating Activities", "terseLabel": "Investment proceeds and miscellaneous receipts, net" } } }, "localname": "ProceedsFromOtherOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [ "r148" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "terseLabel": "Net borrowings on (payments for) line-of-credit arrangements and notes payable" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities": { "auth_ref": [ "r23", "r129", "r230" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.", "label": "Proceeds from Sale of Available-for-sale Securities", "terseLabel": "Proceeds from sales of marketable securities and investments" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r23", "r130" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from dispositions of property, plant and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r312", "r313", "r559" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "Standard and Extended Product Warranty Accrual", "periodEndLabel": "Warranty accrual, end of period", "periodStartLabel": "Warranty accrual, beginning of period" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualPayments": { "auth_ref": [ "r309" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "negatedTerseLabel": "Actual warranty costs" } } }, "localname": "ProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r310" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued.", "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued", "terseLabel": "Provision for warranty" } } }, "localname": "ProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r80", "r287" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment by Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r79", "r285" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Total property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGrossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment, Gross [Abstract]", "terseLabel": "Property, plant and equipment:" } } }, "localname": "PropertyPlantAndEquipmentGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r56", "r57", "r287", "r591" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r78", "r155", "r287" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r56", "r285" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Purchase Commitment, Excluding Long-term Commitment [Line Items]", "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Line Items]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": { "auth_ref": [ "r63", "r551", "r587" ], "lang": { "en-US": { "role": { "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers. Such disclosure may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions.", "label": "Purchase Commitment, Excluding Long-term Commitment [Table]", "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Table]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialDataAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Quarterly Financial Data [Abstract]" } } }, "localname": "QuarterlyFinancialDataAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r183", "r184", "r186" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Quarterly Financial Data [Text Block]" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialData" ], "xbrltype": "textBlockItemType" }, "us-gaap_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by range, including, but not limited to, upper and lower bounds.", "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsTables", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extent of variation, for example, but not limited to, upper and lower bounds.", "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsTables", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r598", "r600" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.", "label": "Realized Investment Gains (Losses)", "negatedTerseLabel": "Net realized (gains) losses on investments" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r113", "r117" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "terseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Member]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": { "auth_ref": [ "r203", "r205" ], "lang": { "en-US": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table]", "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table]" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r203", "r205" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Assets from Segment to Consolidated" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "auth_ref": [ "r202", "r205" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r202", "r205" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of segment profit to consolidated income before taxes" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligation": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Recorded Unconditional Purchase Obligation", "terseLabel": "Recorded Unconditional Purchase Obligation" } } }, "localname": "RecordedUnconditionalPurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueAfterFifthYear": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due after Fifth Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due after Fifth Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueAfterFifthYear", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInFifthYear": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Fifth Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Fifth Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInFifthYear", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Fourth Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Fourth Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInFourthYear", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Second Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Second Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Third Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Third Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Next Twelve Months", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Next Twelve Months" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueWithinOneYear", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r18", "r135" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Payments on long-term borrowings" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r396", "r610" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r32", "r155", "r396" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r3", "r427" ], "lang": { "en-US": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedInvestmentsAtFairValue": { "auth_ref": [ "r605", "r606" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate value of all restricted investments.", "label": "Restricted Investments, at Fair Value", "terseLabel": "Restricted Investments, at Fair Value" } } }, "localname": "RestrictedInvestmentsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsCurrent": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.", "label": "Restricted Investments, Current", "terseLabel": "Restricted investments" } } }, "localname": "RestrictedInvestmentsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r179" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r291", "r293", "r299" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Related Activities Disclosure [Text Block]" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r145", "r289", "r293", "r298" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring Charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring Costs [Abstract]" } } }, "localname": "RestructuringCostsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r290", "r295" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "terseLabel": "Restructuring Reserve" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "auth_ref": [ "r289", "r294" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.", "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Restructuring Reserve, Accrual Adjustment" } } }, "localname": "RestructuringReserveAccrualAdjustment1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveCurrent": { "auth_ref": [ "r289", "r297" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Current", "terseLabel": "Restructuring Reserve, Current" } } }, "localname": "RestructuringReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveNoncurrent": { "auth_ref": [ "r289" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Noncurrent", "terseLabel": "Restructuring Reserve, Noncurrent" } } }, "localname": "RestructuringReserveNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveTranslationAdjustment": { "auth_ref": [ "r290", "r297" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve.", "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)", "terseLabel": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)" } } }, "localname": "RestructuringReserveTranslationAdjustment", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r71", "r331", "r588" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r154", "r155", "r156", "r344" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.", "label": "Revenue Recognition, Policy [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r493" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales [Member]", "terseLabel": "Sales [Member]" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNet": { "auth_ref": [ "r120" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.", "label": "Revenue, Net", "terseLabel": "Net sales" } } }, "localname": "SalesRevenueNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The reporting scenario used to indicate financial results forecast for a future period.", "label": "Scenario, Forecast [Member]", "terseLabel": "Scenario, Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario, Unspecified [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r272" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r272" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major-Class" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Available-for-sale Securities [Line Items]", "terseLabel": "Schedule of Available-for-sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r2", "r237", "r241", "r246", "r247", "r248", "r250", "r569", "r573" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r441", "r442" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r433" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Provision for income taxes [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r89", "r162", "r325", "r328", "r329", "r330", "r536", "r537", "r539", "r575" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Principal components of long-term debt [Table Text Block]" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r424" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Significant components of deferred tax assets and liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r166", "r480", "r481", "r482", "r483", "r484", "r489", "r491", "r495", "r497" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments [Table Text Block]" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r406" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Reconcilation of effective tax rate on inocme before taxes and statutory rate [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r501" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Financial assets and liabilities carried at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r267", "r269" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r267", "r269" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Changes to goodwill by segment" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "U.S. and international components of income before taxes [Table Text Block]" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Schedule of other income (expense), net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r314" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Schedule of Product Warranty Liability" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r80", "r287" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule of Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Schedule of Quarterly Financial Data [Table Text Block]" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r291", "r292", "r296" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r291", "r292", "r296" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring and Related Costs [Table Text Block]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r120", "r213" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Net sales and assets to external customers by geographic area" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r197", "r198", "r199", "r204", "r267" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r197", "r198", "r199", "r204", "r267" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Information regarding industry segments" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r354", "r386" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r386" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]", "terseLabel": "Stock Options Outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r377" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Employee Stock Purchase Plan, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r377" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Stock Options Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Resticted Stock Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r92", "r161", "r319", "r321", "r322", "r325", "r326", "r327", "r328", "r329", "r330", "r331" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r66", "r67", "r68", "r158", "r320", "r321", "r322", "r325", "r326", "r327", "r328", "r329", "r330", "r331" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Schedule of Stock by Class [Table Text Block]" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).", "label": "Schedule of Unrealized Loss on Investments [Table Text Block]", "terseLabel": "Summary of investments with gross unrealized losses and the associated fair value" } } }, "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r169" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for any allowance and reserve accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements.", "label": "Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r180" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of Weighted Average Number of Shares" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segment [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentGeographicalDomain": { "auth_ref": [ "r39", "r213", "r609" ], "lang": { "en-US": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAssetReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Asset Reconciling Item [Line Items]", "terseLabel": "Segment Reporting, Asset Reconciling Item [Line Items]" } } }, "localname": "SegmentReportingAssetReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r188", "r189", "r190", "r200", "r201", "r204", "r205", "r206", "r207", "r208", "r209", "r211", "r213", "r214" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationProfitLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting Information, Profit (Loss) [Abstract]" } } }, "localname": "SegmentReportingInformationProfitLossAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]" } } }, "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentsGeographicalAreasAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segments, Geographical Areas [Abstract]" } } }, "localname": "SegmentsGeographicalAreasAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r124", "r253" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "negatedTerseLabel": "Selling, general and administrative expense", "terseLabel": "Selling, general and administrative expense" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r144" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation [Abstract]" } } }, "localname": "ShareBasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r356" ], "lang": { "en-US": { "role": { "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Options Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "auth_ref": [ "r386" ], "lang": { "en-US": { "role": { "documentation": "Discount rate from fair value on purchase date that participants pay for shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date", "terseLabel": "Employee Purchase Price Discount from Market Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r366" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Restricted Stock Units - Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r371" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Resticted Stock Units Cancelled/forfeited - Weighted-Average Grant-Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r369" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted Stock Units Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r369" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value - Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": { "auth_ref": [ "r368" ], "lang": { "en-US": { "role": { "documentation": "Per share weighted average intrinsic value of equity-based compensation awards not vested. Excludes stock and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share", "terseLabel": "Resticted Stock Units Outstanding Aggregate Intrinsic Value (in millions)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r368" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Nonvested shares - Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted Average Remaining Contractual Term (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r370" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Restricted Stock Units - Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r373" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r370" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Restricted Stock Units Vested - Weighted-Average Grant-Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r380" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r379" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r381" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": { "auth_ref": [ "r380" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend", "terseLabel": "Expected dividend" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r386" ], "lang": { "en-US": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Employee Contribution Rate - Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r357" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "verboseLabel": "Number of Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r386" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r363" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Options Number Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r363" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price - Options Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r373" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Options, Exercises in Period, Total Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r367" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Options - Shares Forfeitures/expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r367" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Options Forfeitured/expired - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r366" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "terseLabel": "Restricted Stock Units - Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r364" ], "lang": { "en-US": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Options - Shares Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]", "terseLabel": "Stock Options Activity" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r386" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value (in millions) - Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r362", "r386" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding end of period", "periodStartLabel": "Outstanding beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "terseLabel": "Options - Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r374" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Options Vested and Expected to Vest - Aggregate Intrinsic Value (in millions)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Options - Shares Vested and Expected to Vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Options Vested and Expected to Vest - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": { "auth_ref": [ "r352", "r386" ], "lang": { "en-US": { "role": { "documentation": "The weighted average of per share prices paid for shares purchased on the open market for issuance to employees under the plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Description of pertinent provisions of equity-based compensation awards that have actual or potential impact upon the company's financial statements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award", "terseLabel": "Options Granted Term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r352", "r358" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options Exercised - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options Granted - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r155", "r354", "r359" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Share-based Compensation Plans" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r382" ], "lang": { "en-US": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r356" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of share-based compensation awards.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r378", "r389" ], "lang": { "en-US": { "role": { "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r386" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Options Exercisable Aggregate Intrinsic Value (in millions)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r386" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (in years) - Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (in years) - Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options Vested and Expected to Vest - Weighted Average Remaining Contractual Term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r360" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r324" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Shares, Issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShippingAndHandlingCostPolicyTextBlock": { "auth_ref": [ "r19", "r34", "r154", "r155", "r345", "r346", "r347" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.", "label": "Shipping and Handling Cost, Policy [Policy Text Block]", "terseLabel": "Shipping and Handling" } } }, "localname": "ShippingAndHandlingCostPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r60", "r554", "r555", "r556", "r582" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r554", "r555", "r582", "r601" ], "lang": { "en-US": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-term Investments [Member]" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": { "auth_ref": [ "r409" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "terseLabel": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit" } } }, "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r155", "r311" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]", "terseLabel": "Warranty" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandbyLettersOfCreditMember": { "auth_ref": [ "r35", "r307", "r315", "r471" ], "lang": { "en-US": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.", "label": "Standby Letters of Credit [Member]", "terseLabel": "Standby Letters of Credit [Member]" } } }, "localname": "StandbyLettersOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r189" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r66", "r67", "r68", "r324" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables", "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r95", "r324" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Statement, Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_StatementGeographicalAxis": { "auth_ref": [ "r39", "r213", "r609" ], "lang": { "en-US": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario [Axis]", "terseLabel": "Statement, Scenario [Axis]", "verboseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r94", "r324", "r325", "r331" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Stock Issued During Period, Shares, Conversion of Convertible Securities" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r67", "r68", "r324", "r331" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r67", "r68", "r324", "r331" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r67", "r68", "r324", "r331", "r365" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Options - Shares Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock Repurchase Program, Remaining Authorized Repurchase Amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r68", "r72", "r73", "r220" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r31", "r68", "r72", "r73", "r158", "r159", "r221", "r323", "r324", "r325", "r326", "r327", "r328", "r331", "r332", "r334" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r544" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r544" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r544" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfIncomeTaxExaminationsTextBlock": { "auth_ref": [ "r411", "r434" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the increase or decrease in the liability from the prior period, and any penalties and interest that have been recorded.", "label": "Summary of Income Tax Examinations [Table Text Block]", "terseLabel": "Summary of income tax years currently under audit or open to examinations [Table Text Block]" } } }, "localname": "SummaryOfIncomeTaxExaminationsTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock": { "auth_ref": [ "r409" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.", "label": "Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]", "terseLabel": "Tabular reconcilation of total amounts of unrecognized tax benefits [Table Text Block]" } } }, "localname": "SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r3", "r425" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax Credit Carryforward, Amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r3", "r427" ], "lang": { "en-US": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardLimitationsOnUse": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of the limitation related to use of the tax credit carryforward.", "label": "Tax Credit Carryforward, Limitations on Use", "terseLabel": "Tax Credit Carryforward, Limitations on Use" } } }, "localname": "TaxCreditCarryforwardLimitationsOnUse", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r3", "r427" ], "lang": { "en-US": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r83" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Income and other taxes payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r69", "r75", "r155", "r216", "r217", "r219", "r222", "r557", "r590" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables. If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.", "label": "Trade and Other Accounts Receivable, Policy [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r453" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r93", "r333" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r93", "r333" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r68", "r324", "r331" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Treasury Stock, Shares, Acquired" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r93", "r333", "r336" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury Stock, Value" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r562" ], "lang": { "en-US": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "US Government Sponsored Agencies [Member]" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r36", "r412" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized tax benefits period end", "periodStartLabel": "Unrecognized tax benefits period start" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation": { "auth_ref": [ "r412" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from foreign currency translation.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation", "negatedTerseLabel": "Currency translation" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r413" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Reductions to tax positions related to prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r415" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedTerseLabel": "Settlements" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r408" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.", "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition", "terseLabel": "Acquisitions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r414" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions to tax positions related to the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation": { "auth_ref": [ "r412" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from foreign currency translation.", "label": "Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation", "terseLabel": "Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r413" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Additions to tax positions related to prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r416" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedTerseLabel": "Lapse of statute of limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due within Five Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due within Five Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due in Next Twelve Months", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due in Twelve Months" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due within Four Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due within Four Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due within Two Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due within Two Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due within Three Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due within Three Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Unrecorded Unconditional Purchase Obligation", "terseLabel": "Unrecorded Unconditional Purchase Obligation" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationDueAfterFiveYears": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due after Five Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due after Five Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationDueAfterFiveYears", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebt": { "auth_ref": [ "r62", "r550", "r586" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Unsecured Debt", "terseLabel": "Unsecured Debt" } } }, "localname": "UnsecuredDebt", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": { "auth_ref": [ "r37", "r399", "r423" ], "lang": { "en-US": { "role": { "documentation": "The portion of a deferred tax asset as of the balance sheet date for which, based on the weight of available evidence, it is more likely than not will not be realized through future reductions of tax-based income.", "label": "Valuation Allowance of Deferred Tax Assets [Member]" } } }, "localname": "ValuationAllowanceOfDeferredTaxAssetsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r169" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.", "label": "Valuation Allowances and Reserves, Balance", "periodEndLabel": "Valuation Allowances and Reserves, Balance Period End", "periodStartLabel": "Valuation Allowances and Reserves, Balance Period Start" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r169" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in the allowances and reserves, which consist of the valuation and qualifying accounts that are either netted against the cost of an asset or that reflect a liability established to represent expected future costs, from charges to costs and expenses.", "label": "Valuation Allowances and Reserves, Additions for Charges to Cost and Expense", "terseLabel": "Valuation Allowances and Reserves, Additions for Charges to Cost and Expense" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r169" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total of the deductions in a given period to allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, representing receivables written off as uncollectible and portions of the reserves utilized, respectively.", "label": "Valuation Allowances and Reserves, Deductions", "negatedTerseLabel": "Deductions" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r169" ], "lang": { "en-US": { "role": { "documentation": "The entity's valuation, qualifying and reserve accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.", "label": "Valuation Allowances and Reserves [Domain]", "terseLabel": "Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease": { "auth_ref": [ "r170" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset or that reflect a liability established to represent expected future costs.", "label": "Valuation Allowances and Reserves, Period Increase (Decrease)", "terseLabel": "Valuation Allowances and Reserves, Period Increase (Decrease)" } } }, "localname": "ValuationAllowancesAndReservesPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired": { "auth_ref": [ "r169" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, acquired in a business combination.", "label": "Valuation Allowances and Reserves, Reserves of Businesses Acquired", "terseLabel": "Other" } } }, "localname": "ValuationAllowancesAndReservesReservesOfBusinessesAcquired", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r169" ], "lang": { "en-US": { "role": { "documentation": "Information by type of valuation and reserve accounts.", "label": "Valuation Allowances and Reserves Type [Axis]", "terseLabel": "Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r169" ], "lang": { "en-US": { "role": { "documentation": "A schedule of allowance and reserve accounts including their beginning and ending balances, as well as a reconciliation by type of activity during the period. Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements.", "label": "Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r505" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation technique.", "label": "Valuation Technique [Axis]", "terseLabel": "Valuation Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r505" ], "lang": { "en-US": { "role": { "documentation": "Valuation techniques used by the entity.", "label": "Valuation Technique [Domain]", "terseLabel": "Valuation Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r175", "r178" ], "calculation": { "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares - diluted", "totalLabel": "Diluted weighted average common shares" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r38", "r174", "r178" ], "calculation": { "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares - basic", "verboseLabel": "Basic weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Glossary": "Accounting Change", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6503790" }, "r1": { "Glossary": "Antidilution", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6505113" }, "r10": { "Glossary": "Current Assets", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6509628" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e),(f),(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r11": { "Glossary": "Current Liabilities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6509677" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e640-108580" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669686-108580" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669619-108580" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669625-108580" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e557-108580" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004921&loc=d3e1436-108581" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r12": { "Glossary": "Current Tax Expense (or Benefit)", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6509736" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3,6,7,9)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3179-108585" }, "r13": { "Glossary": "Deferred Tax Asset", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6510090" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3179-108585" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585" }, "r14": { "Glossary": "Deferred Tax Expense (or Benefit)", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=63044130" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "c", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3098-108585" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586" }, "r15": { "Glossary": "Deferred Tax Liability", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6510232" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18726-107790" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18823-107790" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r16": { "Glossary": "Diluted Earnings Per Share", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6510752" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r17": { "Glossary": "Direct Effects of a Change in Accounting Principle", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=66092750" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1448-109256" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1505-109256" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1500-109256" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r18": { "Glossary": "Financing Activities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6513228" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(j)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=68076893&loc=d3e1280-108306" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=68076893&loc=d3e1570-108306" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=64851502&loc=d3e6003-108592" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599" }, "r19": { "Glossary": "Handling Costs", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51575068" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8615-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8654-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8657-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8660-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8663-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8672-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8721-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8736-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8813-108599" }, "r2": { "Glossary": "Available-for-Sale Securities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6505594" }, "r20": { "Glossary": "Income Tax Expense (or Benefit)", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6515339" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "35", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599" }, "r21": { "Glossary": "Indirect Effects of a Change in Accounting Principle", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6515603" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8475-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "305", "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=66008989&loc=SL6953423-111524" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=66008989&loc=d3e5212-111524" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=66008989&loc=d3e5074-111524" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=66008989&loc=d3e5093-111524" }, "r22": { "Glossary": "Intangible Assets", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6515781" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=65890831&loc=d3e10133-111534" }, "r223": { "Glossary": "Debt Security", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=6509901" }, "r224": { "Glossary": "Equity Security", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=6511694" }, "r225": { "Glossary": "Security", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=6524771" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Subparagraph": "(a)-(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=27723805&loc=d3e24584-111560" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=27723805&loc=d3e25065-111560" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=66010992&loc=d3e26610-111562" }, "r23": { "Glossary": "Investing Activities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6516133" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=66010992&loc=d3e26853-111562" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=66010992&loc=d3e26817-111562" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=66010992&loc=d3e26828-111562" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27198-111563" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27198-111563" }, "r24": { "Glossary": "Level 1 Inputs", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51652821" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27198-111563" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27198-111563" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27232-111563" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27232-111563" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27337-111563" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27340-111563" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "8B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=SL6284393-111563" }, "r25": { "Glossary": "Level 2 Inputs", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51652837" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.M)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=65877573&loc=d3e87990-122713" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266" }, "r26": { "Glossary": "Level 3 Inputs", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51652851" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388280&loc=d3e13777-109266" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=64834752&loc=SL49117168-202975" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a,h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267" }, "r27": { "Glossary": "Market-Corroborated Inputs", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6517519" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r28": { "Glossary": "Net Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831255" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=64802544&loc=d3e202-110218" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=68055307&loc=d3e2420-110228" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r29": { "Glossary": "Other Comprehensive Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831270" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747" }, "r3": { "Glossary": "Carryforwards", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6506874" }, "r30": { "Glossary": "Performance Standby Letter of Credit", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6520341" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=73718637&loc=d3e25287-109308" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=73718637&loc=d3e25336-109308" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=73718637&loc=d3e25383-109308" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68077669&loc=d3e10037-110241" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68077669&loc=d3e10037-110241" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r31": { "Glossary": "Preferred Stock", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6521494" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=73718786&loc=d3e12803-110250" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=28361426&loc=SL5988623-112600" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r32": { "Glossary": "Research and Development", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6523717" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21553-112644" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644" }, "r33": { "Glossary": "Retrospective Application", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6523989" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 13.A.4(a).Q1)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b))", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r34": { "Glossary": "Shipping Costs", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51575562" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b).Q1(c))", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b).Q2)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(c).Q3)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.B.Q1)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "45", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=68075638&loc=d3e60635-111653" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "45", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=68080631&loc=d3e61069-111654" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "45", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=6408413&loc=d3e221937-122793" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79691-111665" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79708-111665" }, "r35": { "Glossary": "Standby Letter of Credit", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6525665" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65897934&loc=d3e1928-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=66904339&loc=d3e4534-113899" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r36": { "Glossary": "Unrecognized Tax Benefit", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6527854" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r37": { "Glossary": "Valuation Allowance", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6528051" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r38": { "Glossary": "Weighted-Average Number of Common Shares Outstanding", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6528421" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-04.(c) Schedule III)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=27047687&loc=d3e5864-122674" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=65896087&loc=d3e11149-113907" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=65896087&loc=d3e11178-113907" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=65896087&loc=d3e11374-113907" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=65895303&loc=d3e17540-113929" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=65880886&loc=d3e23524-113945" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=68052875&loc=d3e28680-109314" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=68052875&loc=d3e28680-109314" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=64814285&loc=d3e30536-109315" }, "r4": { "Glossary": "Cash", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6506951" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e32247-109318" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e32280-109318" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31917-109318" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31928-109318" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31931-109318" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31958-109318" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32718-109319" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32718-109319" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32718-109319" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32718-109319" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=SL6600010-109319" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=SL6600010-109319" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=SL6600010-109319" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=SL6600010-109319" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=SL6600010-109319" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=SL6600010-109319" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32809-109319" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32840-109319" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32559-109319" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32559-109319" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32559-109319" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32621-109319" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32632-109319" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116239&loc=d3e36027-109320" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65896914&loc=d3e39076-109324" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=73531372&loc=d3e2207-128464" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744439&loc=d3e5263-128473" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744439&loc=d3e5263-128473" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744439&loc=d3e5333-128473" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744439&loc=d3e5419-128473" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744439&loc=d3e5504-128473" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744439&loc=d3e5504-128473" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6812-107765" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=66022390&loc=d3e923-111674" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=SL4569616-111683" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=SL4569643-111683" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=d3e5614-111684" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-04)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355119-122828" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6812-107765" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2),(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=d3e41675-113959" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=d3e41678-113959" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=68066869&loc=SL5629052-113961" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986" }, "r5": { "Glossary": "Cash Equivalents", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6507016" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "48", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=65894324&loc=d3e18349-110257" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19190-110258" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=SL7498348-110258" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19279-110258" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=SL6742756-110258" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6447952&loc=d3e13217-108610" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6447952&loc=d3e13220-108610" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13279-108611" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13467-108611" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13476-108611" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13504-108611" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13531-108611" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64836518&loc=d3e30690-110894" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64836518&loc=d3e30700-110894" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=73530178&loc=d3e59706-112781" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(9))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13,16)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.6(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04.13(h))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)-(g)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=50488274&loc=d3e64164-112818" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=68064133&loc=d3e61044-112788" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=68064133&loc=d3e61082-112788" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(f))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f,g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04.3(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r6": { "Glossary": "Change in Accounting Principle", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6507316" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "325", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6485959&loc=d3e22529-158502" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6484115&loc=d3e19393-158473" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6484115&loc=d3e19393-158473" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=28088331&loc=SL29635902-196195" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S35", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=6488548&loc=SL6090579-123006" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.6(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C.9(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28)", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r611": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12b", "Subsection": "1" }, "r612": { "Article": "12", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "13", "Sentence": "Column B" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r7": { "Glossary": "Common Stock", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6508022" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r8": { "Glossary": "Comprehensive Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831223" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r9": { "Glossary": "Contingent Stock Agreement", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6508534" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" } }, "version": "2.0" } ZIP 97 0000012208-17-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000012208-17-000012-xbrl.zip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°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ҿ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

  •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